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1 INTRODUCTION 
1.1 Non-coding small RNAs 
In the last two decades, a vast amount of evidence was discovered that RNA is not only 
functional as a messenger between DNA and protein, but also plays a crucial role in regulation of 
genome organization and gene expression (reviewed in Morris & Mattick 2014). The ENCODE 
(Encyclopedia of DNA elements) project identified 80% of the human genome to serve a 
biochemical purpose (Pennisi 2012), e.g. providing a binding site for transcription factors. In 
total, 76% of the human genome is transcribed to RNA, while only 3% of the whole genome 
codes for a total of 20,687 proteins (Pennisi 2012). In addition, 11,224 pseudogenes, 8,800 small 
RNA molecules and 9,600 long RNA molecules were found to be encoded in the genome (Pennisi 
2012). Many classes of non-protein coding RNAs have been identified to operate on several 
regulatory levels in eukaryotic as well as in prokaryotic cells, adding new levels of complexity to 
the regulatory network in living cells. The regulation of gene expression on a post-transcriptional 
level is the mechanism best described for miRNA (microRNA) dependent regulation (Carthew & 
Sontheimer 2009). Non-coding RNAs are also able to mediate epigenetic regulation, as small 
RNAs as well as long non-coding RNAs can recruit histones, DNA methyltransferases and 
chromatin modifying complexes (reviewed by Holoch & Moazed, 2015). 
This work focuses on one specific, highly conserved class of non-coding RNAs, the miRNAs, and 
their role in post-transcriptional regulation of protein coding transcripts in mammalian kidneys. 
miRNAs have already been identified to be involved in many important signaling processes in 
mammalian cells, e.g. the regulation of somatic stem cell proliferation and differentiation 
(reviewed by Shenoy & Blelloch 2014) or the modulation of autophagy and apoptosis (reviewed 
by Su et al. 2015). Since miRNAs are important for the homeostasis of physiological conditions in 
cells, dysregulation of their levels was proposed to be involved in genesis and progression of a 
broad variety of diseases. They play an important role in the progression of different cancers 
(reviewed by e.g. Hata & Lieberman 2015, Melo & Esteller 2011, Jansson & Lund 2012, Volinia et 
al. 2010), but also in other diseases like Alzheimer’s disease (Codoceno et al. 2015, Feminella et 
al. 2015) or diabetes (reviewed by Guay et al. 2011) and diabetic nephropathy (reviewed by Kato 
& Natarajan 2015). miRNAs have been proposed as potential activators of diseases, biomarkers 
(reviewed by Wang et al. 2015A) and therapy targets. 
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1.1.1 Biogenesis and function of miRNAs in mammalian cells 
miRNAs are small, non-coding RNA molecules with a length of 19-25 nt (nucleotides) that are 
processed in mammalian cells from endogenously generated transcripts. They play an 
exclusively regulatory role in cells, functioning as guide molecules in post-transcriptional gene 
silencing by base pairing with their target, leading to its silencing or degradation (Kim 2005). It 
has been estimated that up to 60% of human protein coding genes are regulated by miRNAs 
(Friedman et al. 2009). For many miRNAs, the sequence of the mature miRNA molecules as well 
as the genomic organization of the precursor transcripts is highly conserved between different 
species, especially between mammalian species like human and mouse. 
miRNA precursor molecules 
The primary miRNA transcript, the pri-miRNA, consists of a hairpin with an imperfectly paired 
stem of ca. 33 nucleotides and flanking sequences that extend on both the 5’-end and the 3’-end 
from the hairpin structure (Carthew & Sontheimer 2009). Transcription of miRNAs is typically 
performed by RNA polymerase II, and the primary transcripts are capped and polyadenylated 
(Kim 2005). miRNA transcripts synthesized by RNA polymerase III have also been described 
(Dieci et al. 2007). miRNAs can be categorized according to their genomic locations: exonic 
miRNAs are processed from their own, non-coding primary transcript that contains one or more 
hairpin structures, while intronic miRNA hairpins are derived from the introns of a protein 
coding or non-protein coding transcript (Kim 2005). A transcript containing several miRNA 
hairpins is called a miRNA cluster (chapter 1.1.2). 
In the first pri-miRNA processing step (Fig. 1.1), occurring in the nuclei of mammalian cells, the 
stem loop structure is cleaved by the enzyme Drosha, releasing the miRNA precursor, the pre-
miRNA (Kim 2005). Drosha, a member of the RNAse III family, and its cofactor DGCR8 (DiGeorge 
syndrome critical region gene 8), which is important for miRNA maturation, are called the 
microprocessor complex (Denli et al. 2004, Nguyen et al. 2015).  
An alternative miRNA maturation pathway uses splicing to form transcripts that mimic the 
structural features of pre-miRNAs, the so-called “mirtrons”, which also can enter the miRNA 
processing pathway after the Drosha processing step (Carthew & Sontheimer 2009). 
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Fig. 1.1: Pathways leading to functional RISCs; after transcription and processing by Drosha and Dicer, the 
mature miRNAs are bound by Ago proteins, forming the RISCs (Meister 2013, modified); Abbreviations: 
DGCR8: DiGeorge syndrome critical region gene 8; NPC: nuclear pore complex; RISC: RNA induced 
silencing complex 
miRNA maturation 
After the pre-miRNA is exported out of the nucleus by XPO-5 (Exportin-5) and released from the 
transport complex in an energy dependent manner (Ha & Kim 2014), the second processing step 
is carried out by the conserved enzyme Dicer (Fig. 1.1), a member of the RNase III family (Kim 
2005). It excises the terminal loop from the hairpin creating a mature miRNA duplex with a 
length of approximately 22 nucleotides (Carthew & Sontheimer 2009). Products of Dicer 
processing possess phosphates at the 5’-end and overhangs of two nucleotides at the 3’-end 
(Meister & Tuschl 2004) and can be loaded into the RISCs (RNA induced silencing complexes). 
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RISC complex formation 
Mammalian cells possess four argonaute proteins, Ago1-4, which are all able to bind mature 
miRNAs to form RISCs. However, only Ago2 has a retained catalytic activity by a functional 
catalytic triad, while the other three Ago proteins might be partially redundant (Meister 2013). It 
has been shown that the different Ago proteins bind different subpopulations of miRNAs 
(Burroughs et al. 2011). The binding to the different Ago proteins seems to be influenced by the 
length of the miRNA. The Ago1 and Ago3 bound miRNAs often contain 23 to 24 nucleotides and 
may possess non-templated additions of mostly one nucleotide at their 3’-end (Dueck et al. 
2012).  
After Dicer processing, the mature miRNA is loaded into the Ago protein. The transfer of the 
double strand to the Ago protein is mediated by Hsp90 (Heat shock protein 90) in humans. By 
conformational changes of the Ago protein, its N domain is driven between the two duplex 
strands, leading to duplex opening and further unwinding (Meister 2013). How unwinding occurs 
in detail, and whether additional factors are needed, is not fully understood yet. After unwinding 
of the duplex, the strand with the less stably paired 5’-end is preferentially loaded into Ago 
proteins (Meister 2013). The passenger strand, often marked with a “*”, is removed and can be 
degraded, but may also be a functional miRNA itself. As an example, both mature miRNAs from 
the mir-9 precursor regulate the tumor suppressor CAMTA1 (Calmodulin binding transcription 
activator 1; Schraivogel et al. 2011).  
Dicer is an enzyme with a broad range of possible substrates, e.g. it is able to generate small 
RNAs with a length of 22 nucleotides from a 70 nucleotide stem loop precursor (Kim 2005). Thus, 
also other double stranded precursor molecules can be processed by Dicer and loaded into Ago 
proteins, e.g. siRNAs (small interfering RNA). 
Posttranscriptional regulation of gene expression by miRNAs 
The miRNAs function as a guide for the Ago proteins to mRNAs, directing the RISC to binding 
sites which are often located in the 3’-UTR of the target genes (Meister 2013). miRNA binding in 
the coding region of genes also has been reported (reviewed by Brümmer & Hausser 2014; 
Gebeshuber et al. 2013). Perfectly paired miRNA-target duplexes can be cleaved by the 
catalytically active Ago2 protein (Meister 2013). In mammals, miRNAs usually bind to partially 
complementary sites, while the “seed region”, the nucleotides on position 2 to 7 or 8 of the 
miRNA, is often fully paired and essential for interaction (Meister 2013).  
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The binding of a miRNA guided RISC to a target mRNA can lead to its translational silencing as 
well as its degradation, with the mRNA destabilization being the main contributor to regulation 
in animal cell cultures (Jonas & Izaurralde 2015). Mammals possess three GW (Glycine-
tryptophan repeat containing) proteins, called TNRC6A-C (Trinucleotide repeat containing 6 A-C), 
that can bind to Ago proteins, PAN3 (Poly (A) specific ribonuclease subunit 3) and NOT9 (also: 
RQCD1: Required for cell differentiation1 homolog) via their tryptophan residues (Jonas & 
Izaurralde 2015). Via PAN3 and NOT9, the deadenylating complexes PAN2-PAN3 and CCR4-NOT 
are recruited to the regulated transcript, leading to its deadenylation, decapping and 
degradation via the cellular 5’-to-3’ mRNA decay pathway (reviewed by Jonas & Izaurralde 
2015). 
Non canonical miRNA processing 
Two parallel studies identified a mature miRNA whose levels were not affected by Dicer loss of 
function, but reduced in mutant zebrafish and mice lacking enzymatic activity of Ago2 (Cifuentes 
et al. 2010, Cheloufi et al. 2010). Dicer requires a double strand of > 19 nucleotides for miRNA 
maturation from a canonical precursor (Fig. 1.2 A). A mature miRNA, miR-451-5p, is encoded in a 
conserved 42 nucleotide hairpin precursor with a stem of only 17 nucleotides (Fig. 1.2 B). This 
short hairpin can be directly bound by Ago2 and cleaved at the opposite strand (Fig. 1.2 C).  
 
Fig. 1.2: Non-canonical miRNA precursors (A) Canonical hairpin precursor mir-144 coding for two mature 
miRNAs, miR-144-5p (blue) and miR-144-3p (red); (B) mir-451 hairpin precursor with shortened stem only 
coding for one mature miRNA, miR-451-5p (red); (C) mir-451 hairpin with predicted Ago2 cleavage site on 
the opposite strand (Cheloufi et al. 2010, modified) 
The mir-451 pre-miRNA seems only to be bound by the only catalytically active argonaute 
protein, Ago2, and artificial precursors mimicking the pre-mir-451 structure will be bound and 
processed by Ago2 (Dueck et al. 2012). PARN (Poly (A) specific ribonuclease) could be identified 
as the enzyme responsible for 3’-5’ exonucleolytic trimming of Ago2 cleaved pre-mir-451 (Yoda 
et al. 2013). 
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Regulation miRNA expression and maturation 
By guiding the RISCs to the 3’-UTRs of target genes, miRNAs function as gene expression 
regulators. Vice versa, since miRNAs are generated from primary transcripts produced by RNA 
polymerase II or III, their expression can be regulated by transcription factors. Many miRNAs 
have been shown to be regulated by transcription factors like p73 and p63 (Tumor proteins P73 
and P63), who have been identified as activators of miR-200 family upregulation (Knouf et al. 
2012). The transcription factor Lmx1b (LIM homeobox transcription factor 1 beta) has been 
found to form a regulatory circuit with miR-135a-2 in brain (Anderegg et al. 2013). A feedback 
loop between the miR-200 family and the transcription factors ZEB1 and ZEB2 (Zinc finger E-box 
binding homeobox 1 and 2), controlling EMT and MET (Epithelial–mesenchymal and 
Mesenchymal–epithelial transition), has also been discovered (Hill et al. 2013). It was reported 
that the miR-709 directly regulates miRNA-15a/16-1 biogenesis on a posttranscriptional level, 
hinting at a possible miRNA hierarchy system (Tang et al. 2012).  
Additionally, processing of miRNAs can be regulated on every stage, i.e. nuclear procession, 
export from the nucleus, cytoplasmic procession and loading into the Ago complex as well as the 
structure of the miRNA itself, e.g. by tailing (reviewed by Ha & Kim 2014). miRNA binding to 
human Ago proteins can also be strongly reduced by Ago phosphorylation (Rüdel et al. 2011). 
1.1.2 Classification of identified miRNAs 
All miRNAs identified from different organisms are registered in the online database miRBase 
(http://www.mirbase.org; Kozomara & Griffiths-Jones 2014; Kozomara & Griffiths-Jones 2011; 
Griffiths-Jones et al. 2008; Griffiths-Jones et al. 2006; Griffiths-Jones 2004). Until September 
2015, 1881 miRNA precursors and 2588 mature miRNAs had been identified in human. In 
mouse, 1193 miRNA precursors and 1915 mature miRNAs had been identified. In the database 
TarBase v7.0 (Vlachos et al. 2014), more than 65,000 interactions of miRNAs and genes 
identified by high-throughput approaches or specific experiments had been indexed until 
September 2015. A database for miRNA involvement in diseases, miR2Disease (Jiang et al. 2009), 
listed 349 miRNAs to be involved in 163 diseases in September 2015. 
Nomenclature of miRNAs 
With the exception of the first two miRNAs discovered in C. elegans, lin-4 (Lee et al. 1993) and 
let-7 (Reinhart et al. 2000), miRNA precursors are numbered chronological according to their 
discovery. To indicate the precursor, the “r” in mir is not capitalized, e.g. mir-191. A prefix 
indicates the specimen the miRNA was found in (e.g. hsa for homo sapiens, mmu for mus 
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musculus, rno for rattus norvegicus). If the precursor is evolutionary conserved, the number will 
be the same in the different organisms, e.g. hsa-mir-22 and mmu-mir-22. To indicate that a 
precursor possesses two different loci in the genome, the precursor is numbered, e.g. hsa-mir-
24-1 and hsa-mir-24-2. The two mature miRNAs that originate from a common precursor are 
indicated with a suffix describing the arm of the precursor they are derived from, e.g. miR-9-5p 
and miR-9-3p. According to the old nomenclature, the miRNA with the lower expression level is 
sometimes marked with a star, e.g. miR-9*. When the sequence of two miRNAs is very similar 
and the sequence of the seed region, the positions 2 to 7 or 8, is identical, the miRNAs are 
grouped into one family, e.g. miR-23a-3p and miR-23b-3p. However, the division into families is 
not very consistent, as e.g. the miRNAs mir-141, mir-200a, mir-200b, mir-200c and mir-429 
belong to the same family, while there is a single base mismatch in the seed regions of miR-
200a-3p and miR-200b-3p. 
miRNA clusters 
A miRNA cluster is a group of miRNA hairpin precursors that are processed from one common 
primary transcript yielding several mature miRNAs. One cluster that has been studied intensively 
is the miR-17~92 cluster, a genomic fragment of 786 base pairs containing 6 hairpin precursors 
(He et al. 2005, Hayashita et al. 2005). A common role of miRNAs organized in a cluster could be 
proven when overexpression of the miR-17~92 cluster enhanced tumor growth in a mouse B-
cell lymphoma model (He et al. 2005) as well as lung cancer cell growth (Hayashita et al. 2005). 
As a second example, the five members of the mir-200 family are organized in two genomic 
clusters, pointing to a common role of miRNAs that are encoded near to each other in the 
genome. The miR-200 family is involved in kidney fibrosis and diabetic nephropathy by 
regulation of the EMT and the EndMT (Endothelial mesenchymal transition) (Srivastava et al. 
2013). Additionally, a feedback loop between the ZEB transcription factors and the miR-200 
family was identified to be an important player in the progression of cancer (Brabletz & Brabletz 
2010). The two mir-23~27~24 clusters, one harboring the precursors mir-23a, mir-27a and mir-
24-2 and the other containing mir-23b, mir-27b and mir-24-1, have been shown to be important 
for cardiovascular disorders, as they are involved in angiogenesis, endothelial apoptosis in 
cardiac ischemia and retinal vascular development (reviewed by Bang et al. 2011). A cooperative 
function of the encoded miRNAs was proposed, since the functional analysis revealed similar 
distributions of enriched genes (Liang et al. 2014). Additionally, the cooperative function of 
miRNAs organized in 20 different clusters in regulating several cell signaling pathways involved in 
cervical cancer has recently been reviewed (Servin-González et al. 2015). 
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1.2 The mammalian kidney 
1.2.1 The anatomy of the mammalian kidney 
The kidneys are an organ serving several important roles in the mammalian organism. Their 
main tasks are filtration of the blood to remove waste products from the organism, maintenance 
of homeostasis of electrolytes and thus, regulation of the blood pressure. The hilum, the place 
where the renal artery enters the kidney and the renal vein as well as the ureter leave the 
kidney, is located on the concave side of the bean-shaped organs. The two major segments of 
the kidney are the outer cortex and the inner medulla. Contrary to the murine kidney (unilobar 
kidney), the parenchyma of the human kidney is divided into several pyramids by projections of 
the renal cortex towards the center. The tip of each pyramid opens out into the calyxes that 
merge into the renal pelvis. 
 
Fig. 1.3: Microscopic anatomy of the mammalian kidney (A) Nephrons spanning the cortex and medulla of 
a mammalian kidney: 1 glomerulus; 2 proximal convoluted tubule; 3 proximal straight tubule; 4 
descending thin limb; 5 ascending thin limb; 6 thick ascending limb; 7 macula densa; 8 distal convoluted 
tubule; 9 connecting tubule; 10 cortical collecting duct; 11 outer medullary collecting duct; 12 inner 
medullary collecting duct (Mount 2014) (B) Schematic representation of a glomerulus with the podocytes 
covering the capillary convolute (Pollak et al. 2014, modified); (C) Scanning electron micrographs of the 
interdigitating processes of adjacent podocytes covering the glomerular capillaries. Micrographs by C. 
Niemann & H. Schmidt, Institute for Molecular & Cellular Anatomy, University of Regensburg 
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The functional units of the kidney are the nephrons. They span the cortex and the medulla of the 
kidney and consist of a glomerulus, where the initial filtration of the blood takes place, and an 
adjacent tubular system in which the primary urine is concentrated (Fig. 1.3 A). 
1.2.2  The glomerulus and the renal filtration barrier 
The mammalian glomerulus contains a capillary convolute, which is covered by highly specialized 
epithelial cells, the podocytes (Fig. 1.3 B, C). In the glomerulus, the primary urine is filtered from 
the blood into the Bowman’s space, from where it flows of into the tubular system. The inner 
part of the glomerulus consists of three main cell types: the endothelial cells lining the 
capillaries, the podocytes and the stabilizing mesangial cells, smooth muscle cells intercalated 
into the capillary convolute (Fig. 1.4 A). In addition, the Bowman’s space surrounding the 
capillary convolute is lined with the PECs (Parietal epithelial cells). In-between their 
interdigitating foot processes, the podocytes build up the slit diaphragm, a delicate protein 
structure crucial for blood filtration. The renal filtration barrier consists of three components: 
The slit diaphragms, i.e. complex protein structures built by two neighboring podocytes in-
between their interdigitating foot processes (Fig. 1.4 B), the glomerular basement membrane 
between the endothelial cells and the podocytes and the fenestrated endothelium of the 
capillaries. 
 
Fig. 1.4: Microscopic anatomy of the filtration barrier (A) the glomerular capillaries are covered by the 
podocytes which form contacts to each other with their interdigitating foot processes; the capillary 
convolute is stabilized by mesangial cells; from the Bowman’s space bordered by the PECs, the primary 
urine is conducted towards the tubular system starting with the proximal tubule (Pozzi & Zent, 2012); (B) 
Electron micrograph of the glomerular filtration barrier: interdigitating processes of adjacent podocytes 
with linking slit diaphragms (arrows), the glomerular basement membrane and the fenestrated capillary 
endothelium (Tryggvason et al. 2006, modified); Abbreviations: FP: foot process; GBM: glomerular 
basement membrane; E: fenestrated endothelium; scale bar: 250 nm 
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In the last years, putative podocyte regeneration has been discussed. Different sources of 
progenitor cells, like parietal epithelial cells or cells of the renin lineage have been proposed 
(reviewed by Grahammer et al. 2013). PECs have been shown to play a role in podocyte 
regeneration in young mice from postnatal day ten (Appel et al. 2009) up to 28 days of age (Eng 
et al. 2015). No regeneration could be found in older mice from five weeks to 18 months of age 
(Berger et al. 2014), a finding that might be explained by the fact that progenitor cells are 
believed to be active in postnatal mice for one to two weeks (Rinkevich et al. 2014). Limited 
podocyte renewal from PECs was observed after diphtheria toxin induced podocyte injury, but 
not under physiological conditions (Wanner et al. 2014). Furthermore, miR-193a-5p was 
identified to play a role in modulating the phenotype and marker expression of cultured PECs 
towards a podocyte phenotype (Kietzmann et al. 2014).  
1.2.3 Models for working with podocytes 
To be able to investigate podocytes in cell culture, immortalized cell lines derived from isolated 
human and murine podocytes have been established previously (Saleem et al. 2002, Schiwek et 
al. 2004). The human as well as the murine cell line are proliferating at 33°C and can be 
differentiated by culturing at 37°C or 38°C, respectively. 
Human podocyte cell line 
Human podocytes were derived by biopsy from a three year old child (Saleem et al. 2002). By 
transfection with a retroviral construct coding for the SV40 large T antigen, primary podocytes 
were immortalized to form a cell culture line: the hPCL (Human podocyte cell line).  
 
Fig. 1.5: Immunofluorescence of immortalized human podocytes; differential expression of Synaptopodin 
(top) and Nephrin (bottom) in proliferating (left) and differentiated (right) immortalized human podocytes 
(Saleem et al. 2002, modified) 
 
When cultured at 33°C, the proliferating cells only show a low expression of synaptopodin and 
nephrin. After differentiation at 37°C for two weeks, expression of synaptopodin as well as 
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nephrin could be detected by immunofluorescence (Fig. 1.5). In the proliferating cells, PCNA 
(Proliferating cell nuclear antigen), a marker of cell proliferation, and CyclinA, a regulator of cell 
cycle progression, are expressed at high levels, but absent in the differentiated cells. Vice versa, 
p27 (Cyclin-Dependent Kinase Inhibitor 1B), a cell cycle inhibitor, and CyclinD1, a driver of G1/S 
phase (Gap 1 phase /Synthesis phase) transition, are absent in the proliferating cells but 
expressed in the differentiated cells. 
Murine podocyte cell line 
Murine podocytes were isolated from kidneys of the “Immorto-Mouse” (Charles River, St. Louis, 
MO, USA) by letting them grow out from isolated glomeruli (Schiwek et al. 2004). These mice 
carry a temperature sensitive mutant of the SV40 large T antigen under the control of the 
interferon-–inducible H-2Kb promoter. The mPCLs (Murine podocyte cell line) differentiate 
when cultured at 38°C for two weeks. Expression of the podocyte marker proteins nephrin and 
Cd2ap (CD2 associated protein) could be demonstrated by Northern Blotting, while expression 
of WT1 (Wilms tumor protein 1), Lmx1b, Neph1 (Kin of IRRE-like protein 1), Cd2ap, podocalyxin 
and other marker proteins was shown by RT-PCR (Reverse transcription polymerase chain 
reaction). By immunofluorescence microscopy, localization of Cd2ap and synaptopodin to the 
actin cytoskeleton at the cell-cell contacts was shown. 
Cell culture of glomeruli isolated from mice 
Glomeruli isolated from mice by magnetic bead perfusion (Takemoto et al. 2002) can be cultured 
in standard cell culture media for several days after isolation from mice (personal 
communication: M. Kubitza). From the seeded glomeruli, glomerular cells including podocytes 
grow out on the cell culture flask surface and can be used for experiments. However, the cells 
dedifferentiate and loose the typical podocyte architecture and marker protein expression 
within some days. 
Freshly isolated murine podocytes 
Using a double-fluorescent Cre reporter mouse (Muzumdar et al. 2007) crossed with a mouse 
with podocyte specific Cre expression (Möller et al. 2003), a mouse harboring podocytes marked 
by green fluorescence can be generated. By isolation of the glomeruli followed by additional 
digestion steps, a single cell suspension can be obtained from which the podocytes can be 
isolated by FACS (Fluorescent activated cell sorting) (Boerries et al. 2013). This method yields a 
pure podocyte sample. On the downside, the sorted podocytes do not adhere any more to cell 
culture substrates and thus cannot be cultured further (personal communication: T. Burghardt). 
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1.3  The role of miRNAs in podocyte integrity 
1.3.1 miRNA expression profiles of the mammalian kidney 
In several studies, miRNAs were isolated from different tissues in order to identify organ or cell 
type enriched miRNAs. In the first examination of nine different mouse tissues, highly enriched 
miRNAs for some of the tissues were identified (Lagos-Quintana et al. 2002). In order to obtain a 
mammalian miRNA expression atlas, more than 250 small RNA libraries from 26 different organ 
systems and cell types of human and rodent were sequenced, including total kidney from human 
as well as mouse (Landgraf et al. 2007). A study sequencing miRNAs isolated from kidney, 
ovaries and testis of adult mice as well as from the mesonephros, kidneys, ovaries and testis 
form the embryonic days E11, E12 and E13 revealed the miRNA profiles of these organs to vary 
during embryogenesis, hinting that miRNAs play an important role for development of murine 
urinary and reproductive systems (Aguilar et al. 2010). 
1.3.2 Podocyte specific knockout of miRNA processing enzymes  
In 2008, three parallel studies showed the importance of miRNAs for podocyte development and 
function (Harvey et al. 2008, Ho et al. 2008, Shi et al. 2008). Mice that expressed the Cre 
recombinase under the control of the podocyte specific NPHS2 promoter (Möller et al. 2003) 
were crossed with mice in which the exons 20 and 21, part of the second RNase III domain of the 
miRNA processing enzyme Dicer, are flanked by loxP (Locus of X-over P1) sites (Harfe et al. 
2005), the Cre recombinase recognition sites. This lead to a conditional, podocyte specific Dicer 
knockout. The affected mice developed proteinuria two to five weeks after birth, leading to end-
stage renal disease and death. During progression of disease, several glomerular abnormalities 
like foot process effacement, crescent formation, wrinkling and split areas of the glomerular 
basement membrane were observed. In the podocytes of the affected kidneys, the expression of 
synaptopodin, ezrin (Harvey et al. 2008), podocin (Shi et al. 2008) and nephrin (Ho et al. 2008) 
was reduced in the knockout podocytes, while expression of -actinin-4 (Harvey et al. 2008) and 
WT1 (Harvey et al. 2008, Ho et al. 2008) remained unchanged. It was shown by in situ 
hybridization directed against mature miRNAs, that miR-30a-5p expression in podocytes is lost in 
the Dicer knockout animals compared to the control animals, whereas the expression of the 
endothelial miR-126-3p and the mesangial miR-145-5p is not affected by the knockout (Harvey 
et al. 2008), thus identifying one mature miRNA highly enriched in podocytes. Vice versa, gene 
expression profiling of glomeruli isolated from Dicer knockout and control mice revealed an 
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enrichment of mRNAs with possible binding sites of the miR-30 family in the knockout glomeruli, 
pointing to a possible role of this miRNA family in podocytes (Shi et al. 2008).  
In a different study, mice expressing the Cre recombinase under the control of the podocyte 
specific NPHS2 promoter (Möller et al. 2003) where crossed with mice possessing loxP sites on 
either side of exon 9 of the miRNA processing enzyme Drosha (Chong et al. 2008), leading to a 
conditional, podocyte specific Drosha knockout (Zhdanova et al. 2011). At about two to three 
weeks of age, mice affected by this knockout developed proteinuria that progressed to renal 
failure and death within four to eight weeks of age. The mice showed podocyte foot process 
effacement as a first pathologic sign, later leading to extensive collapsing glomerulopathy, 
pseudo crescent formation and sclerosis. This was accompanied by the loss of synaptopodin, 
WT1, nephrin and podocin expression, resembling the phenotype of the Dicer knockout mice, 
with the exception of WT1 expression which remained normal in the Dicer knockout mice. To 
determine if miRNAs are not only required for podocyte development, but also podocyte 
function, an inducible Tet-On (Tetracycline-controlled transcriptional activation) system was 
used in the same study to specifically delete Drosha at later time points. Mice showed 
proteinuria around two weeks after beginning of the doxycycline treatment. By histological 
examination, a phenotype very similar to the phenotype observed in the conditional Drosha 
knockout mice was revealed. Thus, this study showed that miRNAs are not only important for 
podocyte development, but also for maintenance of the podocyte filtration barrier in adult 
kidneys. 
1.3.3 Profiles from murine podocytes 
In 2013, expression profiles from murine podocytes were obtained (Boerries et al. 2013). The 
transcriptome as well as proteome of podocytes isolated freshly from double fluorescent Cre 
reporter mice was analyzed. Together with transcripts and proteins enriched in podocytes, a list 
of 35 miRNAs expressed in murine podocytes and non-podocyte glomerular cells was published 
that are in high congruence with the data of the present work (Tab. 5.5). 
1.3.4 Known miRNA functions in the glomeruli and podocytes  
Many studies tried to identify miRNAs important for kidney function. Profiling studies have been 
performed from patients, animal models and cultured podocytes cell lines under different 
conditions to identify miRNAs with altered expression levels (reviewed by Chandrasekaran et al. 
2012, Kato et al. 2012). For some miRNAs expressed in mammalian kidney, not only expression 
data, but functional roles were identified. For instance, miR-26a-5p levels were found to be 
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lowered in swine and human post stenotic kidneys (Zhu et al. 2015) as well as in human patients 
with lupus nephritis or IgA nephropathy (Ichii et al. 2014). Recently, miR-26a-5p was identified to 
target CTGF (Connective tissues growth factor), connecting the downregulation of miR-26a-5p to 
diabetic nephropathy progression in mouse models and humans (Koga et al. 2015). In another 
study, enhanced nephrin acetylation with attenuated renal damage was reported in miR-155-5p 
double knockout mice suffering from hyperglycemia induced nephropathy (Lin et al. 2014). 
Distinct targets have only been identified for some miRNAs in glomeruli and kidneys so far. It 
was reported that miR-135a-5p regulates TRPC1 (Transient receptor potential cation channel, 
subfamily C, member 1) during renal injury promoting renal fibrosis (He et al. 2014B). Under high 
glucose conditions, miR-93-5p regulates VEGF (Vascular endothelial growth factor) in vitro and in 
vivo (Long et al. 2010) and miR-195-5p promotes apoptosis in mouse podocytes by regulating 
BCL2 (B-cell lymphoma 2) activity (Chen et al. 2011). By downregulation of SOCS1 (Suppressor of 
cytokine signaling 1), miR-150-5p promotes renal fibrosis (Zhou et al. 2013). In immortalized 
cultured podocytes under mechanical stress and streptozotocin induced diabetic rats, miR-124-
3p was reported as a putative regulator of Itga3 (Integrin alpha 3) (Li et al. 2013A, Li et al. 2013B) 
miR-17~92 cluster 
The polycistronic miR-17~92 cluster contains 6 miRNA hairpin precursors and has firstly been 
identified to be a potential oncogene (He et al. 2005) which enhances cell proliferation and is 
highly expressed in lung cancers (Hayashita et al. 2005). The expression of this cluster is 
upregulated in mouse models for polycystic kidney disease, while inactivation of this cluster in 
these mouse models retards kidney cyst growth (Patel et al. 2013). Deletion of this cluster in 
nephron progenitor cells impairs cell proliferation and reduces the number of developing 
nephrons during kidney development (Marrone et al. 2014). Postnatally, the affected mice 
developed signs of kidney disease including albuminuria, podocyte foot process effacement and 
glomerulosclerosis, underlining the importance of the cluster for kidney development. 
miR-21-5p 
miR-21-5p has been shown to play an important role in the progression of fibrosis (for review 
see Patel & Noureddine 2012) as well as in the pathogenesis of acute kidney injury (for review 
see Li et al. 2013C). In a study using mir-21 knockout mice and mice treated with miR-21-5p 
antisense oligonucleotides, miR-21-5p was shown to promote fibrosis of the kidney by silencing 
metabolic pathways (Chau et al. 2012). In a different study using a mouse model for Alport 
nephropathy, miR-21-5p silencing resulted in a milder kidney disease (Gomez et al. 2015). On 
the other hand, it was shown that miR-21-5p can also ameliorate glomerular injury induced by 
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TGF-1 (Transforming growth factor beta 1) and hyperglycemia through repression of 
proapoptotic signals (Lai et al. 2015). These studies indicate that this miRNA may play different 
roles and that a tightly controlled physiological level is necessary for healthy kidney function.  
miR-29 family 
The miR-29 family, expressed in the glomeruli of mice, has been shown to play an important role 
in the regulation of kidney fibrosis. It was reported that miR-29b-3p regulates several collagens 
and related genes in Dahl salt sensitive rats (Liu et al. 2010A). By intravenous injection of LNA-
antisense molecules into SS-13BN rats, expression of several collagen genes in the renal cortex as 
well as in the medulla was upregulated. Furthermore, down regulation of these genes by miR-
29b-3p was proven by luciferase assays. 
miR-29c-3p was found to be a signature miRNA under high glucose conditions in diabetic db/db 
mice (mice with deficient leptin receptor activity, Long et al. 2011). It was proven by luciferase 
assays to target Spry1 (Sprouty homolog 1) which is an inhibitor of RhoA (Ras homolog family 
member A) and Rho kinase activation. Knockdown of miR-29c-3p by intraperitoneal injection of 
antisense oligonucleotides into db/db mice led to reduced matrix accumulation and reduced 
apoptosis in the murine glomeruli.  
In another study, wild-type mice showed a reduced expression of miR-29 family and 
development of progressive renal fibrosis after induction of unilateral ureteral obstructive 
nephropathy, whereas Smad3 (Smad family member 3) knockout mice had an increased 
expression of the miR-29 family along with the absence of fibrosis (Qin et al. 2011). In vitro, 
overexpression of miR-29b-3p inhibited, but knockdown of miR-29 family enhanced TGF-1-
induced expression of collagens I and III in renal tubular cells. Delivery of miR-29b-3p blocked 
progressive renal fibrosis, making it a downstream inhibitor of TGF-/Smad3-mediated fibrosis.  
Furthermore, it was reported by a different group that expression of TGF-1 reduces the 
expression of the whole miR-29 family, thus enhancing the expression of proteins of the 
extracellular matrix (Wang et al. 2012). Ectopic expression of the miR-29 family repressed the 
expression of collagen I and collagen IV. Additionally, low miR-29 family levels in three different 
models of renal fibrosis were found. 
Recently, it was shown that miR-29a-3p levels are lowered in glomeruli from mice with 
streptozotocin induced hyperglycemia (Lin et al. 2014). Transgenic overexpression of miR-29a-3p 
in these diabetic mice improved nephrin levels, podocyte viability and renal function while 
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reducing glomerular fibrosis and inflammation reaction compared to wild-type diabetic mice. 
Overexpression of miR-29a-3p restored the acetylation of nephrin by modulation of HDAC4 
(Histone deacetylase 4), thus ameliorating hyperglycemia induced podocyte dysfunction. 
Taken together, maintenance of healthy miR-29 family levels seems to play an important role in 
the prevention of fibrosis and the maintenance of glomerular structure.  
miR-30 family 
miR-30a-5p was firstly identified to be an important podocyte miRNA in the podocyte specific 
Dicer knockout mice, when it was shown that targets with possible miR-30a-5p binding sites are 
upregulated after the knockout (Shi et al. 2008). Additionally, in situ hybridization showed the 
absence of this mature miRNA in glomeruli after the podocyte specific Dicer knockout (Harvey et 
al. 2008). It was shown that miR-30a-5p knockdown in the developing Xenopus pronephros 
phenocopies the defects caused by a pronephric Dicer knockdown, indicating that miR-30a-5p 
plays an important role in pronephros development (Agrawal et al. 2009). Additionally, a major 
transcriptional regulator during kidney development, Xlim1/Lhx1 (Lim homeobox 1), was shown 
to be targeted by miR-30a-5p. In contrast to wildtype mice, miR-30 family expression was 
lowered in albumin/TGF- transgenic mice who suffered from podocyte apoptosis and 
glomerulosclerosis (Shi et al. 2013). In vitro, TGF- is able to downregulate the miR-30 family in 
wildtype and Smad3 deficient, but not Smad2 (Smad family member 2) or Smad2/Smad3 
deficient cultured podocytes. TGF- induced apoptosis could be hindered by lentiviral 
overexpression of miR-30d-5p. Taken together, these results hint that loss of miR-30 family 
signaling is a specific mechanism of TGF- signaling during glomerulosclerosis. 
Later it was reported that downregulation of miRNA-30 facilitates podocyte injury (Wu et al. 
2014). Podocyte cytoskeletal damage and apoptosis after treatment of cells with TGF- and PAN 
(Puromycin amino-glycoside) were ameliorated by exogenous miR-30 expression and aggravated 
by miR-30 knockdown. It was found that the miR-30 family exerts this protective role by direct 
inhibition of Notch1 (Notch homolog 1, translocation-associated) and the transcription factor 
p53 (Tumor protein P53). Similar results were shown in rats, when PAN treatment lead to a 
downregulation of podocyte miR-30s and podocyte damage, while exogenous overexpression of 
miR-30a-5p ameliorated this phenotype. Additionally, glucocorticoid treatment maintained the 
miR-30 expression levels in TGF- and PAN stressed cultured podocytes (Wu et al. 2014).  
In another study, miR-30a-5p was identified to be upregulated in murine injured podocytes, 
while the inhibition of miR-30a-5p prevented PAN induced podocyte apoptosis (Xie et al. 2015). 
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miR-193a-5p 
In 2013, it was shown that FSGS (Focal segmental glomerulosclerosis) can be induced by an 
upregulation of miR-193a-5p, a miRNA that can downregulate the podocyte transcription factor 
WT1 (Gebeshuber et al. 2013). A transgenic mouse with an inducible miR-193a-5p 
overexpression under the CMV (Cytomegalovirus) promoter showed a severe kidney phenotype 
with foot process effacement after two weeks and focal sclerosis after four weeks of induction. 
WT1, a transcription factor regulating several genes important for maintenance of normal 
podocytes structure and function, was shown to be targeted by miR-193a-5p, as a predicted 
miR-193a-5p binding site at the end of the coding region of the WT1 transcript was confirmed as 
functional. miR-193a-5p upregulation in samples from patients suffering from focal segmental 
glomerulosclerosis was suggested to be a new pathogenic mechanism for genesis of this disease. 
miR-193a-5p was also shown to play a crucial role in the transdifferention of PECs towards a 
podocyte phenotype (Kietzmann et al. 2014). PECs express miR-193a-5p in high levels. A stable 
knockdown of this miRNA in immortalized human PECs leads to a shift towards a podocyte-like 
morphology, expression of podocyte marker proteins like WT1, podocalyxin, synaptopodin, -
actinin-4 and nephrin, and a simultaneous decrease of PEC markers. In a mouse model for rapid 
progressive glomerulosclerosis, the nephrotoxic nephritis, the formation of interglomerular 
crescent could be ameliorated by injection of miR-193a-5p-antisense oligonucleotides, again 
linking miR-193a-5p overexpression to progression of glomerulosclerosis.  
 
1.4 Identification of miRNA targets in podocytes 
The podocyte specific Dicer knockout mice as well as the inducible podocyte specific Drosha 
knockout mice displayed foot process effacement of the affected podocytes as well as loss of 
some of the podocyte specific marker proteins (Harvey et al. 2008, Ho et al. 2008, Shi et al. 2008, 
Zhdanova et al. 2011). Thus, miRNAs play an important role not only in the development, but 
also in the maintenance of podocyte ultrastructure. The structural proteins themselves as well 
as the signaling processes needed to maintain the slit diaphragms or the link of the slit 
diaphragm proteins to the actin cytoskeleton might by targets of miRNA dependent regulation. 
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1.4.1 Proteins important for podocyte structure and function 
Podocytes are highly specialized cells with a unique cytoarchitecture. A lot of proteins have been 
identified to be important for podocyte integrity. The slit diaphragm, a highly specialized 
extracellular structure, is built up between the interdigitating foot processes of two neighboring 
podocytes (Fig. 1.2 C, chapter 1.2.1) by nephrin and the members of the NEPH family. By several 
adapter proteins, like e.g. podocin, CD2AP, NCK1 and NCK2 (Non-catalytic region of tyrosine 
kinase adaptor protein 1/2) and the aPKC-PAR3-PAR6 (atypical protein kinase C - Partitioning 
defective 3 homolog - Partitioning defective 6 homolog) complex, it is linked to the actin 
cytoskeleton. 
 
Fig. 1.6: The podocyte slit diaphragm and podocyte-matrix interactions; Cross section of two neighboring 
foot processes and their slit diaphragm (SD): depiction of proteins forming the slit diaphragm and linking 
the podocytes to the GBM (glomerular basement membrane), maintaining foot process structure and 
function (Machuca et al. 2009, modified); Abbreviations: AGTII: Angiotensin 2, aPKC: Atypical protein 
kinase C, AT1 receptor: Angiotensin II receptor type 1, CD2AP: CD2 associated protein, DAG: 
Diacylglycerol, DG: Dystroglycan, EF: Fenestrated endothelium, ER: Endoplasmic reticulum, EZR: Ezrin, 
FAK: Focal adhesion kinase, FP: Foot-process, GBM: Glomerular basement membrane, IP3: Inositol 
triphosphate, IQGAP-1: IQ motif containing GTPase activating protein, ILK: Integrin-linked kinase, Nck1/2: 
Non-catalytic region of tyrosine kinase adaptor protein 1/2, NHERF1/2: Sodium-hydrogen antiporter 3 
regulator 1/2, Par3: Partitioning defective 3 homolog, Par6: Partitioning defective 6 homolog, PI3K: 
Phosphatidylinositol-4,5-bisphosphate 3-kinase, PIP2: Phosphatidylinositol 4,5-bisphosphate, PLC1: 
Phospholipase C epsilon 1, SD: slit diaphragm, Synpo: Synaptopodin, TRPC6: Transient receptor potential 
cation channel, subfamily C, member 6, WASP: Wiskott-Aldrich syndrome protein 
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The podocyte cytoskeleton and its links to the slit diaphragm as well as to the glomerular 
basement membrane (Fig. 1.6) play an important role for maintenance of the delicate podocyte 
structure, making it a key component of podocyte function (reviewed in Welsh & Saleem, 2012). 
Many mutations in genes coding for slit diaphragm proteins and the regulatory network have 
been identified to be mutated in patients with kidney diseases (reviewed by Machuca et al. 
2009). The slit diaphragm components as well as the cell matrix contacts of the podocytes are 
linked to the actin cytoskeleton via numerous protein interactions and signaling pathways (Fig. 
1.7, reviewed in Faul et al. 2007). The proteins involved in the maintenance of the slit diaphragm 
as well as their interaction partners important for regulation and signaling might be targets of 
miRNA dependent regulation. The main slit diaphragm component, nephrin, has been shown to 
interact with several structural proteins like podocin, Neph1-3, CD2AP, synaptopodin and NCK2 
(Fig. 1.6, left), ultimately linking the slit diaphragm to the actin cytoskeleton. Three small 
GTPases, CDC42 (Cell division control protein 42 homolog), RAC1 (Ras-related C3 botulinum 
toxin substrate 1) and RHOA (Ras homolog gene family, member A) have been shown to play an 
important role in mediating the interplay between the slit diaphragm and the actin cytoskeleton 
(Welsh & Saleem, 2012). Additionally, the podocyte actin cytoskeleton is linked to the 
glomerular basement membrane via several adaptor proteins and regulators (Fig. 1.7, right). 
Mutations in proteins involved in cell-matrix adhesion are known to be responsible for the 
genesis of several kidney diseases (reviewed in Sachs & Sonnenberg, 2013).  
 
Fig. 1.7: Links between the actin cytoskeleton and the slit diaphragm proteins (left) and the cell-matrix 
adhesions in podocytes (right) (Faul et al. 2007, modified); Abbreviations: Arp2/3: Arp2/3 complex, 
CaMKII: Ca2+/calmodulin-dependent protein kinase, CapZ: Capping protein (actin filament) muscle Z-line, 
CD2AP: CD2 associated protein, FAK: Focal adhesion kinase, ILK: Integrin-linked kinase, JAM4: Junctional 
cell adhesion molecule 4, MAGI-1/2: Membrane-associated guanylate kinase, WW and PDZ domain-
containing protein 1/2, NCK1/2: Non-catalytic region of tyrosine kinase adaptor protein 1/2, N-Wasp: 
Neural Wiskott-Aldrich syndrome protein, PINCH-1: Particularly interesting new cysteine-histidine-rich 
protein, Synpo: Synaptopodin, TRPC6: Transient receptor potential cation channel, subfamily C, member 
6, ZO-1: Zonula occludens 1 
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Nephrin 
Nephrin, transcribed from the NPHS1 gene, is the main component of the slit diaphragm and 
was identified in 1998 to be mutated in patients suffering from the congenital nephrotic 
syndrome of the Finnish type (Kestilä et al. 1998). It is a transmembrane protein of the 
immunoglobulin family that consists of a large extracellular portion with eight IgG-like domains, 
a single fibronectin type 4 motif and a cytoplasmic domain with eight tyrosine phosphorylation 
sites (Welsh & Saleem 2012). Nephrin is known to interact with CD2AP (see below) as well as 
with IQGAP (IQ motif containing GTPase activating protein), a protein that can regulate the small 
GTPases CDC42 and RAC1, which are both important for actin cytoskeleton reorganization 
(Brandt & Grosse 2007). Additionally, it is a potential key regulator of actin dynamics via 
recruitment of the actin related Arp2/3 complex and/or formin dependent actin polymerization 
machineries (Brandt & Grosse 2007). Nephrin is also known to regulate the phosphoinositide-3-
OH kinase – protein kinase B pathway, which is important for nephrin mediated actin 
reorganization in podocytes (Welsh & Saleem 2012). 
Podocin 
Podocin, a 42 kDa integral membrane protein transcribed from the NPHS2 gene is exclusively 
expressed in developing and mature podocytes and was firstly described in 2000 (Boute et al. 
2000). It was shown to be localized to the slit diaphragm, interacting with nephrin and CD2AP 
(Schwarz et al. 2001). Podocin has a hairpin like structure with both the N- and the C-terminus 
facing the cytosolic side of the slit diaphragm (Welsh & Saleem 2012). It organizes complexes 
containing the ion channel TRPC6 (Transient receptor potential cation channel, subfamily C, 
member 6), who is known to be a sensor of mechanically and osmotically induced membrane 
stretch, giving the slit diaphragm the ability to act as a mechanosensor (Huber et al. 2007). 
Podocin might also serve as a scaffold protein, linking tight junction proteins to the cytoskeleton 
(Shono et al 2007). 
Neph1 
The protein Neph1, also known as Kirrel1 (Kin of IRRE like protein 1), is structurally related to 
nephrin and belongs to a family of three closely related proteins, Neph1-3, which all share a 
binding motif for podocin (Sellin et al. 2002). Neph1 knockout mice suffer from extreme 
proteinuria and die shortly after birth (Donoviel et al. 2001). Neph1 localizes to the slit 
diaphragms in rat kidneys (Barletta et al. 2003). Hetero dimerization of nephrin and Neph1 
(Barletta et al. 2003, Gerke et al. 2003) as well as homodimeric interaction of nephrin and Neph1 
(Gerke et al. 2003) were observed in cell culture. The direct interaction of nephrin and Neph1 
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was proven by co-immunoprecipitation from murine glomerular lysates (Liu et al. 2003). ZO-1 
(Zonula occludens 1), a tight-junction associated protein known to be localized to the slit 
diaphragms in podocytes, was shown to bind to the PDZ domain (Protein domain found in 
PSD95, Dlg1 and ZO-1) of Neph1 (Huber et al. 2003B). Neph1 is phosphorylated by the kinase 
FYN (see below) which results in the recruitment of the adaptor protein Grb2 (Growth factor 
receptor-bound protein 2), an event important for Neph1 induced actin polymerization (Garg et 
al. 2007). By juxtaposing GRB2 and NCK1/2, the Neph1-nephrin complex augments the efficiency 
of actin polymerization (Garg et al. 2007). Phosphorylation dependent binding of Neph1 to Grb2 
also modulates ERK (Extracellular-signal-regulated kinase) signaling (Harita et al. 2008). The 
Neph1-Nephrin complex binds polarity proteins, Par3, Par6 and aPKC, via the PDZ domain of 
Par3 and conserved carboxyl terminal residues in Neph1 and nephrin to regulate podocyte cell 
polarity (Hartleben et al. 2008). 
Expression of Neph2 was detected at the slit diaphragms of murine podocytes (Gerke et al. 
2005). It was shown to interact with nephrin in vivo, but failed to interact with Neph1. Neph3 
has been shown to homodimerize and heterodimerize with Nephrin as well as Neph1, with 
nephrin and Neph1 or Neph3 trans-interactions promoting cell contacts in cell culture 
experiments (Heikkilä et al. 2011). 
CD2AP 
The protein CD2AP was firstly identified as an adapter protein important for the formation of a 
specialized junction between T cells and antigen presenting cells (Dustin et al. 1998). 
Surprisingly, global knockout mice demonstrated a compromised immune function, but died at 
six to seven weeks of age due to renal failure (Shih et al. 1999). The Cd2ap deficient mice 
exhibits defects in epithelial foot processes accompanied by extra cellular matrix deposition 
(Shih et al. 1999), underlining the importance of CD2AP for the organization of the renal 
filtration barrier. CD2AP is localized to the slit diaphragm in murine glomeruli and could be co-
immunoprecipitated with nephrin using differentiated cells from an immortalized murine 
podocyte cell line (Shih et al. 2001). CD2AP has been shown to directly interact with the actin 
cytoskeleton (Lehtonen et al. 2002). It also interacts with the actin binding proteins CapZ, 
cortactin (linking it to the actin cytoskeleton regulating Arp2/3 complex) and synaptopodin (Faul 
et al. 2007). Furthermore, Nephrin and CD2AP associate with PI3K (Phosphoinositide 3-OH 
kinase) and stimulate AKT (Protein kinase B)–dependent signaling (Huber et al. 2003A). 
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Synaptopodin 
Synaptopodin is a proline-rich actin-associated protein expressed in differentiated podocytes 
(Mundel et al. 1997). The fine structure and function of murine podocytes seems unaffected in 
synaptopodin knockout mice (Deller et al. 2003), but the animals display impaired recovery from 
protamine sulfate induced foot process effacement and LPS (lipopolysaccharide)-induced 
nephrotic syndrome (Asanuma et al. 2005). Synaptopodin was shown to interact with the tight 
junction protein MAGI-1 (Membrane-associated guanylate kinase, WW and PDZ domain-
containing protein 1), and both synaptopodin and -actinin-4 localize to the tight junctions 
when expressed in cell culture (Patrie et al. 2002). Synaptopodin is a regulator of RHOA signaling 
and cell migration in podocytes, inducing stress fibers by competitive blocking of Smurf1 (E3 
ubiquitin-protein ligase) -mediated ubiquitination of RHOA (Asanuma et al. 2006). It can also 
inhibit filopodia formation by blocking CDC42 signaling (Yanagida-Asanuma et al. 2007). 
Therefore, it is an important regulator of actin dynamics in podocytes. 
a-Actinin-4 
The structural proteins of the -actinin family are four closely related proteins that were 
originally described as actin-crosslinking proteins (Otey & Carpen 2004). They are present in 
multiple subcellular regions, including cell-cell and cell-matrix contacts, cellular protrusions, 
lamellipodia and stress fibers, link the cytoskeleton to transmembrane proteins and serve as a 
scaffold connecting the cytoskeleton to diverse signaling pathways (Otey & Carpen 2004). 
Knockout mice as well as mice carrying a mutation in their Actn4 gene known from human 
patients with familial focal segmental glomerulosclerosis developed collapsing glomerulopathy 
(Henderson et al. 2008). The structural protein -actinin-4 is also required for podocyte 
adhesion (Dandapani et al. 2007) and its actin bundling activity is regulated by synaptopodin 
(Asanuma et al. 2005). 
The tyrosine kinase FYN 
The Src (SRC proto-oncogene, non-receptor tyrosine kinase) family tyrosine kinase Fyn binds to 
and phosphorylates nephrin, the main slit diaphragm component (Verma et al. 2003). The 
phosphorylation of nephrin is a prerequisite for the recruitment of Nck adapter proteins which 
leads to the assembly of actin filaments (Verma et al. 2006). Fyn also phosphorylates the slit 
diaphragm component Neph1, thus modulating the binding to Grb2 (Harita et al. 2008). Since 
Nephrin phosphorylation triggers Ca2+ signaling by recruitment and activation of PLCG1, 
(Phospholipase C, gamma 1; Harita et al. 2009), Fyn plays an important role in podocyte 
signaling. 
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NCK1 and NCK2 
NCK1 and NCK2 are two closely related adapter proteins that couple phosphotyrosine signals to 
polypeptides that regulate the actin cytoskeleton (Bladt et al. 2003). They are functionally 
redundant in the sense that mice deficient for either one of the proteins are viable, but double 
knockout mice die at embryonic day 9.5 (Bladt et al. 2003). The Nck adapter proteins control 
actin polymerization through their activation of N-WASP (Neuronal Wiskott–Aldrich syndrome 
protein) and WASP (Wiskott–Aldrich syndrome protein) (Tomasevic et al. 2007). Both are key 
players in regulating the actin cytoskeleton via the ARP2/3 complex (Tomasevic et al. 2007). The 
phosphorylation of the slit diaphragm protein nephrin by the kinase Fyn leads to recruitment of 
the Nck adapter protein via the SH2-SH3 (Src homology 2/3) domain, resulting in the Nck-
dependent assembly of actin filaments (Verma et al. 2006). After phosphorylation, the YDxV 
(Tyrosine – aspartic acid – x – valine) domains in the cytoplasmic tail of nephrin represent 
binding motifs for the SH2 domains of Nck2 proteins (Jones et al. 2006). Since the interaction 
between the Nck proteins and nephrin is crucial for actin reorganization, podocyte specific 
deletion of Nck1 and Nck2 leads to foot process deformations and congenital nephrotic 
syndrome in mice (Jones et al. 2006). Additionally, an inducible podocyte specific deletion of 
both Nck proteins in adult mice leads to proteinuria, glomerulosclerosis and foot process 
effacement with loss of slit diaphragms in the affected animals (Jones et al. 2009). Binding of Nck 
to nephrin leads to recruitment and phosphorylation of PAK (p21 activated kinases), activating 
the enzyme and leading to actin remodeling (Zhu et al. 2010). The members of the PAK family of 
serine/threonine kinases are also targets of the Rho family of small GTPases, RAC1 and CDC42, 
and act as regulators of actin dynamics (Welsh & Saleem 2012).  
LMX1B 
LMX1B is a transcription factor important for maintenance of podocyte architecture in adult 
kidneys (Burghardt et al. 2013), comprising two LIM domains (LIM1, LIM2; domain discovered in 
Lin11, Isl-1, Mec-3) that mediate protein-protein interactions and one homeodomain 
responsible for DNA binding. Mutations in the LMX1B gene cause the nail-patella syndrome 
(Dreyer et al. 1998, McIntosh et al. 1998, Vollrath et al. 1998). This autosomal-dominant 
hereditary disease with an incidence of approximately 1:50,000 is characterized by dysplastic 
nails, absent or hypo plastic kneecaps and chronic nephropathy (Sweeney et al. 2003). In ~40% 
of patients, nephrologic symptoms develop over the course of several decades (Witzgall 2008). 
Cd2ap and podocin mRNA and protein levels were lowered in Lmx1b knockout mice, and binding 
of LMX1B to the promoters of CD2AP and NPHS2 (podocin) could be shown in vitro (Miner et al. 
I N T R O D U C T I O N  
 
33 
 
2002). Microarray studies of glomeruli isolated from inducible podocyte specific Lmx1b knockout 
mice showed significant increase of several actin associated proteins, like Abra (Actin-binding 
Rho activating protein) and Arl4c (ADP-ribosylation factor-like 4C) (Burghardt et al. 2013). 
Chromatin immunoprecipitation in vivo showed that LMX1B binds to FLAT (Far linked AT rich 
elements) elements in the promoter regions of ABRA and ARL4C (Burghardt et al. 2013). It has 
also been described to regulate podocin expression together with the transcription factor FoxC 
(He et al. 2014A). Lmx1b also plays an important role during the development of the embryonic 
central nervous system. It is regulated by an auto regulatory feedback loop with miR-135a2, thus 
modulating Wnt1/Wnt signaling (Proto-oncogene protein Wnt-1/Wnt) (Anderegg et al. 2013). 
1.4.2 Manipulation of miRNA levels in cell culture and animal models 
To study the effect of altered miRNA levels in cell culture and in vivo, several techniques to 
elevate or lower miRNA levels have been established. 
miRNA overexpression 
Elevated miRNA levels in cells can be achieved by overproducing either the pri-miRNA, pre-
miRNA, a short hairpin RNA precursor coding for the desired miRNA or a precursor with a 
shortened stemloop structure for Dicer independent processing mimicking miR-451-5p 
maturation.  
One system of generating miRNA overexpression constructs is the pSuper system (oligoengine) 
originally designed for shRNA (short hairpin RNA) expression (Brummelkamp et al. 2002). In this 
system, the future precursor is annealed from two oligonucleotides and cloned directly into the 
backbone. The system was expanded further, now also offering inducible overexpression vectors 
(pSuperior constructs) containing selection markers or resistance genes, like GFP (Green 
fluorescent protein) expression or puromycin resistance. 
The pSuper system has been used for miRNA overexpression in the present work. 
Antisense oligonucleotides 
Antisense oligonucleotides can be used to downregulate endogenous miRNA levels by binding 
irreversible to their targets. Oligonucleotides with a miRNA antisense sequence and a modified, 
non-degradable backbone, like 2’-O-methylation of the ribose (Meister et al. 2004) or the 2’-O-
methylation of the ribose and a phosphorothioate backbone, the so called “antagomirs” 
(Krützfeldt et al. 2005) have been developed. Both techniques have been applied successfully in 
cell culture or mouse model, respectively (Meister et al. 2004, Krützfeldt et al. 2005). 
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Another example for antisense oligonucleotides are the so-called Vivo-Morpholinos (GeneTools), 
single stranded oligonucleotides of usually 25 nucleotides that can be used for a transient 
miRNA knockdown. They bind to their complementary target sequences through standard 
nucleic acid base-pairing. To prevent their degradation by the cellular machinery, they possess a 
modified backbone, in which the ribose ring is substituted by a morpholine ring and the anionic 
phosphodiester bonds are replaced by an uncharged phosphorodiamidate group. At the 3’-end, 
they possess an octaguanidinium residue which facilitates their transport through the cellular 
plasma membrane (Fig. 1.8). Entering and functioning of Vivo-Morpholinos in cultured cells and 
their delivery to several murine tissues including the small intestine, colon, stomach, liver and 
kidney after intravenous injection could be detected (Morcos et al. 2008). In this study, their 
functionality in different tissues of mice was demonstrated using a test system were a splicing 
error is corrected by Vivo-Morpholino binding. 
 
Fig. 1.8: Chemical structure of a vivo-Morpholino; the molecule consists of a oligonucleotide with a 
modified backbone (top) and a octaguanidinium residue (bottom) linked by a linker 
In the present work, Vivo-Morpholinos were used for a short term treatment of mice, knocking 
down two mature miRNAs expressed in podocytes. 
The sponge method 
Another method for miRNA knockdown are the so called “sponges” (Ebert et al. 2007), 
competitive inhibitor transcripts containing multiple binding sites for a mature miRNA of 
interest. They consist of a destabilized GFP gene and a 3’-UTR with several possible binding sites 
with perfect sequence complementary except for a “bulge” at the positions 9 - 12 (Fig. 1.8 C). 
When expressed in a cell, the sponge transcripts bind RISCs containing distinct miRNAs or 
miRNAs of a certain family, rescuing the original target of these miRNAs from regulation (Fig. 1.8 
A, B). 
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Fig. 1.9: Principle of sponge functionality; (A) In the absence of a sponge, the RISC (red) binds to its target 
genes, leading to transcript degradation (dotted line); (B) By sponge expression, RISCs are sequestered 
and target expression is rescued; (C) miR-21 binding to a complementary sponge via a bulged binding site 
(Ebert & Sharp, 2010B) 
Since a perfect match of the sequences is not required for a physiological miRNA-target binding 
in cells, and since members of a miRNA family possess very similar sequences, a sponge can 
downregulate a whole miRNA family. A broad variety of sponges have been developed targeting 
lots of different miRNA families and have been applied for transient and stable knockdown of 
miRNA levels in cell culture (reviewed by Ebert & Sharp 2010B). They have also been used for in 
vivo studies, e.g. for the knockdown of the miR-183/96/182 cluster, which is known to be highly 
expressed in photoreceptor cells (Zhu et al. 2011). Fertilized mouse eggs were injected with a 
construct harboring five binding sites for each of the mature miRNAs, engineering a transgenic 
sponge mouse (Zhu et al. 2011). Another sponge mouse with a transgenic expression of a 
sponge directed against the miR-29 family was developed to investigate immune responses (Ma 
et al. 2011). Several examples for natural sponges have been discovered until now (reviewed by 
Ebert & Sharp 2010A). The Herpesvirus saimiri expresses a small non-coding RNAs with a miR-
27a-3p binding site that can downregulate this miRNA in the host organism (Cazalla et al. 2010). 
A circular RNA expressed in human and mouse brain containing more than 70 conserved miR-7-
5p binding sites (ciRS-7, circular RNA sponge for miR-7) and a testis specific circular RNA (Sry, 
sex-determining region Y) containing 16 putative miR-138-5p binding sites have been proven to 
be functional (Hansen et al. 2013). 
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In the present work, sponges were designed and tested for miRNA families that are expressed in 
high levels in podocytes. 
TALEN mediated genome editing 
TALE (Transcription activator-like effector) nucleases can be used for directed genomic knockout 
of protein coding genes as well as for miRNA knockout. They comprise a non-specific DNA-
cleaving nuclease, FokI, originally derived from Flavobakterium okeanokoites, fused to a 
sequence specific DNA binding domain (Joung & Sander 2013).  
 
Fig. 1.10: Overview of TALE array nucleases; (A) TALEN consisting of a n-terminal domain, the sequence 
specific TALE array, the c-terminal domain and a FokI nuclease domain; (B) TALEN bound to a specific 
target sequence; (C) TALEN pair leading to a directed double strand break (Joung & Sander 2013, 
modified) 
The DNA-binding array consists of TALEs, which are proteins secreted by Xanthomonas spp. to 
alter gene transcription in host plant cells. The protein array forms a super helix around the DNA 
double strand, the positions 12 and 13 positioned in the major groove of the DNA (Fig. 1.9). The 
amino acids at these two positions determine the selectivity of the TALE array (Tab. 1.1). 
Tab. 1.1: List of amino acid combinations in TALE array monomers that bind specifically to DNA 
bases 
Amino acid combination at positions 12 & 13 Recognized base 
Asn - Asn guanine 
Asn - Ile adenine 
His - Asp cytosine 
Asn - Gly thymine 
 
With a pair of TALENs, both containing a sequence specific array and one part of the dimeric or 
heterodimeric FokI nuclease, a double strand break in the DNA can be induced. It has been 
shown that a heterodimeric split of the FokI nuclease enhances its activity (Doyon et al. 2011). 
The cellular repair mechanisms NHEJ (Non homologous end-joining) and HDR (Homology 
directed repair) can both be used for directed genomic engineering (Joung & Sander 2013). NHEJ 
normally leads to deletions of several bases or insertions, causing a frame shift in coding genes. 
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It has been shown that knockout of different target genes in Xenopus embryos can lead to a 
wide variety of deletions and insertions (Lei et al. 2012). By offering a donor template to the cells 
for HDR, desired sequence alterations or marker sequences for mutated clone identification can 
be inserted. Identification of knockout clones by PCR detection of the integrated donor cassette 
has been demonstrated (Uhde-Stone et al. 2014). The TALEN technology has been applied 
successfully for directed gene knockout in a broad variety of organisms until now (reviewed by 
Sun & Zhao 2013). By microinjection of TALEN RNA into one cell stage of embryo and transfer to 
pseudo pregnant mice, mice with mutations in the genomic loci of mir-146a, mir-10a and mir-
10b were generated (Takada et al. 2013). A library of TALEN plasmids for miRNA knockout in 
human cell was engineered (Kim et al. 2013). A total of 540 pairs of TALENs for 274 miRNA loci 
for specific miRNA knockout were designed. The plasmids coding for these TALENs can be 
obtained via http://www.talenlibrary.net/.  
In the present work, a TALEN pair directed against the human mir-30a locus was used to 
generate a miRNA knockout cell line, to establish this technique investigate effects of miRNA loss 
on cells. 
Tab. 1.2: Overview of methods for miRNA level manipulation  
Method Direction/location of 
manipulation 
Regulatory target 
miRNA overexpression upregulation of cytoplasmic levels one specific mature sequence 
(and opposite strand) 
Knockdown by “sponges” knockdown of cytoplasmic levels family of miRNAs 
Knockdown by antisense 
oligonucleotides 
knockdown of  cytoplasmic levels one specific mature sequence 
Knockout by TALENs  knockout on genomic level one specific locus  
(off-target effects possible) 
Knockout by CRISPR/Cas9 knockout on  genomic level one specific locus 
(off-target effects possible) 
 
Recently, an alternative genomic knockout method, the CRISPR/Cas9 (Clustered regularly 
interspaced short palindromic repeats/CRISPR associated protein 9) system, based on a bacterial 
and archaeal immune response system, has been developed (Jinek et al. 2012). The Cas9 
protein, a nuclease able to induce double strand breaks, can be guided to the target site by a 
chimeric guide RNA. The advantages and disadvantages of the different systems for the present 
work will be discussed in chapter 5.4.  
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1.4.3 Methods for miRNA-mRNA pair identification 
In the last years, several techniques have been developed to identify and characterize specific 
regulatory miRNA-mRNA interactions. 
In silico predictions 
Since miRNAs bind to their targets in a sequence dependent manner, many algorithms have 
been developed to predict putative binding sites for miRNAs in transcripts. The platform 
miRWalk and its update miRWalk2 use eight (DIANAmT, miRanda, miRDB, RNAhybrid, PICTAR4, 
PICTAR5, PITA, RNA22 and Targetscan) or 12 (miRWalk, Microt4, miRanda, mirbridge, miRDB, 
miRMap, miRNAMap, Pictar2, PITA, RNA22, RNAhybrid and Targetscan) different prediction 
algorithms, respectively, to generate sorted lists of possible interaction partners (Dweep et al. 
2011). Since total sequence complementary is not required for binding of mammalian miRNAs 
and mismatches are tolerated outside the miRNA seed sequence under physiological conditions 
(Carthew & Sontheimer 2009), the predictions yield long lists of putative regulatory pairs. Using 
in silico predictions, putative pairs of miRNAs expressed in podocytes and mRNAs coding for 
proteins important for podocyte structure and function were predicted. 
Argonaute immunoprecipitation (Ago-IP) 
Target mRNAs bound and silenced by miRNA mediated RISC binding can be identified by 
performing an immunoprecipitation of the argonaute proteins (Beitzinger et al. 2007). With this 
technique, the Ago bound target mRNAs can be purified and identified, e.g. by qPCR 
(quantitative polymerase chain reaction), Northern Blotting or microarray analyses. 
 
Fig. 1.11: Principle of Ago-IP experiment; The RISCs are bound by magnetic beads coupled Ago specific 
antibodies; after clean-up of the complexes by magnetic extraction, the RNA is isolated by protein 
degradation and further analyzed (Long et al. 2012, modified) 
To increase the yield of a protein-RNA complex immunoprecipitation, the complexes can be 
crosslinked with UV (Ultra violet) light. These CLIP (Cross-linking and immunoprecipitation) 
protocols (Ule et al. 2003) can be combined with Ago-IP (Jaskiewicz et al. 2012). In addition, the 
isolated RNAs can be further analyzed by high-throughput sequencing, the HITS-CLIP (High-
throughput sequencing of RNA isolated by crosslinking immunoprecipitation; Licatalosi et al. 
2008). 
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In the present work, miRNA regulated mRNAs were isolated by Ago-IP using hPCLs, mPCLs and 
freshly isolated murine podocytes. 
Luciferase reporter assays 
The susceptibility of a 3‘-UTR for regulation by miRNAs can be tested by luciferase assays, e.g. 
with the pMir-REPORT system (Ambion, modified G. Meister). The 3’-UTR of a putative target 
gene is cloned behind a luciferase gene, which is located on the same plasmid as an untargeted 
renilla luciferase serving as internal control (Fig. 1.11 A). The expression level of luciferase 
protein, which can be measured with the help of a chemo luminescence producing reaction, is 
dependent on the characteristics of the 3’-UTR. By overexpression of the assumed miRNA 
binding partner and/or mutation of the supposed binding site, the levels of luciferase are 
affected and the functionality of a predicted miRNA-mRNA binding pair can be tested in cell 
culture (Fig. 1.11 B). 
 
Fig. 1.12: Principle of miRNA binding Luciferase Assay; (A) Plasmid coding for firefly luciferase containing 
3’-UTR of a putative target gene and untargeted renilla luciferase as control; (B) Situation in cell for 
luciferase assay: cotransfection of cells with luciferase reporter plasmid and miRNA overexpression 
plasmid; if binding of the miRNA to the 3’-UTR occurs, the firefly level is downregulated 
By cotransfection of luciferase reporter constructs and miRNA overexpression constructs into 
cells, binding of predicted regulatory pairs of miRNAs and mRNAs were analyzed in the present 
work. 
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2 AIMS OF THIS WORK 
Due to the improvement of sequencing techniques in the last decade, thousands of miRNAs 
have been identified to be expressed in tissues and organs of many species. From different 
studies working with mice harboring a podocyte specific knockout for miRNA processing 
enzymes (Harvey et al. 2008, Ho et al. 2008, Shi et al. 2008, Zhdanova et al. 2011), it is known 
that miRNAs are important for development as well as for maintenance of podocyte structure 
and function. However, little is known yet about the precise roles of distinct miRNAs in 
maintenance of podocyte structure and function and their respective target mRNAs. Since the 
complex cytoarchitecture of the podocyte foot processes is lost in the Dicer and Drosha 
knockout mice, the proteins building up and stabilizing the slit diaphragms in-between the foot 
processes might be targets for miRNA dependent regulation. 
The aims of the present work were the identification of the podocyte miRNAs essential for the 
maintenance of the slit diaphragm in healthy podocytes and their regulatory miRNA-mRNA pairs 
in order to elucidate the processes leading to podocyte injury and foot process effacement after 
dysregulation of miRNA levels as seen in the Dicer and Drosha knockout mice. 
Many earlier studies as well as the initial experiments of the present work used isolated 
glomeruli, samples consisting of three different cell types. Thus, the first goal of the present 
work was the generation of a podocyte specific reporter mouse using the double fluorescent Cre 
reporter mouse (Muzumdar et al. 2007) to isolate a clean podocyte population from the 
glomerular sample. To elucidate the role miRNAs play in adult podocytes, two strategies were 
applied. An overview of the miRNAs expressed in mammalian podocytes was generated by deep 
sequencing profiles. Putative miRNA-mRNA pairs between miRNAs enriched in podocytes and 
targets known to be important for podocyte structure and function were generated by in silico 
predictions. To validate these predicted mRNA targets, Ago-IP combined with qPCR detection of 
predicted targets and luciferase assays for the identification of binding sites were performed. In 
a second approach, miRNA regulated mRNAs in podocytes were identified by Ago-IP using 
freshly isolated murine podocytes followed by a focused microarray detection of the RISC bound 
targets. Additionally, different techniques for miRNA level manipulation were applied in vivo and 
in cell culture for functional analyses of specific miRNAs. 
It is known that miRNA expression can be regulated by transcription factors. The role of the 
transcription factor Lmx1b, known to be important for podocyte function, in the regulation of 
miRNA levels in podocytes was investigated. 
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3 MATERIALS AND METHODS 
3.1 Materials  
3.1.1 Equipment and consumables 
Instruments 
Equipment Source 
Agarose gel electrophoresis chamber “Owl EasyCast B2” Thermo Scientific 
Autoclave “2540 ML” Tuttnauer 
Autoclave “5050 ELV” Tuttnauer 
Blotting Chamber “Trans-Blotr SD Semi-Dry” BioRad 
Blotting Chamber “Tank Blot SE 600” Hoefer 
Centrifuge “Hitachi himac CT15RE” VWR 
Centrifuge “Multifuge 3 L-R” Hereaus 
Centrifuge “Pico” Hereaus 
Chemiluminescence system “Fusion Fx7” Vilber Lourmat 
CO2 incubator for cell culture Binder 
Electroporator “Gene Pulser Xcell Electroporation System" Bio-Rad 
Fluorescence microscope “Axioskop HBO-50” Carl Zeiss 
Fluorescence microscope camera “AxioCam MRC” Carl Zeiss 
Freezers -20°C Privileg 
Freezers -80°C “Herafreeze" Heraeus 
Gel Documentation System “GelDoc XR+” BioRad 
Gel electrophoresis cell “Mini Protean 3” BioRad 
Glassware (bottles, flasks, beakers) Schott; VWR 
Hybridization oven “HB-1000” and “OV3” UVP; Biometra 
Ice machine Ziegra 
Imaging system “FLA-5000” Fujifilm 
Incubator  Heraeus 
Laboratory pH Meter “CG 842” SCHOTT Gerte GmbH 
Laminar flow bench “Lamin Air HA 2448 GS” Heraeus 
Liquid nitrogen container “ARPEGE TP 170” Air Liquide Medical GmbH 
Luminometer “Mithras LB480” Berthold 
Magnetic collector “IMagnet” BD Bioscience 
Magnetic Stirrer “MR3001” Heidolph 
Neubauer counting chamber (depth 0.1 mm) Marienfeld 
pH electrode “SenTix60” WTW 
Phosphor screen “BAS-IP MS 2025” Fujifilm 
Photometer “NanoDrop” ThermoScientific 
Pipettes Brand; Gilson 
Power Supply “PS608” life technologies 
Power Supply “Standard Power Pack 25” Biometra 
qPCR Cycler “LightCycler 480 II” Roche 
Refrigerators SEG, privileg 
Repetitive pipette “HandyStep electronic” Brand 
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Rotating wheel for Eppendorf-tubes Workshop of University 
Screen eraser for phosphor screens Raytest 
Sequencer “HiSeq 1000” Illumina 
Shaking incubator “Kelvitron t” Infors 
Shaking plate “Duomax 1030” Heidolph 
Thermal cycler “MyCycler" Bio-Rad 
Thermoshaker Hartenstein 
UV/Vis Spectrophotometer “Evolution201” ThermoScientific 
Vortexer “Vortex-Genie2” Scientific Industries 
Water deionizer “Seralpur Pro 90 CN” Seral 
Weighing scale “BL 1500 S” Sartorius 
Weighing scale “Kern 770”  Kern & Sohn GmbH 
Consumables 
Consumables Source 
96-well white non-binding plate for luciferase assay Greiner bio-one 
96-well light cycler plate PP Sarstedt 
96-well light cycler plate PP sealing tape Sarstedt 
Autoclave tape Brand 
Bottle top filter for sterile filtration (45µm) Sarstedt 
Cell culture dishes (P3, P6, P10, P15) Sarstedt 
Cell culture flasks (25 cm2, 75 cm2) Sarstedt 
Cell culture plates (12 well, 24 well) Sarstedt 
Cell scraper 39 cm Sarstedt 
Cell strainer 100 µm BD Falcon/Corning 
Chromotography paper  Whatman 
Cuvette for electroporation (Gene Pulser) Bio-Rad 
CryoPure tubes 1.8 ml Sarstedt 
Filter paper for dialysis Millipore 
Filters for sterile filtration (20 µm, 45 µm) Sarstedt 
Glass Pasteur pipettes VWR 
HyBond Membrane GE Healthcare 
Hypodermic needles Braun 
Microscope cover glass 15 mm R. Langenbrinck 
Microscope slides R. Langenbrinck 
Nitrile gloves Kimtech 
PCR cups 0.2 ml Sarstedt 
Parafilm Pechiney Plastic 
Pipette tips Sarstedt 
Pipette tips with filter (RNAse free) Sarstedt 
Polystyrene cuvettes for spectrophotometer Sarstedt 
Roundbottom tube with cell strainer for FACS BD Falcon 
Tubes (15 ml, 50 ml) Sarstedt 
PVDF transfer membrane (0.45 µm) Millipore 
Reaction tubes (1.5 ml, 2 ml) Sarstedt 
Scalpels Hartenstein 
Serological pipettes (1, 2, 5, 10, 25 ml) Sarstedt 
Syringes Brown 
Task wipes Kimtech 
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3.1.2  Chemicals and reagents 
Chemicals 
Chemical Source 
Acetic acid, glacial Sigma 
Agarose (NEEO quality, ultra quality) Roth 
Ampicillin (Sodium-salt) Roth 
APS (Ammoniumpersulfate) Fluka 
ATP (Adenosine triphosphate; 100 mM) ThermoScientific 
ATP powder for luciferase assay substrate PJK 
Beads, Protein G coupled invitrogen by lifetechnologies 
Beads, tosylactivated invitrogen by lifetechnologies 
Boric acid Merck 
BSA (Bovine serum albumin) Roth 
Bromphenol blue Sigma 
-mercaptoethanol Merck 
Chloroforme Merck 
Coelenterazine, 1000x, for luciferase assay PJK 
CoenzymeA for luciferase assay  PJK 
Coomassie Brilliant Blue R-250 Roth 
D-Luciferin for luciferase assay  PJK 
DABCO (1,4-Diazabicyclo[2.2.2]octan) Roth 
DAPI (4′,6-Diamidin-2-phenylindol) Sigma 
DEPC (Diethylpyrocarbonate) Roth 
DMSO (Dimethylsulfoxide) Sigma 
dNTPs (Deoxynucleotide triphosphates) Fermentas 
Doxycyclin hyclate Applichem 
DTT (1,4-Dithio-DL-threitol) Roth 
EDC (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimid Roth 
Ethanol Sigma 
Ethidium bromide Sigma 
Formamide deionized Roth 
Ficoll 400 Serva 
HEPES(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) Roth 
Hydrochloric acid  Fluka 
Hydrogen peroxide, 30% FisherChemical 
Isopropanole Merck 
G-418-sulfate Invitrogen 
Glucose Merck 
Glycerol Roth 
Glycine FisherChemical 
Glycogen Peqlab 
Kanamycin sulfate Applichem 
Magnesiumchloride (MgCl2*6H2O) Merck 
Magnesiumsulfate Merck 
Methanol Roth 
Methimidazole Roth 
Narcoren Merial 
Nonidet P-40 Applichem 
PEI (Polyethylenimine) Polysciences Inc. 
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PFA (Paraformaldehyde) Merck 
PVP (Polyvinylpyrrolidone) Merck 
Propidiumiodide Applichem 
Potassium chloride Merck 
Potassiumdihydrogenphosphate Merck 
Rabbit IgG Sigma 
Puromycine PAA 
SDS (Sodium dodecylsulfate) Serva 
Skim milk powder Sucofin 
Sodium acetate Roth 
Sodium azide Merck 
Sodium citrate*2H2O Merck 
Sodium chloride Merck 
Sodium EDTA Roth 
Sodium fluoride Merck 
Sodiumdihydrogenphosphate *2H2O Roth 
di-Sodiummonohydrogenphosphate *12H2O Merck 
Sodiumhydroxide solution (1M) Merck 
Sodiumhydroxide pellets Merck 
Sucrose Merck 
TEMED (Tetramethylethylenediamine) Roth 
Tricine Roth 
Tris base Sigma 
Triton-X-100 Roth 
Tween 20 Roth 
 
All standard chemicals not listed in the above table were purchased at Merck, Roth or Sigma. 
Premixed chemicals and solutions 
Premixed chemicals and solutions Source 
30% Acrylamide/0.8% Bisacrylamide solution Serva 
Acid Phenol Roth 
ATP [-32P] (radioactively labeled, stabilized (SRP-501)) Hartmann Analytics 
CollagenI (for coverslip coating) Sigma 
DMEM (Dulbecco's modified Eagle's medium) high glucose Sigma 
EDTA solution (pH=8.0, RNAse free) Ambion 
FCS (Fetal calf serum) PAN Biotech 
Glycogen [35µg/µl] Peqlab 
HBSS (Hank’s balanced salt solution) premix powder Sigma 
Horse serum PAA 
Immersol 518F for Microscope   Carl Zeiss 
ITS-G (100x Insulin-Transferrin-Selenium)  life technologies 
LB-Medium (Lennox) mix Roth 
LB-Agar (Lennox) mix for plates Roth 
Passive lysis buffer for Luciferase Assay Promega 
PeqFECT Peqlab 
qPCR Mastermix: Sensifast Sybr No-Rox Bioline 
qPCR Mastermix: LightCycler480 Sybr Green I Roche 
Roti Aqua-Phenol Roth 
Roti-Quant Roth 
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RNAse away Molecular BioProducts 
RPMI medium 1640 with L-Glutamine Sigma 
SuperSignal West Pico for WesternBlots ThermoScientific 
Trifast Peqlab 
TRIS buffer: pH=8.0, RNAse free gibco by life technologies 
Trypsin Sigma-Aldrich 
TurboFECT ThermoScientific 
Western Lightning-ECL Enhanced Luminol Reagent Perkin Elmer 
Western Lightning-ECL Oxidizing Reagent Perkin Elmer 
Urea gel system: Ultra pure sequagel system National diagnostics 3.1.3  Kits, enzymes and markers 
DNA Work 
Kit Name Source 
GeneJET Plasmid Miniprep Kit Thermo Scientific 
QIAGEN Plasmid Midi Kit QIAGEN 
Qiaquick Gel Extraction Kit QIAGEN 
Qiaquick Nucleotide Removal Kit QIAGEN 
RNA Work 
Kit Name Source 
DNAse I Kit QIAGEN 
iScript DNA Synthesis Kit Bio-Rad 
miRNeasy mini Kit QIAGEN 
miRVana miRNA Isolation Kit life technologies 
RNase free DNAse Set QIAGEN 
RNeasy micro Kit QIAGEN 
Enzymes 
 
DNA modifying enzymes and buffers Source 
Alkaline Phosphatase Roche 
DNase I Applichem 
Phusion High-Fidelity DNA Polymerase NEB (New England Biolabs) 
Phusion HF 5x reaction buffer NEB (New England Biolabs) 
Pfu DNA Polymerase Fermentas 
T4 DNA Ligase Fermentas 
T4 DNA Ligase 10x reaction buffer Fermentas 
T4 DNA Ligase NEB (New England Biolabs) 
T4 DNA Ligase 10x reaction buffer NEB (New England Biolabs) 
T4 PNK (Polynucleotide Kinase) NEB (New England Biolabs) 
T4 PNK (Polynucleotide Kinase) 10x reaction buffer NEB (New England Biolabs) 
Taq DNA Polymerase NEB (New England Biolabs) 
Thermopol 10x buffer NEB (New England Biolabs) 
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Restriction enzymes and buffers Source 
ApaI NEB (New England Biolabs) 
BglII Fermentas 
CutSmart 10x reaction buffer NEB (New England Biolabs) 
EcoRI-HF NEB (New England Biolabs) 
HindIII-HF NEB (New England Biolabs) 
Orange buffer 10x reaction buffer Fermentas 
SacI-HF NEB (New England Biolabs) 
SpeI-HF NEB (New England Biolabs) 
XhoI NEB (New England Biolabs) 
 
RNA modifying enzymes Source 
EPAP (E.coli poly-A polymerase) Ambion 
 
Protein modifying enzymes Source 
Pronase E from Streptomyces griseus Sigma 
Proteinase K Merck 
Collagenase Type II Worthington 
Markers 
Markers Source 
2-log DNA Marker (100 - 10000 bp) NEB (New England Biolabs) 
microRNA MArker NEB (New England Biolabs) 
PageRuler Prestained Protein Ladder ThermoScientific 3.1.5 Cells and plasmids 
Cells  
Cell line/Bacterial strain Source 
HEK293T human embryonic kidney cells ATCC 
hPCL human podocyte cell line, AB 8/13 Saleem et al. 2002 
mPCL murine podocyte cell line, E11 Schiwek et al. 2004 
DH5 E. coli strain DSMZ 
TOP10 E. coli strain life technologies 
Plasmids 
Plasmid Resistance Source 
CMV-d2eGFP-empty ampicillin Addgene, Ebert et al. 2007 
CMV-d2eGFP-21 „pSponge“ ampicillin Addgene, Ebert et al. 2007 
Human-hsa-mir-30a_5’TALEN L1 ampicillin www.talenlibrary.net (Kim et al 2013) 
Human-hsa-mir-30a_5’TALEN R1 ampicillin www.talenlibrary.net (Kim et al 2013) 
pMir-Report (modified) ampicillin Ambion, modified (G. Meister) 
(changed promoter CMVTK; Renilla luciferase on same plasmid) 
pSuper (modified resistance) kanamycin oligoengine, modified (G. Meister) 
pWE2 ampicillin, neomycin ATCC, Cockett et al. 1997 
pWE3 ampicillin, puromycin ATCC, Cockett et al. 1997 
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3.1.6 Software 
Programs 
Program Company 
AIDA Image Analyzer v4.27 Raytest 
Bio1D Vilber Lourmat 
Chromas Lite 2.1.1 Technelysium Pty Ltd 
FileMaker Pro 6 FileMaker, Inc. 
Fusion version 15.18 Vilber Lourmat 
Image Reader FLA-5000 V2.0 Fujifilm 
ImageJ 1.46r National Institutes of Health 
ImageLab V5.2 BioRad 
LightCycler 480 1.5.0   Roche 
Microsoft Excel Microsoft 
Microsoft Powerpoint Microsoft 
Microsoft Word Microsoft 
NanoDrop 2000/2000c ThermoScientific 
Snapgene Viewer 2.7.3 GSL Biotech, LL 
Thermo Insight 1.4.40 ThermoScientific 
ZEN (blue edition) Carl Zeiss MicroImaging 
Internet databases and online programs 
Name of database Internet address 
ensembl www.ensembl.org (Cunningham et al. 2015) 
miR2Disease www.mir2disease.org/ (Jiang et al. 2009) 
mirbase www.mirbase.org (Kozomara & Griffiths-Jones 2014; Kozomara & Griffiths-
Jones 2011; Griffiths-Jones et al. 2008; Griffiths-Jones et al. 2006; Griffiths-
Jones 2004) 
Pubmed www.ncbi.nlm.nih.gov/pubmed 
smirnaDB www.mirz.unibas.ch/cloningprofiles (Hausser et al. 2009) 
UCSC genome browser https://genome.ucsc.edu (Kent et al. 2002) 
TarBase v7.0 http://diana.imis.athena-innovation.gr/DianaTools/ (Vlachos et al. 2014) 
Name of program Internet address 
BLAST www.ncbi.nlm.nih.gov/BLAST 
Primer3 http://primer3.ut.ee (Koressaar et al. 2007, Untegasser et al. 2012) 
miRWalk http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk (Dweep et al. 2011) 
miRWalk2 http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/index.html  
(Dweep et al. 2011) 3.1.7 Prepared solutions and buffers 
50x Denhardt’s solution:  1%   Ficoll 400 
1%   PVP 
1%   BSA 
in H2O  
 
10x DNA loading dye:  50%  glycerol 
0.25%  Bromphenolblue 
     20 mM EDTA 
     in H2O 
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LB-Agar plates (Lennox):  35 g   premixed powder 
     in 1 l H2O 
 
LB-Medium (Lennox):  20 g   premixed powder 
     in 1 l H2O 
 
10x PBS buffer:   137 mM  NaCl 
2.7 mM  KCl 
10 mM  Na2HPO4 
2 mM  KH2PO4 
in H2O, adjusted to pH=7.4 
 
20x SSC buffer:   3 M  NaCl 
     300 mM Na3Citrat 
in H2O, adjusted to pH=7.0 with HCl  
 
10% SDS solution:   347 mM SDS 
     in H2O 
 
50xTAE buffer:   2 M   Tris 
     100 mM  EDTA 
     in H2O, adjusted to pH = 8.0 with acetic acid 
 
10x TBE buffer:   890 mM  Tris base 
890 mM  Boric acid 
20 mM  EDTA 
     in H2O 
Prepared buffers and solutions for protein gel electrophoresis 
4x Lower Tris buffer:    1.5 M Tris, pH = 8.8 
       0.4% SDS 
       in H2O 
 
4x Upper Tris buffer:    0.5 M Tris, pH=6.8 
       0.4% SDS 
       in H2O 
 
10% acrylamide separating gel solution: 30% Acrylamide/0.8% Bisacrylamide  7.2 ml  
       4x Lower Tris buffer   4.5 ml 
       H2O       6.3 ml  
       10% APS in H2O    50 µl 
       TEMED     10 µl 
 
Stacking gel solution:    30% Acrylamide/0.8% Bisacrylamide 1.3 ml  
       4x Upper Tris Buffer   2.5 ml 
       H2O      6.1 ml  
       10% APS in H2O    50 µl   
       TEMED      10 µl   
 
 
 
M A T E R I A L S  A N D  M E T H O D S  
 
49 
 
1x SDS gel running buffer:   0.19 M  glycine 
       25 mM Tris-Cl 
       3.5 mM SDS 
       in H2O 
 
5x Laemmli sample buffer:   60  mM Tris-Cl pH 6.8 
2%   SDS 
10%   glycerol 
5%   β-mercaptoethanol 
0.01%   bromophenol blue 
in H2O 
 
Coomassie blue staining solution:  3 mM   Coomassie Brilliant Blue R-250 
       45%  methanol 
       10%   acetic acid 
       in H2O 
 
Coomassie blue destaining solution:  45%  methanol 
       10%   acetic acid 
       in H2O 3.1.8 External services 
All oligonucleotides used in this work were synthesized by Metabion, Planegg/Steinkirchen. The 
sponge sequences were ordered as genes in a plasmid from Geneart, Regensburg.  
3.2 Cell Culture Work 
3.2.1 General handling of cells 
Cell cultures are maintained in a CO2-incubator at 95% relative humidity and 5% CO2. To avoid 
contamination, all cell culture work is performed under sterile conditions in a laminar flow 
bench. All solutions to be used are bought sterile, autoclaved at 121°C or sterile filtered. All 
plastic ware used in cell culture is bought sterile or autoclaved at 121°C.  
3.2.2 Culturing of cells 
Human podocyte cell line 
The hPCL (human podocyte cell line) “8/13” was originally established in the lab of P. Mundel 
(Saleem et al. 2002). The cells are cultivated in RPMI 1640 medium with 5% FCS (Fetal calf 
serum) and 1x ITS-G (Insulin-Transferrin-Selenium) under permissive conditions at 33°C and 
5% CO2. The medium is changed every two to three days. After growing to ca. 80% confluency, 
cells are detached with trypsin every four to five days and subcultured at 1:5 - 1:6. For 
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differentiation, the cells are seeded at 7200 cells/cm2. The cells are shifted to a higher 
temperature of 37°C 24 h after seeding, and the growth medium is changed every two to three 
days. Cells used for immunostaining are cultured on collagen I coated glass slides. 
Murine podocyte cell line 
The mPCL (murine podocyte cell line) “E11” was originally established in the lab of K. Endlich 
(Schiwek et al. 2004). The cells are cultivated in RPMI 1640 medium with 5% FCS under 
permissive conditions at 33°C and 5% CO2. The medium is changed every two to three days. 
After growing to ca. 80% confluency, cells are detached with trypsin every four to five days and 
subcultured at 1:5 - 1:6. 
HEK293T cells 
The HEK293T cells are cultured in DMEM medium with 5% FCS at 37°C and 5% CO2. The medium 
is changed every two to three days. After growing to ca. 80% confluency, cells are detached with 
trypsin every four to five days and subcultured at 1:10 – 1:20. 
3.2.3 Freezing and thawing of cells 
Freezing of cells  
For freezing, cells are grown in a T75 flask to 80 - 90% confluency. The cells are once washed 
with 1x PBS and afterwards incubated with 1 ml of trypsin for 5 min at 33°C or 37°C, 
respectively. The cells are resuspended in growth medium (RPMI 1640 or DMEM with 10% FCS) 
and centrifuged (300 xg, 5 min, 4°C). The cell pellet is resuspended in 3 ml freezing medium (FCS 
containing 10% DMSO (Dimethyl sulfoxide)) and separated into three cryovials. The cells are 
slowly frozen down to - 80°C and short term stored at - 80°C, long term stored in liquid nitrogen. 
Thawing of cells 
The cryovial containing the frozen cells is thawed and rapidly brought to room temperature. The 
cell suspension is diluted in 10 ml of growth medium (RPMI 1640 or DMEM with 10% FCS) and 
centrifuged (300 xg, 5 min, 4°C). After resuspending the cell pellet in growth medium, the cells 
are seeded in two to three T25 flasks at different densities. The cells recovering the fastest are 
used for future subculturing.  
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3.2.4 Harvesting of cells 
For RNA preparation, proliferating cells are harvested 24 h after seeding, whereas differentiated 
cells are harvested 14 days after the temperature shift to 37°C. Cells are washed twice with ice-
cold 1x PBS and scraped from the plate. The cell suspension is centrifuged (350 xg, 10 min, 4°C). 
The cell pellet is then shock-frosted in liquid nitrogen and stored at - 80°C. 
3.2.5 Immunostaining of cells 
All steps of the staining protocol are carried out at room temperature (RT). Prior to staining, 
proliferating and differentiated hPCLs are washed twice with 1x PBS. Cells are fixed with 4% PFA 
(Paraformaldehyde) for 8 min and washed three times with 1x PBS. After permeabilization with 
0.05% Triton-X-100 in 1x PBS for 30 min, cells are blocked for 30 min with 5% horse serum in 
1x PBS. Cells are incubated with the primary antibody diluted in 5% horse serum in 1x PBS 
according to the following table for 2 h. After washing three times for 5 min with 1x PBS, cells 
are incubated with the secondary antibody diluted according to the following table in 5% horse 
serum in 1x PBS for 30 min. After washing three times with 1x PBS, nuclei are DAPI (4′, 6-
Diamidin-2-phenylindol) stained by incubation with DAPI working solution ( = 0.17 µg/ml) for 
5 min. After washing with 1x PBS three times for 5 min, cells are mounted on glass slides. Cells 
are analyzed by fluorescence microscopy with a 40x oil objective. Samples only treated with the 
secondary antibodies served as controls. 
Tab. 3.1: Antibodies used in immunofluorescence staining  
3.3 Mouse Work 
3.3.1 Used and generated mouse lines 
The mice are kept in the animal lab of the University of Regensburg with unlimited access to 
drinking water and complete food in a 12 h day/night cycle. Mice are mated from the age of 
twelve weeks, pups are separated from the mothers between 21 - 28 days of age. 
Primary antibody  Dilution 
 -Nephrin from guinea pig (BP5030, Acris) 1 : 100 
 -Actinin-4 from rabbit (0042-05, Immunoglobe) 1 : 200 
 -Synaptopodin from rabbit (SC-50459, Santa Cruz 1 : 200 
Secondary antibody  Dilution 
Alexa Fluor 488  -guinea pig from goat (A11073, Molecular Probes) 1 : 200 
Alexa Fluor 488 -rabbit  from goat (A11008, invitrogen) 1 : 200 
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mT/mG x P2.5 Cre 
To generate a mouse strain with sortable podocytes, a mouse in which the expression of the Cre 
recombinase was placed under the regulation of a 2.5 kb fragment of the human NPHS2 
(podocin) promoter (Möller et al. 2003) is crossed with a double fluorescent Cre reporter mouse 
containing the mT/mG cassette (Muzumdar et al. 2007). This mouse expresses membrane-
targeted tandem dimer Tomato (mT) in all cells without Cre expression and monomeric green 
fluorescent protein (mG) after Cre mediated excision of the Tomato cassette in Cre expressing 
cells. This allows FACS (Fluorescent activated cell sorting) analysis of the green fluorescent 
podocytes isolated from murine glomeruli.  
P2.5 rtTA x LC1 x Lmx1b flox 
For isolation of Lmx1b knockout glomeruli, inducible, podocyte specific Lmx1b knockout mice 
(Burghardt et al. 2013) are used. In these mice, two loxP sites are inserted in the Lmx1b gene 
upstream of exon 4 and downstream of exon 6, respectively. The Cre recombinase is controlled 
by the TetOn system, a promoter activated by rtTA (reverse tetracycline transactivator). rtTA is 
placed under the control of the podocyte specific P2.5 promoter that contains a 2.5 kb fragment 
of the promoter of the human NPHS2 gene. Animals not harboring the Cre recombinase gene 
are used as control animals. 
mT/mG x P2.5 rtTA x LC1 x Lmx1b flox 
A mouse harboring all genes for a doxycycline inducible, podocyte specific Lmx1b knockout 
(Burghardt et al. 2013) is crossed with a double fluorescent Cre reporter mouse containing the 
mT/mG cassette (Muzumdar et al. 2007). The generated mouse expresses membrane-targeted 
tandem dimer Tomato (mT) in all cells and wildtype Lmx1b in podocytes prior to Cre mediated 
excision. By induction of podocyte specific Cre expression through administration of doxycycline, 
the tomato cassette as well as the DNA binding domain of Lmx1b is excised from the genome. 
This yields Lmx1b knockout podocytes expressing monomeric GFP, allowing FACS analysis of the 
green fluorescent Lmx1b knockout podocytes isolated from murine glomeruli. Animals with 
wildtype Lmx1b genes not harboring the loxP sites for Cre recombinase recognition are used as 
control animals.  
3.3.2 Genotyping of animals 
All laboratory animals are genotyped by PCR using genomic DNA isolated from tail biopsies. 
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Isolation of genomic DNA of laboratory animals 
Tail buffer:   100 mM TRIS buffer (pH = 8.0) 
 5 mM  EDTA  
200 mM NaCl 
0.2%  SDS 
    in H2O 
 
Tail biopsies of laboratory animals are digested in 700 µl of tail buffer with 7 µl Proteinase K 
solution (20 mg/ml) overnight at 50°C under rotation. The next day, the sample is vortexed and 
centrifuged (16,000 xg, 30 min, 4°C). The supernatant is mixed with 700 µl of isopropanol and 
the precipitated DNA is transferred to 600 µl of ethanol and pelleted by centrifugation 
(16,000 xg, 15 min, 4°C). After removal of the supernatant, the DNA pellet is dried at 37°C for 
30 min and dissolved overnight at 50°C in 50 µl water under rotation.  
Genotyping of laboratory animals 
Genotypes of animals are determined by PCR using isolated DNA. Dependent on the primer pair, 
PCR is performed with different primers and annealing temperatures (Tab. 3.2) according to the 
following standard protocol using the Taq polymerase. 
Standard reaction mix for genotyping PCR: 
    Thermopol 10x reaction buffer:  2.5 µl 
 Primers (10 µM):    0.5 µl (each) 
 dNTPs (10 mM each):   0.5 µl 
 Taq Polymerase:    0.5 µl 
 Mouse DNA solution (100 ng/µl): 2.5 µl 
 ad 25 µl with H2O 
 
Standard PCR protocol for genotyping:  
95°C  5 min 
    95°C  1 min 
    58–63°C 1 min              35 cycles 
    68°C  1 min 
    68°C  5 min 
 
The PCR products from the genotyping PCRs are analyzed for size by agarose gel electrophoresis. 
2-3 g of agarose is suspended in 100 ml of 1xTAE buffer and heated in a microwave until the 
solution is clear. After adding 50 µl of a 1 mg/ml ethidium bromide solution, the gel is cast in a 
tray with a comb were it solidifies. For each sample, 9 µl of the PCR reaction mixture is mixed 
with one part 10x DNA loading dye. The samples and 10 µl of 2-log DNA marker are loaded into 
the wells. Gel electrophoresis is performed in 1x TAE buffer at 140 V for 60 min. The results are 
recorded with the GelDocXR+ system (BioRad). 
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Tab. 3.2: PCR Primer for mouse genotyping; mut: length of PCR product from animals harboring 
the mutation; wt: length of PCR product from wildtype animals; pos: length of PCR product for 
animals harboring the transgene 
3.3.3 Induction of Lmx1b knockout in the mouse model 
For the inducible Lmx1b knockout, mT/mG x P2.5rtTA x LC1 x LMX1b-flox or 
P2.5rtTA x LC1 x LMX1b-flox mice receive drinking water containing 2 mg/ml doxycycline, a 
structural analog of tetracycline, and 50 mg/ml sucrose for 9 days. To analyze for proteinuria, 
the laboratory animals are placed in metabolic cages on the 8th day of induction to collect urine 
samples. Glomeruli or podocytes are only isolated from knockout animals showing proteinuria 
and control animals not showing proteinuria. 
Check for proteinuria in laboratory animals 
For protein separation, 10% acrylamide gels are cast using the Mini Protean 3 gel system 
(BioRad). The separating gel is cast firstly and covered with a thin layer of water to achieve a 
smooth surface. After 60 min of polymerization, the excessive water is removed, the stacking gel 
is cast and a comb is inserted into the stacking gel. After polymerization for 45 min, the gel is 
inserted into the gel chamber and pre-run at 250 V for 30 min. As samples, 1 µl of spot urine is 
mixed with H2O and 5x Laemmli sample buffer and heated to 95°C for 5 min. As control samples, 
1, 3 and 10 µg of BSA (Bovine serum albumin) are diluted in H2O and treated like the mouse 
urine samples. The samples are loaded on the gel together with 3 µl of prestained protein 
marker. After applying 150 V for 5 min to allow the samples to enter the gel, the voltage is 
increased to 250 V for 30 min. For staining, the gel is placed in Coomassie staining solution and 
shaken slowly (15 min, RT). For destaining, the gel is placed in Coomassie blue destaining 
Primer name Sequence PCR product Annealing 
temperature 
mT/mG forward CTCTGCTGCCTCCTGGCTTCT wt: 330 bp 
mut: 250 bp 
63°C 
mT/mG reverse1 CGAGGCGGATCACAAGCAATA 
mT/mG reverse2 TCAATGGGCGGGGGTCGTT 
Cre forward TGGACATGTTCAGGGATCGC pos: 613 bp 60°C 
Cre reverse TCAGCTACACCAGAGACGGA 
rtTA forward CCCACTTCTGAGACAAGC pos: 188 bp 58°C 
rtTA reverse GGTCAAAGTCGTCAAGGG 
Lmx1b flox forward AGGCTCCATCCATTCTTCTC wt: 220 bp 
mut: 330 bp 
59°C 
Lmx1b flox reverse CCACAATAAGCAAGAGGCAC 
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solution shaking slowly at room temperature. The destaining solution is changed every 15-
20 min until the BSA control samples are all clearly visible. 
3.3.4 Isolation of glomeruli and tubules from mice 
The mouse glomeruli are isolated from laboratory animals by magnetic beads perfusion. The 
isolation protocol used is a modification of a protocol published by Takemoto et al. (2002). Mice 
are anesthetized by intraperitoneal injection of Narcoren (0.12–0.16 mg/g bodyweight) in two to 
three doses. 40 ml of magnetic bead suspension containing 2x106 beads/ml in 1x PBS, are 
injected with a syringe into the left ventricle. The abdominal aorta is opened and the bead 
solution is perfused at a constant pressure of 60 mmHg. After removal of the renal capsule, the 
kidney is cut into small pieces with a scalpel, subsequently resuspended in collagenase A 
digestion solution (1 mg/ml in 1x PBS) and digested for 30 min at 37°C. The sample is pushed 
through a 100 µm cell strainer and the glomeruli are isolated from the filtrate with a magnetic 
collector. The isolated glomeruli are washed 8 - 10 times with 1x PBS to get rid of the tubular 
fragments. The washing fractions 3 - 6 are collected and centrifuged (450 xg, 10 min, 4°C) to 
pellet the tubular fragments that serve as a control cell population in the experiments. The clean 
glomerular fraction and the tubular fraction are shock frozen in liquid nitrogen and stored at       
-80°C. 
3.3.5 Isolation of podocytes and endothelial/mesangial cells from mice  
The mouse podocytes are isolated from laboratory animals by magnetic beads perfusion. The 
isolation protocol used is a modification of a protocol published by Boerries et al. (2013). 
Preparation of perfusion solutions 
HBSS (Hank’s buffered salt solution) is prepared by solving 9.7 g of premixed salt solution 
powder per 1 l of H2O. The buffer is adjusted to pH = 7.4, sterile filtered and stored at 4°C. 
HBSS buffer:   1.26 mM  CaCl2 
 5.37 mM  KCl 
 0.44 mM KH2PO4 
 0.138 M  NaCl 
 0.33 mM Na2HPO4 
 0.81 mM  MgSO4 
 5.55 mM D-Glucose 
 
Bead solution:   2*106 /ml Tosylactivated magnetic beads    
     in HBSS buffer 
 
The beads are washed three times with HBSS before being diluted to the working concentration. 
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Bead solution with enzymes: 2*106 /ml Tosylactivated magnetic beads    
     1 mg/ml Collagenase Type II 
     1 mg/ml Pronase E 
     100 U/ml DNase I 
     in HBSS buffer 
 
Digestion solution:   1 mg/ml Collagenase Type II 
     1 mg/ml Pronase E 
     100 U/ml DNase I 
     in HBSS buffer 
Isolation of glomeruli 
Mice are anesthetized by intraperitoneal injection of Narcoren (0.12 – 0.16 mg/g bodyweight) in 
two to three doses. The kidneys with their adjacent blood vessels are dissected from the mice 
and perfused ex vivo through the arteria renalis with 1 ml HBSS buffer, 4 ml bead solution and 
1 ml bead solution with enzymes per kidney. The capsule is removed and the kidney is minced 
into small pieces using a scalpel, subsequently suspended in 2 ml digestion solution and digested 
at 37°C for 10 min on a shaking rotator plate in an incubator. The digest is filtered through a 
100 µm cell strainer and pelleted by centrifugation (450 xg, 5 min, 4°C). The pellet is 
resuspended in HBSS buffer and transferred to 2 ml cups. The glomeruli are collected using a 
magnetic collector. The collected glomeruli are washed with HBSS buffer four to six times until 
the supernatant is void of tubular fragments. 
Single cell preparation 
The isolated glomeruli are resuspended in 2 ml of digestion solution, and incubated for 45 min at 
37°C in and thermomixer shaking at 1400 rpm. Samples are treated during incubation as follows: 
5 min:  pipetted up and down through glass pipet 
10 min: vortexed and pipetted up and down through glass pipet 
15 min:  sheared through a 27G needle 
20 min:  vortexed and pipetted up and down through glass pipet 
25 min:  pipetted up and down through glass pipet 
30 min: vortexed and pipetted through a 200 µl pipet tip put on a 1000 µl pipet tip  
35 min:  pipetted up and down through glass pipet 
40 min: vortexed and pipetted through a 200 µl pipet tip put on a 1000 µl pipet tip  
45 min:  sheared through a 27G needle 
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Detachment of the green fluorescent podocytes and some red fluorescent endothelial or 
mesangial cells is observed after 45 min by fluorescence microscopy. 
Preparation of FACS samples 
The samples are put on the magnet again to get rid of beads and glomerular structures void of 
podocytes. The supernatants are pooled and sieved through a 40 µm pore size filter. The single 
cells are collected from the suspension by centrifugation (450 xg, 5 min, 4°C) and resuspended in 
475 µl of 1x PBS containing 0.2% FCS. Afterwards, 25 µl propidium iodide solution ( = 1 mg/ml) 
is added to the cell suspension to stain non-viable cells. 
3.3.6 FACS analysis of isolated podocytes 
FACS analysis is performed by Jaqueline Igl (Department for Internal Medicine III: Hematology 
and Internal Oncology, University Hospital Regensburg, Regensburg) using a cell sorter (BD 
FACSAria Ilu sorter, BD Biosciences). Propidium iodide positive cells are discarded, viable green 
and red fluorescent cells are collected. The sorted cells are pelleted by centrifugation (450 xg, 
10 min, 4°C). The supernatant is discarded and the dry cell pellets are either shock frozen in 
liquid nitrogen and stored at -80°C or directly used for RNA preparation (A. Dueck, Department 
of Biochemistry I, University of Regensburg). 
3.4 RNA Work 
3.4.1 General handling of RNA samples 
To avoid degradation of RNA during preparation, water, solutions and buffers to be used in RNA 
preparation are treated with DEPC (Diethylpyrocarbonate, 1 ml/l) overnight followed by 
autoclaving at 121°C. TRIS buffer (1 M; pH = 8.0), and EDTA solution (0.5 M, pH = 8.0) are 
purchased RNase free. Glassware used for RNA preparation is heated to 200°C for 3 h. Plastic 
ware is treated with RNAse Away and rinsed with DEPC-H2O (DEPC treated water) afterwards. 
3.4.2  RNA isolation and quantification 
For further analysis, RNA samples were isolated from cultured cells and freshly isolated murine 
cells. 
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RNA isolation for Northern Blotting 
For Northern Blotting, RNA is isolated from cells stored at -80°C according to the TriFast protocol 
(peqlab). Up to five million cells are resuspended and lysed in 1 ml TriFast solution and 
incubated (5 min, RT). After addition of 0.2 ml chloroform, the tube is shaken by hand for 15 s 
and afterwards incubated (5 min, RT). After centrifugation (12,000 xg, 5 min, RT), the upper 
aqueous phase is transferred to a new cup and mixed with 0.5 ml isopropanol. For RNA 
precipitation, 1 µl of glycogen ( = 35 µg/µl) is added and RNA is precipitated overnight at -20°C. 
The next day, RNA is pelleted by centrifugation (12,000 xg, 15 min, 4°C). The pellet is washed 
twice with 75% ethanol in DEPC-H2O and centrifuged (12,000 xg, 10 min, 4°C). After drying the 
pellet (30 min, 37°C), it is dissolved in 20 – 50 µl DEPC-H2O. The RNA solution is stored at -80°C. 
Its concentration is measured using a NanoDrop photometer. 
Isolation of miRNAs for qPCR 
For qPCR, RNA is isolated from cells frozen at -80°C with the miRVana Kit (Ambion) according to 
the manufacturer’s protocol. Shortly, the cell pellet is resuspended and lysed in 600 µl 
lysis/binding buffer, vortexed and the lysate is incubated with 60 µl of miRNA homogenate 
additive on ice for 10 min. After addition of 600 µl acid Phenol:Chloroform-mixture and 
vortexing for 1 min, the sample is centrifuged (12,000 xg, 5 min, RT). The upper aqueous phase is 
mixed with ethanol in a new cup and the mixture is then passed through the first filter cartridge. 
The eluate is mixed with 533 µl ethanol and passed to a second filter cartridge. Both cartridges 
containing the long and small RNA fraction are then washed three times with 700 µl or 500 µl of 
the washing buffers 1 and 2/3, respectively, by centrifugation (16,000 xg, 1 min, RT). After spin 
drying of the filter for 1 min, the bound RNA is eluted from the filter cartridges with 100 µl DEPC-
H2O preheated to 95°C. The RNA solution is stored at -80°C and the concentration is measured 
using a NanoDrop photometer. 
Isolation of long RNAs for qPCR 
For qPCR, the long RNA fraction (see above) is concentrated and cleaned using the miRNeasy kit 
(Qiagen) combined with the DNase I kit (Qiagen) using a modified protocol. Shortly, the aqueous 
RNA solution is mixed with the double amount of ethanol and passed through a spin column. 
After washing the membrane once with RWT buffer, the sample is incubated on column with 
DNAse I in RDD buffer for 1 h at 28°C. Three washing steps with 350 µl RWT buffer of 500 µl RPE 
buffer, respectively, are followed by spin drying the column for 1 min. The long RNAs are eluted 
with 30 µl DEPC-H2O. The RNA solution is stored at -80°C. The concentration of RNA solutions is 
measured with a NanoDrop photometer.  
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3.4.3 Gel electrophoresis and Northern Blotting 
Gel solution per gel:  Urea concentrate  4.8 ml 
     Urea diluent   4.2 ml 
     Urea buffer   2.0 ml 
     APS (10% in DEPC-H2O) 80 µl   
     TEMED   8 µl   
 
Crosslinking solution:  Methylimidazole  61.25 µl 
     1 M HCl   75 µl 
     EDC     0.18825 g  
    in 6 ml DEPC-H2O 
 
Prehybridization buffer:  20x SSC in DEPC-H2O    15 ml   
     Na2HPO4 solution, pH = 7.2, in DEPC-H2O 1.2 ml   
     10% SDS in DEPC-H2O    42 ml   
     50x Denhardt’s solution in DEPC-H2O  1.2 ml   
 
Blot washing solution 1:  5x SSC buffer 
     1% SDS 
     in DEPC-H2O 
 
Blot washing solution 2:  1x SSC buffer 
     1% SDS 
     in DEPC-H2O 
 
Gel preparation 
miRNAs are separated on 12% denaturing urea polyacrylamide gels cast with premixed solutions 
from the Ultra pure sequagel system. Urea concentrate, urea diluent and gel buffer are mixed 
according to the manufacturer’s protocol (see above). After addition of 160 µl 10% APS 
(Ammonium persulfate) in DEPC-H2O and 16 µl TEMED (Tetramethylethylenediamine), gels are 
cast using the Mini Protean3 gel chambers (BioRad). Gels are left for polymerization for 45 min 
and prerun in 1x TBE buffer in DEPC-H2O at 250 V for 45 min. 
Sample and marker preparation  
For each lane, the desired amount of isolated RNA is diluted with DEPC-H2O to a total sample 
volume of 20 – 30 µl. The sample is mixed with the same amount of RNA loading dye comprising 
formamide with 0.1% bromphenolblue and preheated to 65°C for 5 min. Additionally, 3 µl of the 
microRNA marker are diluted with 17 µl of DEPC-H2O and mixed with 20 µl of RNA loading dye. 
Gel Run and Blotting of miRNAs 
After rinsing the gel pockets, the samples are loaded on the gel and separated at 250 V for 
45 min. The RNA is then blotted semidry in water from the gel onto a Hybond membrane at 20 V 
M A T E R I A L S  A N D  M E T H O D S  
 
60 
 
for 30 min in a Semi-Dry blotting chamber. From bottom to top, the stack consists of 3 layers of 
chromatography paper, the membrane, the gel, and another 3 layers of chromatography paper. 
Crosslinking of miRNAs to the membrane 
The microRNA marker is crosslinked to the membrane by exposure to UV light ( = 312 nm) for 
3 min. Afterwards, the other RNAs were crosslinked to the membrane by immersion with the 
crosslinking solution for 1.5 h at 50°C. 
Preparation of Northern Blot probes 
The oligonucleotides (Tab. 3.3) are labeled using -P32-ATP by addition of a radioactive 
phosphate to the 5’-end of the oligonucleotides by the T4-PNK (Polynucleotide kinase). 
Probe labeling mix:    Marker  U6   miRNAs 
DNA probe  5 µl (20 ng/µl) 1 µl (20 mM) 1 µl (20 mM) 
T4-PNK   1 µl   1 µl   1 µl 
10x PNK buffer 2 µl   2 µl   2 µl 
-P32-ATP  1 µl   1 µl   6 µl 
DEPC-H2O  11 µl   15 µl   10 µl 
 
The probe labeling mix is incubated at 37°C for 45 min and denatured at 65°C for 10 min. The 
labeled probes are cleaned with the Qiaquick nucleotide removal kit (Qiagen) according to the 
manufacturer’s protocol. Shortly, the labeling mixtures are diluted in 200 µl of PNI buffer and 
passed through a spin column by centrifugation (3,380 xg, 1 min, RT). The column is washed two 
times with 500 µl of PE buffer and afterwards spun dry by centrifugation (16,000 xg, 1 min, RT). 
The labeled probe is eluted from the spin column with 100 µl of DEPC-H2O.  
Tab. 3.3: Sequences of probes used for snRNA U6 and miRNA detection in Northern Blotting 
Small RNA to be detected Northern Blotting probe sequence 
hsa/mmu-U6 GCC ATG CTA AAT CTT CTC TGT AT 
hsa/mmu-miR-10a-5p CAC AAA TCC GGA TCT ACA GGG TA 
hsa/mmu-miR-10b-5p CAC AAA TTC GGT TCT ACA GGG TA 
hsa/mmu-miR-19b-3p TCA GTT TTG CAT GGA TTT GCA CA 
hsa/mmu-miR-22-3p GTT CTT CAA CTG GCA GCT T 
hsa/mmu-miR-23a-3p GGA AAT CCC TGG CAA TGT GAT 
hsa/mmu-miR-23b-3p GGT AAT CCC TGG CAA TGT GAT 
hsa/mmu-miR-24-3p CTG TTC CTG CTG AAC TGA GCC A 
hsa/mmu-miR-26a-5p AGC CTA TCC TGG ATT ACT TGA A 
hsa/mmu-miR-27a-3p GCG GAA CTT AGC CAC TGT GAA 
hsa/mmu-miR-27b-3p GCA GAA CTT AGC CAC TGT 
hsa/mmu-miR-29a-3p TAA CCG ATT TCA GAT GGT GCT A 
hsa/mmu-miR-29c-3p TAA CCG ATT TCA AAT GGT GCT A 
hsa/mmu-miR-30a-5p CTT CCA GTC GAG GAT GTT TAC A 
hsa/mmu-miR-30a-3p GCT GCA AAC ATC CGA CTG AAA G 
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Small RNA to be detected Northern Blotting probe sequence 
hsa/mmu-miR-92a-3p CAG GCC GGG ACA AGT GCA ATA 
hsa/mmu-miR-99a-5p CAC AAG ATC GGA TCT ACG GGT T 
hsa/mmu-miR-107-3p TGA TAG CCC TGT ACA ATG CTG CT 
hsa/mmu-miR-130a-3p ATG CCC TTT TAA CAT TGC AC 
hsa/mmu-miR-146b-5p AGC CTA TGG AAT TCA GTT CTC A 
hsa/mmu-miR-148a-3p ACA AAG TTC TGT AGT GCA CTG A 
hsa/mmu-miR-196b-5p CCC AAC AAC AGG AAA CTA CCT A 
hsa-miR-424-3p ATA GCA GCG CCT CAC GTT TTG 
hsa-miR-503-5p CAG AAC TGT TCC CGC TGC TA 
hsa/mmu-miR-542-3p TTT CAG TTA TCA ATC TGT CAC A 
Prehybridization and hybridization of the blot 
After crosslinking, the membrane is cut according to the regions that are to be hybridized with 
the different probes. The marker lane is separated from the sample lanes. The sample lanes are 
cut to separate the locations of the snRNA (small nuclear RNA) U6 and the mature miRNA 
signals. The parts of the blot are prehybridized in hybridization buffer for 1 h at 50°C. 
Afterwards, the labeled probes eluted in DEPC-H2O are added to the hybridization buffers. The 
blots are hybridized slowly shaking at 50°C overnight. 
Washing of the blots and developing of signals 
The next day, blots are washed twice for 10 min with blot washing solution 1 and once for 
10 min with blot washing solution 2. The blots are afterwards covered in plastic film. A storage 
phosphor screen is exposed to the radioactive signals of the blots and developed with an image 
reader. The time of exposure was 2 h for the U6 signal and the marker signal. For the miRNA 
signals, the exposure time was 9 - 10 days for the northern blots with RNA isolated from murine 
glomeruli and tubules and from HEK293T cells and 14 days for the northern blots with RNA 
isolated from hPCLs. The intensity of the signals was measured with the Bio1D program (Vilber 
Lourmat). 
3.4.4 Quantitative real-time PCR (qPCR) 
cDNA preparation for miRNA qPCR  
To generate templates long enough for qPCR from isolated miRNAs, a miRNA elongation 
protocol (Hurteau et al. 2006) is used. In the first step, the miRNA is elongated by addition of a 
poly-A-tail by the EPAP (Ambion). Afterwards, an adapter primer consisting of a poly-T-sequence 
and a universal sequence is annealed to the poly-A-tail. Before cDNA synthesis, the reaction mix 
is split into the sample and a nonRT control sample, in which everything but the reverse 
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transcriptase is added. The poly-A-poly-T-double strand is then used as a starting point for cDNA 
generation with the iScript Select cDNA synthesis kit (BioRad). All synthesis steps are performed 
in a PCR cycler. 
miRNA elongation reaction mix:   
 Isolated small RNAs   0.2-0.5 µg 
    5x EPAP buffer    4 µl 
    MnCl2 (25 mM)    2 µl 
    ATP (10 mM)    2 µl 
    EPAP      0.8 µl 
    ad 20 µl with DEPC-H2O 
 
The miRNA elongation reaction mix is incubated for Poly-A-tail synthesis at 37°C for 60 min. 
Afterwards, the reaction mix is denatured at 65°C for 15 min and rapidly cooled to 4°C. 
Poly-A-tail annealing reaction mix: 
 miRNA elongation reaction mix  20 µl 
 Universal adapter primer   1 µl 
 
The Poly-A-tail annealing reaction mix is heated to 65°C for 5 min and afterwards cooled down 
1°C/min until the sample reaches 4°C. 
cDNA synthesis reaction mix:   
 Poly-A-tail reaction mix   18 µl  
    iScript select 5x reaction mix  5 µl  
    iScript reverse transcriptase  1.25 µl 
    DEPC-H2O     0.75 µl 
 
NonRT control synthesis reaction mix:  
 Poly-A-tail reaction mix   3 µl 
    iScript select 5x reaction mix  1.25 µl  
    DEPC-H2O     0.75 µl 
 
After incubating the cDNA synthesis reaction mix at 25°C for 5 min, the cDNA synthesis is 
performed by incubation at 42°C for 60 min. After denaturation of the reaction mix at 85°C for 
5 min, it is rapidly cooled to 4°C. 
cDNA preparation for long RNA qPCR 
The concentration of RNA solutions is measured with a NanoDrop photometer. cDNA from 
isolated long RNA species is synthesized with the iScript Select cDNA synthesis kit (BioRad) 
according to the following protocol. After incubating the cDNA synthesis protocol at 25°C for 
5 min, the cDNA synthesis is performed by incubation at 42°C for 60 min. After denaturation of 
the reaction mix at 85°C for 5 min, it is rapidly cooled to 4°C. The cDNA synthesis is performed in 
a PCR cycler (BioRad). 
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cDNA synthesis reaction mix:     cDNA sample nonRT control 
Isolated long RNA   <1 µg   <1 µg 
iScript select 5x reaction mix 4 µl   4 µl 
    random primer mix  2 µl   2 µl 
iScript reverse transcriptase 1 µl   ----- 
    DEPC-H2O    3 µl   4 µl 
RT-qPCR 
For relative quantification by qPCR, the cDNAs reverse transcribed from short or long RNA is 
prediluted 1:5 to 1:10 depending on the amount of RNA used. Samples to be compared are 
diluted equally. The qPCR analyses are performed in a LightCycler480II in 96 well plates. 
qPCR reaction mix: cDNA sample  2 µl 
    Primer forward  1 µl 
    Primer reverse  1 µl 
    H2O    6 µl 
    qPCR Mastermix  10 µl 
 
Standard program for qPCR:   
95°C  7 min 
    95°C  10 s 
    55–62°C 10 s             55 cycles 
    68°C  10 s 
    95°C  5 s 
    40°C  1 min            melting curve 
    +2.2°C/min until 97°C 
    → 4°C/∞ 
 
The relative quantification of cDNAs synthetized from mRNAs (Tab. 3.4) is performed at 60°C. 
Most miRNAs (Tab. 3.5) are analyzed with an annealing temperature of 62°C, while relative 
quantification of miR-146b-5p and miR-322-3p is performed with an annealing temperature of 
55°C, and relative quantification of miR-130a-3p, miR-148a-3p and miR-542-3p is performed 
with an annealing temperature of 59°C. The melting curves in all wells are monitored to exclude 
the synthesis of more than one product. For every RNA sample isolated, a non-RT control is 
treated like the cDNA sample. Only samples where the non-RT control does not yield a product 
are used for relative quantification. In every relative quantification run, the efficiencies of all 
primer pairs used are measured with the help of dilution standard curves from the used cDNAs. 
The relative quantification of the unknown samples is performed using the efficiencies measured 
in the same run with the LightCycler software, version 1.5.0.39. As internal standards for relative 
quantification, snRNA U6 is used for relative quantification of small RNAs and LaminA/C is used 
as an internal standard for relative quantification of long RNAs. 
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Tab. 3.4: Primer for detection of long transcripts in human (h) and murine (m) samples by qPCR 
Primer name Sequence  
hCD2AP-Forw TGG AGC TGA AAG TGG GAG T 
hCD2AP-Rev TTG AGG GAA ACA GTC CCA AC 
mCd2ap-Forw AAC TCA CAA CGC TCA GGA GGA 
mCd2ap-Rev TGT GCA ACT GAT CCG GGA 
mCD31-Forw AGC CAG TAG CAT CAT GGT CA 
mCD31-Rev AGC AGG ACA GGT CCA ACA AC 
hE2F1-Forw GGT CCC TGA GCT GTT CTT CT 
hE2F1-Rev CTT CCC TCA CTT TCC CAA TA 
mE2F1-Forw GCA CGA TCC ATA CCC TCT GT 
mE2F1-Rev CAA CAT CCT TCC CAT TTT GG 
hFYN-Forw GAA CGC CCC ACT TTT GAG TA 
hFYN-Rev GGC CTT ACA GGT TTT CAC CA 
mFyn-Forw TCT GCG ATC AGC AAA CAT TC 
mFyn-Rev CTT CAA TCA ACC GAG CCA AT 
hLamin-Forw CTC GTC GTC CTC AAC CAC AGT 
hLamin-Rev TGC GTA CGG CTC TCA TCA ACT 
mLamin-Forw TGA CTT GGT GTG GAA GGC G 
mLamin-Rev CAG TGG AGT TGA TGA GAG CGG 
mLmx1b-Forw GAG CAA AGA TGA AGA AGC TGG C 
mLmx1b-Rev GGC CAC GAT CTG CTG CTG 
hNCK2-Forw ACC GCA TCT ACG ACC TCA AC 
hNCK2-Rev CAC CAG GGA CAA CTC ATC CT 
mNck2-Forw CAA GGT GTC CTC AGA CAG CA 
mNck2-Rev TTG GCA CGC AGT TAC AAG AG 
hNEPH1-Forw CTT TGG CCT AGG GAC ATG AA 
hNEPH1-Rev TGC AGA CAA CAG AGG GAC TG 
mNeph1-Forw GGA GGG TGC AAC ATT CAG TT 
mNeph1-Rev TGT GGC CTC TGT CTT CTG TG 
hNephrin-Forw CAC TCA GAG CTC CAC GGT CA 
hNephrin-Rev GAG CGG TAA TAC GGC TCT GC 
hNOTCH1-Forw ATG ACC AGT GGC TAC GTG TG 
hNOTCH1-Rev ATA CAC GTG CCC TGG TTC AG 
hPodocin-Forw CTC CCA GCA ACA GAA CTC AGG 
hPodocin-Rev GTG GCT CAA CAG GTT TGG AAG 
mPodocin-Forw GCG AGC GAC CAG AGG AAG 
mPodocin-Rev GAG GCG AGG ACA AGA AGC C 
 
Tab. 3.5: Primers for miRNA detection by qPCR 
Primer name Sequence  
URT-Adapter AAC GAG ACG ACG ACA GAC TTT TTT TTT TTT TTT  
Universal reverse primer AAC GAG ACG ACG ACA GAC TTT 
cxcr4-control TGT TAG CTT TCT GAA AAC TT 
snRNA-U6 Forward CGC TTC GGC AGC ACA TAT AC 
snRNA-U6 Reverse TTC ACG AAT TTG CGT GTC AT 
hsa/mmu-miR-10a-5p CCC TGT AGA TCC GAA TTT GTG 
hsa/mmu-miR-21-5p AGC TTA TCA GAC TGA TGT TGA 
hsa/mmu-miR-22-3p AAG CTG CCA GTT GAA GAA C 
hsa/mmu-miR-23a-3p ATC ACA TTG CCA GGG ATT TC 
hsa/mmu-miR-24-3p GGC TCA GTT CAG CAG GAA CA 
hsa/mmu-miR-26a-5p TTC AAG TAA TCC AGG ATA GGC 
hsa/mmu-miR-27a-3p TTC ACA GTG GCT AAG TTC C 
hsa/mmu-miR-29a-3p AGC ACC ATC TGA AAT CGG TTA 
hsa/mmu-miR-30a-5p TGT AAA CAT CCT CGA CTG GAA G 
hsa/mmu-miR-30b-5p TGT AAA CAT CCT ACA CTC AGC 
hsa/mmu-miR-30c-5p TGT AAA CAT CCT ACA CTC TCA GC 
hsa/mmu-miR-30e-5p TGT AAA CAT CCT TGA CTG GAA G 
hsa/mmu-miR-92a-3p GCA CTT GTC CCG GCC TGT 
hsa/mmu-miR-99a-5p AAC CCG TAG ATC CGA TCT TGT 
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Primer name Sequence  
hsa/mmu-miR-107-3p AGC AGC ATT GTA CAG GGC TA 
hsa/mmu-miR-126-3p TCG TAC CGT GAG TAA TAA TGC 
hsa/mmu-miR-127-3p CGG ATC CGT CTG AGC TTG 
hsa/mmu-miR-130a-3p AGT GCA ATG TTA AAA GGG CAT 
hsa/mmu-miR-143-3p TGA GAT GAA GCA CTG TAG C 
hsa/mmu-miR-145-5p GTC CAG TTT TCC CAG GAA TC 
hsa/mmu-miR-146b-5p GAA CTG AAT TCC ATA GGC T 
hsa/mmu-miR-148a-3p TCA GTG CAC TAC AGA ACT TT 
hsa/mmu-miR-191-5p AAC GGA ATC CCA AAA GCA G 
hsa/mmu-miR-192-5p CTG ACC TAT GAA TTG ACA GC 
hsa/mmu-miR-200a-3p AAC ACT GTC TGG TAA CGA TGT 
hsa/mmu-miR-200b-3p AAT ACT GCC TGG TAA TGA TGA 
hsa/mmu-miR-200c-3p ATA CTG CCG GGT AAT GAT GG 
hsa/mmu-miR-203-3p GTG AAA TGT TTA GGA CCA CT 
hsa/mmu-miR-210-3p CTG TGC GTG TGA CAG CGG 
mmu-miR-322-3p ACA TGA AGC GCT GCA ACA 
mmu-miR-351-5p AGG AGC CCT TTG AGC CTG 
hsa/mmu-miR-429-3p TAA TAC TGT CTG GTA ATG C 
mmu-miR-503-3p TAG CAG CGG GAA CAG TAC TG 
hsa/mmu-miR-542-3p TGT GAC AGA TTG ATA ACT GAA A 
hsa/mmu-miR-1839-5p AAG GTA GAT AGA ACA GGT CTT G 
3.5 In silico predictions of putative miRNA-mRNA pairs 
For in silico predictions of putative miRNA-mRNA pairs, the free online prediction programs 
miRWalk and miRWalk2 are used. In addition to being a prediction algorithm itself, miRWalk also 
uses eight additional programs (DIANAmT, miRanda, miRDB, RNAhybrid, PICTAR4, PICTAR5, 
PITA, RNA22 and Targetscan), to generate a list showing the number of programs that predict a 
certain interaction. miRWalk2 is the succeeding program that is able to compare the prediction 
results of twelve programs (miRWalk, Microt4, miRanda, mirbridge, miRDB, miRMap, 
miRNAMap, Pictar2, PITA, RNA22, RNAhybrid and Targetscan). Since prediction of possible 
targets yields enormous lists of possible protein targets, the predictions are done the other way 
round, predicting miRNAs that are able to bind to a specific 3’-UTR. The miRNA lists are searched 
for the candidate miRNAs and sorted according to the number of programs predicting a certain 
interaction. 
3.6  Argonaute Immunoprecipitation (Ago-IP) 
To identify the transcript regulated by miRNAs in vivo, argonaute immunoprecipitation (Ago-IP) 
is used to isolate the RISCs including the regulatory miRNAs as well as the regulated mRNAs. For 
the immunoprecipitation from human cells, a monoclonal antibody directed against the human 
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Ago2 protein is used (Rüdel et al. 2008). As control, an unrelated monoclonal antibody directed 
against the complement system protein RmC from rat is used (Dueck et al. 2012). For the 
immunoprecipitation from murine cells, a commercially available antibody directed against the 
murine Ago2 is used (Tab. 3.6). An unspecific IgG isolated from rabbit served as a control. 
Cell lysis buffer:  0.5%  Nonidet P40 
    150 mM  KCl 
    25 mM  Tris (pH = 7.5) 
    2 mM  EDTA 
    1 mM  NaF 
 
IP washing buffer:  0.1%  Nonidet P40 
 300 mM NaCl 
    50 mM Tris (pH = 7.5) 
    5 mM  MgCl2 
 
Digestion buffer:  300 mM NaCl 
    200 mM Tris (pH = 7.5) 
    25 mM EDTA 
    2%  SDS 
 
Tab. 3.6: Antibodies used in Ago immunoprecipitation  
3.6.1 Western Blotting detection of Argonaute2 
Preparation of antibody-coupled beads 
Magnetic Protein G-coupled beads are vortexed on the fastest level for 1 min. For each sample, 
80 µl of the suspension are transferred to a new cup and washed three times with 1x PBS. The 
beads are mixed with the -Ago2 antibody solutions or the control antibody solutions (Tab. 3.6). 
The beads/antibody mixtures are incubated at 4°C overnight on a rotating wheel. 
Cell lysis  
The cell pellets are resuspended in 1 ml of cell lysis buffer per 25 million cells by pipetting up and 
down. After 5 s of vortexing on the highest level, the lysates are incubated at 4°C on a rotating 
wheel for 15 min, followed by centrifugation (17,000 xg, 45 min, 4°C). The supernatant is used 
for further experiments.  
Antibody for Ago2-IP and Western Blot  Amount of antibody per experiment 
-Ago2 human 
(11A9) 
G. Meister Department of Biochemistry I, 
University of Regensburg; Rüdel et al. 2008 
1 ml hybridoma supernatant 
-RMC rat 
(control)
G. Meister, Department of Biochemistry I, 
University of Regensburg; Dueck et al. 2012 
1 ml hybridoma supernatant 
-Ago2 murine Wako (clone 2D4)  16 µg 
rabbit IgG Sigma-Aldrich 16 µg 
-Mouse-IgG Sigma-Aldrich (HRP conjugated) Dilution 1:20,000 
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Protein quantification 
The protein mass concentration of the supernatant is measured with the Bradford method. In 
order to prepare a calibration curve, solutions of BSA in cell lysis buffer ranging from 0 µg/µl to 
5 µg/µl are prepared. From each calibration solution and each sample, 1 µl is mixed with 1 ml 
Roti-Quant solution in a plastic cuvette. After incubation (10 min, RT), the ratio of absorbances 
at 595 nm and 450 nm is calculated for each sample. Unknown sample concentrations are 
calculated using the calibration curve.  
Protein gel electrophoresis 
For protein separation, 10% acrylamide gels are cast with the Protean 3 system. The separating 
gel is cast firstly and covered with a thin layer of water to achieve a smooth surface. After 60 min 
of polymerization, the excessive water is removed, the stacking gel is cast and a comb is inserted 
into the stacking gel. After polymerization for 45 min, the gel is inserted into the gel chamber 
and pre-run at 250 V for 30 min. Four parts of sample are mixed with one part 5x Laemmli 
sample buffer and heated to 95°C for 5 min. Together with 3 µl of prestained protein marker, 
the samples are loaded on the gel. After applying 150 V for 5 min to allow the samples to enter 
the gel, the voltage is increased to 250 V for 30 min. 
Western Blotting of proteins 
After being separated by polyacrylamide gel electrophoresis, the proteins are transferred to a 
0.45 µm PVDF-membrane using three different protocols. 
Semi-dry blot transfer buffer: 25 mM  Tris 
     192 mM Glycine 
     20%  methanol 
     0.02%  SDS 
     in H2O 
 
Tank blot transfer buffer: 50 mM  Tris 
     384 mM  Glycine 
     20%   methanol 
     0.01%  SDS 
     in H2O 
 
For semi-dry blotting, the PVDF membrane is first soaked in 100% methanol for 1 min. The 
membrane as well as six pieces of chromatography papers is soaked in semi-dry blot transfer 
buffer. On the bottom of a Trans-Blot Semi-Dry system, a stack of from bottom to top three 
layers of chromatography paper, the membrane, the gel, and another three layers of 
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chromatography papers is built up. The blotting chamber is closed and the proteins are 
transferred onto the membrane by applying 22 V for 1.5 h.  
For tank blotting, the PVDF membrane is first soaked in 100% methanol for 1 min. The 
membrane as well as six pieces of chromatography papers is soaked in tank blot transfer buffer. 
A stack of from bottom to top three layers of chromatography paper, the membrane, the gel, 
and another three layers of chromatography papers is built up on the middle tray of the Tank 
Blotting chamber. The chamber is then filled up with tank blot transfer buffer and the proteins 
are transferred to the membrane either using 1 A for 3 h or 20 V for 18 h. 
Antibody detection of mAgo2 
Blocking solution:   5%  Skim milk powder 
     0.1% Tween-20 
     in 1x PBS buffer 
 
Washing solution:   0.1% Tween-20 
     in 1x PBS buffer 
 
After blotting, the membrane is blocked by incubation in blocking solution (30 min, RT). After 
washing the membrane three times with washing solution (each 10 min, RT), and once with 
1x PBS, the blot is incubated overnight at 4°C in blocking solution containing the first antibody, 
-mAgo2, diluted 1:500. The next day, the blot is washed three times with washing solution and 
incubated with the second antibody, diluted 1:20,000 (30 min, RT). After washing the blot three 
times with washing solution (each 10 min, RT), and once with 1x PBS, the blot is developed with 
the Western Lightning Chemoluminiscence Reagent or the SuperSignal West Pico 
Chemiluminescent Substrate. In both cases, the luminol solution and the oxidation reagent are 
mixed in equal amounts and the membrane is incubated with the mixture according to the 
respective protocols. The signal from the membrane is recorded with the chemoluminescence 
system Fusion Fx7. 
3.6.2 Argonaute Immunoprecipitation using hPCLs and mPCLs 
Preparation of antibody-coupled beads 
Magnetic Protein G-coupled beads are vortexed on the fastest level for 1 min. For each sample, 
80 µl of the suspension are transferred to a new cup and washed three times with 1x PBS. The 
beads are mixed with the antibody solutions (Tab. 3.6). The beads/antibody mixtures are 
incubated at 4°C overnight on a rotating wheel. 
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Cell lysis  
The cell pellets are resuspended in 1 ml of cell lysis buffer per 25 million cells by pipetting up and 
down. After 5 s of vortexing on the highest level, the lysates are incubated at 4°C on a rotating 
wheel for 15 min, followed by centrifugation (17,000 xg, 45 min, 4°C). 
As input control, 200 µl of the supernatant are taken and the rest of the supernatant is split in 
half. One sample is incubated with the -Ago2 coupled beads, whereas the other half is 
incubated with the control beads for 4 h at 4°C on a rotating wheel. 
Preparation of input RNA sample 
For RNA isolation, the input sample is mixed with an equivalent volume of TriFast (peqlab) and 
incubated for 5 min at room temperature. After addition of 40 µl of chloroform, the samples are 
shaken by hand for 15 s, incubated for 5 min at room temperature and centrifuged (12,000 xg, 
15 min, 4°C). The RNA extraction from the upper, aqueous phase is performed with the 
miRNeasy Kit (Qiagen) using a modified protocol. Shortly, the upper phase is mixed with 1.5 
volumes of pure ethanol. The mixture is passed through an RNeasy spin column by 
centrifugation (13,000 xg, 15 s, RT). After washing once with RWT buffer, the column is 
incubated with 10 µl DNase I in 70 µl RDD buffer for 1 h at 28°C for DNA digestion. Afterwards, 
the column is once washed with buffer RWT and twice with buffer RPE by centrifugation (17,000 
xg, 1 min, RT). After dry centrifugation (17,000 xg, 2 min, RT), the RNA is eluted from the column 
with 30 µl DEPC-H2O and stored at -80°C. 
Preparation of IP-RNA samples 
After 4 h of incubation with the protein lysate, the magnetic beads of both samples are washed 
four times with the IP washing buffer by placing the tube at the magnet and removing the 
supernatant. Afterwards, the beads are incubated in 250 µl Protease K buffer containing 2 µl of 
20 mg/ml Proteinase K solution for 15 min at 65°C. 300 µl of acid phenol is added and the 
mixture is centrifuged (12,000 xg, 10 min, 4°C). The RNA extraction from the upper, aqueous 
phase is done with the miRNeasy Kit using a modified protocol. Shortly, the upper phase is 
mixed with 1.5 volumes of pure ethanol. The mixture is passed through an RNeasy spin column 
by centrifugation (13,000 xg, 15 s, RT). After washing once with RWT buffer, the column is 
incubated with 10 µl DNase I in 70 µl RDD buffer for 1 h at 28°C for DNA digestion. Afterwards, 
the column is once washed with buffer RWT and twice with buffer RPE by centrifugation (17,000 
xg, 1 min, RT). After dry centrifugation (17,000 xg, 2 min, RT), the RNA is eluted from the column 
with 30 µl DEPC-H2O and stored at -80°C. 
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cDNA synthesis 
cDNA from isolated long RNA species (≥ 200 nt) from the input sample, Ago2 sample and control 
antibody sample is synthesized with the iScript Select cDNA synthesis kit (BioRad) according to 
the following protocol. 
cDNA synthesis mixture:   cDNA sample  non-RT control 
 RNA solution   25 µl    5 µl 
 iScript 5x reaction mix  8 µl    1.6 µl 
 random primer solution  4 µl    0.8 µl 
 iScript reverse transcriptase 2 µl    ----- 
 DEPC-H2O    1 µl    0.6 µl 
 
After incubating the cDNA synthesis protocol at 25°C for 5 min, the cDNA synthesis is performed 
by incubation at 42°C for 60 min. After denaturation of the reaction mix at 85°C for 5 min, it is 
cooled rapidly to 4°C. The cDNA synthesis is performed in a PCR cycler (BioRad). 
qPCR of samples isolated from Ago2 
The qPCR analyses are performed in duplicates for every potential target and the positive 
control. 
qPCR reaction mix:  
 qPCR Mastermix   10 µl 
 Primer 1 (10 µM)   1 µl 
 Primer 2 (10 µM )  1 µl 
 cDNA sample/ nonRT control 2 µl 
 H2O     6 µl 
 
Calculation of the cp value of each sample is done with the LightCycler software, version 
1.5.0.39. Enrichment of target in the -Ago2 sample from the input is calculated using Excel. Cp 
values of the samples isolated from the control antibodies serve as background control. The 
nonRT control sample is checked for DNA contamination and only experiments with a clean 
nonRT control are evaluated. 
3.6.3 Argonaute Immunoprecipitation using murine podocytes 
Preparation of antibody-coupled beads 
Magnetic Protein G-coupled beads are vortexed on the fastest level for 1 min. For each sample, 
80 µl of the suspension are transferred to a new cup and washed three times with DEPC treated 
1x PBS. For each sample, 16 µg of antibody (Tab. 3.6) are diluted in 200 µl 1x PBS containing 
0.01% Nonidet P40 and the beads/antibody mixtures are incubated at 4°C overnight on a 
rotating wheel. 
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Cell lysis  
The cell pellets are resuspended in 1 ml of cell lysis buffer per sample by pipetting up and down. 
After 5 s of vortexing on the highest level, the lysates are incubated at 4°C on a rotating wheel 
for 15 min, followed by centrifugation (17,000 xg, 45 min, 4°C). A small sample for Bradford 
quantification (chapter 3.6.1) is taken from the supernatant, the rest of the supernatant is mixed 
with the rabbit IgG coupled beads (see next paragraph) and incubated at 4°C for 1 h on a 
rotating wheel. 
Sample incubation with clearance beads  
After coupling overnight, the beads coupled with the control antibody are washed twice with 
cell lysis buffer. Afterwards, they are mixed with the supernatant after centrifugation and 
incubated at 4°C for 1 h on a rotating wheel. 
Sample incubation with Argonaute specific beads  
After coupling overnight, the beads coupled with the -Ago2 antibody are washed twice with 
cell lysis buffer. Afterwards, they are mixed with the supernatant after clearance and incubated 
at 4°C for 4 h on a rotating wheel. 
RNA isolation from beads after IP 
After immunoprecipitation, the magnetic beads are washed with washing buffer four times. 
Afterwards, 2 µl of Proteinase-K solution (20 mg/ml) in 250 µl digestion buffer is added and the 
beads are incubated for digestion for 15 min at 65°C. After addition of 300 µl acid phenol and 
vortexing, the samples are centrifuged (12,000 xg, 10 min, 4°C). The upper phase is mixed with 
500 µl ethanol and the RNA is then purified with the miRNeasy micro Kit (Qiagen) using a 
modified protocol. Shortly, the RNA is bound to the column by centrifugation, and washed with 
buffer RW1. For DNA digestion, 10µl DNase I in 70µl RDD buffer is added and the samples are 
incubated at 28°C for 1 h. The column is once washed with buffer RW1, once with buffer RPE 
and once with 80% ethanol in DEPC-H2O. After dry centrifugation, the sample is eluted from the 
column with 14 µl DEPC-H2O and frozen at -80°C. The samples are further analyzed by the KFB 
(Kompetenzzentrum fluoreszente Bioanalytik, Biopark, Regensburg) on a GeneChiP-Array 
(Mouse Transcriptome Array, Gen2.0/2.1ST, Affymetrix). 
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3.7  Luciferase Assay 
Using luciferase assays, regulatory processes in cells can be analyzed. Cells are transfected with 
plasmids coding for firefly luciferase and containing putative regulatory elements. After 
harvesting and lysis of the cells, the amount of luciferase is measured using a 
chemoluminescence producing reaction. In the present work, the binding between miRNAs and 
the 3’-UTRs of protein coding transcript as well as the functionality of miRNA-“sponges” is 
investigated by luciferase assays. 
3.7.1 Design and generation of Luciferase Assay constructs 
Bacterial cells containing plasmids harboring the ampicillin resistance gene are cultured in LB 
medium and on LB agar plates containing 100 µg/ml ampicillin. Bacterial cells containing 
plasmids harboring the kanamycin resistance gene are cultured in LB medium and on LB agar 
plates containing 50 µg/ml kanamycin. 
Preparation of vectors 
The pMir-Report vectors coding for a targeted firefly luciferase under the control of the TK 
promoter and an untargeted renilla luciferase as control are obtained from the Department for 
Biochemistry I, University of Regensburg. The pMir-Report plasmid is digested with SpeI/SacI 
yielding the pMir-Report vector for further cloning. The sponge plasmids that contain seven 
bulged binding sites for miR-21-5p in its 3’-UTR or the negative control that do not contain any 
binding sites, CMV-d2eGFP-21 and CMV-d2eGFP-empty, are obtained from Addgene. The CMV-
d2eGFP-21 plasmid is digested with XhoI/ApaI yielding the pSponge vector for further sponge 
design. 
Digestion of pMir-Report vector: 
    pMir-Report plasmid    <1 µg 
    SpeI-HF [20 U/µl]      0.5 µl 
    SacI-HF [20 U/µl]     0.5 µl 
    CutSmart 10x buffer    2 µl 
    ad 20 µl H2O 
 
Digestion of CMV-d2e-GFP-21 to generate sponge vector: 
    CMV-d2e-GFP-21 plasmid   <1 µg 
    XhoI [20 U/µl]     0.5 µl 
    ApaI [50 U/µl]     0.5 µl 
    CutSmart 10xbuffer    2 µl 
    ad 20µl H2O 
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The digestion mixes are incubated for 2 h at 37°C. After 1 h, 1 µl of alkaline phosphatase is 
added to each of the mixtures.  
After the digestion, the vectors are cleaned via agarose gel electrophoresis using a 1% agarose 
gel running in 1x TAE buffer for 2 h at 120 V. The digested vector band is extracted from the gel 
using a scalpel and isolated using the Qiaquick Gel Extraction Kit (Qiagen). Shortly, the excised 
piece of gel is melted in three volumes of QG buffer by incubation for 10 min at 50°C. The 
mixture is then passed through a spin column (16,000 xg, 1 min, RT). The column is then washed 
twice with PE buffer (16,000 xg, 1 min, RT). After spin drying the column (16,000 xg, 2 min, RT), 
the DNA is eluted with 50 µl of H2O and quantified using a NanoDrop photometer. 
Preparation of inserts  
The 3’-UTR inserts with wildtype sequence or mutated binding sites (chapter 3.7.2) and the 
insert for sponge functionality analysis (chapter 3.7.4) are purified and isolated using a 1.5% 
agarose gel running in 1x TAE buffer for 1 - 2 h at 140 V. The inserts are excised from the gel and 
isolated using the Qiaquick Gel Extraction Kit (see above). The inserts are digested using 
SpeI/SacI or XhoI/ApaI afterwards. 
Digestion of inserts for pMir-Report: 
PCR product isolated from agarose gel 0.5-1.3 µg 
    SpeI-HF [20 U/µl]     0.5 µl 
    SacI-HF [20 U/µl]     0.5 µl 
    CutSmart 10x buffer    3 µl 
    ad 30 µl H2O 
 
Digestion of inserts for pSponge: 
PCR product isolated from agarose gel 0.5-1.3 µg 
    XhoI-HF [20 U/µl]     0.5 µl  
ApaI-HF [50 U/µl]     0.5 µl 
    CutSmart 10x buffer    3 µl 
    ad 30 µl H2O 
 
The digestion mix is incubated for 2 h at 37°C. After digestion of the insert ends with SpeI/SacI or 
XhoI/ApaI the inserts are purified using the Qiaquick Nucleotide Removal Kit (Qiagen). Shortly, 
the reaction mix is mixed with five volumes of PNI buffer and passed through a spin column 
(3,380 xg, 1 min, RT). After washing the column twice with PE buffer (16,000 xg, 1 min, RT), the 
column is spin dried (16,000 xg, 2 min, RT). The DNA is eluted with 50 µl of H2O and quantified 
using a NanoDrop photometer. 
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Ligation of pMir-Report constructs and pSponge constructs 
For ligation, vector and insert are mixed in a molar ratio between 1:3 and 1:5. The ligation 
mixture is mixed and incubated for 2 h at room temperature. Afterwards, the mixture is slowly 
cooled from 16°C to 4°C in a water bath overnight. 
Ligation of pMir-Report and pSponge constructs: 
    Vectors       60 - 100 ng 
    Inserts      50 - 100 ng 
    T4-Ligase      1 µl 
    10x Ligase buffer     2 µl 
    ad 20 µl H2O 
Electroporation  
The day after ligation, the ligase is deactivated by heating the ligation mix to 65°C for 10 min. 
The ligation mix is dialyzed in a Petri dish filled with water on a dialysis filter paper (1 h, RT). It is 
then mixed with 80 µl of freshly thawed electro competent E.coli suspension in an 
electroporation cuvette and electroporated (2,500 V). The electroporated cells are immediately 
diluted in 500 µl LB medium and incubated in a shaking incubator for 1 h at 37°C. The cell 
suspension is then plated on agarose plates containing ampicillin or kanamycin for selection. 
Screening for positive clones 
The plates with the transformed E.coli cells are incubated at 37°C overnight. The next day, 
colonies are picked from the plates and transferred to 5 ml of LB medium containing ampicillin 
or kanamycin and grown overnight in a shaking incubator. The next day, the plasmids are 
isolated from the E.coli cells using the GeneJET Plasmid Miniprep Kit (Thermo Scientific). Shortly, 
the bacterial cells from 5 ml overnight culture are collected by centrifugation (16,000 xg, 1 min, 
RT). The pellets are resuspended in 250 µl of resuspension solution. After adding 250 µl lysis 
solution and 350 µl neutralization solution, the samples are centrifuged (16,000 xg, 5 min, RT). 
The supernatant is then passed through a GeneJet column (16,000 xg, 1 min, RT), which is then 
washed twice with washing solution (16,000 xg, 1 min, RT). After spin drying the column by 
centrifugation (16,000 xg, 1 min, RT), the DNA is eluted using 50 µl H2O. The concentration is 
measured using a NanoDrop photometer. The isolated plasmids are analyzed using restriction 
digest or sequencing. 
Plasmid isolation for cell transfection 
For transfection in cell culture, larger amounts of plasmids are isolated using a Plasmid plus 
Midiprep Kit (Qiagen) from a 50 ml overnight culture. The bacterial cells are pelleted by 
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centrifugation (4,000 xg, 15 min, 4°C). After resuspending the pellet in 2 ml of P1 buffer, 2 ml of 
P2 buffer are added and the solution is incubated for 3 min. After addition of 2 ml of S3 buffer, 
the lysate is put in a filter cartridge and incubated for 10 min at room temperature, filtered 
through the cartridge and mixed with 2 ml of BB buffer. Using vacuum, the solution is then 
drawn through the midi spin column. The spin column is then washed with 700 µl ETR buffer and 
700 µl PE buffer by centrifugation (10,000 xg, 1 min, RT). After spin drying the column 
(10,000 xg, 1 min, RT), the DNA is eluted using 200 µl H2O and the concentration is measured 
using a NanoDrop photometer.  
3.7.2 pMir-Report constructs containing 3’-UTRs of putative target genes 
For the miRNA binding assays, a luciferase reporter system based on the pMir-report vector 
(Ambion, modified) is used. Additionally to the targeted firefly luciferase, the plasmids code for 
an untargeted control, a renilla luciferase, and the CMV promoter is exchanged for a TK 
promoter (chapter 3.1.5). The construct containing a 3’-UTR is cotransfected with a pSuper 
construct (oligoengine, modified) coding for a mature miRNA or a control sequence, harboring 
kanamycin resistance (chapter 3.1.5). 
Amplification of wildtype 3’-UTRs 
The wildtype target 3’-UTRs are amplified from DNA extracted from hPCL cells with primers 
containing restriction sites for SpeI and SacI, respectively (Tab. 3.7).  
Tab. 3.7: Primers for PCR amplification of 3’-UTR fragments from genomic hPCL DNA 
Primer name Sequence 
pMIR-Report-hCD2AP_3'UTR_SpeI_F CAT TGC CAA ATT ACT AGT GAA TGT ATA GTT CA 
pMIR-Report-hCD2AP_3'UTR_SacI_R GAG AGA AGC GAG CTC TTA AAT ACA GCA C 
pMIR-Report-hFYN_3'UTR_SpeI_F GTG AAA ACT AGT AAG GCC CG 
pMIR-Report-hFYN_3'UTR_SacI_R GCA ATG AGC TCC AAA TGT AAA ATG CTC TCT T 
pMIR-Report-hNCK2_3'UTR_SpeI_F GAG AAG CAC TAG TTC GTC AGG GC 
pMIR-Report-hNCK2_3'UTR_SacI_R GCA ATG AGC TCA TGT GCC ATC TCA AGA CGT 
pMIR-Report-hNEPH1_3'UTR_SpeI_F CAC TCG GAC TAG TGC CAG CGA  
pMIR-Report-hNEPH1_3'UTR_SacI_R GCA ATG AGC TCC CCT GTT CGC TCC CTT CTG C 
 
The 3’-UTRs of FYN and NCK2 are amplified using an annealing temperature of 54°C, while the 
primers amplifying the CD2AP and the NEPH1 3’-UTR are annealed at 57°C or 59°C, respectively. 
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PCR amplification of target 3’-UTRs: 
    Thermopol 10x reaction buffer   2.5 µl  
 Primers (10 µM)     0.5 µl (each) 
 dNTPs (10 mM each)    0.5 µl 
 Taq polymerase     0.5 µl 
 Pfu polymerase:     0.1 µl 
 DNA from hPCLs     ca. 100 ng 
 ad 25 µl with H2O 
 
Standard program for Luciferase insert PCR:   
 95°C  5 min 
    95°C  1 min 
    54–59°C 1 min      35 cycles 
    68°C  3 min 
    68°C  10 min 
 
The PCR products are purified and isolated by agarose gel electrophoresis (see above).  
Amplification of point-mutated 3’-UTRs  
For luciferase assay, constructs containing 3’-UTRs with point mutated putative binding sites are 
designed. To destroy the putative binding sites for the miRNA seed regions, the positions 2, 4 
and 6 are mutated. For the CD2AP construct containing a mutated miR-30a-e-5p binding site, 
the 3’-UTR amplification PCR is performed with a reverse primer harboring a mutated miR-30a-
e-5p binding site (Tab. 3.8) according to the same protocol as the wildtype 3’-UTRs. For the 
constructs containing a mutated binding site in the middle of the 3’-UTR, two PCRs are 
performed with one of the flanking forward or reverse primers from above combined with a 
reverse or forward primer harboring the mutated binding site (Tab. 3.8). The two PCR products 
are purified and isolated using a 1.5% agarose gel running in 1x TAE buffer for 1 h at 140 V and 
mixed in the molar ratio of 1:1. 
First PCR for 3’-UTR fragment generation: 
    Phusion 5x HF-buffer    5 µl 
 Primers (10 µM)     1 µl (each) 
 dNTPs (10 mM each)    1 µl 
 Phusion polymerase    0.25 µl 
 DNA from hPCLs     ca. 100 ng 
 ad 25 µl with H2O 
 
Program for first PCR for 3’-UTR parts generation: 
 95°C  5min 
    95°C  30s 
    57–60°C 1min       35 cycles 
    72°C  1min 
    72°C  5min 
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The first PCR is performed using an annealing temperature of 57°C for the CD2AP_92a/b-3p 
fragments and an annealing temperature of 60°C for the Neph1_29a-c-3p fragments. 
Tab. 3.8: Primers for binding site mutations in 3’-UTRs 
Primer Name Sequence 
hCD2AP_30a-e-5p_R GAG AAG CGA GCT CTT AAA TAC AGC ACC TCT TAT CAA GTT 
AGT GAA GTA 
hCD2AP_92a/b-3p_F GCT GTA GCA ATA AAA TGA CCA AGT CCT AAG ACT TGA 
hCD2AP_92a/b-3p_R TTA TTA AAT CAA GTC TTA GGA CTT GGT CA 
hNEPH1_29a-c-3p_F CAC CCC GTC CCG AGG ATG TTA CGC TGT 
hNEPH1_29a-c-3p_R CTG GGG CAT GCA CAG CGT AAC ATC 
 
The two products are annealed heating them up to 98°C for 5 min, incubating the mixture for 
10 min at 70°C and then either by slowly cooling of the mixture from 70°C to 25°C (-1°C/min) 
(CD2AP_92a/b-3p) or a rapid cooling from 68°C to 4°C (Neph1_29a-c-3p). The fill-up reaction 
mix is incubated for 15 min at 72°C.  
Fill-up reaction after the annealing 
    Annealing mix     16.5 µl 
 Phusion 5x HF-buffer    2.5 µl 
 dNTPs (10 mM each)    1 µl 
 Phusion polymerase    0.3 µl 
    ad 25 µl H2O 
 
After filling up the cross-annealed products, the inserts are amplified by a second PCR using both 
flanking primers. The second PCR is performed with an annealing temperature of 57°C for the 
CD2AP_92a/b-3p 3’-UTR and an annealing temperature of 60°C for the Neph1_29a-c-3p 3’-
UTR.  
Second PCR for full length 3’-UTRs generation: 
    Fill-up reaction mix    25 µl 
    Flanking primers     1 µl each 
 Phusion 5x HF-buffer    0.5 µl 
 ad 30 µl with H2O 
 
Program for second PCR for full length 3’-UTRs generation: 
 95°C  5 min 
    95°C  30 s 
    57–60°C 1 min      35 cycles 
    72°C  1 min 
    72°C  5 min 
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3.7.3 pSuper constructs for miRNA overexpression 
The inserts for the miRNA overexpression constructs are designed according to the pSuper 
manual. After phosphorylation, oligonucleotides containing the hairpin precursor of the mature 
miRNA sequence, are annealed, thus forming overhangs at both ends corresponding to the 
restriction sites of the vector backbone.  
Oligo phosphorylation mixture: 
    Oligonucleotide (10 µM)    2 µl 
    T4 PNK 10x buffer     2 µl 
    ATP (100 mM)     0.2 µl 
    T4 PNK      1 µl 
    ad 20 µl H2O 
 
The oligo phosphorylation mixture is incubated at 37°C for 45 min. The two fitting single strands 
(Tab. 3.9) are mixed in a molar ratio of 1:1 and annealed by heating the mixture to 95°C for 
10 min, incubating them at 70°C for 10 min and cooling from 70°C to 25°C (-1°C/min). 
Afterwards, they are isolated by gel electrophoresis. 
Tab. 3.9: Precursor-oligonucleotides for annealing and cloning into pSuper overexpression vector 
Name of annealed oligo Sequence of annealed oligo 
pSuper_control_Forw GAT CCC CTG TTA GCT TTC TGA AAA CTT TTC AAG AGA 
AAG TTT TCA GAA AGC TAA CAT TTT TA 
pSuper_control_Rev AGC TTA AAA ATG TTA GCT TTC TGA AAA CTT TCT CTT 
GAA AAG TTT TCA GAA AGC TAA CAG GG 
pSuper_23b-3p_Forw GAT CCC CAT CAC ATT GCC AGG GAT TAC CTT CAA GAG 
AGG TAA TCC CTG GCA ATG TGA TTT TTT A 
pSuper_23b-3p_Rev AGC TTA AAA AAT CAC ATT GCC AGG GAT TAC CTC TCT 
TGA AGG TAA TCC CTG GCA ATG TGA TGG G 
pSuper_27b-3p_Forw GAT CCC CTT CAC AGT GGC TAA GTT CTG CTT CAA GAG 
AGC AGA ACT TAG CCA CTG TGA ATT TTT A 
pSuper_27b-3p_Rev AGC TTA AAA ATT CAC AGT GGC TAA GTT CTG CTC TCT 
TGA AGC AGA ACT TAG CCA CTG TGA AGG G 
pSuper_29a-3p_Forw GAT CCC CTA GCA CCA TCT GAA ATC GGT TAT TCA AGA 
GAT AAC CGA TTT CAG ATG GTG CTA TTT TTA 
pSuper_29a-3p_Rev AGC TTA AAA ATA GCA CCA TCT GAA ATC GGT TAT CTC 
TTG AAT AAC CGA TTT CAG ATG GTG CTA GGG 
pSuper_30a-3p_Forw GAT CCC CTG TAA ACA TCC TCG ACT GGA AGT TCA AGA 
GAC TTC CAG TCG AGG ATG TTT ACA TTT TTA 
pSuper_30a-3p_Rev AGC TTA AAA ATG TAA ACA TCC TCG ACT GGA AGT CTC 
TTG AAC TTC CAG TCG AGG ATG TTT ACA GGG 
pSuper_92a-3p_Forw GAT CCC CTA TTG CAC TTG TCC CGG CCT GTT TCA AGA 
GAA CAG GCC GGG ACA AGT GCA ATA TTT TTA 
pSuper_92a-3p_Rev AGC TTA AAA ATA TTG CAC TTG TCC CGG CCT GTT CTC 
TTG AAA CAG GCC GGG ACA AGT GCA ATA GGG 
pSuper_130a-3p_Forw GAT CCC CCA GTG CAA TGT TAA AAG GGC ATT TCA AGA 
GAA TGC CCT TTT AAC ATT GCA CTG TTT TTA 
pSuper_130a-3p_Rev AGC TTA AAA ACA GTG CAA TGT TAA AAG GGC ATT CTC 
TTG AAA TGC CCT TTT AAC ATT GCA CTG GGG 
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Name of annealed oligo Sequence of annealed oligo 
pSuper_146b-5p_Forw GAT CCC CTG AGA ACT GAA TTC CAT AGG CTT TCA AGA 
GAA GCC TAT GGA ATT CAG TTC TCA TTT TTA 
pSuper_146b-5p_Rev AGC TTA AAA ATG AGA ACT GAA TTC CAT AGG CTT CTC 
TTG AAA GCC TAT GGA ATT CAG TTC TCA GGG 
 
First digestion of pSuper plasmids: 
    pSuper Plasmid   5 µg 
    BglII [10 U/µl]   1 µl 
    10x buffer orange   2 µl 
    ad 20 µl H2O 
 
The first digestion mix is incubated at 37°C for 1 h. The vector is purified using a 1% agarose gel 
running in 1x TAE buffer for 1 h at 140 V and a subsequent gel extraction (see above). 
Second digestion of pSuper plasmids: 
    pSuper Plasmid/BglII  29 µl 
    HindIII-HF [20 U/µl]   1 µl 
    10x buffer CutSmart  4 µl 
    Alkaline Phosphatase  1 µl 
 ad 40µl H2O 
 
The second digestion mix is incubated at 37°C for 1 h. The vector is purified using the Qiaquick 
nucleotide removal kit (see above). 
Ligation of pSuper constructs: 
    pSuper vector    80 ng 
    Annealed insert mixture  1 µl 
    T4 Ligase 10x buffer  1.5 µl 
    T4 Ligase (Fermentas)  1 µl 
    ad 15 µl H2O 
 
The ligation mixture is mixed and incubated for 2 h at room temperature. Afterwards, the 
mixture is slowly cooled from 16°C to 4°C in a water bath overnight. 
3.7.4 Constructs for sponge functionality Luciferase Assay  
Sponge insert harboring seven bulged binding sites for miRNAs and miRNA families of interest 
containing 7 bulged binding sites for mature miRNAs are designed and subsequently ordered at 
Geneart (Regensburg).  
For the design of a negative control mock sponge, a sequence from the trimethylamine 
methyltransferase, a gene from the archaeal organism Methanosarcina mazei is taken and 
mutated until no similarity to mammalian sequences is found anymore in BLAST analyses. 
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miR-23a/b-3p sponge sequence (bulged) (169 nt): 
5`CTCGAGGGAAATCCCCCGAATGTGATCCGGGAAATCCCCCGAATGTGATCATGGAAATCCCCCGAATGTG
ATCGCGGAAATCCCCCGAATGTGATTCAGGAAATCCCCCGAATGTGATGTGGGAAATCCCCCGAATGTGATA
AGGAAATCCCCCGAATGTGATGGGCCC 3’ 
miR-24-3p sponge sequence (bulged) (176 nt): 
5`CTCGAGCTGTTCCTGCCTTCTGAGCCACCGCTGTTCCTGCCTTCTGAGCCACATCTGTTCCTGCCTTCTG
AGCCACGCCTGTTCCTGCCTTCTGAGCCATCACTGTTCCTGCCTTCTGAGCCAGTGCTGTTCCTGCCTTCTG
AGCCAAACTGTTCCTGCCTTCTGAGCCAGGGCCC 3’ 
miR-27a/b-3p sponge sequence (bulged) (169 nt): 
5`CTCGAGGCGGAACTTCGGACTGTGAACCGGCGGAACTTCGGACTGTGAACATGCGGAACTTCGGACTGTG
AACGCGCGGAACTTCGGACTGTGAATCAGCGGAACTTCGGACTGTGAAGTGGCGGAACTTCGGACTGTGAAA
AGCGGAACTTCGGACTGTGAAGGGCCC 3` 
miR-29a-c-3p sponge sequence (bulged) (176 nt): 
5`CTCGAGTAACCGATTTTCTTGGTGCTACCGTAACCGATTTTCTTGGTGCTACATTAACCGATTTTCTTGG
TGCTACGCTAACCGATTTTCTTGGTGCTATCATAACCGATTTTCTTGGTGCTAGTGTAACCGATTTTCTTGG
TGCTAAATAACCGATTTTCTTGGTGCTAGGGCCC 3` 
miR-92a/b-3p sponge sequence (bulged) (169 nt): 
5`CTCGAGCAGGCCGGGGTTGTGCAATACCGCAGGCCGGGGTTGTGCAATACATCAGGCCGGGGTTGTGCAA
TACGCCAGGCCGGGGTTGTGCAATATCACAGGCCGGGGTTGTGCAATAGTGCAGGCCGGGGTTGTGCAATAA
ACAGGCCGGGGTTGTGCAATAGGGCCC 3` 
mock sponge sequence (169 nt): 
5`CTCGAGAGCAACTTCCGCGACGGAGCCCGAGCAACTTCCGCGACGGAGCCATAGCAACTTCCGCGACGGA
GCCGCAGCAACTTCCGCGACGGAGCGCAAGCAACTTCCGCGACGGAGCGTGAGCAACTTCCGCGACGGAGCA
AAGCAACTTCCGCGACGGAGCGGGCCC 3` 
 
Fig. 3.1: Sequences of sponge inserts; black: miRNA binding sites; red: XhoI restriction sites; green: ApaI 
restriction sites; blue: linkers between miRNA binding sites 
Generation of pSponge insert for sponge assay 
The sponge inserts (see above) are digested with XhoI/ApaI from the pMA plasmids they were 
delivered in and ligated into the pSponge vector (chapter 3.7.1). Positive clones are identified by 
restriction digestion and sequencing. 
Generation of pMir-report insert for sponge assay 
The sponge inserts for pMir-Report vector are amplified by PCR using primers containing SpeI or 
SacI restriction sites (Tab. 3.10).  
PCR for sponge insert amplification 
    10x Pfu reaction buffer  5 µl 
 Primers (10 µM)   1 µl (each) 
   dNTPs (10 mM each)  1 µl 
 Pfu-Polymerase   0.5 µl 
 sponge plasmid   ca. 50 ng 
 ad 25 µl with H2O 
M A T E R I A L S  A N D  M E T H O D S  
 
81 
 
Program for sponge insert amplification PCR: 
 95°C  5 min 
    95°C  30 s 
    58°C  1 min               35 cycles 
    72°C  1 min 
    72°C  5 min 
 
Tab. 3.10: Primer for PCR amplification of sponge sequences for cloning into pMir-Report vector 
Primer name Sequence 
pMir-Report-sponge21-SpeI-F CGC CTC GAG ACT AGT CCG GTC AAC 
pMir-Report-sponge21-SacI-R  TTA AAC GGG CCC GAG CTC GCG ATC C 
pMir-Report-sponge23-SpeI-F  CAA TCA ACT AGT GGG AAA TCC 
pMir-Report-sponge23-SacI-R  TAA GAG GTA CCG AGC TCA TCA C 
pMir-Report-sponge24-SpeI-F  GGC CGC ATC AAC ACT AGT CTC GAG 
pMir-Report-sponge24-SacI-R  ACT CGA GAT GAT TGA GCT CTG G 
pMir-Report-sponge27-SpeI-F  CAT GAG CTA CTA GTG GCG GAA CTT 
pMir-Report-sponge27-SacI-R  AGA TGA TTG AGC TCT TCA CAG TC 
pMir-Report-sponge29-SpeI-F  GAG CCA GGG CCC AAT CAT CTA GT 
pMir-Report-sponge29-SacI-R  GGT ACC GAG CTC TAG CAC CAA G 
pMir-Report-sponge92-SpeI-F  TAG GCG CGC CAT GAA CTA GTC GAG 
pMir-Report-sponge92-SacI-R  ATG ATT GAG CTC TAT TGC ACA AC 3.7.5  Luciferase Assay procedure  
To investigate the regulation of mRNAs by miRNAs that are predicted in the in silico predictions 
and to access sponge functionality, luciferase assays are performed in cell culture. 
Transfection of cells for luciferase assay 
For the miRNA-mRNA binding assay, HEK293T cells are seeded in 24 well plates at a density of 
50,000 cells per well 24 h before transfection. Per well, 200 ng luciferase plasmid and 300 ng 
pSuper miRNA overexpression plasmid are mixed in 100 µl of DMEM medium. After addition of 
2 µl of peqFECT or Turbofect transfection reagent, the mix is incubated at room temperature for 
20 min and then added to the wells. For each condition, three biological replicates are 
transfected. 
To test sponge functionality, hPCLs are seeded in 24 well plates at a density of 10,000 cells per 
well 24 h before transfection. Per well, 200 ng luciferase reporter plasmid and 300 ng pSponge 
plasmid are mixed in 100 µl of RPMI 1640 medium. After addition of 2.4 µl of PEI 
(Polyethylenimine, 1 mg/ml in H2O), the mix is incubated at room temperature for 20 min. The 
medium is removed from the cells and they are incubated with the transfection mix. After 6 h, 
the transfection mix is removed and normal medium is added to the cells. For each condition, 
three biological replicates are transfected. 
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Luciferase assay substrate 
To measure the amount of expressed luciferase in the transfected cells, buffers containing the 
substrates for firefly luciferase and renilla luciferase are prepared for measurement. 
Firefly luciferase substrate:  
470 µM  D-Luciferin  
    530 µM ATP   
    270 µM  Coenzyme A  
    20 mM  Tricine 
    5.34 mM  MgSO4 
    0.1 mM  EDTA 
    in H2O 
 
The buffer is first prepared without D-Luciferin. After adjusting to pH = 8.0, D-Luciferin is added. 
The substrate solution is then sterile filtered, aliquoted and stored at -80°C. Prior to luciferase 
assay, 33.3 µl 1 M DTT solution per ml substrate is added. 
Renilla luciferase substrate:  
2.2 mM  EDTA 
    0.22 M KxPO4, pH = 5.1 (from 1 M stock) 
    0.44 mg/ml BSA 
    1.1 M  NaCl 
    1.3 mM NaN3 
    in H2O 
 
After adjusting to pH = 5.0, the buffer is sterile filtered, aliquoted and stored at -20°C. Prior to 
luciferase assay, 1 µl of 1000x coelenterazine per ml substrate is added. 
Harvesting of cells for luciferase assay 
24 h after transfection, the cells are washed once with cold 1x PBS and lysed with 1x passive lysis 
buffer (promega). After 15 min of shaking at room temperature, the lysates are collected and 
centrifuged (16,000 xg, 10 min, 4°C). The supernatant is frozen at -80°C. 
Measuring luciferase assays 
To test for miRNA-mRNA binding, 3 µl of the HEK293T lysate mixed with 22 µl water are pipetted 
in 96 well plates. To test for sponge functionality, 10 µl of the hPCL lysate mixed with 15 µl water 
are pipetted in 96 well plates. For each biological replicate, three technical replica are measured. 
The luminescence is measured using a luminometer (Berthold). In each well, 20 µl of the firefly 
luciferase substrate are injected and firefly luciferase luminescence intensity is measured after a 
delay of 3 s. Afterwards, 20 µl of the renilla luciferase substrate are injected in each well and 
renilla luciferase luminescence intensity is measured after a delay of 3 s. For analysis, the 
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background of non-transfected cells is measured and deducted from the measured values. 
Afterwards, the ratio of firefly luciferase luminescence intensity to renilla luciferase 
luminescence intensity is calculated. 
3.8 miRNA knockout techniques in vivo and in cell culture 
To investigate the effect of lowered miRNA levels in vivo and in cell culture, two different 
methods for miRNA level manipulation, the Vivo-Morpholinos and the miRNA sponges, were 
tested. 
3.8.1 miRNA level manipulation by Vivo-Morpholinos 
For a short-term knockdown of miRNAs in the kidney, male eight weeks old C57/bl6 (C57black6) 
mice weighting 20 - 25 g receive three injections of Vivo-Morpholino solutions directed against 
certain miRNAs or a control Vivo-Morpholino, respectively. The first injection is performed by 
Prof. Frank Schweda (Institute for Physiology, University of Regensburg). In the first injection, 
5 nmol of antisense Vivo-Morpholinos diluted in 200 µl 1x PBS is injected directly into the renal 
aorta of left kidney. The aorta and vein are clamped for 15 min to enhance the retention time of 
Vivo-Morpholinos in the kidney. The second and third injection after 24 h and 48 h, respectively, 
are performed by Andrea Schreiber. In the second and third injection, 25 nmol of Vivo-
Morpholinos are injected by retro orbital injection. After 48 h, urine of the animals is collected in 
metabolic cages for 16 h and checked for proteinuria.  
3.8.2 miRNA knockout by TALEN constructs  
The plasmids coding for a TALE nuclease pair directed against the human genomic locus of miR-
30a-5p are derived from www.talenlibrary.net (Kim et al. 2013). Clones of HEK293T cells are 
generated by cotransfection with plasmids coding for antibiotic resistance, pWE2 (G418 
resistance, ATCC) and pWE3 (puromycin resistance, ATCC). 
In total, 0.5*106 HEK293T cells are seeded 24 h before transfection in a T25 flask. Cells are 
transfected with 3 µg of TALEN-L1, 3 µg TALEN-R1 and 0.6 µg of pWE2 or pWE3 plasmid. The 
plasmids are previously mixed with 13.2 µl peqFECT in 1 ml DMEM medium not containing any 
serum and incubated for 20 min. 24 h after transfection, the cells are trypsinized and seeded in 
three different densities. For selection, G418 (200 µg/mL) or puromycin (1 µg/mL) is added to 
the growing medium. After selection for nine to twelve days, clones are picked and further 
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cultivated separately in 12- or 24- well plates and expanded for DNA and RNA preparation in P10 
cell culture dishes. Over the whole time, the cells are cultured in media containing G418 or 
puromycin.  
The RNA is isolated and analyzed by Northern Blotting and qPCR according to the protocols in 
chapter 3.4. For genome analysis, the DNA is isolated according to the TriFast protocol (chapter 
3.4.2). Shortly, the lower organic phase is mixed with 0.5 ml of 100% ethanol after removal of 
the RNA. After incubation (2 min, RT), the sample is centrifuged (18,700 xg, 15 min, 4°C). The 
DNA pellet is washed twice with 1 ml of sodium citrate in 10% ethanol. Every washing step 
consists of an incubation step (15 min, RT) and a centrifugation step (18,700 xg, 15 min, 4°C). 
The pellet is then washed twice with 2 mL of 75% ethanol, each washing step consisting of an 
incubation step (15 min, RT) and a centrifugation step (18,700 xg, 15 min, 4°C). After drying the 
pellet at 37°C for 15 min, the DNA is resuspended 100 µl of 8 mM NaOH solution. The DNA 
solution is brought to pH = 8.4 with 0.66 µl of 1 M HEPES-buffer.  
The genomic locus of the mir-30a precursor is amplified using isolated genomic DNA from the 
putative knockout cell clones (Tab. 3.11). The PCR products are purified and isolated by agarose 
gel electrophoresis and sequenced.  
Reaction mix for genomic locus PCR: 
 Thermopol 10x reaction buffer  5 µl 
 Primers (10 µM)    2 µl (each) 
 dNTPs (10 mM each)   2 µl 
 Taq-Polymerase (5 U/µl)   2 µl 
 HEK293T clone DNA     500 ng 
 ad 50 µl with H2O 
 
PCR protocol for genomic locus PCR: 
95°C  1 min 
    95°C  30 s  
    60°C  1 min   35 cycles 
    68°C  1 min 
    68°C  1 min 
 
Tab. 3.11: Primer for amplification of the human genomic locus of mir-30a 
Primer name Sequence 
hsa-genloc-30a-F ACA GAA TCG TTG CCT GCA 
hsa-genloc-30a-R GCA GAA AGG GCA GGA CAA AA 
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4 RESULTS 
4.1 Characterization of human podocyte cell line  
To investigate podocytes in cell culture, immortalized cell lines derived from isolated human 
podocytes had been established (Saleem et al. 2002). These cells proliferate at 33°C and 
differentiate when cultured at 37°C for two weeks.  
4.1.1 Immunostaining for podocyte proteins in hPCLs 
To characterize the hPCLs (human podocyte cell line), proliferating and differentiated podocytes 
were stained with antibodies against proteins expressed in podocytes (chapter 3.2.5): the 
podocyte marker protein nephrin, the structural proteins synaptopodin and -actinin-4. 
With all three antibodies (-nephrin, -synaptopodin, --actinin-4), distinct differences in the 
staining could be detected. Proliferating hPCLs stained with the -nephrin antibody showed only 
a weak staining around the nucleus (Fig. 4.1 A, B). Differentiated hPCLs showed localization of 
the protein to the cellular membrane, either in a punctual distribution (Fig. 4.1 C, D) or in a linear 
distribution along the cellular membrane (Fig. 4.1 E, F). Proliferating hPCLs stained with the -
synaptopodin antibody showed nuclear staining of the cells with very weak staining of the 
cellular periphery (Fig. 4.2, A, B). In differentiated hPCLs, numerous fine lines run through the 
cytoplasm (Fig. 4.2, C-F), indicating that synaptopodin is localized to the actin cytoskeleton in the 
differentiated podocytes. Proliferating cells stained with the --actinin-4 antibody show 
staining in lines throughout the cell (Fig. 4.3, A, B), arguing for an actin localization of -actinin-4 
in proliferating hPCLs. In differentiated hPCLs, the protein relocates to “spikes” at the cellular 
membrane together with some punctual spots in the periphery of the cells (Fig. 4.3, C-F). 
Taken together, all three proteins are expressed in distinct patterns in proliferating hPCLs 
compared to differentiated hPCLs. All of them show a relocalization after differentiation, arguing 
for structural and thus metabolic and functional differences between the proliferating and the 
differentiated state. 
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Fig. 4.1: Immunostaining of proliferating and differentiated hPCLs with -Nephrin antibody; (A, B) 
Proliferating human podocytes stained with -Nephrin antibody showing weak, non-localized perinuclear 
staining; (C-F) Differentiated human podocytes stained with -Nephrin antibody; cells show nephrin 
localization at the plasma membrane of the cells, either as distinct punctual accumulation (arrows: C, D) or 
as line shaped accumulation along the plasma membrane (arrowheads: E, F) of the cells 
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Fig. 4.2: Immunostaining of proliferating and differentiated hPCLs with -Synaptopodin antibody; (A,B) 
Proliferating human podocytes stained with -Synaptopodin antibody show nuclear staining of the cells 
with a very weak cytoplasmic staining; (C-F) Differentiated hPCL cells stained with -Synaptopodin 
antibody; cells show Synaptopodin localization in fine lines throughout the whole cell body (arrows), 
indicating actin association of the protein 
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Fig. 4.3: Immunostaining of proliferating and differentiated hPCLs with -actinin-4 antibody; (A,B) 
Proliferating human podocytes stained with -actinin-4 antibody show -actinin-4 localization in lines 
throughout the cell, indicating actin association of the protein; (C-F) Differentiated human podocytes 
stained with -actinin-4 antibody show an altered -actinin-4 localization, with relocation of the 
protein into “spikes” at the cell cortex (arrows) 
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4.1.2  Northern Blotting of miRNAs expressed in human podocyte cell line 
By Northern Blotting (see chapter 3.4.3), hPCLs were tested for expression of miRNAs that were 
found to be expressed in murine glomeruli (chapter 4.2) and murine podocytes (chapter 4.3). For 
each of the candidate miRNAs, expression in proliferating and differentiated cells was 
investigated. 
 
Fig. 4.4: Northern Blotting of candidate miRNAs isolated from proliferating and differentiated cells; 
detection of miRNA expression in 15 µg of total RNA isolated from proliferating (P) and differentiated (D) 
hPCLs; detection of internal standard (snRNA U6) and mature miRNAs 
The intensity of the signals was measured with the Bio1D program (Vilber Lourmat). The 
expression ratio of the mature miRNAs was calculated for all candidate miRNAs with the U6 
signals serving as an internal standard (Tab. 4.1).  
Tab. 4.1: Relative expression of mature miRNAs in proliferating and differentiated hPCLs 
Mature miRNA Diff:Prolif ratio 
miR-10b-5p 0.5 : 1 
miR-92a-3p 0.6 : 1 
miR-130a-3p 1.4 : 1 
miR-30a-5p 1.4 : 1 
miR-146b-5p 2.5 : 1 
miR-29a-3p 1.0 : 1 
miR-23b-3p 2.2 : 1 
miR-22-3p 2.3 : 1 
miR-107(-3p) 1.3 : 1 
miR-27b-3p 2.3 : 1 
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The mature miRNAs miR-10b-5p, miR-92a-3p, miR-130a-3p, miR-mir-30a-5p, miR-146b-5p, miR-
29a-3p, miR-23b-3p, miR-22-3p, miR-107 and miR-27b-3p were expressed in the proliferating as 
well as in the differentiated human podocyte cell line (Fig. 4.4). miR-10b-5p and miR-92a-3p 
showed a reduction of expression after differentiation, while eight miRNAs were expressed at 
higher levels in the differentiated hPCLs. miR-148a-3p, miR-196b-5p, miR-424-5p, miR-542-3p 
and miR-503-5p could neither be detected in the proliferating nor in the differentiated cells. 
4.2 miRNA expression in murine glomeruli and tubules 
4.2.1 Deep sequencing profiles 
For miRNA expression analyses, glomeruli and tubules were isolated from six female 12 week old 
C57bl/6 mice (see chapter 3.3.6). RNA extraction and library preparation was performed by A. 
Dueck (Department of Biochemistry I, University of Regensburg). One deep sequencing profile 
was generated from the total RNA preparation, while the second profile was generated from the 
small RNA fraction enriched by gel electrophoresis. The RNA samples were sequenced on a 
HiSeq1000 sequencer (Illumina). The annotation of the sequenced libraries to the known miRNA 
sequences (miRBase Version 18) was performed by N. Eichner (Department of Biochemistry I, 
University of Regensburg). 
From the total RNA isolated, a glomerular library containing 5.38 million reads and a tubular 
library containing 3.78 million reads were generated. From the enriched small RNA fraction, a 
glomerular library of 4.44 million reads and a tubular library of 5.71 million reads were 
generated (Tab. 10.1). In total, 260 mature miRNA sequences have been identified to be 
expressed more than 5 ppm reads in at least one of the libraries. A total of 69 miRNAs were 
glomerular enriched according to both profiles, while 27 mature miRNAs were detected to be 
glomerular enriched in one of the profiles and equally expressed in the other profile. In addition, 
84 miRNAs were equally expressed in glomeruli and tubules, while 62 miRNAs were tubular 
enriched and 18 miRNAs were tubular enriched in one of the profiles and equally expressed in 
the other profile. 
4.2.2 miRNA library validation by Northern Blotting and qPCR 
The miRNA profiles obtained from murine glomeruli and tubules were validated by Northern 
Blotting and qPCR. 
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Northern Blotting of miRNAs from murine glomeruli and tubules 
For miRNA expression analyses by Northern Blotting (Fig.4.5), RNA was extracted from glomeruli 
and tubules isolated from six female 12 week old C57bl/6 mice with the TriFast protocol (chapter 
3.4.2). Four candidate miRNAs, expressed in murine glomeruli and tubules according to the deep 
sequencing profiles, were chosen to be validated. Two candidates, miR-10a-5p and miR-99a-5p 
were expected to be equally expressed in glomeruli and tubules, whereas miR-27b-3p was 
enriched in glomeruli. miR-26a-5p was equally expressed in the deep-sequencing profile from 
total RNA and slightly glomerular enriched in the profile from the small RNA fraction. 
 
Fig. 4.5: Northern Blotting of mature miRNAs in total RNA isolated from murine glomeruli (G) and tubules 
(T); Detection of internal standard (snRNA U6) and the mature miRNAs 
The intensity of the signals was measured with the Bio1D program (Vilber Lourmat). The 
expression ratio of the mature miRNAs was calculated for all candidate miRNAs using the U6 
signals as an internal standard. The results were compared to the miRNA enrichment according 
to the deep sequencing profiles (Tab. 4.2).  
Tab. 4.2: Relative expression of mature miRNAs in murine glomeruli and tubules; quantification 
of Northern Blotting results 
miRNA Glom:Tub ratio in deep sequencing Glom:Tub ratio in 
Northern Blotting small RNA total RNA 
miR-10a-5p 1.2 : 1 1.1 : 1 0.7 : 1 
miR-26a-5p 2.8 : 1 1.4 : 1 0.9 : 1 
miR-27b-3p 4.7 : 1 4.8 : 1 2.0 : 1 
miR-99a-5p 0.7 : 1 0.9 : 1 0.9 : 1 
 
All four mature miRNAs, miR-10a-5p, miR-26a-5p, miR-27b-3p and miR-99a-5p could be 
detected in total RNA isolated from murine glomeruli as well as in total RNA isolated from 
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murine tubules (Fig. 4.5). For miR-10a-5p, miR-26a-5p and miR-99a-5p, the equal expression in 
glomeruli and tubules could be validated. For miR-27b-3p, the glomerular enrichment could be 
validated. 
qPCR of miRNAs from murine glomeruli and tubules 
To validate expression of a subset of miRNAs, glomeruli and tubules were isolated from six 
female 12 week old C57bl/6 mice. From the isolated small RNA fractions, cDNA was reverse 
transcribed. The relative enrichment of miRNAs in the glomeruli compared to tubules was 
calculated and compared to the result from the deep sequencing profile. The snRNA U6 served 
as an internal control. Since qPCR with normal DNA primers cannot distinguish between miRNAs 
that differ only by one base, enrichment results were treated as total enrichment of whole 
miRNA families. The qPCR was performed on a LightCycler 480II (Roche). The results were 
gathered and analyzed with the LightCycler 480 1.5.0 software (Roche). 
 
Fig. 4.6: Relative enrichment of miRNAs in murine glomeruli compared to tubular expression; internal 
standard: snRNA U6 
Expression ratio between glomeruli and tubules were investigated by qPCR for five miRNAs or 
miRNA families enriched in glomeruli (miR-126-3p, miR-23a/b-3p, miR-145-5p, miR-24-3p and 
miR-27a/b-3p), five miRNAs or miRNA families supposed to be equally expressed in glomeruli 
and tubules (miR-26a/b-5p, miR-92a/b-3p, miR-10a/b-5p, miR-29a/b/c-3p and miR-191-5p) and 
five miRNAs or miRNA families that were enriched in tubules according to the deep sequencing 
profiles (miR-99a/b-5p, miR-21-5p, miR-22-3p, miR-192-5p and miR-200a-3p). All mature 
miRNAs could be detected in both of the samples (Fig. 4.6). 
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Tab. 4.3: Glomerular enrichment of miRNAs; comparison of qPCR experiment and miRNA 
enrichment in the previously obtained deep sequencing profiles 
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The results of the qPCR analysis were compared to the results from the deep sequencing profiles 
(Tab. 4.3). miR-126-3p, miR-145-5p, miR-24-3p and miR-27a/b-3p showed a clear glomerular 
enrichment in both deep sequencing profiles as well as in the qPCR. Both miR-23a-3p and miR-
23b-3p were glomerular enriched in the deep sequencing profile from total RNA, but not in the 
deep sequencing from enriched small RNAs. Glomerular enrichment of this miRNA family could 
be shown by qPCR. miR-26a/b-5p was slightly glomerular enriched in the qPCR analysis, while 
the results from the deep sequencing analyses differ from profile to profile and for both family 
members. For miR-92a/b-3p, miR-10a/b-5p, miR-29a/b/c-3p and miR-191-5p, equal expression 
between glomeruli and tubules was found in the deep sequencing profiles as well as in the qPCR 
analysis. miR-21-5p, miR-192-5p and miR-200a-5p were all found to be tubular enriched in qPCR, 
confirming the results from both deep sequencing profiles. miR-99a/b-5p and miR-22-3p both 
showed equal expression in the deep sequencing profiles but tubular enrichment in the qPCR 
analysis. 
Taken together, expression of the candidate miRNAs and miRNA families could be validated in 
glomeruli and tubules. The enrichment from the deep sequencing profiles could be validated for 
eleven of 15 miRNAs. For miR-23a/b-3p family, the qPCR result matches one of the deep 
sequencing profiles. For miR-26a/b-5p, the qPCR result can be explained by the fact that miR-
26a-5p, which is glomerular enriched in the profile obtained from total RNA, is higher expressed 
than miR-26b-5p. For miR-99a/b-3p and miR-22-3p, enrichment in the qPCR analyses does not fit 
the result from the deep sequencing profiles. 
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4.3 Differential miRNA expression in the different glomerular cell types 
The mammalian glomeruli consist of the three main cell type, the podocytes, the mesangial and 
the endothelial cells (Fig. 4.7 A), meaning that a miRNA expressed in the glomeruli is not 
necessarily a miRNA important for podocyte structure and function.  
 
Fig. 4.7: Cell populations in mammalian glomeruli; (A) Representation of the localization of the three main 
cell types in the mammalian glomerulus (Aitsebaomo et al. 2008, modified) (B) Genomic organization of 
the mTmG x P2.5Cre mouse 
A double fluorescent Cre reporter mouse crossed with a mouse expressing podocyte specific Cre 
recombinase under the control of the NPHS2 promotor was used for podocyte isolation (Fig. 4.7 
B). The mTomato gene in these mice is flanked by loxP sites, the Cre recombinase recognition 
sites. In cells expressing Cre recombinase, the Tomato cassette is cut out and the mGFP cassette 
is transcribed, leading to green fluorescent cells while the rest of the animal cell show red 
fluorescence. 
 
Fig. 4.8: Double fluorescent glomeruli from mTmG x P2.5Cre mice; (A) freshly isolated glomeruli consisting 
of green podocytes and red endothelial and mesangial cells; (B) After second digestion, the green 
podocytes are detached from the glomerular structure; (C) The green and red fluorescent cell populations 
are separated by FACS analysis 
Glomeruli consisting of green and red fluorescent cells were isolated from male mTmG x P2.5Cre 
mice of 12 - 30 weeks of age (Fig. 4.8 A). After the second digestion step (chapter 3.3.6), the 
green fluorescent podocytes were detached from the glomerular structure (Fig. 4.8 B). The cell 
suspension consisting of green and red fluorescent cells could be sorted by FACS (Fig. 4.8 C). 
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4.3.1 Confirmation of cell populations 
To check for identity of the sorted green and red fluorescent cell population, the “green cells” 
and the “red cells”, qPCR was performed against cell type specific miRNAs. In the podocyte 
specific Dicer knockout mouse, it was shown by in situ hybridization that the Dicer knockout 
leads to a strong miR-30a-5p reduction in the mouse glomeruli, whereas the expression levels of 
miR-126-3p and miR-145-5p seem to be unaffected (Harvey et al. 2008). miR-126-3p seemed to 
be a miRNA predominantly expressed in the endothelium, while miR-145-5p seemed to be 
mesangially expressed. The strong enrichment of miR-30a-5p in the podocytes as well as the 
endothelial and mesangial expression, respectively, of miR-126-3p and miR-145-5p could be 
validated by qPCR (Fig. 4.9 left). Furthermore, it could be shown that the podocyte-specific 
transcription factor Lmx1b and the podocyte-specific slit diaphragm component podocin were 
highly enriched in the green cell population. Both enrichments were measured to be higher than 
20-fold over the expression levels in the red cell population (Fig. 4.9 right). The residual 
expression of these two markers in the red cell population can be explained by a small 
population of podocytes still expressing the mTomato gene, meaning that the Cre recombinase 
mediated “switch” from red to green fluorescence did not work in these cells. Additionally, 
expression of the endothelial marker CD31 (Newman et al. 1990) could only be detected in the 
red cell population, proving the presence of endothelial cells in the mixed red cell population. 
Taken together, these results confirm that the green cell population consists of podocytes, while 
the red population is a mixture of endothelial cells, mesangial cells and some residual podocytes. 
 
Fig. 4.9: Identification of cell types in glomerular cell population; cell type specific expression of mature 
miRNAs (left) and protein coding genes (right) in the green and red cell populations 4.3.2 Deep-sequencing profiles 
Two independent miRNA deep sequencing profiles from green and red fluorescent cells were 
generated from around 150,000 green fluorescent podocytes and 150,000 red fluorescent 
mesangial and endothelial cells or around 100,000 green fluorescent podocytes and 100,000 red 
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fluorescent mesangial and endothelial cells. The samples were each isolated from six 12 to 14 
weeks old male mTmG x P2.5Cre mice.  
Tab. 4.4: Podocyte enriched miRNAs; enrichment according to two deep sequencing profiles 
derived from freshly isolated murine podocytes and the red fluorescent cell population  
miRNAs 
podocytes vs. red fluorescent cells 
1st profile 2nd profile 
Red Cells  
reads 
Red Cells   
‰ 
Podocytes         
reads 
Podocytes         
‰ 
Ratio (Pc/ 
Red C.) 
Red Cells   
reads 
Red  
Cells ‰ 
Podocytes         
reads 
Podocytes         
‰ 
Ratio (Pc/ 
Red C.) 
mmu-let-7e-3p 81 0.02 214 0.04 2.65 79 0.01 211 0.04 2.76 
mmu-miR-23b-3p 8,916 1.68 20,360 3.84 2.29 7,866 1.46 22,111 4.25 2.90 
mmu-miR-24-1-5p 27 0.01 60 0.01 2.23 27 0.01 113 0.02 4.32 
mmu-miR-27b-5p 339 0.06 847 0.16 2.51 279 0.05 760 0.15 2.81 
mmu-miR-30a-3p 17,250 3.24 60,898 11.48 3.54 23,919 4.45 92,817 17.83 4.01 
mmu-miR-30a-5p 221,539 41.63 1,080,588 203.78 4.90 110,666 20.60 738,560 141.87 6.89 
mmu-miR-30b-3p 195 0.04 623 0.12 3.21 237 0.04 946 0.18 4.12 
mmu-miR-30b-5p 2,663 0.50 8,906 1.68 3.36 3,197 0.59 10,086 1.94 3.26 
mmu-miR-30c-2-3p 4,969 0.93 19,948 3.76 4.03 5,423 1.01 24,398 4.69 4.64 
mmu-miR-30c-5p 11,104 2.09 36,253 6.84 3.28 14,980 2.79 58,989 11.33 4.06 
mmu-miR-30d-3p 114 0.02 355 0.07 3.13 70 0.01 282 0.05 4.16 
mmu-miR-30d-5p 27,942 5.25 146,004 27.53 5.24 24,399 4.54 127,730 24.54 5.40 
mmu-miR-99a-3p 64 0.01 495 0.09 7.76 33 0.01 169 0.03 5.29 
mmu-miR-99a-5p 134 0.03 795 0.15 5.95 182 0.03 485 0.09 2.75 
mmu-miR-107-3p 530 0.10 2,513 0.47 4.76 788 0.15 3,170 0.61 4.15 
mmu-miR-125b-2-3p 70 0.01 436 0.08 6.25 59 0.01 248 0.05 4.34 
mmu-miR-125b-5p 333 0.06 952 0.18 2.87 642 0.12 1,273 0.24 2.05 
mmu-miR-130a-3p 994 0.19 4,660 0.88 4.70 998 0.19 3,059 0.59 3.16 
mmu-miR-146b-5p 542 0.10 13,295 2.51 24.62 455 0.08 7,755 1.49 17.59 
mmu-miR-148a-3p 1,376 0.26 6,333 1.19 4.62 2,292 0.43 5,082 0.98 2.29 
mmu-miR-149-5p 24 0.00 310 0.06 12.96 61 0.01 448 0.09 7.58 
mmu-miR-196b-5p 908 0.17 4,904 0.92 5.42 1,396 0.26 9,553 1.83 7.06 
mmu-miR-210-3p 199 0.04 1,595 0.30 8.04 166 0.03 856 0.16 5.32 
mmu-miR-322-3p 1,810 0.34 14,940 2.82 8.28 3,093 0.58 13,469 2.59 4.49 
mmu-miR-330-3p 25 0.00 222 0.04 8.91 23 0.00 120 0.02 5.39 
mmu-miR-330-5p 37 0.01 306 0.06 8.30 21 0.00 112 0.02 5.50 
mmu-miR-340-5p 1,281 0.24 3,535 0.67 2.77 925 0.17 3,263 0.63 3.64 
mmu-miR-351-3p 3 0.00 54 0.01 18.06 15 0.00 46 0.01 3.17 
mmu-miR-351-5p 1,332 0.25 8,439 1.59 6.36 1,400 0.26 5,192 1.00 3.83 
mmu-miR-450a-5p 272 0.05 962 0.18 3.55 378 0.07 1,000 0.19 2.73 
mmu-miR-450b-5p 64 0.01 334 0.06 5.24 64 0.01 296 0.06 4.77 
mmu-miR-503-3p 38 0.01 152 0.03 4.01 50 0.01 197 0.04 4.07 
mmu-miR-503-5p 591 0.11 2,677 0.50 4.55 713 0.13 1,832 0.35 2.65 
mmu-miR-542-3p 550 0.10 1,829 0.34 3.34 626 0.12 3,334 0.64 5.50 
mmu-miR-574-3p 369 0.07 1,473 0.28 4.01 725 0.13 2,017 0.39 2.87 
mmu-miR-615-3p 21 0.00 167 0.03 7.98 45 0.01 134 0.03 3.07 
mmu-miR-652-3p 315 0.06 878 0.17 2.80 278 0.05 847 0.16 3.14 
mmu-miR-873a-5p   170 0.03   1 0.00 80 0.02 82.57 
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RNA extraction and library preparation was performed by A. Dueck and N. Eichner (Department 
of Biochemistry I, University of Regensburg). For both profiles, the small RNAs were enriched by 
gel electrophoresis. The RNA samples were sequenced on a HiSeq1000 sequencer (Illumina). The 
annotation of the sequenced libraries to the known miRNA sequences (miRBase Version 19) was 
performed by N. Eichner (Department of Biochemistry I, University of Regensburg). 
Fig. 4.10: miRNAs enriched in podocytes; miRNAs showing a more than two fold enrichment in podocytes 
compared to the red fluorescent cell population in two deep sequencing profiles; Left: miRNAs showing 
more than ten-fold enrichment in one of the profiles; right: miRNAs showing less than ten-fold enrichment 
in both profiles 
 
The two deep sequencing profiles, consisting of 4.19 million reads from podocytes and 4.02 
million reads from the red fluorescent cell population and 4.45 million reads from podocytes and 
3.88 million reads from the red fluorescent cell population showed a very good result overlap 
(Tab. 10.2). A total of 38 miRNAs were enriched more than two-fold in the podocytes compared 
to the red fluorescent cell population in both profiles (Tab. 4.4, Fig. 4.10). Four mature miRNAs 
were only detected as podocyte enriched in one profile. As mmu-miR-873a-5p was not detected 
in the red fluorescent cell population in the first profile, a ratio could not be calculated. In total, 
69 miRNAs were equally expressed in both cell populations according to the profiles, while 93 
miRNAs were enriched in the red fluorescent cell population both times. One miRNA was 
enriched in podocytes in one profile but enriched in the red cell population in the other profile. 
A total of 42 miRNAs were found to be enriched in one of the profiles while being equally 
expressed in the other profile and 47 miRNAs were only detected in one of the profiles. 
Surprisingly, only ten miRNAs that had earlier been identified as glomerular enriched could be 
identified as podocyte enriched miRNAs. Seven miRNAs were equally expressed in the 
glomerular cell populations, while the majority of 36 mature miRNAs, was enriched in the 
endothelial and mesangial cells, with some of them hardly expressed in podocytes. 
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4.3.3 Profile validation by qPCR 
To validate the deep sequencing profiles, a subset of 23 miRNAs expressed in the murine 
podocytes and the endothelial and mesangial cells was analyzed for relative enrichment by 
qPCR. For validation, the small RNA fraction was isolated from 700,000 podocytes and 330,000 
endothelial and mesangial cells from six female 14 week old mTmGxP2.5Cre mice. Equal 
amounts of RNA were reverse transcribed to cDNA. The relative enrichment of miRNAs in the 
podocytes compared to the endothelial and mesangial cells was calculated and compared to the 
result from the deep sequencing profiles. The snRNA U6 served as an internal control. Since 
qPCR with normal DNA primers cannot distinguish between miRNAs that differ only by one base, 
enrichment results were treated as total enrichment of whole miRNA families. The qPCR was 
performed on a LightCycler 480II (Roche). The results were gathered and analyzed with the 
LightCycler 480 1.5.0 software (Roche). 
 
Fig. 4.11: qPCR quantification of mature miRNAs enriched in podocytes; relative expression in the murine 
podocytes (green) and the red fluorescent cell population (red) was calculated (expression in red 
fluorescent cell population = 1) 
For ten miRNAs that were podocyte enriched in both deep sequencing profiles, miR-146b-5p, 
miR-30a/d/e-5p, miR-322-3p, miR-130a-3p, miR-503-5p, miR-210-3p, miR-351-5p, miR-542-3p, 
miR-148a-3p and miR-107-3p, podocyte enrichment could be confirmed by qPCR (Fig. 4.11, Tab. 
4.5). miR-22-3p which was podocyte enriched in one of the profiles, and miR-26a/b-5p, where 
only one family member was podocyte enriched in one of the deep sequencing profiles, were 
podocyte enriched in the qPCR analysis. miR-24-3p was equally expressed according to both 
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deep sequencing profiles, but podocyte enriched in the qPCR. The miR-29a/b/c-3p family was 
equally expressed in both profiles as well as in the qPCR. 
Tab. 4.5: Enrichment of mature miRNAs in podocytes; enrichment according to qPCR analyses 
and two deep sequencing profiles in green fluorescent podocytes compared to red fluorescent 
endothelial and mesangial cells 
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Relative expression was also validated for miRNAs that were enriched in the red cell population 
according to the deep sequencing profiles (Fig. 4.12, Tab. 4.6). In the miR-27a/b-3p family, one 
miRNA was equally expressed and one family member was enriched in the red fluorescent cell 
population according to the profiles. The total result from the qPCR showed it to be equally 
expressed. miR-23a-3p was enriched in the red fluorescent cell population while miR-23b-3p was 
enriched in the podocytes according to both deep sequencing profiles. In total, the miR-23a/b-3p 
family was enriched in the red fluorescent cell population in the qPCR. 
 
Fig. 4.12: qPCR quantification of mature miRNAs enriched in the red fluorescent cell population; relative 
expression in the murine podocytes (green) and the red fluorescent cell population (red) was calculated 
(expression in red fluorescent cell population = 1) 
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Tab. 4.6: Enrichment of mature miRNAs in “red fluorescent cell population”; enrichment 
according to qPCR analyses and two deep sequencing profiles in green fluorescent podocytes 
compared to the red fluorescent cell population 
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For six miRNAs, miR-200a-3p, miR-200c-3p, miR-143-3p, miR-145-5p, miR-126-3p and miR-127-
3p, enrichment in the red fluorescent cell population could be validated by qPCR. According to 
both deep sequencing profiles, miR-92a-3p is expressed in much higher amount than miR-92b-3p 
(> 100 in podocytes and > 300 in the red fluorescent cell population). This explains why the qPCR 
result is mainly influenced by miR-92a-3p. In total, podocyte enrichment could be validated for 
ten miRNAs or miRNA families. One miRNA family was equally expressed in both profiles as well 
as in the qPCR analyses, while seven miRNAs could be validated as enriched in the red 
fluorescent cell population. 
4.4 miRNA target prediction by different in silico tools 
In this work, the main focus lies on the specific interactions between the mRNAs coding for 
proteins important for maintenance of podocyte structure and function and the miRNAs that are 
enriched or highly expressed in podocytes.  
Initial screening for putative miRNA targets using miRWalk 
The first in silico predictions were performed using miRWalk, a prediction algorithm itself that 
also assesses the prediction results of seven other prediction programs (DIANAmT, miRanda, 
miRDB, RNAhybrid, PICTAR4, PICTAR5, PITA, RNA22 and Targetscan). The human 3‘-UTRs of 
mRNAs coding for proteins important for podocyte structure and function were analyzed for 
binding sites of miRNAs enriched or highly expressed in podocytes. Only miRNAs that were 
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predicted as possible regulators by at least half of the programs, N ≥ 4, were considered hits 
(Tab. 4.7). When members of a miRNA family received different numbers of hits, the number for 
the family member with the highest score is given in the table. 
 
Tab. 4.7: Podocyte miRNAs target prediction using miRWalk; podocyte candidate miRNAs 
predicted to target mRNAs coding for proteins important for podocyte structure and functions 
(chapter 1.4.1); in column “hits”, the number of different programs predicting a certain 
interaction is given 
Potential target miRNA hits (max. = 8) 
ACTN4 – -Actinin-4 no hits meeting the criteria  
ACTR2 – Actin related protein 2 
(member of ARP2/3 complex) 
hsa-miR-23a/b-3p 
hsa-miR-107 
hsa-miR-22-3p 
hsa-miR-27a/b-3p 
hsa-miR-340-5p  
hsa-miR-450b-5p 
hsa-miR-503-5p 
6 
6 
5 
5 
5 
5 
5 
CD2AP – CD2 associated protein hsa-miR-26a/b-5p 
hsa-miR-27a/b-3p  
hsa-miR-30a-e-5p  
hsa-miR-92a/b-3p 
hsa-miR-340-5p 
hsa-miR-130a-3p 
hsa-miR-450b-5p 
hsa-miR-503-5p 
hsa-miR-107 
6 
6 
6 
6 
6 
5 
5 
5 
4 
CDC42 – Cell division control protein 42 homolog hsa-miR-29a-c-3p 
hsa-miR-27a/b-3p 
hsa-miR-92a/b-3p 
hsa-miR-107 
6 
5 
4 
4 
CLIC5 – Chloride intracellular channel protein 5 hsa-miR-26a/b-5p 
hsa-miR-340-5p 
4 
4 
EZR - Ezrin hsa-miR-27a/b-3p 
hsa-miR-22-3p 
hsa-miR-23a/b-3p 
hsa-miR-148a-3p 
hsa-miR-450b-5p 
hsa-miR-107 
hsa-miR-130a-3p 
7 
6 
5 
5 
5 
4 
4 
FAT1 - Protocadherin Fat 1 hsa-miR-26a/b-5p 4 
FYN – Proto-oncogene tyrosinkinase Fyn hsa-miR-27a/b-3p 5 
GRB2 – Growth factor receptor-bound protein 2 hsa-miR-27a/b-3p 
hsa-miR-10a/b-5p 
hsa-miR-22-3p 
hsa-miR-149-5p 
hsa-miR-450b-5p 
hsa-miR-107  
hsa-miR-146b-3p 
8 
5 
5 
5 
5 
4 
4 
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Potential target miRNA hits (max. = 8) 
IQGAP1 – Ras GTPase-activating-like protein IQGAP1 hsa-miR-107 
hsa-miR-146b-5p 
hsa-miR-24-3p 
hsa-miR-30a-e-5p 
hsa-miR-340-5p  
hsa-miR-542-5p 
6 
6 
5 
5 
5 
5 
LMX1B – LIM homeobox transcription factor 1-beta hsa-miR-210-3p 
hsa-miR-149-5p 
5 
4 
NCK1 - Non-catalytic region of tyrosine kinase adaptor 
protein 1 
hsa-miR-542-3p 
hsa-miR-340-5p 
6 
5 
NCK2 - Non-catalytic region of tyrosine kinase adaptor 
protein 2 
hsa-miR-30a-e-5p 
hsa-miR-92a/b-3p  
hsa-miR-340-5p 
hsa-miR-450b-5p 
4 
4 
4 
4 
NEPH1 (KIRREL) - Kin of IRRE-like protein 1 hsa-miR-29a-c-3p 
hsa-miR-10a/b-5p 
hsa-miR-107 
hsa-miR-149-5p  
6 
5 
5 
4 
NEPH3 (KIRREL2) - Kin of IRRE-like protein 1 hsa-miR-149-5p 4 
NOSTRIN - Nitric oxide synthase trafficking hsa-miR-196b-5p 4 
NPHS1 – Nephrin hsa-miR-107 5 
NPHS2 – Podocin hsa-miR-450b-5p  
hsa-miR-542-3p 
5 
5 
PARD3 - Partitioning defective 3 homolog no hits meeting the criteria  
PARD6A - Partitioning defective 6 homolog alpha no hits meeting the criteria  
PARD6B - Partitioning defective 6 homolog beta hsa-miR-23a/b-3p 
hsa-miR-27a/b-3p 
hsa-miR-10a/b-5p 
hsa-miR-92a/b-3p 
hsa-miR-146b-5p 
hsa-miR-340-5p 
hsa-miR-503-5p 
hsa-miR-542-3p 
hsa-miR-196b-5p 
6 
6 
5 
5 
5 
5 
5 
5 
4 
PODXL - Podocalyxin Hsa-miR-149-5p 
hsa-miR-22-3p 
hsa-miR-107 
hsa-miR-148a-3p 
hsa-miR-340-5p 
5 
4 
4 
4 
4 
RAC1 - Ras-related C3 botulinum toxin substrate 1 hsa-miR-542-3p 
hsa-miR-146b-5p 
hsa-miR-148a-3p 
hsa-miR-340-5p 
hsa-miR-450b-5p 
hsa-miR-574-3p 
5 
4 
4 
4 
4 
4 
RHOA - Ras homolog gene family, member A hsa-miR-340-5p 
hsa-miR-146b-5p 
6 
4 
TLN1 – Talin-1 hsa-miR-196b-5p 
hsa-miR-503-5p 
4 
4 
TRPC6 - Transient receptor potential cation channel, 
subfamily C, member 6 
hsa-miR-10a/b-5p 
hsa-miR-29a-c-3p 
hsa-miR-30a-e-5p 
hsa-miR-26a/b-5p 
6 
6 
6 
5 
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Potential target miRNA hits (max. = 8) 
hsa-miR-340-5p 
hsa-miR-23a/b-3p 
5 
4 
VEGFA - Vascular endothelial growth factor A hsa-miR-29a-c-3p 
hsa-miR-24-3p 
hsa-miR-107 
hsa-miR-503-5p 
hsa-miR-23a/b-3p 
7 
6 
6 
5 
4 
WASL - Neural Wiskott-Aldrich syndrome protein hsa-miR-130a-3p 
hsa-miR-92a/b-3p 
hsa-miR-148a-3p 
hsa-miR-23a/b-3p 
hsa-miR-27a/b-3p 
hsa-miR-30a-e-5p 
hsa-miR-196b-5p 
hsa-miR-340-5p 
hsa-miR-10a/b-5p 
hsa-miR-107 
hsa-miR-503-5p 
7 
6 
6 
5 
5 
5 
5 
5 
4 
4 
4 
WT1 - Wilms tumor protein hsa-miR-503-5p 
hsa-miR-23a/b-3p  
hsa-miR-340-5p 
6 
5 
5 
 
To narrow down the candidate set, proteins that are important for the slit diaphragm predicted 
to be targeted by miRNAs expressed in podocytes in sufficiently high levels were chosen as a first 
candidate set. A group of four putative target proteins, CD2AP, Fyn, Nck2, Neph1, all known to 
directly interact with nephrin, the main protein of the slit diaphragm, was selected for the first 
further studies. In silico predictions for these four candidates were refined using miRWalk2, a 
prediction platform that compares the results of 12 different prediction algorithms, miRWalk, 
Micro4t, miRanda, mirbridge, miRDB, miRMap, miRNAMAp, Pictar2, PITA, RNA22, RNAhybrid 
and Targetscan (Tab. 4.8 – 4.15). Additionally, the alignment analysis of the human and murine 
3’-UTRs was performed to identify conserved binding sites. 
CD2AP 
The human and murine protein coding transcripts of CD2AP, NM_012120 and NM_009847, both 
possess relatively long 3’-UTRs of 3,036 and 3,377 nucleotides, respectively. For both transcripts, 
possible miRNA interaction partners were predicted with miRWalk2 using 12 different prediction 
algorithms (Tab. 4.8 and 4.9).  
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Tab. 4.8: miRWalk2 predictions of miRNAs targeting human CD2AP 3’-UTR; criterion: sum of 
predictions ≥4 
Gene Transcript number Mature miRNA 
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CD2AP NM_012120 hsa-miR-92a-3p 1 1 1 0 1 1 0 1 1 1 1 1      10
CD2AP NM_012120 hsa-miR-92b-3p 0 1 1 1 1 1 0 1 1 1 1 1      10
CD2AP NM_012120 hsa-miR-27b-3p 0 1 1 0 1 1 0 1 1 1 1 1 9 
CD2AP NM_012120 hsa-miR-450b-5p 1 1 1 0 1 1 0 1 1 0 1 1 9 
CD2AP NM_012120 hsa-miR-27a-3p 0 1 1 0 1 1 0 1 1 1 1 1 9 
CD2AP NM_012120 hsa-miR-30b-5p 1 1 1 0 0 1 0 0 1 1 1 1 8 
CD2AP NM_012120 hsa-miR-30e-5p 1 1 1 0 0 1 0 0 1 1 1 1 8 
CD2AP NM_012120 hsa-miR-30c-5p 1 1 1 0 0 1 0 0 1 1 1 1 8 
CD2AP NM_012120 hsa-miR-340-5p 1 1 1 0 1 1 0 0 1 0 1 1 8 
CD2AP NM_012120 hsa-miR-30a-5p 1 1 1 0 0 1 0 0 1 1 1 1 8 
CD2AP NM_012120 hsa-miR-503-5p 1 1 0 0 0 1 0 0 1 1 1 1 7 
CD2AP NM_012120 hsa-miR-30d-5p 1 1 1 0 0 1 0 0 1 0 1 1 7 
CD2AP NM_012120 hsa-miR-130a-3p 0 1 1 0 0 1 0 0 1 0 1 1 6 
CD2AP NM_012120 hsa-miR-107 1 1 0 0 0 1 0 0 1 1 1 0 6 
CD2AP NM_012120 hsa-miR-29b-3p 0 1 0 0 0 1 0 0 1 1 1 0 5 
CD2AP NM_012120 hsa-miR-29c-3p 0 1 0 0 0 1 0 0 1 1 1 0 5 
CD2AP NM_012120 hsa-miR-450a-5p 0 0 1 0 0 1 0 0 1 0 1 1 5 
CD2AP NM_012120 hsa-miR-29a-3p 0 1 0 0 0 1 0 0 1 1 1 0 5 
CD2AP NM_012120 hsa-miR-30e-3p 0 0 1 0 0 1 0 0 0 0 1 1 4 
CD2AP NM_012120 hsa-miR-23b-3p 0 1 0 0 0 0 0 0 1 1 1 0 4 
CD2AP NM_012120 hsa-miR-30d-3p 0 0 1 0 0 1 0 0 0 0 1 1 4 
CD2AP NM_012120 hsa-miR-30a-3p 0 0 1 0 0 1 0 0 0 0 1 1 4 
CD2AP NM_012120 hsa-miR-23a-3p 0 1 0 0 0 0 0 0 1 1 1 0 4 
 
Equivalent predictions were performed for the murine 3’-UTR of Cd2ap. 
Tab. 4.9: miRWalk2 predictions of miRNAs targeting murine Cd2ap 3’-UTR; criterion: sum of 
predictions ≥4 
Gene Transcript number Mature miRNA 
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Cd2ap NM_009847 mmu-miR-92a-3p 1 1 1 0 1 1 0 0 1 1 1 1 9 
Cd2ap NM_009847 mmu-miR-92b-3p 1 1 1 0 1 1 0 0 1 1 1 1 9 
Cd2ap NM_009847 mmu-miR-27a-3p 1 1 1 0 1 1 0 0 1 0 1 1 8 
Cd2ap NM_009847 mmu-miR-27b-3p 1 1 1 0 1 1 0 0 1 0 1 1 8 
Cd2ap NM_009847 mmu-miR-340-5p 1 1 1 0 0 1 0 0 1 0 1 1 7 
Cd2ap NM_009847 mmu-miR-542-3p 1 0 0 0 0 1 0 0 1 1 1 1 6 
Cd2ap NM_009847 mmu-miR-503-5p 1 1 0 0 0 1 0 0 1 0 1 1 6 
Cd2ap NM_009847 mmu-miR-107-3p 1 1 0 0 0 1 0 0 1 1 1 0 6 
Cd2ap NM_009847 mmu-miR-29b-3p 1 1 0 0 0 1 0 0 1 1 1 0 6 
Cd2ap NM_009847 mmu-miR-30f 1 0 1 0 0 1 0 0 0 0 1 1 5 
Cd2ap NM_009847 mmu-miR-29a-3p 0 1 0 0 0 1 0 0 1 1 1 0 5 
Cd2ap NM_009847 mmu-miR-23a-3p 1 1 0 0 0 1 0 0 1 0 1 0 5 
Cd2ap NM_009847 mmu-miR-30c-2-3p 1 0 0 0 0 1 0 0 0 1 1 1 5 
Cd2ap NM_009847 mmu-miR-450b-5p 1 0 0 0 0 1 0 0 1 1 1 0 5 
Cd2ap NM_009847 mmu-miR-23b-3p 1 1 0 0 0 1 0 0 1 0 1 0 5 
Cd2ap NM_009847 mmu-miR-29c-3p 1 1 0 0 0 1 0 0 1 0 1 0 5 
Cd2ap NM_009847 mmu-miR-30a-5p 1 1 0 0 0 0 0 0 1 0 1 0 4 
Cd2ap NM_009847 mmu-miR-30e-5p 1 1 0 0 0 0 0 0 1 0 1 0 4 
Cd2ap NM_009847 mmu-miR-30b-3p 1 0 0 0 0 1 0 0 0 1 1 0 4 
Cd2ap NM_009847 mmu-miR-196b-5p 0 0 0 0 0 1 0 0 1 1 1 0 4 
Cd2ap NM_009847 mmu-miR-30b-5p 1 1 0 0 0 0 0 0 1 0 1 0 4 
Cd2ap NM_009847 mmu-miR-30c-1-3p 0 0 0 0 0 1 0 0 0 1 1 1 4 
Cd2ap NM_009847 mmu-miR-30c-5p 1 1 0 0 0 0 0 0 1 0 1 0 4 
Cd2ap NM_009847 mmu-miR-30d-5p 1 1 0 0 0 0 0 0 1 0 1 0 4 
Cd2ap NM_009847 mmu-miR-130b-3p 1 0 0 0 0 0 0 0 1 1 1 0 4 
Cd2ap NM_009847 mmu-miR-322-3p 1 0 0 0 0 1 0 0 1 0 1 0 4 
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Only the 3’-end of the 3’-UTRs of the human and the murine transcript show a good interspecies 
alignment. The region was especially analyzed for conserved miRNA binding sites (Fig. 4.13). 
Murine  2683  ACAGCATTGAATCTGTCATTGCCAAATTATTAGTGAATGTATAGTTCAGATTTGCTAGTC  2742 
              ||||||| |||||  ||||||||||||||||||||||||||||||||||    | || || 
Human   2259  ACAGCATGGAATC--TCATTGCCAAATTATTAGTGAATGTATAGTTCAG----G-TATTC  2311 
 
Murine  2743  TTTGA-A-ACACAGCACTCCTAAGTTTCT-AACAGGATTCCAATGTTATTTTGGTGTGTT  2799 
              ||||| | |||||| | || | | ||||| ||  | ||| || |||||||||  | |||| 
Human   2312  TTTGAGACACACAGTA-TCATTAATTTCTGAATTGTATTTCAGTGTTATTTT--T-TGTT  2367 
 
Murine  2800  TGTGACCACTAAGCTTGCT-TCTTACTATAAAGGTATTACCT-CTATACAACTGTACAGG  2857 
              |||||||||||||||| || ||||| || |||| | |||||| ||| | || | || | | 
Human   2368  TGTGACCACTAAGCTT-CTGTCTTAATACAAAGCTGTTACCTTCTACAGAA-TTTA-A-G  2423 
 
Murine  2858  ACTTCACAGAAAATCAGAAGATGCAGAGAGAGTGGGCCCGGTCTTAACAG-AG-GACTC-  2914 
               | | | || |  | | |||| | ||| | |   ||||  ||  |||||| ||  ||||  
Human   2424  TC-TGA-AG-ATGT-A-AAGA-G-AGA-ACA---GGCCTTGT-GTAACAGAAGATACTCT  2471 
 
Murine  2915  --CTTACACTCCTAACTGTGATCACAGACAAGAAAT-ACCTTCCGAAGTGCTCTGTAGAt  2971 
                 |||  ||||| |||||||||||||| || || | |   ||| ||||||||| ||||  
Human   2472  TTTTTATGCTCCTTACTGTGATCACAGA-AA-AATTAAAAATCC-AAGTGCTCTCTAGA-  2527 
 
Murine  2972  ttttttGATGAATGTTTTATGCTTGCATTTAAACTTGAAATGTATGAGCAGAATGAGACA  3031 
              ||| ||||| ||  |||||||||||||||||||||||||||||||||||||||||||||| 
Human   2528  TTTGTTGATAAACATTTTATGCTTGCATTTAAACTTGAAATGTATGAGCAGAATGAGACA  2587 
 
Murine  3032  ATCT-TTACAATCAGAATTGAGAAGTGTTACAATTGAATGGCCTTG---TGCTGTAGCAA  3087 
              |||  ||| |||||||| |||||||| ||| |||  || |||||||   ||||||||||| 
Human   2588  ATCAGTTA-AATCAGAAATGAGAAGTATTATAATGTAAAGGCCTTGTTTTGCTGTAGCAA  2646 
 
Murine  3088  TAAAATGACCAAGTGCAATGAC----TTTAATAAAATCATCTTTCAAACGTTGCTGCTAT  3143 
              ||||||||||||||||||||||    |||||||||||||| ||| ||| ||||||||||| 
Human   2647  TAAAATGACCAAGTGCAATGACTTGATTTAATAAAATCATATTTTAAAAGTTGCTGCTAT  2706 
 
Murine  3144  TAATATTTTTAGTTAACAAAATT  3166 
               ||||||||| | ||  |||||| 
Human   2707  GAATATTTTTGGCTAT-AAAATT  2728 
Fig. 4.13: Alignment of the 3’UTRs of CD2AP transcripts from human (NM_012120) and mouse 
(NM_009847); predicted seed binding sites are indicated as follows: yellow: miR-27a/b-3p; red: miR-
92a/b-3p; turquoise: miR-107-3p; boxed: miR-503-5p (overlapping with miR-107-3p binding site) 
The possible binding site of the seed region of miR-27a/b-3p, miR-92a/b-3p, miR-107-3p and 
miR-503-5p are conserved between the two species (Fig. 4.13). Furthermore, the 3’-end of the 
human CD2AP 3’-UTR contains a miR-30a-e-5p and a miR-29a-c-3p binding site which are not 
conserved between human and mouse (Fig. 4.14). 
Human  2728  TTACCCTGACTTGCTTTCAATAACTGTTACGTAATGCAGTTGATGTGTAACCTAACATTC  2788 
 
Human  2789  CAAAAAAAAAATTGAGAGGGGGAATCTCAAAATAGTATATACTTCACTAACTTGTTTACA  2849 
 
Human  2851  GGTGCTGTATTTAAAAGCAUGCTTCTC  2878 
Fig.4.14: 3’-end of human 3’-UTR of CD2AP transcript (NM_012120); predicted seed binding sites are 
indicated as follows: yellow: miR-30a-e-5p; red: miR-29a-c-3p 
The 3’-end fragment of the human 3’-UTR of CD2AP with a length of 606 bp was cloned into the 
luciferase reporter vector (pMir-Report, modified) for subsequent luciferase assay (chapter 4.6). 
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The tyrosine kinase Fyn 
The longest human and murine protein coding transcripts for the tyrosine kinase Fyn, 
NM_002037 and NM_008054, possess a 3‘-UTR of 1,407 nucleotides and 1,409 nucleotides, 
respectively. For both transcripts, possible miRNA interaction partners were predicted with 
miRWalk2 using 12 different prediction algorithms (Tab. 4.10 and 4.11). 
Tab. 4.10: miRWalk2 predictions of miRNAs targeting human FYN 3’-UTR; criterion: sum of 
predictions ≥4 
Gene Transcript number Mature miRNA 
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FYN NM_002037 hsa-miR-146b-5p 1 1 1 0 0 1 1 0 0 0 1 1 7 
FYN NM_002037 hsa-miR-27a-3p 1 1 0 0 0 1 0 1 0 1 1 1 7 
FYN NM_002037 hsa-miR-27b-3p 1 1 0 0 0 1 0 1 0 1 1 1 7 
FYN NM_002037 hsa-miR-30e-5p 1 1 0 0 0 1 0 1 0 1 1 1 7 
FYN NM_002037 hsa-miR-130a-3p 0 1 1 0 0 1 0 0 0 1 1 1 6 
FYN NM_002037 hsa-miR-23a-3p 1 1 0 0 0 1 1 0 0 1 1 0 6 
FYN NM_002037 hsa-miR-24-3p 1 0 1 0 0 1 1 0 0 0 1 1 6 
FYN NM_002037 hsa-miR-29a-3p 1 1 0 0 0 1 0 1 0 0 1 1 6 
FYN NM_002037 hsa-miR-29b-3p 1 1 0 0 0 1 0 1 0 0 1 1 6 
FYN NM_002037 hsa-miR-29c-3p 1 1 0 0 0 1 0 1 0 0 1 1 6 
FYN NM_002037 hsa-miR-30a-5p 1 1 0 0 0 1 0 1 0 0 1 1 6 
FYN NM_002037 hsa-miR-30b-5p 1 1 0 0 0 1 0 1 0 0 1 1 6 
FYN NM_002037 hsa-miR-30c-5p 1 1 0 0 0 1 0 1 0 0 1 1 6 
FYN NM_002037 hsa-miR-30d-5p 1 1 0 0 0 1 0 1 0 0 1 1 6 
FYN NM_002037 hsa-miR-340-5p 1 1 0 0 0 1 1 0 0 0 1 1 6 
FYN NM_002037 hsa-miR-450b-5p 0 1 1 0 0 1 0 0 0 0 1 1 5 
FYN NM_002037 hsa-miR-149-5p 0 1 0 0 0 1 1 0 0 1 1 0 5 
FYN NM_002037 hsa-miR-23b-3p 1 1 0 0 0 1 1 0 0 0 1 0 5 
FYN NM_002037 hsa-miR-30a-3p 0 1 0 0 0 1 1 0 0 0 1 1 5 
FYN NM_002037 hsa-miR-503-5p 0 1 0 0 0 1 1 0 0 0 1 0 4 
FYN NM_002037 hsa-miR-23c 1 1 0 0 0 1 0 0 0 0 1 0 4 
FYN NM_002037 hsa-miR-30d-3p 0 1 0 0 0 1 0 0 0 0 1 1 4 
 
Equivalent predictions were performed for the murine 3’-UTR of Fyn. 
Tab. 4.11: miRWalk2 predictions of miRNAs targeting murine Fyn 3’-UTR; criterion: sum of 
predictions ≥4 
Gene Transcript number Mature miRNA 
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Fyn NM_008054 mmu-miR-27b-3p 1 0 1 0 0 1 1 0 0 0 1 1 6 
Fyn NM_008054 mmu-miR-27a-3p 1 0 1 0 0 1 0 0 0 0 1 1 5 
Fyn NM_008054 mmu-miR-30f 1 0 1 0 0 1 0 0 0 0 1 1 5 
Fyn NM_008054 mmu-miR-29a-3p 1 0 0 0 0 1 1 0 0 0 1 1 5 
Fyn NM_008054 mmu-miR-322-3p 1 0 1 0 0 1 0 0 0 0 1 1 5 
Fyn NM_008054 mmu-miR-30e-5p 1 0 0 0 0 1 0 0 0 0 1 1 4 
Fyn NM_008054 mmu-miR-30b-5p 1 0 0 0 0 1 0 0 0 0 1 1 4 
Fyn NM_008054 mmu-miR-29b-3p 1 0 0 0 0 1 0 0 0 0 1 1 4 
Fyn NM_008054 mmu-miR-29c-3p 1 0 0 0 0 1 0 0 0 0 1 1 4 
Fyn NM_008054 mmu-miR-30c-5p 1 0 0 0 0 1 0 0 0 0 1 1 4 
Fyn NM_008054 mmu-miR-30d-5p 1 0 0 0 0 1 0 0 0 0 1 1 4 
Fyn NM_008054 mmu-miR-30a-5p 1 0 0 0 0 1 0 0 0 0 1 1 4 
 
Both 3’-UTRs show good alignment over their complete length, but not all predicted binding 
sites are conserved between the human and murine transcript (Fig. 4.15). 
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Murine  14    AGACGCCTCTTCCC-GAGGCCTCCCTACCCCTCCCCATTAGCTTCCAATTCTGTAGCCAG  72 
              ||| ||||  |||| |||||  ||| |||||||||||||||||| |||||| |||||||| 
Human   18    AGAGGCCTTGTCCCAGAGGCTGCCCCACCCCTCCCCATTAGCTTTCAATTCCGTAGCCAG  77 
 
Murine  73    CTGCCCCAGAGCAGCGAGAACCGTCCAGGATCAGATTGCATGTGACTCTGAAGCT---GA  129 
              |||| ||  ||||||| |||||| |||||||||||||||||||||||||||||||   || 
Human   78    CTGCTCCCCAGCAGCG-GAACCGCCCAGGATCAGATTGCATGTGACTCTGAAGCTGACGA  136 
 
Murine  130   ACTTCCACGGCCCTCATTAATGACACTTGTCCCCCAGTCCGAACCTCCTCTGTGAACCAT  189 
              ||||||| |||||||||||||||||||||||||| | ||||||||||||||||||| ||| 
Human   137   ACTTCCATGGCCCTCATTAATGACACTTGTCCCCAAATCCGAACCTCCTCTGTGAAGCAT  196 
 
Murine  190   CTGAGACAGAAGCGTGTTATTTCTCAGACTT-GG-AAATGCATTGTATCGATGTTATGTC  247 
                ||||||||| | ||||||||||||||||| || ||||||||||||||||||||||||  
Human   197   TCGAGACAGAACCTTGTTATTTCTCAGACTTTGGAAAATGCATTGTATCGATGTTATGTA  256 
 
Murine  248   AAAGGCCAAACCTCTGTTCAGTGTAAATAGCTGCTCCTGTGCCAACAATCCCAGTGCTTT  307 
              |||||||||||||||||||||||||||||| | |||| ||||||||||||| |||||||| 
Human   257   AAAGGCCAAACCTCTGTTCAGTGTAAATAGTTACTCCAGTGCCAACAATCCTAGTGCTTT  316 
 
Murine  308   CCTTTTTTaaaaaagaaaaaGCAAATCCTATGTGATTTTAACTCTGTCTTCACCTGATTC  367 
              |||||||||      |||| |||||||||||||||||||||||||||||||||||||||| 
Human   317   CCTTTTTTA------AAAATGCAAATCCTATGTGATTTTAACTCTGTCTTCACCTGATTC  370 
 
Murine  368   AACTaaaaaaaaaaaaGTATTATTTTCCAAAAGTGGCCTCTTTGTCTAAAACAATAAAAt  427 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Human   371   AACTAAAAAAAAAAAAGTATTATTTTCCAAAAGTGGCCTCTTTGTCTAAAACAATAAAAT  430 
 
Murine  428   tttttttCATGTTTTAACAAAAAATGATCAGGACAGGTGTTTGGGttttttttccctttt  487 
              |||||||||||||||||||||||   |||||||||||||||||  ||| ||||  ||||| 
Human   431   TTTTTTTCATGTTTTAACAAAAACCAATCAGGACAGGTGTTTGTTTTTGTTTT--CTTTT  488 
 
Murine  488   ttATACATATG-ATATATATGTTAACATATGTTCCTGTACATACACCATGTGGGTGCTAC  546 
              ||||| ||||| ||||||||  ||  |||||| |||||||||| || ||||||||||||  
Human   489   TTATAAATATGAATATATATAATAT-ATATGTCCCTGTACATATACAATGTGGGTGCTAA  547 
 
Murine  547   CATGGAGACTG-G-CCAGCGTAGGCCACATAGCTACAGGACCG-GAGTGGGGATT--ACT  601 
                ||||||||| | || || |  |||||  |||| | |||||  ||| | |||||  ||| 
Human   548   TGTGGAGACTGTGGCCGGCCTGAGCCACCAAGCTGCGGGACCCAGAGGGAGGATTTTACT  607 
 
Murine  602   GCAGAACCCTGCCAGCAAAGCACTGGTGTCAGCCTGCAAGC-CG-GTGGCCTCATTTTTT  659 
              ||| |  |  | || |||||||| ||||| |  ||| || | |  ||||||||||||||  
Human   608   GCA-AGTCA-G-CATCAAAGCACCGGTGTTATTCTGAAAACACCAGTGGCCTCATTTTTG  664 
 
Murine  660   GACTTCTACGAAGCATGACGTCCTCTCCATTTGGACTGCACTTTTTTGGTTCCTAATCAT  719 
              | ||| | | ||||||||  |  | | |||||||| ||||||||  |||||| | |   | 
Human   665   G-CTTTTGCAAAGCATGAATTTTT-T-CATTTGGATTGCACTTTCCTGGTTCATGACTGT  721 
 
Murine  720   ACCTATAGAT--T-GTTCATGTGACTTTTTTCAGGTCCCAGGGCCTA-G-TCA-----CG  769 
              |||| ||| |  | |||  | ||||| ||||||||  |||   || | | | |     |  
Human   722   ACCTGTAGGTGGTTGTTACTTTGACTCTTTTCAGGAACCACCCCCCAAGCTGAATTTACA  781 
 
Murine  770   AGTTTTAGTGCCAGTTTTTGCTCCAGCGAACTGTGATTCGTTCTTGAAACTTAGGAGTGA  829 
              |||| |  |  || | |||||| || |  |||| |||| |||||  |||||||  | | | 
Human   782   AGTTCTGTTAGCACTATTTGCTTCAACTTACTGCGATTTGTTCTCAAAACTTAAAAATAA  841 
 
Murine  830   GCATTTTAAGCAAAAAGCAGCCAGCCAGTTCTACCACAAGAGCTGCAAGACGGAGACCAC  889 
              |||    | |||||  |  ||  |  | | ||||||  ||| ||| |||| ||| ||||| 
Human   842   GCA----A-GCAAAT-G--GCT-G--A-TACTACCAAGAGAACTGGAAGATGGATACCAC  889 
 
Murine  890   ACAAACTTCCTGTAT--AAATATGAATGCTGAAGGGTT-CAGGTGTTTTCCTTTTATTTA  946 
              ||||||||| |||||  ||||||||||||||||  ||| |||   ||||  |   ||||| 
Human   890   ACAAACTTCTTGTATAAAAATATGAATGCTGAAATGTTTCAGACATTTT--TA--ATTTA  945 
 
Murine  947   ATAAATCTTGTAACCACATTTAAATGGTCT-AAACCCATAGCATTGTAGTCATGGCAACC  1005 
              ||||| | ||||||||||||||| || ||| ||||||||||||||||||||||||||||| 
Human   946   ATAAACC-TGTAACCACATTTAAGTGATCTAAAACCCATAGCATTGTAGTCATGGCAACC  1004 
 
Murine  1006  TACTAAACTTTCTCATGCAACTAAAAATTATGGGAAGGCAA-G-GGTGGGGGGTTGTACA  1063 
                |||||||||||||||||||||||| || ||||  || || | ||  |||||||||||| 
Human   1005  CGCTAAACTTTCTCATGCAACTAAAATTTCTGGG--GGAAATGAGGGTGGGGGTTGTACA  1062 
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Murine  1064  CGTCCCATTGTAAAATAAGTGTTTTAC-TGTCCTGTACTGCTAATGAGTGACTCTCCGT-  1121 
                ||||||||||||||||||||||||  |||||||||||||||| || ||||| ||  |  
Human   1063  TTTCCCATTGTAAAATAAGTGTTTTAAATGTCCTGTACTGCTAACGAATGACTTTCTATA  1122 
 
Murine  1122  -GT-CAGGAGTGCTCCAGT-GAATAACTATGCACTACTTTACATTTCATGGGGGTGCACa  1178 
               || ||||||| ||||||| ||||||||||||||||||||||||||||||||| |||||| 
Human   1123  TGTCCAGGAGTTCTCCAGTGGAATAACTATGCACTACTTTACATTTCATGGGGATGCACA  1182 
 
Murine  1179  aaaaaaaaaaaGTATTACATTTTTAGTTGCTGTTTGTACCAACCTCGAATTACGTATGTT  1238 
              |||| ||||||||||||||||||||||||||||||||||||||||  |||||| |||||| 
Human   1183  AAAACAAAAAAGTATTACATTTTTAGTTGCTGTTTGTACCAACCTTAAATTACATATGTT  1242 
 
Murine  1239  TAACAACAA-A--TCAAT--TCCTATTTCTATTGAGTTTTTTAATACTGACTAGCAATTC  1293 
              ||||||||| |  ||||   |||||||||||||||| |||||||||||||||||||| || 
Human   1243  TAACAACAACAAATCAAAAATCCTATTTCTATTGAG-TTTTTAATACTGACTAGCAACTC  1301 
 
Murine  1294  TGAAGTCTTAATTCCttttttttGTTAATGATTTACTTGTGAGTTTACATTTTTAAATTG  1353 
              |||||||||||||||||||||  ||| |||||||| |||||||||||||||||||||||| 
Human   1302  TGAAGTCTTAATTCCTTTTTT--GTT-ATGATTTATTTGTGAGTTTACATTTTTAAATTG  1358 
 
Murine  1354  TTTAACTTTCCTAATTTAGTAATTAAAAAGAGAGCATTTTACATTTGaa  1402 
              |||||||||| |||||||||||||||||||||||||||||||||||||| 
Human   1359  TTTAACTTTCTTAATTTAGTAATTAAAAAGAGAGCATTTTACATTTGAA  1407 
Fig. 4.15: Alignment of the 3’UTRs of longest Fyn transcripts in human (NM_002037) and mouse 
(NM_008054); predicted seed binding sites are indicated as follows: purple: miR-23a/b-3p; turquoise: 
miR-24-3p; dark green: miR-27a/b-3p; dark grey: miR-29a-c-3p; pink: miR-30a-f-5p; light green: miR-130a-
3p; yellow: miR-146b-5p; blue: miR-149-5p; light grey: miR-322-3p and miR-503-5p; red: miR-340-5p 
The possible binding site of the seed region of miR-30a-e-5p, miR-340-5p and two binding sites 
for miR-130a-3p are conserved between the two species. Additionally, two of three binding sites 
for miR-23a/b-3p, one of two binding sites for miR-27a/b-3p and one of two binding sites for 
miR-149-5p are conserved between human and mouse, while the binding site for miR-24-3p and 
two binding sites for miR-146b-5p are not conserved between human and mouse. 
The full length 3’-UTR of the human FYN transcript length of 1,407 bp was cloned into the 
luciferase reporter vector (pMir-report, modified) for subsequent luciferase assay (chapter 4.6). 
Nck2 
The longest human and murine protein coding transcripts for Nck2, NM_003581 and 
NM_010879, possess a 3‘-UTR of 1,098 nucleotides and 1,173 nucleotides, respectively. For both 
transcripts, possible miRNA interaction partners were predicted with miRWalk2 using 12 
different prediction algorithms (Tab. 4.12 and 4.13).  
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Tab. 4.12: miRWalk2 predictions of miRNAs targeting human NCK2 3’-UTR; criterion: sum of 
predictions ≥4 
Gene Transcript number Mature miRNA 
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NCK2 NM_003581 hsa-miR-92a-3p 1 1 0 0 0 1 0 1 0 1 1 1 7 
NCK2 NM_003581 hsa-miR-92b-3p 1 1 0 0 0 1 0 1 0 1 1 1 7 
NCK2 NM_003581 hsa-miR-30c-5p 1 1 0 1 0 1 0 1 0 0 1 1 7 
NCK2 NM_003581 hsa-miR-30a-5p 1 1 0 0 0 1 0 1 0 0 1 1 6 
NCK2 NM_003581 hsa-miR-340-5p 0 1 1 0 1 1 0 0 0 0 1 1 6 
NCK2 NM_003581 hsa-miR-450b-5p 1 1 0 0 0 1 0 0 0 1 1 1 6 
NCK2 NM_003581 hsa-miR-30d-5p 1 1 0 0 0 1 0 1 0 0 1 1 6 
NCK2 NM_003581 hsa-miR-30b-5p 1 1 0 0 0 1 0 0 0 0 1 1 5 
NCK2 NM_003581 hsa-miR-30e-5p 1 1 0 0 0 1 0 0 0 0 1 1 5 
NCK2 NM_003581 hsa-miR-30c-1-3p 0 0 1 0 0 1 0 0 0 1 1 1 5 
NCK2 NM_003581 hsa-miR-23a-3p 1 1 0 0 0 1 0 0 0 0 1 0 4 
NCK2 NM_003581 hsa-miR-23b-3p 1 1 0 0 0 1 0 0 0 0 1 0 4 
NCK2 NM_003581 hsa-miR-30c-2-3p 0 0 1 0 0 1 0 0 0 0 1 1 4 
NCK2 NM_003581 hsa-miR-23c 1 1 0 0 0 1 0 0 0 0 1 0 4 
 
Equivalent predictions were performed for the murine 3’-UTR of Nck2. 
Tab. 4.13: miRWalk2 predictions of miRNAs targeting murine Nck2 3’-UTR; criterion: sum of 
predictions ≥4 
Gene Transcript number Mature miRNA 
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Nck2 NM_010879 mmu-miR-340-5p 1 1 1 0 1 1 0 0 1 0 1 1 8 
Nck2 NM_010879 mmu-miR-450b-5p 1 1 1 0 0 1 0 0 1 1 1 1 8 
Nck2 NM_010879 mmu-miR-30d-5p 1 1 0 0 0 1 0 0 1 0 1 1 6 
Nck2 NM_010879 mmu-miR-30a-5p 1 1 0 0 0 1 0 0 1 0 1 1 6 
Nck2 NM_010879 mmu-miR-30e-5p 1 1 0 0 0 1 0 0 1 0 1 1 6 
Nck2 NM_010879 mmu-miR-30b-5p 1 1 0 0 0 1 0 0 1 0 1 1 6 
Nck2 NM_010879 mmu-miR-30c-5p 1 1 0 0 0 1 0 0 1 0 1 1 6 
Nck2 NM_010879 mmu-miR-196b-5p 1 0 0 0 0 1 0 0 1 0 1 1 5 
Nck2 NM_010879 mmu-miR-23a-3p 1 1 0 0 0 1 0 0 1 0 1 0 5 
Nck2 NM_010879 mmu-miR-23b-3p 1 1 0 0 0 1 0 0 1 0 1 0 5 
Nck2 NM_010879 mmu-miR-27a-3p 1 0 0 0 0 0 0 0 1 1 1 0 4 
Nck2 NM_010879 mmu-miR-503-5p 0 0 0 0 0 1 0 0 1 1 1 0 4 
Nck2 NM_010879 mmu-miR-27b-3p 1 0 0 0 0 0 0 0 1 1 1 0 4 
Nck2 NM_010879 mmu-miR-148a-3p 0 1 0 0 0 1 0 0 1 0 1 0 4 
 
The 3’-half of the 3’-UTRs of the full length transcripts of human and mouse show good 
alignment over the whole length, but not all predicted binding sites are conserved between the 
human and murine transcript. 
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Murine  542   tGGCTCCAGGCAC--TGCA-GGAGTCCAAAAC-TGTGCGGATAGCAATACTGGAAACCCT  597 
              ||||||| || ||  |||| |||| || | || | ||| |||||||||||||||| | |  
Human   448   TGGCTCCCGG-ACTGTGCAGGGAG-CCGATACGTTTGCTGATAGCAATACTGGAACCACC  505 
 
Murine  598   GGG-GAGATGGTGGTGAGAAAACTGCCCAGTGCCTTTGAGGCTGTACTTGCAATAAAAGA  656 
              ||| | |||||  ||||| | ||||||||||||||||| |||||| ||||||||||| || 
Human   506   GGGTGCGATGGCAGTGAGGAGACTGCCCAGTGCCTTTGGGGCTGTGCTTGCAATAAA-GA  564 
 
Murine  657   GGGTTTTGGTAAGAGTTGGTCTGCAAAAGAGGAAGGTGGCAACACAGAAAGAAAGGTACT  716 
                 |  ||| || ||   |||||||||||||| |   ||  || |||||||| || |  | 
Human   565   ATTTCCTGG-AA-AGGCAGTCTGCAAAAGAGGGAACCGGTGACTCAGAAAGACAGATGTT  622 
 
Murine  717   CTGGTGATGTCCCCCAGGTGTGCCATCCACATCGTGCTT-------TTGCCCTTGGGCTT  769 
               |||| || | |||||  |||||||||||||| ||||||       |||||||| ||||| 
Human   623   TTGGTAATTTACCCCAAATGTGCCATCCACATAGTGCTTTTTCCTCTTGCCCTTCGGCTT  682 
 
Murine  770   GTTTGAATTTCACAATTATGTATTTAATTCTCAAAGTAATATGTATCTGTAGCTGGTTGT  829 
              |||||||| ||||||||||||||||||||||||||| |||||||||||||||| | |||| 
Human   683   GTTTGAATCTCACAATTATGTATTTAATTCTCAAAGAAATATGTATCTGTAGCCGTTTGT  742 
 
Murine  830   TGACACTAATA-ACATGATTAAGGAAAACAGCTGATCTCTTGGGAAGGGGAGCTACCAAT  888 
              ||||||||||| | |||||||||||||||||||||||| | ||||| ||||||||||||  
Human   743   TGACACTAATACAGATGATTAAGGAAAACAGCTGATCTTTGGGGAA-GGGAGCTACCAAC  801 
 
Murine  889   ACTTTATACATACACtatatatatatatata-atatgtgtatattatatatatattatTT  947 
              |||||||||| |||| | |  |  | | | | | |     | | ||||||||||| || | 
Human   802   ACTTTATACACACAC-ACACGTGCACACACACACACACACACACTATATATATAT-ATAT  859 
 
Murine  948   GCTTTACAGGGAAATTTTTCAGGGTTTACAAAAGAATATGTGATTAGTAGTA--------  999 
                ||||||||||||||||||||||||||||||||| ||||||||| ||||||         
Human   860   TATTTACAGGGAAATTTTTCAGGGTTTACAAAAGAGTATGTGATTGGTAGTAAGAGACAC  919 
 
Murine  1000  ACAGAATGTTTATGAAGAAATTGCATTTTCATTTTTCTTTACATTTGAACTTCTTTATAG  1059 
              |||||||||||||||||||||||||||||| |||| |||||||||||||||||||||||| 
Human   920   ACAGAATGTTTATGAAGAAATTGCATTTTCTTTTTCCTTTACATTTGAACTTCTTTATAG  979 
 
Murine  1060  TTTGACTATAGAGTCTTGAGATGGCACATTCCTACAATTGAAGAAGGGGTCTTGGGATCC  1119 
              ||| | ||||  ||||||||||||||||||||||| |||||||||||||||||| ||||| 
Human   980   TTTAAATATAACGTCTTGAGATGGCACATTCCTACGATTGAAGAAGGGGTCTTGAGATCC  1039 
 
Murine  1120  CCTAAACTTGCATACCCGGTTTTTTGAATATTGTAATaaaaaaaaGTATTATGA  1173 
              ||||||||||||||||| |||||||| ||||||||||||||||||||||||||| 
Human   1040  CCTAAACTTGCATACCCAGTTTTTTGGATATTGTAATAAAAAAAAGTATTATGA  1093 
Fig. 4.16: Alignment of the 3’UTRs of longest Nck2 transcripts in human (NM_003581) and mouse 
(NM_010879); predicted seed binding sites are indicated as follows: purple: miR-23a/b-3p; pink: miR-30a-
f-5p; red: miR-92a/b-3p; yellow: miR-340-5p; green: miR-450b-5p; 
Binding sites for miR-23a/b-3p, miR-30a-e-5p, miR-340-5p and miR-450b-5p are conserved 
between both transcripts. A binding site for miR-92a/b-3p seems to be preserved in the 
sequences, but is not predicted for the murine transcript. The full length human 3’-UTR of 
1,098 bp was cloned into the luciferase reporter vector (pMir-Report, modified) for subsequent 
luciferase assay (chapter 4.7). 
Neph1 
The 3‘-UTR of the longest human protein coding transcript of NEPH1, also known as KIRREL, 
(NM_001286349) consists of 5,141 nucleotides and shows a good overlap with the 3’-UTR of the 
murine protein coding transcript, NM_130867. The 3’-UTR of a shorter human protein coding 
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transcript, NM_018240, corresponds to the first 533 nucleotides of the longer human transcript. 
For in silico predictions, the shorter human 3’-UTR was used (Tab. 4.14 and 4.15). 
Tab. 4.14: miRWalk2 predictions of miRNAs targeting human NEPH1/KIRREL; criterion: sum of 
predictions ≥4 
Gene Transcript number Mature miRNA 
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KIRREL NM_018240 hsa-miR-29a-3p 1 1 1 0 0 1 0 1 1 1 1 1 9 
KIRREL NM_018240 hsa-miR-30c-1-3p 1 1 1 0 1 1 0 0 0 1 1 1 8 
KIRREL NM_018240 hsa-miR-29b-3p 0 1 1 0 0 1 0 1 1 1 1 1 8 
KIRREL NM_018240 hsa-miR-29c-3p 0 1 1 0 0 1 0 1 1 1 1 1 8 
KIRREL NM_018240 hsa-miR-149-5p 1 1 0 0 0 1 0 1 1 1 1 1 8 
KIRREL NM_018240 hsa-miR-30c-2-3p 1 1 1 0 0 1 0 0 0 1 1 1 7 
KIRREL NM_018240 hsa-miR-27a-3p 1 1 0 0 0 1 0 0 1 1 1 0 6 
KIRREL NM_018240 hsa-miR-107 0 1 0 0 0 1 0 0 1 1 1 1 6 
KIRREL NM_018240 hsa-miR-27b-3p 1 1 0 0 0 1 0 0 1 1 1 0 6 
KIRREL NM_018240 hsa-miR-30b-3p 0 1 1 0 0 1 0 0 0 1 1 1 6 
KIRREL NM_018240 hsa-miR-24-3p 0 1 0 0 0 1 0 0 1 1 1 0 5 
KIRREL NM_018240 hsa-miR-148a-3p 0 1 0 0 0 1 0 0 1 1 1 0 5 
KIRREL NM_018240 hsa-miR-210-3p 0 1 0 0 0 1 0 0 0 1 1 0 4 
KIRREL NM_018240 hsa-miR-450b-5p 0 1 0 0 0 1 0 0 0 1 1 0 4 
KIRREL NM_018240 hsa-miR-130a-3p 0 0 0 0 0 1 0 0 1 1 1 0 4 
 
Equivalent predictions were performed for the murine 3’-UTR of Neph1. 
Tab. 4.15: miRWalk2 predictions of miRNAs targeting murine Neph1/Kirrel; criterion: sum of 
predictions ≥4 
Gene Transcript number Mature miRNA 
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Kirrel NM_130867 mmu-miR-107-3p 1 0 1 0 1 1 0 0 0 0 1 1 6 
Kirrel NM_130867 mmu-miR-29b-3p 1 0 1 0 0 1 0 0 1 0 1 1 6 
Kirrel NM_130867 mmu-miR-29c-3p 1 0 1 0 0 1 0 0 1 0 1 1 6 
Kirrel NM_130867 mmu-miR-351-5p 1 0 1 0 0 1 0 0 1 0 1 1 6 
Kirrel NM_130867 mmu-miR-29a-3p 1 0 1 0 0 1 0 0 1 0 1 1 6 
Kirrel NM_130867 mmu-miR-30b-3p 1 0 1 0 0 1 0 0 0 0 1 1 5 
Kirrel NM_130867 mmu-miR-30e-5p 1 0 1 0 0 1 0 0 0 0 1 1 5 
Kirrel NM_130867 mmu-miR-23a-3p 1 0 1 0 0 1 0 0 0 0 1 1 5 
Kirrel NM_130867 mmu-miR-27b-3p 1 0 1 0 0 1 0 0 0 0 1 1 5 
Kirrel NM_130867 mmu-miR-30b-5p 1 0 1 0 0 1 0 0 0 0 1 1 5 
Kirrel NM_130867 mmu-miR-30f 1 0 1 0 0 1 0 0 0 0 1 1 5 
Kirrel NM_130867 mmu-miR-30c-1-3p 1 0 1 0 0 1 0 0 0 0 1 1 5 
Kirrel NM_130867 mmu-miR-322-3p 1 0 1 0 0 1 0 0 0 0 1 1 5 
Kirrel NM_130867 mmu-miR-340-5p 1 0 1 0 0 1 0 0 0 0 1 1 5 
Kirrel NM_130867 mmu-miR-23b-3p 1 0 1 0 0 1 0 0 0 0 1 1 5 
Kirrel NM_130867 mmu-miR-30c-2-3p 1 0 1 0 0 1 0 0 0 0 1 1 5 
Kirrel NM_130867 mmu-miR-30c-5p 1 0 1 0 0 1 0 0 0 0 1 1 5 
Kirrel NM_130867 mmu-miR-30d-3p 1 0 1 0 0 1 0 0 0 0 1 1 5 
Kirrel NM_130867 mmu-miR-30a-3p 1 0 1 0 0 1 0 0 0 0 1 1 5 
Kirrel NM_130867 mmu-miR-30d-5p 1 0 1 0 0 1 0 0 0 0 1 1 5 
Kirrel NM_130867 mmu-miR-27a-3p 1 0 1 0 0 1 0 0 0 0 1 1 5 
Kirrel NM_130867 mmu-miR-30a-5p 1 0 1 0 0 1 0 0 0 0 1 1 5 
Kirrel NM_130867 mmu-miR-30e-3p 1 0 1 0 0 1 0 0 0 0 1 1 5 
Kirrel NM_130867 mmu-miR-196b-5p 1 0 1 0 0 1 0 0 0 0 1 1 5 
Kirrel NM_130867 mmu-miR-542-3p 1 0 1 0 0 1 0 0 0 0 1 1 5 
Kirrel NM_130867 mmu-miR-149-5p 1 0 0 0 0 1 0 0 0 0 1 1 4 
Kirrel NM_130867 mmu-miR-148a-3p 1 0 0 0 0 1 0 0 0 0 1 1 4 
Kirrel NM_130867 mmu-miR-24-1-5p 1 0 0 0 0 1 0 0 0 0 1 1 4 
Kirrel NM_130867 mmu-miR-24-2-5p 1 0 0 0 0 1 0 0 0 0 1 1 4 
Kirrel NM_130867 mmu-miR-24-3p 1 0 0 0 0 1 0 0 0 0 1 1 4 
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Murine  10   CTGGCTGGGGTATCTCTGCGGGGCAGAGGAGATGGCTTCC-CAGCTGTTCCCTGACATTC  68 
             |||||||||| ||||||||||||||||||||| ||||| | |||||||||||||| |||| 
Human   11   CTGGCTGGGGCATCTCTGCGGGGCAGAGGAGAAGGCTTTCACAGCTGTTCCCTGATATTC  70 
 
Murine  69   AGGGACATTGCTCATTGCTCCTTTCATGGACCCAGCCTTTCTCCTCCTGGCCATCACAAA  128 
             |||| |||||||||||||||| |||  ||||| ||||||  ||||||   ||||  ||   
Human   71   AGGGGCATTGCTCATTGCTCCCTTCTCGGACC-AGCCTTCTTCCTCCCA-CCATGGCAGG  128 
 
Murine  129  TGAGGAGCAGGTCTCCCAGTAACATCCCATCCCAAGGATGGTGCTCTGCGCAGGCCCCAG  188 
             || |||||||||||||||| |||| ||| |||| |||||||||||||| ||| ||||||| 
Human   129  TGGGGAGCAGGTCTCCCAGAAACACCCCGTCCCGAGGATGGTGCTCTGTGCATGCCCCAG  188 
 
Murine  189  TCTCCCGGGCCTGCCCTTTCCTCTCCTTCAGGAGAATGT--CTCTTCTGACCTTTGCTCT  246 
              |||| |||||||||||| ||||| |||| |||| ||||  ||||||||||||   |||| 
Human   189  CCTCCTGGGCCTGCCCTTCCCTCTTCTTCGGGAGGATGTGTCTCTTCTGACCTGCACTCT  248 
 
Murine  247  -GCCTGACCCAAGCATggggaaagg-agaggggaggttggggaaggggaggagaagggag  304 
              ||||||||| || ||||||| ||| | || | ||||| |||||    || ||| ||| | 
Human   249  TGCCTGACCCTAGAATGGGGACAGGGAAAGTGAAGGTTAGGGAA----AGCAGAGGGGGG  304 
 
Murine  305  aggagaagaaTACAATTTATCATTTCCTATCTGGCCTGCTCCTCTGGTCTCCCATAAGAG  364 
                        ||  |||| |||| ||| |||  ||  | |||||| ||||||||||| | 
Human   305  C----------ACTTTTTAGCATTCCCTTTCTATCCCACCCCTCTGATCTCCCATAAGTG  354 
 
Murine  365  GGCATGGAGCTAAGCTGAGGCGGGCAGGCT  394 
             |  |||| | ||  | | |  ||||||||| 
Human   355  GAAATGGGGGTACCCAGGGATGGGCAGGCT  384 
Fig. 4.17: Alignment of the 3’-UTR of Neph1 transcripts in human (NM_018240) and mouse (NM_130867); 
predicted binding sites; turquoise: miR-29a-c-3p; yellow: miR-30b/c-3p; 
A binding site for miR-29a-c-3p as well as a minding site for miR-30b/c-3p is conserved between 
the human and the murine transcript. The 3’-UTR of the human protein coding transcript of 
NEPH1 with a length of 533 bp, NM_018240, was cloned into the luciferase reporter vector 
(pMir-Report, modified) for subsequent luciferase assay (chapter 4.7). 
4.5 Argonaute immunoprecipitation (Ago-IP) applied for target identification 
To analyze mRNAs that are targeted by miRNAs in vivo, Ago-IP (Argonaute immunoprecipitation) 
was established to isolate the regulated mRNAs from the RISCs. 
4.5.1 Ago-IP using hPCLs and subsequent target detection by qPCR 
The first Ago-IP was performed using proliferating human podocytes. The targets isolated by 
Ago-IP were identified by qPCR.  
To confirm the specificity of the used primer for the predicted targets, PCR was performed with 
cDNA generated from RNA isolated from proliferating human podocytes. The PCR products were 
isolated by agarose gel electrophoresis and subsequently sequenced. For all primer pairs used, 
the identity of the amplified targets could be validated (Tab. 10.3).  
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To verify targets predicted to be regulated by miRNAs in human podocytes, three independent 
Ago-IP experiments were performed from proliferating hPCLs (M. Billmeier) according to 3.6.2. 
The Ago-IPs were performed using ca. 75 millions of proliferating hPCLs per experiment. 
 
Fig. 4.18: Ago-IP from proliferating hPCLs; enrichment of transcript in the IP sample compared to the 
control antibody sample, enrichment referring to the input; data of 3 independent experiments 
In the Ago-IP from hPCLs, the validated miRNA target E2F1 (personal communication G. 
Meister), a transcription factor belonging to the E2F family, could be identified to be enriched in 
the Ago-IP sample compared to the control antibody background. The four mRNAs predicted to 
be potential miRNA targets, CD2AP, FYN, NCK2 and NEPH1 could be identified to be Ago2 bound 
as well.  
4.5.2 Ago-IP using mPCLs and subsequent target identification by qPCR 
Before the Ago-IP from freshly isolated murine podocytes, preliminary experiments using the 
immortalized murine podocyte cell line were performed. 
Testing of -mAgo2 antibody 
Before Ago-IP was performed from freshly isolated murine podocytes, the antibody was tested 
with lysates from proliferating mPCLs. 50 µl cell lysate ( = 3.1 µg/µl) of total protein was 
compared with the same amount of supernatant after Ago-IP. A faint band of ca. 100 kDa 
indicated a low expression of Ago2 protein in the mPCLs. As the band was not detectable in the 
supernatant after IP, this proved the functionality of the -Ago2 antibody (Fig. 4.19 A). To 
confirm the binding of the Ago2 protein to the antibody coupled beads, the protein bound to the 
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beads was extracted and also investigated by Western Blotting. This time, Ago2 protein could 
neither be detected in 50 µl of the lysate ( = 3.4 µg/µl) nor in the supernatant after IP, but a 
very strong signal was detected in the sample derived from the beads, indicating that the Ago2 
protein present in the lysate was bound to the beads (Fig. 4.19 B). Since Ago2 protein was hard 
to detect in mPCLs, mPCL lysates were compared to lysates of N2A cells, a murine brain 
neuroblastoma cell line known to express Ago2 protein in high amounts (N2A lysate was a kind 
gift of D. Hasler, Department of Biochemistry I, University of Regensburg; N2A lysis buffer: 
50 mM Tris/HCl (pH = 8.0), 150 mM NaCl, 5% glycerol, 0.1% Tween20). Using 170 µg of total 
protein, Ago2 could be detected in high amount in the N2A cell lysate, but practically not in the 
mPCL lysate (Fig. 4.19 C), confirming a low level of Ago2 in mPCLs. 
 
Fig. 4.19: -Ago2 Western Blot with lysates from mPCLs and N2A cells; (A) -Ago2 Western Blot of mPCL 
cell lysate before and after IP with -Ago2 coupled beads; (50 µl mPCL lysate=155 µg total protein before 
IP) (B) -Ago2 Western Blot of mPCL cell lysate before and after IP with -Ago2 coupled beads, and -
Ago2 coupled beads after IP; (50 µl lysate=170 µg total protein before IP per lane); (C) -Ago2 Western 
Blot of mPCL cell lysate and N2A cell lysate; 170 µg total protein/lane 
Taken together, it could be shown that Ago2 is expressed in proliferating mPCLs (Fig. 4.17 A), but 
at low levels compared to N2A cells (Fig. 4.17 C). Nevertheless, it is extensively bound by the -
Ago2 coupled beads (Fig. 4.18 B), enabling extraction of RISCs from murine cells. 
Ago-IP using mPCLs 
The targets isolated by Ago-IP were identified by qPCR. To confirm the specificity of the used 
primer for the predicted targets, PCR was performed with cDNA generated from RNA isolated 
from proliferating mPCL cells. The PCR products were isolated by agarose gel electrophoresis 
and sequenced. For all primer pairs used, the identity of the amplified targets could be validated 
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(Tab. 10.4). Ago-IP was performed from five million proliferating mPCLs as described previously. 
The enrichment of the predicted targets was analyzed by subsequent qPCR (Fig. 4.20). 
 
Fig. 4.20: Ago-IP from proliferating mPCLs; enrichment of possible target mRNAs in Ago-IP above control 
antibody background; analyses by qPCR 
The Ago-IP from five million proliferating mPCLs yielded enough RNA for the qPCR analyses of 
five targets. The validated miRNA target E2f1 could be detected as enriched in the Ago bound 
sample. All four putative miRNA targets, Cd2ap, Fyn, Nck2 and Neph1 could be measured to be 
clearly enriched above the background, hinting them to be miRNA regulated targets in 
proliferating mPCLs as well. 
4.5.3 Ago-IP using freshly isolated murine podocytes and analysis using microarray 
For a focused approach to identify miRNA regulated targets in podocytes under physiological 
conditions, Ago-IP was performed using isolated green podocytes freshly isolated from double 
fluorescent reporter mice (mTmG x P2.5 Cre, chapter 4.3). 
In total, 6.5 million green podocytes were isolated from 39 male mTmGxP2.5Cre mice aged 
between 16 and 30 weeks. The Ago-IP was performed according to the protocol in chapter 3.6.3. 
The RNA of miRNA targets in podocyte was isolated from the -Ago2 coupled beads, while the 
RNA isolated from the rabbit IgG coupled beads served as a background control. The two 
isolated RNA samples were analyzed on a murine GeneChiP-Array (Mouse Transcriptome Array, 
Gen2.0/2.1ST, Affymetrix) at the Center of Excellence for Fluorescent Bioanalytics (Biopark, 
University of Regensburg). 
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The enrichment of mRNAs of transcripts in the Ago2 bound sample in relation to the sample 
isolated from IgG coupled beads, was calculated. In total, 425 transcripts were enriched more 
than 2-fold in the Ago2 bound sample, 23 of which were enriched more than 10-fold. 
Additionally, the enrichment of transcripts in the Ago2 bound sample generated from podocytes 
compared to their enrichment in the red fluorescent cell population was calculated. A total of 
262 transcripts were found to be enriched more than 2-times in podocytes, with one transcript 
being enriched more than 10-fold in the podocyte sample. Both lists were analyzed for mRNAs 
coding for proteins known to be important directly for kidney structure. 
Tab. 4.16: miRNA targets isolated in Ago-IP from murine podocytes; genes important for 
filtration function with enrichment above background ≥2 (bold); grey: enrichment factors <2 
Gene 
Symbol 
Gene Description Annotated 
Gene 
Accession 
number 
Fold
Podocytes 
-Ago2  
vs 
Podocytes 
IgG 
Change 
Podocytes
-Ago2 
vs 
“red cells”
-Ago2 
Actg1 Actin, gamma, cytoplasmic 1 BC018571 5.61 3.99 
Podxl Podocalyxin-like AK134723 4.26 3.59 
Itgb1 Integrin beta 1 (fibronectin receptor beta) AK076526 3.55 2.94 
Vegfa Vascular endothelial growth factor A AY120866 3.34 2.27 
Cd2ap CD2-associated protein AK045218 2.58 1.99 
Nphs2 Nephrosis 2 homolog, podocin AK052746 2.51 2.40 
Fyn Fyn proto-oncogene AK156584 2.23 2.34 
Actbl2 Actin, beta-like 2 AK029110 2.20 1.88 
Itgb5 Integrin beta 5 AK087476 2.20 2.35 
Wipf3 WAS/WASL interacting protein family, 
member 3 
BC044880 1.54 2.40 
 
These results represent preliminary data, as only one hybridisation was performed so far. The 
experiment will be repeated with independent murine samples. 
4.6 Luciferase assay for confirmation of predicted miRNA-mRNA pairs  
To check for possible interaction of miRNAs with the 3’-UTRs of the target genes, luciferase 
assays were performed. HEK293T cells were transfected with two plasmids. One plasmid, a 
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modified pMir-Report construct (pMir-Report modified, life technologies/G. Meister) coded for a 
firefly luciferase containing the 3’-UTR of the possible target genes and a renilla luciferase as an 
untargeted control. The second plasmid, a pSuper construct were the ampicillin resistance was 
exchanged for a kanamycin resistance (pSuper modified, oligoengine/G. Meister) contained a 
shRNA precursor for a miRNA predicted to be a possible regulator of the respective gene. 
To be sure that the candidate miRNA is present in sufficient amount in the cells, luciferase assays 
were performed with a parallel overexpression of the miRNA of interest. The control cells were 
transfected with pSuper construct overexpressing the CXCR4 control sequence (Ebert et al. 
2007) to provide comparable environments in both samples.  
A paired student’s t-test was performed using the results to identify regulative pairs of miRNAs 
and mRNAs. P-values were calculated over the five repetitions of each combination of target 
gene and miRNA compared to the respective control. 
Transfection of HEK293T cells 
To test for transfection efficiency, HEK293T cells were transfected using a control plasmid coding 
for d2eGFP (Destabilized enhanced green fluorescent protein). The transfection efficiency was 
controlled by fluorescence microscopy (Fig. 4.21). 
 
Fig 4.21: Transfection efficiency test using HEK293T cells; plasmid transfected: empty sponge control 
plasmid coding for d2eGFP (Ebert et al. 2007) 
The control transfection showed very good and also very stable transfection efficiency. In every 
luciferase experiment, a transfection control with the eGFP (Enhanced green fluorescent 
protein) coding plasmid was performed to monitor transfection efficiencies. The high 
transfection rate was reproducible in every single experiment. 
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CD2AP 
For the CD2AP luciferase assay, the c-terminal part of the 3’-UTR of the human CD2AP gene, 
consisting of 606 bp (chapter 4.4), was cloned into the modified pMir-Report luciferase 
construct. The luciferase construct was used to co-transfect HEK293T cells together with 
respective pSuper constructs either overexpressing the control sequence (green bars) or a 
functional miRNA. The overexpression of miR-27b-3p and miR-29a-3p did not seem to have an 
effect on the expression of the targeted luciferase, while a reduction of luminescence ratio to 
values between 60% and 84% (70%, 67%, 72%,84% and 60%) compared to the control conditions 
could be measured when cotransfecting with the pSuper construct overexpressing miR-92a-3p. 
 
Fig. 4.22: Luciferase assay using 3’-end of human CD2AP-3’-UTR, screening for putative regulatory miRNAs: 
cotransfection of luciferase containing the 3’-end of the CD2AP 3’-UTR with pSuper constructs 
overexpressing a control sequence (green bars), miR-27b-3p, miR-29a-3p or miR-92a-3p, respectively 
(blue bars); n.s. not significant; **: p < 0.01; p-values for five repetitions of experiment compared to the 
control 
To confirm binding of miR-92a-3p to the binding site which was predicted consistently by the 
prediction algorithms at the 3’-UTR positions 2,660-2,665, it was destroyed by mutating the 
positions 2, 4 and 6 in the binding region of the miRNA seed region. The luciferase reporter 
constructs containing the wildtype 3’-UTR or the 3’-UTR with the mutated binding site were 
cotransfected with the pSuper constructs overexpressing the control sequence or miR-92a-3p 
(Fig. 4.23). 
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The first notable result is the reduced reduction of luciferase intensity of the wildtype construct 
by coexpression of miR-92a-3p, showing the varying results between several experiments. Only a 
slight, but not significant reduction of luciferase activity could be measured (95%, 103%, 93%, 
88% and 85%), while the overexpression of the control sequence or miR-92a-3p did not have an 
effect on the luciferase containing the 3’-UTR harboring the mutated miR-92a/b-3p binding site. 
In conclusion, it seems like the co-expression of miR-92a-3p has a repression effect on the 
luciferase containing the wildtype CD2AP 3’-UTR, but the results of different experiments differ 
due to the biological variability between the single experiments. The mutation of the assumed 
binding site has no effect on the luciferase intensity, which might prove the functionality of the 
predicted binding site. 
 
Fig. 4.23: Luciferase assay using 3’-end of human CD2AP-3’-UTR and miR-92a/b-3p: cotransfection of 
luciferase containing either CD2AP wildtype 3’-UTR or CD2AP 3’-UTR with mutated miR-92a-3p binding 
site together with pSuper constructs coding for control sequence or miR-92a-3p; n.s. not significant; p-
values for five repetitions of experiment compared to the control 
Additionally, miR-30a-5p was checked for targeting of CD2AP. In the predicted binding site of the 
seed region of miR-30a-5p in the 3’-UTR, positions 2,844-2,849, the positions 2, 4 and 6 were 
mutated to destroy the binding site of the seed region. The wildtype 3’-UTR construct as well as 
the mutated construct were used to cotransfect HEK293T cells together with either a pSuper 
construct overexpressing the control sequence or the mature miR-30a-5p. 
 
Fig. 4.24: Luciferase assay using 3’-end of human CD2AP-3’-UTR and miR-30a-e-5p; cotransfection of 
luciferase containing either CD2AP wildtype 3’-UTR or CD2AP 3’-UTR with mutated miR-30a-3p binding 
site together with pSuper constructs coding control sequence or for miR-30a-5p; n.s. not significant; *: 
p < 0.05; p-values for five repetitions of experiment compared to the control 
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It could be shown that an overexpression of the mature miR-30a-5p leads to a reduction of the 
luminescence intensity of the luciferase construct containing the wildtype 3’-UTR to values 
between 79% and 99% (87%, 79%, 78%, 99% and 95%) compared to the cotransfection with the 
pSuper construct expressing the control sequence (Fig. 4.24). When cotransfected with the 
mutated construct lacking the binding site, the coexpression of miR-30a-5p does not influence 
the intensity of the targeted luciferase compared to coexpression with the control sequence. 
This shows that the predicted binding site seems to be active and accessible for miR-30a-5p. 
Taken together, these results hint that human CD2AP might be regulated by miR-30a-5p as well 
as miR-92a-3p in the cell. 
FYN 
For the FYN luciferase assay, the whole 3’-UTR of the longest human FYN transcript, consisting of 
1407 bp (chapter 4.4), was cloned into the modified pMir-Report luciferase construct. The 
luciferase construct was used to co-transfect HEK293T cells together with respective pSuper 
constructs either overexpressing the control sequence (green bars) or a functional miRNA (blue 
bars) (Fig.4.25).  
 
Fig. 4.25: Luciferase assay using complete human FYN-3’-UTR, screening for putative regulatory miRNAs: 
cotransfection of luciferase containing FYN 3’-UTR together with pSuper constructs coding for control 
sequence (green bars), miR-23b-3p or miR-27b-3p, respectively (blue bars); n.s. not significant; p-values 
for five repetitions of experiment compared to the control 
The overexpression of miR-23b-3p and miR-27b-3p did not seem to have an effect on the 
expression of the targeted luciferase, meaning that the predicted binding sites are not functional 
under these conditions. 
Additionally, possible targeting of miR-130a-3p and miR-146b-5p was investigated (Fig. 4.26) by 
coexpressing either the control sequence (green bars) or the pSuper constructs coding for the 
mature miRNAs (blue bars). 
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Fig. 4.26: Luciferase assay using complete human FYN-3’-UTR, screening for putative regulatory miRNAs 
and putative cooperative regulation: cotransfection of luciferase containing Fyn 3’-UTR with pSuper 
constructs coding for control sequence (green bars) or miR-130a-3p or miR-146b-5p, respectively (blue 
bars, left) or miR-130a-3p and miR-146b-5p (blue bars, right); n.s. not significant; *: p < 0.05; p-values for 
five repetitions of experiment compared to the control 
The overexpression of miR-130a-3p did not have a reproducible effect on the expression of the 
targeted luciferase, while coexpression of miR-146b-5p lead to a reproducible reduction of 
luciferase activity to intensity values of 78% to 97% (97%, 83%, 80%, 87% and 78%) of the 
control intensity. This indicates a specific interaction between the human 3’-UTR of FYN and 
miR-146b-5p. 
Since the 3‘-UTR of human FYN contains two predicted binding sites for miR-130a-3p as well as 
for miR-146b-5p, and the two miRNAs might have a cooperative effect, the luciferase construct 
containing the wildtype 3’-UTR of human FYN was cotransfected with a mixture of pSuper 
constructs overexpressing miR-130a-3p and miR-146b-5p. The reduction caused by the 
cotransfection of pSuper_130a-3p and pSuper_146b-5p to values between 71% and 95% (79%, 
71%, 79% 91% and 95%; Fig. 4.26 right) compared to the control sequence was similar to the 
reduction caused by the miR-146b-5p alone. 
Taken together, FYN seems to be regulated by miR-146b-5p in human cells. The putative 
regulation of FYN by miR-146b-5p was further investigated using a luciferase construct harboring 
the FYN 3’-UTR with mutated miR-146b-5p binding sites (bachelor thesis K. Heizler). The 
reduction is lost when either of the miR-146b-5p binding sites is mutated. This will be further 
investigated with a construct with both binding sites mutated. 
NCK2 
For the NCK2 luciferase assay, the whole 3’-UTR of the longest human protein coding transcript, 
consisting of 1,098 bp (chapter 4.4), was cloned into the modified pMir-Report luciferase 
construct. The luciferase construct was used to co-transfect HEK293T cells together with pSuper 
constructs either overexpressing the control sequence (green bars) or a functional miRNA. The 
R E S U L T S  
 
122 
 
overexpression of miR-23b-3p and miR-92a-3p does not have a big effect on the expression of 
the targeted luciferase, while miR-30a-5p causes a reduction to values between 73% and 98% 
(88%, 98%, 88%, 73% and 77%) compared to the control sequence. Compared to the other 
luciferase assays, the experiment showed higher standard deviations, making it harder to 
register reductions of luciferase activity (Fig. 4.27). 
 
Fig. 4.27: Luciferase assay using complete human NCK2-3’-UTR, screening for putative regulatory miRNAs: 
cotransfection of luciferase containing Nck2 3’-UTR with pSuper constructs coding for control sequence 
(green bars) or miR-23b-3p, miR-30a-5p or miR-92a-3p, respectively (blue bars); n.s. not significant; *: 
p < 0.05; p-values for five repetitions of experiment compared to the control 
Since coexpression of miR-30a-5p shows a reduction of luciferase intensity, a possible binding 
might be investigated more closely by mutating the putative binding site in the 3’-UTR. 
NEPH1 
For the NEPH1 luciferase assay, the 3’-UTR of the human protein coding transcript NM_018240, 
consisting of 533 bp (chapter 4.4), was cloned into the modified pMir-Report luciferase 
construct. The luciferase construct was used to co-transfect HEK293T cells together with pSuper 
constructs either overexpressing the control sequence (green bars) or the mature miR-29a-3p.  
 
Fig. 4.28: Luciferase assay using human NEPH1-3’-UTR, investigating miR-29a-3p regulation; cotransfection 
of luciferase containing NEPH1 3’-UTR with pSuper construct coding for control sequence (green bars) or 
miR-29a-3p (blue bars); n.s. not significant; p-values for three repetitions of experiment compared to the 
control 
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Coexpression of miR-29a-3p lead to a small, but reproducible reduction of luciferase activity of 
luciferase containing the NEPH1 3’-UTR to values between 84% and 94% (84%, 94% and 85%) 
compared to the control sequence (Fig. 4.28).  
The predicted miR-29a-c-3p binding site at the positions 167-172 was mutated by exchange of 3 
bases at the positions 2, 4 and 6 of the predicted seed binding site. The constructs containing the 
wildtype 3’-UTR or the 3’-UTR with the mutated binding site were cotransfected with the pSuper 
constructs overexpressing the control sequence or miR-29a-3p. 
 
Fig. 4.29: Luciferase assay using human NEPH1 3’-UTR, investigating miR-29a-3p regulation: cotransfection 
of luciferase containing either NEPH1 wildtype 3’-UTR or NEPH1 3’-UTR with mutated miR-29a-3p binding 
site with pSuper constructs coding for control sequence or miR-29a-3p; n.s. not significant; p-values for 
three repetitions of experiment compared to the control 
The small reduction of luciferase activity by coexpression of miR-29a-3p that was detected in 
earlier experiments could not be reproduced in these experiments. Furthermore, the 
overexpression of miR-29a-3p seemed to have no influence on the luciferase construct with the 
3’-UTR containing the mutated binding sites (Fig. 4.29).  
Taken together, these results suggest that if there is a regulation of Neph1 by miR-29a-3p, the 
effect is rather small. 
4.7 Sponge constructs for miRNA knockdown 
One possibility for functional analysis of mature miRNAs in cell culture and in vivo is the 
downregulation of their levels. Competitive inhibitors, so-called “sponges”, were designed to 
target miRNA families known to be expressed in high levels in murine podocytes. The miRNA 
families miR-23-3p, miR-27-3p, miR-29-3p and miR-92-3p as well as the mature miRNA miR-24-
3p, all highly expressed in murine podocytes, were chosen as a candidate set. 
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Detection of studied miRNAs in hPCLs by Northern Blotting  
Since the sponge constructs were to be tested for functionality in proliferating hPCLs, expression 
of the target miRNAs in was checked by Northern Blotting. For each mature miRNA, 10 µg of 
total RNA was analyzed. 
 
Fig. 4.30: Northern Blotting of sponge candidate miRNAs using proliferating hPCLs: detection of miRNA 
expression in 10 µg of total RNA isolated from proliferating hPCLs; detection of snRNA U6 as internal 
standard and the mature miRNAs 
The expression of miR-23a-3p, miR-23b-3p, miR-24-3p, miR-27a-3p, miR-27b-3p, miR-29a-3p and 
miR-92a-3p in proliferating hPCLs could be validated. Interestingly, miR-29c-3p could not be 
detected. The sequences of mature miR-29a-3p and miR-29c-3p differ by just one base. Thus, 
this experiment also demonstrates the high sequence specificity in Northern Blotting. 
Proof of sponge functionality by dual luciferase assay 
The functionality of competitive inhibitors, the “sponges”, was tested in proliferating hPCLs 
(cloning and measurement performed by G. Knoll). The sponges, transcripts coding for a 2 h 
destabilized GFP reporter gene containing seven binding sites for a specific miRNA in its 3’-UTR, 
were checked for functionality in dual luciferase assays. hPCLs were cotransfected using pMir-
Report construct expressing firefly luciferase containing seven binding sites for a specific miRNA 
and untargeted renilla luciferase and a pSponge construct not harboring any binding sites or a 
pSponge construct containing seven fitting miRNA binding sites in its 3’-UTR. The firefly 
luciferase intensity was measured and normalized to intensity of the untargeted renilla 
luciferase. Each experiment was normalized to the conditions where an empty sponge was 
cotransfected. A functional sponge directed against miR-21-5p served as a positive control (Ebert 
et al. 2007). 
By cotransfection of a matching sponge construct, the signal intensity of the targeted firefly 
luciferase could be rescued for the positive control miR-21-5p as well as for the candidate 
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miRNA families miR-23a/b-3p, miR-24-3p, miR-27/a-3p, miR-29a/b/c-3p and miR-92a/b-3p (Fig. 
4.31). The sponge construct harboring binding sites for a non-functional mock sequence was not 
able to rescue the firefly luciferase signal intensity of the pMir-report construct for miR-24-3p, 
proving the miRNA-sponge binding to be functional and specific. 
 
  
Fig. 4.31: Sponge functionality analysis by luciferase assay using hPCLs; pMir-Report-TK/RenillaLuc 
constructs and empty sponge constructs or matching sponges were cotransfected into hPCLs; luciferase 
intensity ratio was measured and set to 1 in cells not transfected with sponge constructs; *: p < 0.05; **: p 
< 0.01 
Taken together, it could be shown by dual luciferase assay that sponges directed against miRNA 
families miR-23a/b-3p, miR-27a/b-3p, miR-29a/b/c-p and miR-92a/b-3p as well as against the 
mature miRNA miR-24-3p are able to bind their targets, thus downregulating miRNA levels in 
cells. 
4.8 In vivo knockdown of miRNAs using Vivo-Morpholinos 
For transient miRNA knockdown by the so-called Vivo-Morpholinos (GeneTools), male C57bl/6 
mice which were eight weeks of age were split into groups of two and injected with two 
different Vivo-Morpholinos or control solutions. Two groups of mice received antisense 
oligonucleotides against miR-30a-5p and miR-322-3p, respectively. Since the first two animals 
receiving anti-miR-322-3p oligonucleotides died shortly after injection from general, not kidney 
related problems, the experiment was repeated with half the dose of anti-miR-322-3p Vivo-
Morpholinos. The two control groups were injected with a negative control Vivo-Morpholino 
directed against a human -globin intron mutation provided by the manufacturer or plain 
1x PBS, respectively. The urine of these mice was collected before the experiment as spot urine 
and after the third injection 16 h overnight by metabolic cages.  
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Fig. 4.32: Urine gel of vivo-Morpholino treated mice; Coomassie-stained SDS-gel of urines collected before 
experiment (0) and after the third injection from metabolic cages (mc); 0.5 µl urine per lane; size of 
albumin: ca. 66 kDa 
Both Vivo-Morpholinos directed against two miRNAs highly enriched in podocytes, anti-miR-30a-
5p and anti-miR-322-3p, lead to proteinuria in the treated animals. Since the mice which 
received the control Vivo-Morpholino also developed a proteinuria after treatment, an 
additional control group was injected with control Morpholinos. Morpholinos possess the same 
nucleotide sequence, but lack the octaguanidinium residue at the 3’-end. Opposed to the 
injection of the control Vivo-Morpholino, the control Morpholino did not lead to a proteinuria in 
the animals, hinting that the octaguanidinium residue is nephrotoxic and has a big influence 
itself, independent of the sequence of the attached oligonucleotide. Since the Morpholinos lack 
this residue, the control oligonucleotide seems to not affect the kidney, but the expected 
permeation of the cells is much worse. If the uptake into the cells is slower, it might lead to a 
severe problem in targeting the Morpholinos specifically to the kidney, as the time a kidney can 
be clamped is limited. The effect of anti-miRNA Morpholinos in the kidney could be tested in a 
similar experiment. 
4.9 TALE-Nucleases for miR-30a knockout in HEK293T cell line 
To characterize the role of miR-30a-5p, HEK293T knockout cell clones were generated with the 
help of a TALEN pair directed against the miR-30a locus (bachelor thesis C. Blessing, 2014). 
The efficiency of the TALEN-mediated knockout was assessed by Northern Blotting analyses of 
the amount of mature miR-30a-5p in the 30 µg total RNA isolated from different putative 
knockout cell clones. Three knockout clones showed a reduced expression of mature miR-30a-5p 
compared to the wildtype control (Fig. 4.33 A). They were analyzed for their Notch1 expression 
levels by qPCR, since Notch1 is a validated target of miR-30a-5p in glomeruli (Wu et al. 2014). 
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Fig. 4.33: Identification of miR-30a-5p knockout clones; (A) Northern Blotting for mature miR-30a-5p from 
30 µg total RNA; internal control: snRNA U6; (B) qPCR of cDNA transcribed from long RNA fraction for 
Notch1 expression, a validated miR-30a-5p target in glomeruli 
In the knockout clones 1 and 2, Notch1 was upregulated, while no changes in the expression 
levels are observed for knockout clone 3 (Fig. 4.33 B). To investigate the knockout on a genomic 
level, the genomic locus of mir-30a was amplified by PCR and the resulting PCR product was 
sequenced and aligned to the wildtype sequence for mutation analyses (Fig. 4.34). 
Fig. 4.34: Genomic organization of miR-30a-5p knockout clones; the genomic locus of mir-30a 
(chromosome:GRCh37:6:72113201:72113339:-1) was amplified by PCR and sequenced; underlined: 
sequence of pre-mir-30a; light blue: sequence of mature miR-30a-5p; dark blue: seed region of miR-30a-
5p; light green: sequence of mature miR-30a-3p; dark green: seed region of miR-30a-3p; dash: gap in 
sequenced products; red: insertions in sequenced product 
The three knockout clones show different reorganization patterns: in clone 1, the seed region of 
the miR-30a-5p is nearly completely deleted, in clone 2 the whole mir-30a precursor sequence is 
missing. Knockout clone 3 is heterozygous for the knockout: while one allele is not affected by 
the knockout at all, the other allele shows an insertion of one base. The presence of one 
wildtype allele in knockout clone 3 might explain why the Notch1 expression is not dysregulated 
in this clone. 
Taken together, the TALEN mediated knockout can lead to different genomic reorganization 
patterns, resulting in downregulation of the mature miR-30a-5p expression and a dysregulation 
of a validated target gene, Notch1, in HEK293T cells. 
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4.10 Renal miRNA expression patterns in NPS disease models 
The nail-patella syndrome is a human disease which is caused by mutations in the LMX1B gene. 
This gene codes for the transcription factor LMX1B which is known to be important for podocyte 
maintenance (Miner et al. 2002). Since the expression of miRNAs can be controlled by 
transcription factors, a reduced or absent function of LMX1B might also have an influence on 
miRNA expression in podocytes. 
4.10.1 Profiles of glomerular and tubular miRNAs in Lmx1b knockout mice 
To investigate if Lmx1b knockout has a direct or indirect influence on the miRNA levels in 
affected glomeruli, transgenic mice with a doxycycline inducible podocyte specific Lmx1b 
knockout were used (Fig. 4.35). 
 
Fig. 4.35: Genomic organization of the triple transgenic Lmx1b knockout mice; exposure to doxycycline 
leads to podocyte specific reorganization of the genomic locus of Lmx1b; Abbreviations: Dox: doxycycline; 
Lim1, 2: Lim domain 1, 2; TetO: Tet-On promoter; rtTA: reverse tetracycline transactivator 
Lmx1b knockout in mice was induced by adding doxycycline to their drinking water for 7 days. 
Spot urine of the Lmx1b knockout animals used for glomeruli isolation was checked for 
proteinuria by SDS-PAGE. All four mice used for glomeruli isolation showed a distinct 
proteinuria, which was not detected in the control urine (Fig. 4.36). 
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Fig. 4.36: Coomassie stained urine gel of triple transgenic Lmx1b knockout mice; urines of Cre+ knockout 
animals (1 - 4) showing a distinct proteinuria after doxycycline induction and a control; 0.5 µl urine per 
lane; size of albumin: ca. 66 kDa 
The glomeruli of four Cre+ Lmx1b knockout mice and six Cre- control mice, all female and aged 
between 12 and 14 weeks, were isolated by magnetic beads perfusion. RNA extraction and 
library preparation was performed by A. Dueck (Department of Biochemistry I, University of 
Regensburg). One deep sequencing profile was generated from the total RNA preparation, while 
the second profile was generated from the small RNA fraction enriched by gel electrophoresis. 
The RNA samples were sequenced on a HiSeq1000 sequencer (Illumina). The annotation of the 
sequenced libraries to the known miRNA sequences was performed by N. Eichner (Department 
of Biochemistry I, University of Regensburg). 
The profiles from enriched small RNAs yielded 26.5 millions of miRNA reads of good quality from 
the control animals and 28.7 millions of miRNA reads from the Lmx1b knockout animals. The 
profile generated from total RNA consisted of 16.6 millions of miRNA reads in the control 
animals and 14.4 millions of miRNA reads from the Lmx1b knockout animals. For the profiles 
generated from small and total RNA, enrichments between the knockout animals and the 
control animals were calculated (Tab. 10.5). 
In total, 247 mature miRNAs reached more than 430 total reads in all four libraries, which 
corresponds to more than five reads per million. There was no mature miRNA that was 
upregulated more than 2-fold in the knockout glomeruli in both profiles, but seven mature 
miRNAs that were downregulated more than 2-fold after the Lmx1b knockout, miR-28-5p, miR-
200a-3p, miR-200b-3p, miR-200c-3p, miR-203-3p, miR-429-3p and miR-1839-5p. 
The mature miRNAs miR-200a-3p, miR-200b-3p, miR-200c-3p, and miR-429-3p all belong to a 
miRNA family consisting of 5 members that is organized in two clusters. The fifth family member, 
miR-141-3p, was equally expressed with and without Lmx1b knockout according to both profiles. 
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4.10.2 Validation of miRNA expression by qPCR 
To validate the deep-sequencing profiles generated from Lmx1b knockout mice and control 
mice, the expression of a subset of miRNAs was analyzed by qPCR. Two male 34 week old Lmx1b 
knockout mice and one male 34 week old control mouse received doxycycline containing 
drinking water for seven days. Their urine was checked for proteinuria after induction (Fig. 4.37 
A). The glomeruli were isolated by magnetic beads perfusion (chapter 3.3.5). The long and small 
RNA fractions were isolated and reverse transcribed to cDNA (chapter 3.4.2 & 3.4.4). The cDNA 
generated from the long RNA sample was checked for Lmx1b expression. In the knockout mice, 
Lmx1b mRNA reduction to 59.8% was measured (Fig. 4.38 B). 
 
Fig. 4.37: Characterization of Lmx1b knockout validation animals; (A) Coomassie stained urine gel of triple 
transgenic Lmx1b knockout mice; both Cre+ knockout animals (Pos1, Pos2) show a distinct proteinuria 
after doxycycline induction, while the urine sample from the Cre- control animal (Neg) does not contain 
protein; 0.5 µl urine per lane; size of albumin: ca. 66 kDa (B) qPCR of Lmx1b transcript in Cre+ Lmx1b 
knockout mice compared to Lmx1b transcript level in Cre- control mice; internal control: snRNA U6 
The enrichment of mature miRNAs between the control mouse sample and the sample 
generated from the knockout mice was calculated and compared to the result from the deep 
sequencing profiles.  
All mature miRNAs from the subset to be validated seemed to be downregulated in the 
knockout animals compared to the control animals (Fig. 4.38). To check if the general reduction 
is due to a change in the miRNA processing pathway, the expression levels of Drosha, Dicer, and 
the Argonaute proteins were analyzed by qPCR, but no changes were found (bachelor thesis M. 
Billmeier, 2012, data not shown).  
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Fig. 4.38: Relative expression levels of mature miRNAs in Lmx1b knockout animals and control animals; 
internal standard: snRNA U6 
It is known that miR-145-5p is a miRNA not expressed in the podocytes, but in the mesangial 
cells of the glomerulus (our data; Harvey et al. 2008), meaning that the Lmx1b knockout cannot 
have a direct effect on its expression levels. Therefore, for further analyses of the miRNA 
expression, the ratio of miR-145-5p between the knockout animals and the control animals was 
set to 1 (Fig. 4.39). 
 
Fig. 4.39: Relative expression levels of mature miRNAs in Lmx1b knockout animals and control animals; 
miR-145-5p ratio set to 1; internal standard: snRNA U6 
When the expression ratios are normalized to the expression of miR-145-5p, miR-200a-3p and 
miR-200b-3p are still reduced more than 2-fold in the knockout animals compared to the 
control. The miRNAs miR-200c-3p, miR-203-3p, miR-429-3p and miR-1839-5p are still reduced, 
but do not reach the threshold. Interestingly, an additional mature miRNA, miR-192-5p, also 
seemed to be reduced in the Lmx1b knockout animals. This miRNA was reduced to 51% 
expression in the profile generated from enriched small RNAs, but only reduced to 68% in the 
profile generated from total RNA. 
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4.10.3 Profiles of podocyte and endothelial/mesangial miRNAs in Lmx1b knockout mice 
To assess if the miRNA levels changed in Lmx1b knockout glomeruli were caused by altered 
miRNA expression in the podocytes, the triple transgenic inducible podocyte specific Lmx1b 
knockout mice were crossed with the mT/mG reporter mice (Fig. 4.40). In these quadruple 
transgenic mice, doxycycline induction not only leads to Lmx1b knockout, but also to a switch 
from expression of the red fluorescent mTomato marker to expression of GFP, yielding mice 
with sortable green fluorescent Lmx1b knockout podocytes. As knockout samples, animals 
homozygous for the floxed Lmx1b locus harboring the transgenes for podocyte specific rtTA 
expression, the TetOn controlled Cre recombinase expression and the mT/mG reporter cassette, 
were used. As a control group, mice possessing two Lmx1b wildtype alleles were used. 
 
Fig. 4.40: Genomic organization of the quadruple transgenic Lmx1b knockout reporter mice; exposure to 
doxycycline leads to podocyte specific reorganization of the genomic loci of Lmx1b and of the mT/mG 
reporter cassette; Abbreviations: Lim1, 2: Lim domain 1, 2; GFP: green fluorescent protein; mT/mG: 
mTomato-GFP reporter cassette 
The Lmx1b knockout mice and the control group received drinking water with doxycycline for 
eight days. On the seventh day of doxycycline induction, spot urine of the animals was checked 
for proteinuria by SDS-PAGE. Only knockout animals showing a clear proteinuria and control 
animals that did not show proteinuria were chosen for the experiment. Podocytes were isolated 
from the animals on the eighth day after induction. 
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Fig. 4.41: Coomassie stained urine gel of quadruple transgenic Lmx1b knockout mice; all knockout animals 
(1-4) show a distinct proteinuria after doxycycline induction; 1µl urine per lane; size of albumin: ca. 66 kDa 
All Lmx1b knockout animals showed a distinct proteinuria after doxycycline induction for eight 
days (Fig. 4.41), while the control animals did not show proteinuria after doxycycline induction 
for eight days (Fig. 4.42). 
 
Fig. 4.42: Coomassie stained urine gel of quadruple transgenic control mice; all animals harboring a 
wildtype Lmx1b gene do not show proteinuria after doxycycline induction; 1µl urine per lane; size of 
albumin: ca. 66 kDa 
In total, 98,000 green podocytes and 200,000 cells of the red cell population were isolated from 
four female Lmx1b knockout mice, while 91,000 green podocytes and 188,000 cells of the red 
cell population were isolated from seven female control mice. All animals used were aged 
between 12 and 14 weeks. 
RNA extraction and library preparation from small RNAs was performed by A. Dueck 
(Department of Biochemistry I, University of Regensburg). The RNA samples were sequenced on 
a HiSeq1000 sequencer (Illumina). The annotation of the sequenced libraries to the known 
miRNA sequences was performed by N. Eichner (Department of Biochemistry I, University of 
Regensburg). The annotation of the sequenced libraries to the known miRNA sequences was 
performed by N. Eichner (Department of Biochemistry I, University of Regensburg). 
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From Lmx1b knockout podocytes and control podocytes, libraries with 2.97 million and 2.96 
million sequence reads were generated. From the red cell population, libraries with 2.82 million 
reads from Lmx1b knockout animals and 2.96 million reads from control animals were generated 
(Tab. 10.6). In total, 262 mature miRNAs were identified to expressed over the threshold of 
more than five reads per million in at least one of the generated libraries. A total of 210 mature 
miRNAs were expressed in one of the podocyte samples. To identify miRNAs that might be 
regulated directly by Lmx1b, the profiles were searched for miRNAs with altered expression in 
the podocytes with and without Lmx1b knockout, while the expression in the red fluorescent cell 
population stays the same. In total, 48 mature miRNAs were upregulated after the Lmx1b 
knockout, while 40 mature miRNAs were downregulated. The miR-200 family was mainly 
expressed in the red fluorescent cell population, while miR-192-5p was expressed in control 
podocytes on a very low level and even more downregulated after the Lmx1b knockout. 
Of the 38 podocyte miRNAs, all except one (mmu-miR-24-1-5p) could be identified in the miRNA 
profiles generated from the Lmx1b knockout mice as well as the control mice, underlining again 
the relyability of the generated data sets. For 21 mature miRNAs, expression levels in the 
podocytes and in the red fluorescent cell populations remained stable before and after the 
knockout. Five miRNAs, let-7e-3p, miR-30b-5p, miR-30c-5p, miR-125b-2-3p and miR-340-5p, 
were upregulated in the podocytes after the knockout and equally expressed in the red 
fluorescent cell population, while four miRNAs, miR-196b-5p, miR-330-3p, miR-450b-5p and 
miR-542-3p were downregulated in the podocytes after the knockout and equally expressed in 
the red fluorescent cell population. These nine miRNAs might be the most interesting targets for 
further analyses. Two miRNAs, miR-149-5p and miR-210-3p were upregulated in podocytes and 
downregulated in the red fluorescent cell population. Four miRNAs were downregulated in both 
cell populations, miR-30b-3p, miR-330-5p, miR-450a-5p and miR-615-3p. One single miRNA, miR-
873a-5p, was downregulated in podocytes but upregulated in the red fluorescent cell 
population. Of the candidate miRNAs, miR-330-5p was the only one to totally vanish after the 
knockout, but only in the red fluorescent cell population, while residual expression persisted in 
the podocytes after knockout. As some miRNA are expressed at low levels, the calculated ratios 
might be more error-prone compared with miRNAs expressed at high levels. This underlines the 
need for a validation of the measured miRNA expression changes. 
 
D I S C U S S I O N  
 
135 
 
5 DISCUSSION 
5.1 Models for investigation of podocytes 
To investigate the role of miRNAs in glomeruli and podocytes, three main model systems can be 
used: immortalized cell lines in cell culture, podocytes isolated freshly from mice and 
manipulations inside the murine organism. In mammalian organisms, podocytes are placed in a 
very specific environment. In vivo, they cover the capillary of the glomerulus. The renal filtration 
barrier is composed of three layers: the fenestrated endothelium including the glycocalyx, the 
glomerular basement membrane between the endothelium and the podocytes and the slit 
diaphragm between the interdigitating podocyte foot processes. All three parts are crucial for 
successful blood filtration. The elaborate glycocalyx covering the endothelial cell and its 
fenestrae already restricts particulate blood components and larger molecules like 
immunoglobulins and albumin (Schlöndorff 2014). The glomerular basement membrane and the 
slit diaphragm come into play as second and third level of filtration, all together providing the 
highly effective permselectivity of the filter and preventing it from clogging up (Schlöndorff 
2014). A very elaborate and tightly regulated cross-talk between the glomerular cells is 
necessary for a fully functional renal filtration barrier. 
5.1.1  Differences between animal model and cell culture 
In metanephric organ culture, it has been shown that podocytes develop before the other cell 
types, hinting that an intrinsic development program is used for podocyte differentiation during 
development (Schlöndorff 2014). However, it is not known how a podocyte recognizes its 
neighboring podocyte to build up the interdigitating foot processes and the slit diaphragms in-
between the processes. It has been shown that the fenestrae formation in the endothelium is 
caused by VEGF (Vascular endothelial growth factor) signaling, a signal protein produced by 
podocytes (Chen et al. 2002). The fenestration of the endothelium and its characteristic 
glycocalyx is dependent on podocyte VEGFA (Vascular endothelial growth factor A) and the 
presence of the fitting receptor, VEGFR-2 (Vascular endothelial growth factor receptor 2), in the 
endothelium (Schlöndorff 2014). While studies have elucidated the molecular basis of signaling 
from podocyte to endothelial cell and from endothelial cell to mesangial cell, potential 
mediators have yet to be identified for cross-talk between podocytes and mesangial cells as well 
as unidirectional signaling from endothelial cells to podocytes and from mesangial to endothelial 
cells (Schlöndorff 2014). A first hint for signaling from endothelial cells to the podocytes was 
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given when medium conditioned from glomerular endothelial cells grown under permanent 
laminar shear stress decreased podocyte monolayer resistance and increased phosphorylation 
of vasodilator-stimulated phosphoprotein, showing a possible endothelium-to-podocyte 
crosstalk in cell culture (Slater et al. 2012).  
The composition of the glomerular basement membrane has recently been studied by mass-
spectrometry based proteomics (Byron et al. 2014). It was reported that cell type specific 
differences in the extra cellular matrix composition could be identified. Additionally, the extra 
cellular matrix deposition in co-cultured cells was different from the matrix in monocultures, 
hinting at cross-talk between the cell types. It has been tried to mimic the physiological state 
using hydrogel scaffolds (Bruggeman et al. 2012) or a bioartificial membranes containing 
collagen I (Slater et al. 2011) for culturing endothelial cells and podocytes on the two sides of a 
central substrate. But still, the very specialized three-dimensional podocyte architecture with 
the interdigitating foot processes of two neighboring podocytes embracing the capillaries has 
not been copied in cell culture yet. 
Taken together, podocytes are placed in a very complex environment under physiological 
conditions, including a lot of signaling in-between the different cell types of the glomerulus. 
Additionally, the three-dimensional architecture of podocytes is not conserved in cells being 
cultured in two-dimensional cell culture. Thus, it is plausible that immortalized podocyte cell 
lines do not exhibit all characteristics of a podocyte in vivo. 
5.1.2  Immortalized human cell line as model for podocytes  
To investigate podocytes in cell culture, immortalized cell lines derived from isolated human and 
murine podocytes, that can be switched from a proliferating to a differentiated state, have been 
established (Saleem et al. 2002, Schiwek et al. 2004). For the human immortalized podocytes, 
the creators showed by immunofluorescence microscopy that the expression of nephrin as well 
as synaptopodin are low and diffuse in proliferating cells, but changes to a punctual pattern for 
nephrin and an actin associated pattern for synaptopodin in differentiated cells. 
In the present work, the differentiation of immortalized human podocytes could also be nicely 
demonstrated by the changing localization of the podocyte marker nephrin, and the two actin 
associated adapter proteins synaptopodin and -actinin-4 between the proliferating and the 
differentiated state of hPCLs. Similar to the to the results published before (Saleem et al. 2002), 
it could be shown that nephrin relocalizes from a weak nuclear staining to a spot-like or linear 
localization at the cellular membrane in differentiated human podocytes. Synaptopodin localizes 
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from nuclear staining with weak cytoplasmic staining to fibers spanning the whole differentiated 
cell, arguing for an actin colocalization of synaptopodin in differentiated hPCLs. Additionally, -
actinin-4, an actin crosslinking protein known to be mutated in some patients with familial focal 
segmental glomerulosclerosis (Henderson et al. 2008), could be shown to relocate from fibers 
spanning the whole cytoplasm to “spike”-like protrusions at the cortex of the cells. All three 
proteins known to be important for podocyte structure show a distinct relocation pattern 
between the proliferating and the differentiated state, indicating a reorganization of the actin 
cytoskeleton and enhanced expression of nephrin and synaptopodin after differentiation. 
Additionally, the experiments showed that ten mature miRNAs that were found to be expressed 
in freshly isolated murine podocytes, miR-10b-5p, miR-92a-3p, miR-130a-3p, miR-30a-5p, miR-
146b-5p, miR-29a-3p, miR-23b-3p, miR-22-3p, miR-107 and miR-27b-3p, are also expressed in 
immortalized human podocytes. These miRNAs show differential expression between 
proliferating and differentiated hPCLs, also arguing for an altered metabolic and structural state 
of the differentiated cells. In contrast, the expression of another set of five mature miRNAs 
expressed in freshly isolated murine podocytes, miR-148a-3p, miR-196b-5p, miR-424-5p, miR-
542-3p and miR-503-5p, could neither be detected in the proliferating nor in the differentiated 
immortalized human podocytes. This shows either species specific expression of mature miRNAs 
or a gap between the situation of differentiated podocyte cell line and the physiological in vivo 
state. Since the immortalized murine podocytes can also be switched to the differentiated state 
by culturing them at 38°C for 14 days, expression of the miRNAs detected in freshly isolated 
murine podocytes might be checked in proliferating and differentiated mPCLs. Thus, it could be 
investigated if the differences are due to the different species or due to the difference between 
immortalized cell lines and in vivo podocytes. 
The immortalized human podocytes show distinct differences between the proliferating and the 
differentiated state, in the expression and distribution of important structural proteins as well as 
their miRNA expression. Thus, they are a suitable model for regulatory mechanisms in human 
podocytes. There is, however, still a big difference between differentiated podocytes in the two-
dimensional cell culture flask and the in vivo environment of podocytes. As freshly isolated 
human podocytes cannot be obtained, the immortalized human podocyte cell line is the best 
human model for experiments on the function of podocytes. For studies focusing on the delicate 
structure of podocytes in the mammalian organism, freshly isolated murine podocytes represent 
the most accurate model for podocyte structure and function under physiological conditions, 
since they are fully differentiated cells isolated from their natural environment. 
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5.1.3  Freshly isolated murine podocytes 
The major limitation in working with podocytes freshly isolated from reporter mice is the yield. 
By modifications of the original podocyte isolation protocol (Boerries et al. 2013), adding an 
additional rinsing step prior to perfusion of the kidney and prolonging the podocyte digestion 
step by five minutes, it was possible to increase the cell yield to an average of around 200,000 
green fluorescent podocytes per animal in this work. This makes the isolation of five to six 
million cells a possible, but laborious task demanding many laboratory animals. Immortalized 
podocyte cell lines like the hPCLs and mPCLs can be expanded to millions of cells quite easily in a 
relatively short amount of time, while breading of a sufficient amount of laboratory animals 
takes several months and is considerably costlier. 
The number of cells per glomerulus was estimated to be 211 ± 29 by the dissector/fractionator 
method (Basgen et al. 2006), while the number of podocytes per glomerulus was estimated to 
be around 89 ± 10 with the fractionator/dissector method (Nicholas et al. 2011). The number of 
nephrons in a healthy murine kidney has been investigated by several studies. By physical 
dissector/fractionator combination, the number of nephrons per kidney in 129Sv/C57bl/6 hybrid 
mice after the sixth backcross to C57bl/6 background was estimated to be 13440 ± 1275 (Cullen-
McEwen et al. 2003). In a study focusing on the nephron number during kidney development, 
the number of nephrons in the adult kidney of four week old C57bl/6J mice varied between 9266 
and 13453 with an mean value of 11359 when analyzed with the fractionator/dissector method 
(Zhong et al. 2012). Differences of nephron numbers between male and female mice have been 
reported, when 19341 ± 859 nephrons in male C57bl/6 mice, but 22830 ± 1117 nephrons in 
female C57bl/6 mice were counted in individuals of eight weeks of age (Murawski et al. 2010).  
By magnetic beads perfusion, 20,131 ± 4699 glomeruli could be isolated from mice with 
different backgrounds (C57bl/6, 129/SV or hybrids of the two strains, Takemoto 2002). Finally, it 
was reported that up to 500,000 podocytes can be isolated from one double fluorescent Cre 
reporter mouse (Boerries et al. 2013).  
These numbers show that the number of nephrons, and thus, the number of podocytes per 
mouse varies with the age, sex, and genetic background of the laboratory animal, making an 
average of 200,000 podocytes per mouse a realistic yield. 
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5.2 miRNA expression in murine glomeruli and podocytes 
To investigate the role of miRNAs for maintenance of structure and function of glomeruli and 
podocytes, the first step is the identification of miRNAs that are expressed in podocytes under 
physiological conditions. The starting point for the present study were miRNA deep sequencing 
profiles generated from glomeruli and tubules isolated from C57bl/6 wildtype mice. 
5.2.1 Identification of glomerular and podocyte enriched miRNAs 
In the deep sequencing profiles generated from glomeruli and tubules as well as from podocytes 
and the red cell population, enrichment factors were calculated for every miRNA between the 
two populations. A factor of ≥ 2 in either direction was considered enrichment, while a lower 
factor was considered as equal expression between two cell populations.  
Identification glomerular enriched miRNAs 
In total, 260 mature miRNA sequences have been identified to be expressed in murine glomeruli 
and tubules by two deep sequencing profiles. According to both profiles, 69 miRNAs were 
glomerular enriched, while 27 mature miRNAs were detected to be glomerular enriched in one 
of the profiles and equally expressed in the other profile. A total of 84 miRNAs were equally 
expressed in glomeruli and tubules, while 62 miRNAs were tubular enriched and 18 miRNAs 
were tubular enriched in one of the profiles and equally expressed in the other profile. Since 
glomeruli consist of at least three different cell types, the podocytes, endothelial and mesangial 
cells, a mature miRNA found to be enriched in glomeruli is not necessarily expressed in 
podocytes. Thus, double fluorescent Cre reporter mice were bred for further investigation of the 
expression of miRNAs in podocytes. 
Identification of podocyte enriched miRNAs 
Using the two deep sequencing profiles of podocytes and the red fluorescent cell population 
isolated from mice, 143 mature miRNAs that were detected in both profiles were identified. A 
total of 38 miRNAs were enriched more than 2-fold in the podocytes compared to the red 
fluorescent cell population in both profiles, while 69 miRNAs were equally expressed in both cell 
populations according to the profiles and 93 miRNAs were enriched in the red fluorescent cell 
population both times. One miRNA was enriched in podocytes in one profile but enriched in the 
red fluorescent cell population in the other profile. A total of 42 miRNAs were found to be 
enriched in one of the profiles while being equally expressed in the other profile.  
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The results of these two deep sequencing profiles were compared to the miRNAs detected to be 
enriched in glomeruli in the earlier profiles (Fig. 5.1, Tab. 5.1). 
 
Fig. 5.1: Relative enrichment of miRNAs identified in murine glomeruli and podocytes; enrichment of 
glomerular enriched miRNAs in podocytes and the red fluorescent cell population (left) and enrichment of 
podocyte enriched miRNAs in the glomerular and tubular profiles (right) 
A total number of 59 mature miRNAs identified to be glomerular enriched in both deep 
sequencing analyses performed with RNA isolated from murine glomeruli and tubules were 
identified in both deep sequencing profiles obtained from podocytes and the red fluorescent cell 
population. The majority of 36 miRNAs was found to be enriched in the red fluorescent cell 
population with some of them not being expressed in podocytes at all. Additionally, three 
miRNAs were enriched in the red fluorescent cells in one profile and equally expressed in the 
other profile, and seven miRNAs were equally expressed in both profiles. Strikingly, only ten of 
the glomerular enriched miRNAs were found to be podocyte enriched, with additionally three 
miRNAs being enriched in one of the profiles and equally expressed in the other profile. This 
underlined the importance of the double fluorescent reporter mouse model, meaning that 
studies concentrating on the glomerular miRNA expression might be dealing with non-podocyte 
miRNAs their effects. 
Vice versa, 31 mature miRNAs enriched in podocytes had been identified previously in both the 
deep sequencing profiles of glomeruli and tubules. Eleven podocyte miRNAs had already been 
found to be glomerular enriched, while seven mature miRNAs were glomerular enriched in one 
of the profiles and equally expressed in the other profile. A total of twelve mature miRNAs was 
equally expressed in the profile derived from glomeruli and tubules, while two miRNAs were 
tubular enriched in one profile and two miRNAs were tubular enriched in both profiles. 
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Tab. 5.1: Glomerular and tubular expression of podocyte enriched miRNAs 
miRNAs 
accession 
number 
mature 
miRNA 
(murine) 
podocytes vs. 
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mmu-let-7e-3p MIMAT0017016 0,02 0,04 2,7 0,01 0,04 2,8 0,002 0,005 2,6 0,003 0,009 3,3
mmu-miR-23b-3p MIMAT0000125 1,68 3,84 2,3 1,46 4,25 2,9 0,306 2,345 7,7 0,187 0,325 1,7
mmu-miR-24-1-5p MIMAT0000218 0,01 0,01 2,2 0,01 0,02 4,3 0,000 0,002 6,3 0,001 0,002 2,6
mmu-miR-27b-5p MIMAT0004522 0,06 0,16 2,5 0,05 0,15 2,8 0,003 0,016 5,4 0,007 0,064 9,4
mmu-miR-30a-3p MIMAT0000129 3,24 11,48 3,5 4,45 17,83 4,0 0,474 0,787 1,7 0,525 0,765 1,5
mmu-miR-30a-5p MIMAT0000128 41,63 203,78 4,9 20,60 141,87 6,9 13,55 27,69 2,0 11,09 12,03 1,1
mmu-miR-30b-3p MIMAT0004524 0,04 0,12 3,2 0,04 0,18 4,1 0,003 0,007 2,2 0,007 0,010 1,5
mmu-miR-30b-5p MIMAT0000130 0,50 1,68 3,4 0,59 1,94 3,3 0,118 0,230 2,0 0,098 0,153 1,6
mmu-miR-30c-2-3p MIMAT0005438 0,93 3,76 4,0 1,01 4,69 4,6 0,161 0,303 1,9 0,291 0,576 2,0
mmu-miR-30c-5p MIMAT0000514 2,09 6,84 3,3 2,79 11,33 4,1 0,812 0,801 1,0 0,867 0,619 0,7
mmu-miR-30d-3p MIMAT0017011 0,02 0,07 3,1 0,01 0,05 4,2 0,009 0,011 1,3 0,007 0,005 0,6
mmu-miR-30d-5p MIMAT0000515 5,25 27,53 5,2 4,54 24,54 5,4 3,431 5,417 1,6 3,914 3,407 0,9
mmu-miR-99a-3p MIMAT0016981 0,01 0,09 7,8 0,01 0,03 5,3 0,004 0,003 0,7 0,005 0,001 0,1
mmu-miR-99a-5p MIMAT0000131 0,03 0,15 6,0 0,03 0,09 2,8 0,104 0,070 0,7 0,149 0,133 0,9
mmu-miR-107-3p MIMAT0000647 0,10 0,47 4,8 0,15 0,61 4,2 0,092 0,033 0,4 0,070 0,015 0,2
mmu-miR-125b-2-3p MIMAT0004529 0,01 0,08 6,3 0,01 0,05 4,3 0,012 0,011 0,9 0,012 0,002 0,2
mmu-miR-125b-5p MIMAT0000136 0,06 0,18 2,9 0,12 0,24 2,0 0,083 0,074 0,9 0,137 0,131 1,0
mmu-miR-130a-3p MIMAT0000141 0,19 0,88 4,7 0,19 0,59 3,2 0,064 0,161 2,5 0,078 0,111 1,4
mmu-miR-146b-5p MIMAT0003475 0,10 2,51 24,6 0,08 1,49 17,6 0,263 0,997 3,8 0,339 1,186 3,5
mmu-miR-148a-3p MIMAT0000516 0,26 1,19 4,6 0,43 0,98 2,3 0,573 0,831 1,5 0,362 0,308 0,9
mmu-miR-149-5p MIMAT0000159 0,00 0,06 13,0 0,01 0,09 7,6 0,013 0,013 1,0 0,007 0,006 0,8
mmu-miR-196b-5p MIMAT0001081 0,17 0,92 5,4 0,26 1,83 7,1 0,412 0,222 0,5 0,155 0,174 1,1
mmu-miR-210-3p MIMAT0000658 0,04 0,30 8,0 0,03 0,16 5,3 0,005 0,006 1,2 0,007 0,007 1,0
mmu-miR-322-3p MIMAT0000549 0,34 2,82 8,3 0,58 2,59 4,5 0,026 0,302 11,7 0,026 0,195 7,6
mmu-miR-330-3p MIMAT0000569 0,00 0,04 8,9 0,00 0,02 5,4 0,001 0,001 2,8 --- 0,001 ---
mmu-miR-330-5p MIMAT0004642 0,01 0,06 8,3 0,00 0,02 5,5 0,002 0,001 0,9 0,004 0,005 1,1
mmu-miR-340-5p MIMAT0004651 0,24 0,67 2,8 0,17 0,63 3,6 0,200 0,092 0,5 0,142 0,029 0,2
mmu-miR-351-3p MIMAT0017042 0,00 0,01 18,1 0,00 0,01 3,2 --- 0,001 --- 0,000 0,003 9,0
mmu-miR-351-5p MIMAT0000609 0,25 1,59 6,4 0,26 1,00 3,8 0,036 0,489 13,5 0,058 0,730 12,7
mmu-miR-450a-5p MIMAT0001546 0,05 0,18 3,5 0,07 0,19 2,7 0,002 0,025 11,8 0,003 0,027 8,0
mmu-miR-450b-5p MIMAT0003511 0,01 0,06 5,2 0,01 0,06 4,8 0,001 0,010 18,6 0,001 0,002 1,9
mmu-miR-503-3p MIMAT0004790 0,01 0,03 4,0 0,01 0,04 4,1 ---- 0,001 --- 0,000 0,003 15,4
mmu-miR-503-5p MIMAT0003188 0,11 0,50 4,5 0,13 0,35 2,7 0,003 0,017 5,3 0,004 0,036 8,9
mmu-miR-542-3p MIMAT0003172 0,10 0,34 3,3 0,12 0,64 5,5 0,003 0,032 9,2 0,001 0,011 7,9
mmu-miR-574-3p MIMAT0004894 0,07 0,28 4,0 0,13 0,39 2,9 0,007 0,046 6,2 0,002 0,007 4,2
mmu-miR-615-3p MIMAT0003783 0,00 0,03 8,0 0,01 0,03 3,1 0,017 0,013 0,8 0,028 0,030 1,0
mmu-miR-652-3p MIMAT0003711 0,06 0,17 2,8 0,05 0,16 3,1 0,032 0,125 3,9 0,045 0,159 3,5
mmu-miR-873a-5p MIMAT0004936 0,03 0,00 0,02 82,6 --- 0,000 --- 0,000 0,000 2,6
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Several miRNAs had already been identified to be expressed in glomeruli and to be important for 
glomerular function in vivo. It could be verified with the deep sequencing profiles generated 
from podocytes and red fluorescent cells, that miR-30a-5p is a miRNA highly expressed in 
podocytes, while miR-126-3p and miR-145-5p are expressed in the endothelial and mesangial 
cells, as it was reported before (Harvey et al. 2008). miR-30a-5p was identified to be the most 
abundant mature miRNA in podocytes. Also other miRNAs that were reported earlier to 
important for glomerular and podocyte function, like miR-21a-5p, miR-26a-5p, the miR-29 
family, the whole miR-30 family and miR-92a/b-3p were detected as expressed in podocytes as 
well as in the red fluorescent cell population. Not all of them were podocyte enriched though. 
Interestingly, these miRNAs were among the most abundant miRNAs in glomeruli and 
podocytes. The miRNAs with lower expression levels might not have been in the focus until now, 
but they are interesting candidates for important regulatory functions in podocytes, as a miRNA 
expressed at low levels might still be the regulator of an important target gene. The mature miR-
193a-5p was not detected in both deep sequencing profiles from podocytes. It was shown that 
miR-193a-5p expression in podocytes can induce focal segmental glomerulosclerosis 
(Gebeshuber et al. 2013) and that parietal epithelial cells loosing miR-193a-5p expression 
differentiate towards a podocyte like phenotype (Kietzmann et al. 2014). Both results fit the 
finding that miR-193a-5p is not expressed in podocytes under physiological conditions. 
Little is known about the role of the miRNAs showing the highest enrichment in podoytes for 
podocyte function. However, some had already been identified to be expressed and functional 
in mammalian kidneys (Tab. 5.5). For miR-873a-5p, no function in kidney has been reported so 
far. It was identified to act as a tumor suppressor in in glioblastoma tumorigenesis and 
metastasis by downregulating the expression of IGF2BP1 (Insulin-like growth factor 2 mRNA-
binding protein 1) (Wang et al. 2015B). miR-146a-5p and miR-146b-5p have been found to be 
induced by carbamylated albumin and to be enriched in renal cell carcinoma tumors (Ha et al. 
2010). When delivered into the kidneys of a fibrosis mouse model using polyethylenimine 
nanoparticles, miR-146a-5p is able to attenuate renal fibrosis (Morishita et al. 2015). 
Additionally, miR-146a-5p levels are increased in mice suffering from chronic renal inflammation 
(Ichii et al. 2012). In the 3’-UTR of the renalase, a signaling molecule in cardiovascular and 
metabolic disease, a SNP (Single nucleotide polymorphism) that is common in humans creates a 
functional binding site for miR-146a-5p (Kalyani et al. 2015). The mature miRNA miR-330-3p was 
reported to be expressed in the juxtaglomerular cells, balancing its smooth muscle phenotype 
together with miR-125b-5p (Medrano et al. 2011). Additionally, miR-330-3p might regulate VEGF 
(Ye et al. 2008). In renal clear cell carcinoma, miR-107-3p was identified as a putative tumor 
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suppressor gene (Song et al. 2015) and a mutation in mir-149 has been linked to renal clear cell 
carcinoma (Wang et al. 2014). No role in the kidney has been assigned to miR-130a-3p, miR-
148a-3p, and miR-196b-5p so far. The miR-130/301 family are signaling molecules in the 
crosstalk between endothelial cells and smooth muscle cells controlling vasoconstriction in 
pulmonary hypertension (Bertero et al. 2014), while the miR-148/152 family can modulate the 
innate response and antigen presenting capacity of dendritic cells (Liu et al. 2010B). 
Expression levels and enrichment of miRNAs 
To identify miRNAs that might be important for podocyte structure and function, the enrichment 
of the glomerular and podocyte miRNAs compared to a control cell population, tubules or the 
red fluorescent cell population of glomerular cells, was calculated. Only one miRNA, miR-873a-
5p, might be exclusively expressed in podocytes, while all other miRNAs expressed in podocytes 
were also detected in the other glomerular cells or in the tubules. The enrichment is one 
possible way to sort for miRNAs that might be important for a podocyte specific function rather 
than a general regulatory mechanism. Nonetheless, miRNAs can have different functions in 
different cell populations, meaning that a miRNA not exclusively expressed in podocytes might 
still be a regulator of a podocyte specific transcript. In June 2015, the online database TarBase 
v7.0 (Vlachos et al. 2014) listed over 65,000 miRNA-gene interactions derived from specific and 
high-throughput experiments, proving that a mature miRNA regulates more than one specific 
target in different species, cell types and developmental stages. The expression level of a miRNA 
might also give hints to its physiological importance. The miR-92a-3p has a lower relative 
expression level in podocytes compared to the red fluorescent cells. However, in absolute 
numbers, it is the 19th highest expressed miRNA in podocytes, meaning it might also regulate a 
transcript important for podocyte function. It is reasonable to assume that a miRNA expressed in 
high levels plays a role in maintenance of cell function. Additionally, it is important to keep in 
mind that a rather rare miRNA can be extremely important for a cell. 
Patterns of miRNAs expressed in podocytes 
The miRNAs that were found to be podocyte enriched were analyzed for patterns to get hints 
concerning their role in podocyte function. In some cases, e.g. four members of the mir-30 
family, mir-330 and mir-503, both mature miRNAs that are processed from the same precursor 
are enriched in podocytes (Tab. 5.1). The miRNA expressed at lower levels might just be the 
passenger strand, which is degraded after the other miRNA forms the functional RISC together 
with the Argonaute protein, but both miRNAs from the same precursor might also be functional 
miRNAs in the cell.  
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Tab. 5.2: Genomic organization of murine podocyte miRNAs 
miRNAs Genomic coordinates of 
the precursor mirna in 
mouse 
Genomic organization in 
mouse (ensembl, UCSC, 
miRbase) 
clustered 
miRNAs 
(<10 kb) in 
mouse 
mmu-let-7e-3p chr17: 17,830,352-17,830,444 [+] antisense to gene Gm25927  mmu-let-7e,  
mmu-mir-99b,  
mmu-mir-125a 
mmu-miR-23b-3p chr13: 63,300,484-63,300,557 [+] intron of protein coding gene 
2010111I01Rik 
(together with mir-27b, mir-24-1,  
mir-3074 (antisense)) 
mmu-mir-23b 
mmu-mir-27b  
mmu-mir-24-1; 
antisense:  
mmu-mir-3074-1 
mmu-miR-24-1-5p chr13: 63,301,208-63,301,275 [+] intron of protein coding gene 
2010111I01Rik 
(together with mir-27b, mir-24-1,  
mir-3074 (antisense)) 
mmu-mir-23b 
mmu-mir-27b  
mmu-mir-24-1; 
antisense:  
mmu-mir-3074-1 
mmu-miR-27b-5p chr13: 63,300,712-63,300,784 [+] intron of protein coding gene 
2010111I01Rik 
(together with mir-27b, mir-24-1,  
mir-3074 (antisense)) 
mmu-mir-23b 
mmu-mir-27b  
mmu-mir-24-1; 
antisense:  
mmu-mir-3074-1 
mmu-miR-30a-3p chr1: 23,272,269-23,272,339 [+] intergenic   
mmu-miR-30a-5p chr1: 23,272,269-23,272,339 [+] intergenic   
mmu-miR-30b-3p chr15: 68,337,415-68,337,510 [-] directly upstream of Gm26621  
 
mmu-mir-30d, 
mmu-mir-30b 
mmu-miR-30b-5p chr15: 68,337,415-68,337,510 [-] directly upstream of Gm26621 mmu-mir-30d,  
mmu-mir-30b 
mmu-miR-30c-2-3p chr1: 23,291,701-23,291,784 [+] part of lincRNA Gm27028   
mmu-miR-30c-5p locus 1:  
chr4: 120,769,534-120,769,622 [-] 
locus 2:  
chr1: 23,291,701-23,291,784 [+] 
Locus 1: 
intron of NFYC (nuclear transcription 
factor Y gamma)  
Locus 2:  
part of lincRNA Gm27028 
locus 1:  
mmu-mir-30f,  
mmu-mir-30e, 
mmu-mir-30c-1 
mmu-miR-30d-3p chr15: 68,341,208-68,341,289 [-] part of lincRNA Gm20732 mmu-mir-30d,  
mmu-mir-30b 
mmu-miR-30d-5p chr15: 68,341,208-68,341,289 [-] part of lincRNA Gm20732 mmu-mir-30d,  
mmu-mir-30b 
mmu-miR-99a-3p chr16: 77,598,936-77,599,000 [+] intron of lincRNA MIR99AHG  
(mir-99a host gene) 
mmu-mir-99a, 
mmu-let-7c-1 
mmu-miR-99a-5p chr16: 77,598,936-77,599,000 [+] intron of lincRNA MIR99AHG 
(mir-99a host gene) 
mmu-mir-99a, 
mmu-let-7c-1 
mmu-miR-107-3p chr19: 34,820,687-34,820,773 [-] intron of Pank1  
(pantothenate kinase 1) 
  
mmu-miR-125b-2-3p chr16: 77,646,273-77,646,343 [+] intron of lincRNA MIR99AHG  
(mir-99a host gene) 
  
mmu-miR-125b-5p locus 1:  
chr9: 41,581,926-41,582,002 [+]  
locus2:  
chr16: 77,646,273-77,646,343 [+] 
Locus 1: 
intron of lncRNA 2610203C20Rik  
Locus 2:  
intron of lincRNA MIR99AHG  
(mir-99a host gene) 
  
mmu-miR-130a-3p chr2: 84,741,115-84,741,178 [-] intergenic   
mmu-miR-146b-5p chr19: 46,342,762-46,342,870 [+] intron of Tmem180  
(Transmembrane protein 180) 
  
mmu-miR-148a-3p chr6: 51,269,812-51,269,910 [-] intergenic   
mmu-miR-149-5p chr1: 92,850,378-92,850,443 [+] intron of Gpc1 (Glypican 1)   
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miRNAs Genomic coordinates of 
the precursor mirna in 
mouse 
Genomic organization in 
mouse (ensembl, UCSC, 
miRbase) 
clustered 
miRNAs 
(<10 kb) in 
mouse 
mmu-miR-196b-5p chr6: 52,230,081-52,230,165 [-] intron of Hoxa9 (Homeobox A9) 
processed transcript exon of Hoxa9 
retained intron  
exon of pseudogene 9930038K12  
  
mmu-miR-210-3p chr7: 141,221,384-141,221,493 [-] intergenic   
mmu-miR-322-3p chrX: 53,054,255-53,054,349 [-] ensembl: intergenic, downstream of 
lncRNA C430049B03  
UCSC: part of lncRNA C430049B03 
mmu-mir-322,  
mmu-mir-503, 
mmu-mir-351,  
mmu-mir-542,  
mmu-mir-450a-1, 
mmu-mir-450a-2, 
mmu-mir-450b 
mmu-miR-330-3p chr7: 19,181,465-19,181,562 [+] intron of Eml2 (echinoderm 
microtubule associated protein like 2) 
  
mmu-miR-330-5p chr7: 19,181,465-19,181,562 [+] intron of Eml2 (echinoderm 
microtubule associated protein like 2) 
  
mmu-miR-340-5p chr11: 50,069,702-50,069,799 [+] intron of RNF130  
(ring finger protein 130) 
  
mmu-miR-351-3p chrX: 53,053,255-53,053,353 [-] ensembl: intergenic, upstream of 
lincRNA Gm28730  
UCSC: exon of lncRNA C430049B03 
  
mmu-miR-351-5p chrX: 53,053,255-53,053,353 [-] ensembl: intergenic, upstream of 
lincRNA Gm28730  
UCSC: exon of lncRNA C430049B03 
  
mmu-miR-450a-5p locus 1:  
chrX: 53,048,154-53,048,244 [-]  
locus 2:  
chrX: 53,048,299-53,048,367 [-] 
intergenic mmu-mir-322,  
mmu-mir-503,  
mmu-mir-351,  
mmu-mir-542,  
mmu-mir-450a-1, 
mmu-mir-450a-2, 
mmu-mir-450b 
mmu-miR-450b-5p chrX: 53,047,997-53,048,078 [-] intergenic   
mmu-miR-503-3p chrX: 53,053,984-53,054,054 [-] ensembl: intergenic  
UCSC: exon of lncRNA C430049B03 
  
mmu-miR-503-5p chrX: 53,053,984-53,054,054 [-] ensembl: intergenic  
UCSC: exon of lncRNA C430049B03 
  
mmu-miR-542-3p chrX: 53,049,403-53,049,487 [-] intergenic   
mmu-miR-574-3p chr5: 64,970,318-64,970,395 [+] intron of Fam114a1 (family with 
sequence similarity 114, member A1) 
  
mmu-miR-615-3p chr15: 103,014,910-103,015,001 [+] intron of Hoxc5  
(homeobox C5) 
  
mmu-miR-652-3p chrX: 142,739,000-142,739,097 [+] intron of Tmem164  
(transmembrane protein 164) 
  
mmu-miR-873a-5p chr4: 36,668,510-36,668,586 [-] intron of Lingo2 (leucine rich repeat 
and Ig domain containing 2) 
mmu-mir-873b,  
mmu-mir-873a 
 
Another possibility to identify miRNAs that might have a cooperative function in podocytes is the 
analysis of the genomic organization. miRNAs which are processed from clusters, i.e. transcripts 
that contain several miRNA precursors, have been shown to perform cooperative tasks in cells, 
like the miR-17~92 cluster that enhances cell proliferation (Hayashita et al. 2005) and is crucial 
for developing nephrons during kidney development (Marrone et al. 2014) or the mir-23~27~24 
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clusters, which play an important role in angiogenesis, endothelial apoptosis in cardiac ischemia 
and retinal vascular development (reviewed by Bang et al. 2011).  
The miRNAs were analyzed for genomic location and putative common precursor transcripts. 
Since the three precursors mmu-mir-23b, mmu-mir-27b and mmu-mir-24-1 are located in the 
same intron of the protein coding gene 2010111I01Rik, they are probably transcribed together. 
The precursors mir-30b and mir-30d are located in proximity in the genome, but since mir-30d is 
part of the lincRNA (long intergenic non-coding RNA) Gm20732 and mir-30b is located directly 
upstream of lincRNA Gm27028, they might be transcribed independently from each other. On 
the other hand, the distance between the mir-125b-2 and mir-99a position in the genome is 
> 50 kb, but they are located in the same lncRNA host gene, which supports a possible common 
transcription. 
Interestingly, eight miRNAs that were found to be podocyte enriched in both deep sequencing 
profiles are encoded in a genomic area of ca. 5,800 bp on reverse strand of the X-chromosome 
(Fig. 5.2). The arrangement is conserved between human and mouse, with the mmu-mir-322 
being exchanged for hsa-mir-424 and the mir-351 missing in human. In rat, the putative cluster is 
not only conserved, but two similar arrangements are present in the genome on the X 
chromosome. The genomic organization of the mirna precursors was analyzed using the UCSC 
genome browser and the ensembl database. For the comparison, the human genome (UCSC: 
GRCh38/hg38; ensembl: GRCh38.p3) and the murine genome (UCSC: GRCm38; ensembl: 
GRCm38.p4) were used. 
According to the UCSC genome browser, mmu-mir-322, mmu-mir-503 and mmu-mir-351 are 
part of the lncRNA C430049B03, arguing for a common transcription. The transcriptional start 
site of this transcript is located ca. 2,800 bp upstream of the mir-322 precursor. In the database 
ensembl, however, the lncRNA is annotated to be shorter and its transcription ends upstream of 
the seven precursors (chromosome X: 53,055,046 - 53,057,190 according to ensembl). According 
to ensembl, lincRNA Gm28730 is located between mmu-mir-351 and mmu-mir-542 on the same 
strand, but does not stretch to the miRNA precursors downstream of it. The four precursors 
mmu-mir-542, mmu-mir-450a-2, mmu-mir-450a-1 and mmu-mir-450b are all annotated to be 
intergenic in the UCSC as well as in ensembl. However, it might be that a common primary 
transcript has not been identified yet, since the processing of the initial transcript, e.g. a lncRNA, 
might be very fast. Especially the very narrow gaps in-between the members of the mir-450 
family might be a hint for common or alternate transcription. 
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Fig. 5.2: Putative podocyte miRNA cluster; genomic arrangement of seven miRNA precursors (green boxes) 
coding for mature miRNAs enriched in murine podocytes and overlapping transcripts (grey boxes) in 
mouse (top) and human (bottom) on the reverse strand of the X-chromosome; numbers indicate the 
distances in basepairs between precursors; start of lncRNAs indicated by dotted lines 
In human, hsa-mir-503 is located in an intron of lncRNA MIR503HG, the hsa-mir-503 host gene, 
while the location of hsa-mir-424 overlaps with the annotated first exon of this lncRNA. The four 
remaining precursors, hsa-mir-542, hsa-mir-450a-2, hsa-mir-450a-1 and hsa-mir-450b are all 
annotated to be intergenic according to the UCSC as well as ensembl in human like in mouse 
(Tab. 5.3; for all human podocyte miRNAs, Tab. 10.7). 
Tab. 5.3: genomic organization of podocyte miRNAs in human 
miRNAs human 
accession 
number mature 
miRNA 
Genomic coordinates of 
the precursor mirna in 
human 
Genomic organization in 
human (UCSC, ensembl) 
hsa-miR-424-3p MIMAT0004749 chrX: 134,546,614-134,546,711 [-] overlapping to lncRNA MIR503HG 
hsa-miR-450a-5p MIMAT0001545 Locus 1:  
chrX: 134,540,341-134,540,431 [-] 
Locus 2:  
chrX: 134,540,508-134,540,607 [-] 
intergenic 
hsa-miR-450b-5p MIMAT0004909 chrX: 134,540,185-134,540,262 [-] intergenic 
hsa-miR-503-3p MIMAT0022925 chrX: 134,546,328-134,546,398 [-] Intron of lncRNA MIR503HG  
(mir-503 host gene) 
hsa-miR-503-5p MIMAT0002874 chrX: 134,546,328-134,546,398 [-] Intron of lncRNA MIR503HG  
(mir-503 host gene) 
hsa-miR-542-3p MIMAT0003389 chrX: 134,541,341-134,541,437 [-] intergenic 
 
As the mature miRNAs derived from these precursors were enriched in both deep sequencing 
profiles from freshly isolated murine podocytes, they are an interesting target for knockout and 
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overexpression studies, representing putative regulators of genes important for podocyte 
structure and function. For some miRNAs encoded in the putative cluster, a regulatory role has 
been identified. However, a common function has not been described yet. 
For some of these miRNAs, involvement in different regulatory processes has been proposed. 
For example, neural stem cell morphogenesis is mediated by miR-351-5p (Li et al. 2012). miR-
322-3p mediates osteoblast differentiation (Gamez et al. 2013) and inhibits Smurf2 (SMAD 
specific E3 ubiquitin protein ligase 2) translation, thus modulating TGF-/Smad2 signaling (Cao et 
al. 2014). Inhibiting G1/S translation by downregulation of cyclin D3 and E2F3 (E2F transcription 
factor 3) in hepatocellular carcinoma (Xiao et al. 2013) and inhibiting EMT in gastric cancer (Peng 
et al. 2014) are only two examples of different roles miR-503-5p has been shown to play in 
progression of different cancers. Also for miR-542-3p, different roles in the progression of 
cancers like suppressing cell growth of gastric cancer cells (Shen et al. 2015) or suppressing 
tumor growth by downregulating survivin in neuroblastomas (Althoff et al. 2015) have been 
reported. Little is known about the regulatory role of the mir-450 family in kidney so far. In rat 
kidney, rno-miR-450a-5p was identified to be enriched in the cortex compared to the medulla 
(Tian et al. 2008), which is consistent with a higher expression in the podocytes, since glomeruli 
are located in the cortex of mammalian kidneys. In the same study, Hnrpk (Heterogeneous 
nuclear ribonuclear protein K) was identified as a putative target of miR-450a-5p. 
For three mature miRNAs, miR-424-3p, miR-503-5p and miR-542-3p, expression was investigated 
in proliferating and differentiated immortalized human podocytes (chapter 4.1.2). Neither in 
proliferating nor in differentiated cells, could expression be detected. This could be due to the 
expression levels of the mature miRNAs, which were also mid-level in the deep sequencing 
profiles. It might also show the differences between the differentiated immortalized podocytes 
and the freshly isolated podocytes. Additionally, a species dependent expression is possible, 
which can be tested by Northern Blotting of these miRNAs from proliferating and differentiated 
cells from the immortalized murine podocyte cell line. 
5.2.2 miRNA expression validation  
Using the modern sequencing techniques like deep sequencing, it is now possible to generate 
miRNA profiles from tissues or cell types that consist of millions of single reads, identifying 
hundreds of expressed miRNAs. However, many reaction steps are needed to gain the final 
results, like extraction, ligation of adaptors, reverse transcription and up-scaling PCRs, which can 
all be biased or distorted by statistical effects. Therefore, a profile can be used as a starting 
point, but has to be validated by different methods. For miRNA expression analyses, there are 
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two main methods, Northern Blotting and qPCR, which both harbor different advantages and 
disadvantages.  Experiments have been performed to find a “housekeeping” miRNA to use as an 
internal standard for relative quantification, e.g. by comparing miRNA expression profiles of 
different colorectal cancer samples and normal tissue control samples (Chang et al. 2010). 
However, since all miRNAs might be functional regulatory miRNAs themselves and play different 
roles in different cell types, they might also still be differentially expressed between two distinct 
cell types. The small nuclear RNA U6, a part of the spliceosome, is often used as an internal 
standard in both qPCR and Northern Blotting, since it is expected to be rather equally expressed 
in all different cell types.  
A general challenge for miRNA detection is their shortness. Northern Blotting probes as well as 
PCR primers need a minimum length of around 18 - 20 bp to hybridize with their target 
sequence, which is about the length of a miRNA. This prevents the selection of a sequence 
region suitable for hybridization, meaning that there might be miRNA sequences that are more 
suited for hybridization than others. In Northern Blotting, miRNAs are detected by hybridization 
of a fitting antisense strand. Dependent on the hybridization temperature that is used to 
hybridize a precise miRNA probe to the target miRNA, single mismatches can be detected, thus 
enabling the identification of miRNAs belonging to the same family (Fig. 4.28). Furthermore, due 
to the separation of the samples by gel electrophoresis, the miRNA precursor can be clearly 
distinguished from the mature miRNA (Fig. 5.3 A). Northern Blotting requires a lot of isolated 
RNA, making it the method of choice for experiments using cell culture material, but unfavorable 
for samples isolated from laboratory animals. In this study, 9 – 30 µg total RNA isolated from cell 
culture or laboratory animals was used for Northern Blotting, which translates to ca. three to 
four mice needed for one validated miRNA. 
 
Fig. 5.3: Comparison of miRNA profile validation techniques; (A) Northern Blot of miR-19b expression in 
HeLa cells: hybridization signal of precursor (top) and mature miRNA (bottom); (B) qPCR of HeLa cells 
transfected with empty pSuper construct or pSuper construct overexpressing miR-30a-5p analyzed by 
qPCR with primers directed against miR-30 family members 
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By qPCR, the presence of miRNAs can be detected already at very low levels, making it a very 
suitable method if the amount of sample is limited. With less material than needed for one 
Northern Blotting lane, tens to more than one hundred miRNAs, dependent on their expression 
levels, can be detected. This enables qPCR based screening for a subset of miRNAs. Especially if 
the samples used are collected from laboratory animals, saving material is a huge advantage of 
this method. Additionally, miRNAs expressed at low levels might rather be detected by qPCR 
than by Northern Blotting. 
When using normal DNA primer in the qPCR reaction, single mismatches between miRNAs 
belonging to the same family cannot be detected. When miR-30a-5p is overexpressed in cells, 
qPCR with the normal DNA primers against miR-30a-5p and miR-30e-5p both detect a similar 
level of upregulation (Fig. 5.3 B), showing that one mismatch between the mature miRNA 
sequences is not sufficient to distinguish between the two miRNAs. Both the primers directed 
against miR-30b-5p and miR-30c-5p, two miRNAs with 7 and 5 mismatches when compared to 
miR-30a-5p (Tab. 5.4), did not detect an upregulation of their target. This proves that qPCR is 
suitable for detection of miRNAs with several mismatches between their mature sequences. 
Tab. 5.4: Sequences of mature miR-30 family members; mismatching nucleotides: marked in red 
mature miRNA Sequence 
seed region                                                      number of mismatches 
miR-30a-5p UGUAAACAUCCUCGACUGGAAG  
miR-30b-5p UGUAAACAUCCUACACUCAGCU 7 mismatches 
miR-30c-5p UGUAAACAUCCUACACUCUCAGC  5 mismatches 
miR-30d-5p UGUAAACAUCCCCGACUGGAAG 1 mismatch 
miR-30e-5p UGUAAACAUCCUUGACUGGAAG 1 mismatch 
 
Furthermore, the miRNA precursors, which normally is present in cells at much lower levels than 
the mature miRNA, might also be amplified and give a signal. To check for amplification of 
molecules other than the desired mature miRNA, melting curves of the PCR products are 
recorded and checked for additional peaks indicating the presence of additional products. 
Especially for miRNAs derived from the 5’-end of the precursors, a longer product should be 
detected if the precursor is amplified. For all miRNAs, only one peak was observed. To bypass 
these disadvantages, especially designed primer molecules like LNATM (locked nucleic acid; 
Exiqon) primers for detection of miRNAs without including the rest of the family, as well as 
Taqman® assays (lifetechnologies) for the detection of pri-miRNAs can be used. 
Northern Blotting was used for the detection of ten miRNAs in proliferating and differentiated 
immortalized human podocytes and miR-30a-5p detection in HEK293T knockout cell clones. It 
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was also used for the expression validation of a subset of four miRNAs expressed in murine 
glomeruli and tubules isolated from C57bl/6 wildtype mice. For validation of miRNA expression 
of eleven miRNAs in murine glomeruli and tubules isolated from C57bl/6 wildtype mice, as well 
as for validation of relative expression of 18 miRNAs between podocytes and the red fluorescent 
cell population obtained from transgenic reporter animals, qPCR was used. 
5.3 Identification of miRNA-mRNA pairs 
The vast number of mRNAs and miRNAs expressed in podocytes contributes to the complexity of 
the physiological equilibrium in living cells, complicating the identification of single miRNA-
mRNA interaction pairs. Different strategies were used to narrow down the candidates to find 
possible interaction partners. A combined approach using in silico predictions, Ago-IPs from 
immortalized human and murine podocytes and freshly isolated podocytes and luciferase assays 
was used to identify regulatory miRNA-mRNA pairs in podocytes. Four putative targets, CD2AP, 
FYN, NCK2 and NEPH1, all known to directly interact with the main component of the slit 
diaphragm, nephrin, were analyzed in detail (Tab. 5.5).  
5.3.1 In silico prediction of miRNA-mRNA pairs 
To generate a starting point for our experiments, in silico predictions were performed for 
transcripts coding for proteins known to be important for podocyte structure and function and 
miRNAs we identified to be enriched or highly expressed in podocytes. In the last years, several 
miRNA-mRNA interaction prediction programs have been published. Many of them can be run 
online one the respective websites. However, the amount of possible interaction partners 
obtained by these programs is rather overwhelming. Starting predictions with miRNAs, 
thousands of mRNAs that could potentially be regulated by these miRNAs are predicted. Vice 
versa, starting with a single mRNA, hundreds of miRNAs are predicted as possible regulators. 
Prediction of interaction between podocyte miRNAs and genes important for 
podocyte maintenance 
The in silico predictions were performed for putative miRNA-mRNA pairs. Binding sites for 
miRNAs that were enriched or highly expressed in podocytes were searched in the 3’-UTRs of 
transcripts coding for proteins that are known to be important for podocyte structure and 
function. This approach excludes possible interactions in the promoter regions of the genes as 
well as in the 5’-UTRs and coding regions of the transcripts, which are still a small minority in the 
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whole number of verified interactions. It also limits the predicted dataset to proteins that are 
already known to play an important role for podocyte structure and function. The first 
predictions were performed for 29 transcripts coding for proteins known to be important for 
podocyte structure and function using the miRWalk prediction platform. From this initial 
candidate set, four putative targets, CD2AP, FYN, NCK2 and NEPH1, all known to play an 
important role in the maintenance of the podocyte slit diaphragms, were selected as first 
candidates and analyzed in more detail using miRWalk2. 
Boundaries of in silico predictions 
To be able to concentrate on the most promising predictions in the further experiments, the 
prediction program miRWalk (Dweep et al. 2011) was used. miRWalk does not only predict 
interactions itself, but also obtains the predictions of up to eight different algorithms. Recently, 
the miRWalk2 program was released (Dweep et al. 2011), now also enabling prediction of 
binding sites in 3’-UTRs with twelve programs, in coding regions with seven programs and 5’-
UTRs with six programs. Additionally, prediction of binding sites in the promoter regions is now 
possible with four programs. To shrink the enormous dataset obtained from the prediction 
programs, a score consisting of the number of programs that predict a certain interaction was 
introduced. An interaction was counted to be predicted when it was predicted by at least half of 
the used programs.  
All in silico prediction programs use a kind of score or threshold to determine if a certain miRNA-
mRNA pair is predicted for interaction. A second possible way to shrink the dataset, next to 
using different programs, could be a stricter adjustment of these thresholds in the prediction 
algorithms. These strategy harbors two possible disadvantages: Firstly, it is nearly impossible to 
determine which algorithm is the best in predicting miRNA-mRNA interaction pairs. They can be 
tested with miRNA-mRNA pairs that were proven to be functional, but that does not imply that 
they will be the best in predicting still unknown interaction pairs. Secondly, all programs work 
with models that are used to calculate the probability of binding, like the thermodynamic 
stability of the double stranded RNA to be built. Since these models may deviate from the 
situation in cells, physiological interactions might get rejected with a threshold that is set to 
strictly. 
For the miRNAs enriched in podocytes, and some miRNAs that are not enriched, but highly 
expressed in podocytes, in silico target predictions were performed using the algorithms 
miRWalk and miRWalk2 (Dweep et al. 2011). For 20 candidate miRNAs, binding sites in the 3’-
UTRs of human transcripts coding for podocyte proteins were predicted (Tab. 5.5). 
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Tab. 5.5: Podocyte miRNAs and targets – prediction and known functions 
miRNAs 
identified in 
murine 
podocytes 
predicted 
human targets 
by miRWalk & 
miRWalk2 
Expression in mammalian kidney Function in kidney 
mmu-let-7e-3p   Expressed in murine glomeruli  
(smirnadb database) 
  
mmu-miR-23b-3p ACTR2, EZR, PARD6B, 
TRPC6, VEGFA, 
WASL, WT1 
Expressed in murine glomeruli  
(smirnadb database) 
  
mmu-miR-24-1-5p       
mmu-miR-27b-5p       
mmu-miR-30a-3p       
mmu-miR-30a-5p CD2AP, IQGAP1, 
NCK2, TRPC6, WASL 
Highly expressed in podocytes  
(Harvey et al. 2008)  
Expressed in murine glomeruli  
(smirnadb database) 
Expressed in podocytes  
(Boerries et al. 2013) 
Affected in podocyte Dicer knockout  
(Harvey et al. 2008, Shi et al. 2008)  
Important for Xenopus kidney development 
(Agrawal et al. 2009) 
mir-30 family is involved in TGF- signaling 
during glomerulosclerosis (Shi et al. 2013) 
Downregulation of mir-30 family facilitates 
podocyte injury, miR-30s target Notch1  
(Wu et al. 2014) 
Upregulated in injured podocytes, prevents 
PAN induced podocyte apoptosis  
(Xie et a. 2015) 
mmu-miR-30b-3p       
mmu-miR-30b-5p   Expressed in murine glomeruli  
(smirnadb database) 
Expressed in podocytes  
(Boerries et al. 2013) 
  
mmu-miR-30c-2-3p       
mmu-miR-30c-5p   Expressed in murine glomeruli  
(smirnadb database) 
Expressed in podocytes  
(Boerries et al. 2013) 
  
mmu-miR-30d-3p       
mmu-miR-30d-5p   Expressed in murine glomeruli  
(smirnadb database) 
  
mmu-miR-99a-3p       
mmu-miR-99a-5p   Expressed in rat kidney cortex and 
medulla (Tian et al. 2008) 
  
mmu-miR-107-3p ACTR2, CD2AP, 
CDC42, EZR, GRB2, 
NEPH1, NPHS1, 
PODXL, VEGFA, WASL 
  Putative tumor suppressor in renal clear cell 
carcinoma (Song et al. 2015) 
mmu-miR-125b-2-3p       
mmu-miR-125b-5p   Expressed in rat kidney cortex and 
medulla (Tian et al. 2008)  
Marks juxtaglomerular cells  
(Medrano et al. 2012) 
Balances juxtaglomerular cells' smooth 
muscle phenotype (Medrano et al. 2012) 
mmu-miR-130a-3p CD2AP, EZR, WASL, 
FYN 
Expressed in murine glomeruli  
(smirnadb database) 
  
mmu-miR-146b-5p GRB2, FYN, IQGAP, 
PARD6B, RAC1, 
RHOA 
Increased in renal cell carcinoma  
(Ha et al. 2010) 
Expressed in podocytes  
(Boerries et al. 2013)  
Attenuates renal fibrosis  
(Morishita et al. 2015) 
Targets mutated renalase  
(Kalyani et al. 2015) 
mmu-miR-148a-3p EZR, PODXL, RAC1, 
WASL 
    
mmu-miR-149-5p GRB2, LMX1B, 
NEPH1, NEPH3, 
PODXL 
Expressed in murine glomeruli 
(smirnadb database) 
When mutated, involved in renal clear cell 
carcinoma (Wang et al. 2014) 
mmu-miR-196b-5p NOSTRIN,PARD6B, 
TLN1, WASL 
Expressed in murine glomeruli  
(smirnadb database) 
  
mmu-miR-210-3p LMX1B     
mmu-miR-322-3p   Expressed in murine glomeruli  
(smirnadb database) 
Expressed in podocytes  
(Boerries et al. 2013) 
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miRNAs 
identified in 
murine 
podocytes 
predicted 
human targets 
by miRWalk & 
miRWalk2 
Expression in mammalian kidney Function in kidney 
mmu-miR-330-3p Marks juxtaglomerular cells  
(Medrano et al. 2012) 
Balances juxtaglomerular cells' smooth 
muscle phenotype (Medrano et al. 2012) 
Regulates VEGF (Ye et al. 2008) 
mmu-miR-330-5p       
mmu-miR-340-5p ACTR2, CD2AP, 
CLIC5, IQGAP1, 
NCK1, NCK2, 
PARD6B, PODXL, 
RAC1, TRPC6, WASL, 
WT1 
    
mmu-miR-351-3p       
mmu-miR-351-5p       
mmu-miR-450a-5p   Expressed in murine glomeruli  
(smirnadb database) 
Enriched in rat kidney cortex  
(Tian et al. 2008)  
Expressed in podocytes  
(Boerries et al. 2013) 
Regulates Hnrpk (Tian et al. 2008) 
mmu-miR-450b-5p ACTR2, CD2AP, EZR, 
GRB2, NCK2, NPHS2, 
RAC1 
    
mmu-miR-503-3p       
mmu-miR-503-5p ACTR2, CD2AP, 
PARD6B, TLN1, 
VEGFA, WASL, WT1 
Expressed in murine glomeruli  
(smirnadb database) 
  
mmu-miR-542-3p IQGAP1, NCK1, 
NPHS2, PARD6B, 
RAC1 
    
mmu-miR-574-3p RAC1 Expressed in murine glomeruli  
(smirnadb database) 
Expressed in podocytes  
(Boerries et al. 2013) 
  
mmu-miR-615-3p       
mmu-miR-652-3p       
mmu-miR-873a-5p       
mmu-miR-22-3p ACTR2, EZR, GRB2, 
PODXL 
Expressed in murine glomeruli  
(smirnadb database) 
 
mmu-miR-24-3p IQGAP1, VEGFA Expressed in rat kidney cortex and 
medulla (Tian et al. 2008) 
 
mmu-miR-26a-5p CD2AP, CLIC5, FAT1, 
TRPC6 
Expressed in murine glomeruli 
(smirnadb database) 
Lowered levels in post stenotic kidneys 
(Zhu et al. 2015) 
Lowered levels in patients with lupus 
nephritis or IgA nephropathy 
(Ichii et al. 2014) 
Targets CTGF, involved in nephropathy  
(Koga et al. 2015) 
mmu-miR-27a/b-3p ACTR2, CD2AP, 
CDC42, EZR, FYN, 
GRB2, PARD6B,  
WASL 
Expressed in murine glomeruli  
(smirnadb database) 
Expressed in rat kidney cortex and 
medulla (Tian et al. 2008) 
 
mmu-miR-29a-c-3p CDC42, NEPH1, 
TRPC6, VEGFA 
Expressed in murine glomeruli  
(smirnadb database) 
Signature miRNA under high glucose 
conditions  
(Long et al. 2011) 
Regulates several collagens  
(Liu et al. 2010A) 
Targets Spry1 (Long et al. 2011) 
Blocks progressive renal fibrosis  
(Qin et al. 2011) 
Represses expression of collagens  
(Wang et al. 2012) 
Modulates nephrin acetylation (HDAC4)  
(Lin et al. 2014) 
mmu-miR-92a-3p CD2AP, CDC42, 
NCK2, PARD6B,  
WASL 
Expressed in murine glomeruli 
(smirnadb database) 
Expressed in rat kidney cortex and 
medulla (Tian et al. 2008) 
miR-17~92 cluster retards cyst growth  
(Patel et al. 2013) 
miR-17~92 cluster is crucial for kidney 
development (Marrone et al. 2014) 
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5.3.2 Regulated mRNAs identified by Ago-IP and microarray 
To validate putative targets generated by in silico predictions, Ago-IP with a subsequent qPCR 
detection of four predicted targets was performed using proliferating immortalized human and 
murine podocytes. Enrichment could be detected for CD2AP, FYN, NCK2 and NEPH1 in the Ago-
IP samples from the human as well as in the murine cells, proving them to be regulated by 
miRNAs in proliferating cells. Thus, with the combination of in silico prediction of putative 
miRNA regulation of genes important for podocyte structure and function and their detection by 
qPCR in the Ago-IP samples, four miRNA regulated genes could be identified.  
Nonetheless, this approach only allows the detection of targets that are already known to be 
important in podocytes. For an unbiased identification of transcripts bound by miRNAs, Ago-IP 
was performed from freshly isolated murine podocytes. The transcripts isolated were analyzed 
on a microarray. Of the four targets that were in silico predicted and investigated more closely 
by Ago-IP from human and murine podocyte cell lines, two targets, Cd2ap and Fyn, were also 
enriched in the Ago-IP samples from freshly isolated murine podocytes. Additionally, seven more 
proteins known or expected to be important for podocyte structure and function, Itgb1, Vegfa, 
Actg1, Nphs2, Actbl2, Itgb5 and Wipf3 were detected to be enriched in the Ago2 bound sample 
when compared to the background control or the Ago-IP from the red fluorescent cells, being 
the next candidates for prediction of putative binding sites of podocyte miRNAs. 
Limitations of first microarray 
Since the Ago2 bound transcripts are only a part of the whole transcriptome, a certain number 
of cells is needed to generate enough RNA for subsequent microarray analysis. As samples from 
many animals are needed to perform the analyses, it has been done only once until now. To 
generate reliable results, the whole procedure will be repeated to test if the transcripts 
enrichment detected in the first microarray can be validated for the new candidate transcripts. 
The transcripts identified to be enriched in the Ago-IP samples will be the next interesting 
candidates for in silico predictions and miRNA-mRNA pair identification via luciferase assay. 
The errors in detection of transcript expression occur according to the Gaussian distribution, 
meaning most enrichment factors are detected rather correctly, while some enrichment factors 
are highly over- or underestimated. With an independent second and ideally third microarray, 
regression to the mean should occur, strengthen the results and allowing the identification of 
truly enriched transcripts. For these statistical reasons, more repetitions would be desirable, but 
are hardly possible due to the amount of animals needed per experiment. 
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5.3.3 miRNA-mRNA pair validation by luciferase assays 
Four or two targets important for the structure of the slit diaphragms of podocytes, respectively, 
could be identified as miRNA targets by in silico predictions followed by the isolation of 
transcripts by Ago-IP from immortalized human and murine podocytes or freshly isolated murine 
podocytes. To identify the miRNAs responsible for the regulation of these targets in vivo, 
luciferase assays were performed.  
Confirmed miRNA-mRNA interaction 
For the first set of four candidate target transcripts, CD2AP, FYN, NCK2 and NEPH1, the human 
3’-UTRs were cloned into luciferase reporter assay constructs. To check for regulation by 
different miRNAs, the reporter constructs were cotransfected into HEK293T cells together with 
miRNA overexpressing pSuper constructs. For CD2AP, a putative regulation by miR-30a-5p and 
miR-92a-3p could be detected. For the tyrosine kinase FYN, miR-146b-5p might be a functional 
regulator, as indicated by the repression after cotransfection. The luciferase repression seems to 
vanish when the predicted miR-146b-5p binding sites are mutated (bachelor thesis K. Heizler). In 
the initial screening experiment, NCK2 seemed to be regulated by coexpression miR-30a-5p. 
With further experiment using a 3’-UTR construct containing a mutated binding site, binding 
might be confirmed.  
Cd2ap and Fyn could be identified to be regulated in vivo by Ago-IP from freshly isolated murine 
podocytes (Tab. 5.6). The miR-92a/b-3p binding site is not only conserved between the human 
and the murine CD2AP transcript, but is also the binding site predicted with the highest score for 
each of them. The miR-30a-5p binding site is only present in and predicted for the human 
transcript. Thus, the miR-92-3p binding site might be active in murine podocytes in vivo as well 
as in humans. The miR-146b-5p binding site in the human FYN 3’-UTR is predicted with very 
good scores and appears to be functional in luciferase assays, but it is not conserved to the 
murine 3’-UTR. Thus, other miRNAs might be responsible for the regulation of the murine 
transcript in vivo. For miR-130a-3p, two binding sites are conserved between the human and 
murine 3’-UTR. However, regulation could not be confirmed by luciferase assay.  
NCK2 appeared to be targeted in luciferase assays by miR-30a-5p but could not be isolated by 
Ago-IP from freshly isolated podocytes. One possible explanation might be different regulatory 
mechanism in human and mouse. A second explanation might be the fact that the luciferase 
assay is performed under artificial conditions, with the miRNAs being overexpressed to 
guarantee sufficient miRNA levels for the luciferase transcripts whose transcription is driven by 
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the TK promoter. An excess level of a certain miRNA might bind to a putative binding site that is 
not active under physiological conditions. In spite of the miRNA overexpression during the 
luciferase assay, several predicted binding pairs did not show regulation, which proves that 
overexpression of a possibly fitting miRNA is not enough to artificially activate a binding site.  
Tab. 5.6: Analyzed miRNA targets in podocytes; X: interaction tested negative; : interaction 
confirmed; ?: interaction not proven yet 
Target Physiological function Detected by 
Ago-IP using 
hPCLs/ mPCLs/ 
freshly isolated 
podocytes 
miRNAs predicted to target 
human/ murine 3’-UTR 
conserved 
binding sites 
Luciferase 
Assay using 
human 3'-UTR 
CD2AP adaptor protein linking 
nephrin to the 
cytoskeleton 
yes/yes/yes  miR-23a/b-3p no  
  miR-27a/b-3p miR-27a/b-3p yes X 
   miR-29a-c-3p miR-29a-c-3p no X 
   miR-30a-e-5p  no  
   miR-92a/b-3p miR-92a/b-3p yes ? 
   miR-107(-3p) miR-107-3p yes  
   miR-130a-3p  no  
   miR-340-5p miR-340-5p no  
   miR-450a/b-5p  no  
   miR-503-5p miR-503-5p yes  
    miR-542-3p no  
Fyn phosphorylates slit 
diaphragm 
components nephrin 
(prerequisite to Nck 
recruitment and Ca2+ 
dependent signaling) 
and Neph1 
yes/yes/yes miR-23a/b-3p  yes/yes/no X 
  miR-24-3p  no  
  miR-27a/b-3p miR-27a/b-3p no X 
  miR-29a-c-3p miR-29a-c-3p yes  
   miR-30a-e-5p miR-30a-e-5p yes  
   miR-130a-3p  yes/yes X 
   miR-146b-5p  no/no  
   miR-149-5p  yes/no  
    miR-322-3p 
(miRNA not 
conserved) 
yes   
   miR-340-5p  yes  
   miR-450b-5p  no  
       
Nck2 Adapter protein 
recruited after nephrin 
phosphorylation, 
regulates assembly of 
actin filaments 
yes/yes/no  miR-23a/b-3p yes X 
  miR-30a-e-5p miR-30a-e-5p yes ? 
  miR-92a/b-3p  yes X 
    miR-196b-5p no  
   miR-340-5p miR-340-5p yes/yes  
   miR-450b-5p miR-450b-5p yes  
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Target Physiological function Detected by 
Ago-IP using 
hPCLs/ mPCLs/ 
freshly isolated 
podocytes 
miRNAs predicted to target 
human/ murine 3’-UTR 
conserved 
binding sites 
Luciferase 
Assay using 
human 3'-UTR 
Neph1 localized to the slit 
diaphragms, binds to 
nephrin  
yes/yes/no  miR-23a/b-3p no  
  miR-24-3p  no  
   miR-27a/b-3p miR-27a/b-3p ?  
   miR-29a-c-3p miR-29a-c-3p yes X 
   miR-30b/c-3p miR-30b/c-3p yes  
    miR-30a-e-5p no  
   miR-107(-3p) miR-107-3p ?  
   miR-148a-3p  no  
   miR-149-5p  no  
    miR-196b-5p no  
    miR-322-3p no  
    miR-351-5p 
(miRNA not 
conserved) 
no  
    miR-340-5p no  
    miR-542-3p no  
 
To verify the in silico predictions, putative regulatory pairs that seem to be active have to be 
further analyzed by mutation of the predicted binding site. In the experiments using the CD2AP 
3’-UTR harboring the mutated miR-92a/b-3p binding site, the reduction of the luciferase assay 
activity by miR-92a/b-3p could not be validated, as the reduction could only be measured in 
some of the experiments. Luciferase assays are performed in cell culture, which leads to a high 
biological variance between the single experiments, since little deviations during the culturing 
might have a big influence on the state of the cells. This might explain the differing results in the 
different experiments. For miR-30a-5p, the predicted binding site in the 3’-UTR could be 
confirmed.  
The 3’-UTR of FYN contains two putative binding sites for miR-146b-5p. Constructs containing 
the CD2AP 3’-UTR with single or double mutations will be used to identify the active binding site. 
Consequences of miRNA level dysregulation in podocytes 
The architecture of podocyte foot processes is regulated by a delicate interplay of several 
proteins that build up the slit diaphragm and link it to the cytoskeleton. It was shown by 
different studies that a podocyte specific deletion of the miRNA processing enzyme Dicer 
(Harvey et al. 2008, Ho et al. 2008, Shi et al. 2008) as well as an inducible podocyte specific 
deletion of the miRNA processing enzyme Drosha (Zhadanova et al. 2011) leads to a severe 
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phenotype alteration, including the loss of slit diaphragms and effacement of podocyte foot 
processes. This proves that miRNA levels are important for the development maintenance of 
podocyte structure and function, including the slit diaphragms. 
CD2AP is an adapter protein important for the structure of the podocyte foot processes. It is 
localized to the slit diaphragm in murine glomeruli (Shih et al. 2001) and interacts directly with 
the actin cytoskeleton (Lehtonen et al. 2002), thus linking the slit diaphragm to the actin 
cytoskeleton. The CD2AP knockout mouse exhibits defects in epithelial foot processes and extra 
cellular matrix deposition (Shih et al. 1999). In vivo, CD2AP and nephrin interact with the p85 
regulatory subunit of PI3K, which leads to recruitment of PI3K to the plasma membrane and 
stimulates PI3K-dependent AKT signaling in podocytes together with podocin (Huber et al. 
2003A). If the available amount of CD2AP is the bottleneck of this initial signaling step, an 
upregulation of CD2AP would enhance AKT signaling in the podocyte. The serine/threonine 
kinase AKT, also known as PKB (Protein kinase B), is a central signaling node and controls many 
cellular processes like cell proliferation, survival and metabolism (Hers et al. 2011). Since AKT 
influences many pathways that favor tumorigenesis, like blocking the apoptosis pathway at 
several points, it is the most frequently hyper activated protein kinase in human cancer and a 
potential therapeutic target (Hers et al. 2011). Thus, a non-physiological upregulation of the AKT 
pathway might be one explanation for changes in podocytes after miRNA knockout.  
CD2AP also interacts with podocin at the slit diaphragm (Schwarz et al. 2001). Since podocin, 
who was also identified to be miRNA regulated in the Ago-IP using freshly isolated murine 
podocytes, organizes a complex containing the ion channel TRPC6, a sensor of mechanically and 
osmotically induced membrane stretch (Huber et al. 2007), a dysregulated level of CD2AP might 
reduce the podocyte’s ability to cope with changing pressure, easing podocyte injury.  
The phosphorylation of the slit diaphragm main component nephrin by the tyrosine kinase FYN 
(Verma et al. 2003) is a prerequisite for the recruitment of the NCK adapter proteins, leading to 
the assembly of actin filaments (Verma et al. 2006). The NCK adapter proteins control actin 
polymerization through their activation of N-WASP and WASP, which are important for the 
regulation of the actin cytoskeleton via the ARP2/3 complex (Tomasevic et al. 2007). The 
upregulation of FYN levels by miRNA knockout might lead to increased phosphorylation of 
nephrin and, via the NCK mediated pathway, to an increase of actin polymerization.  
Non-physiological levels of actin polymerization have been shown to disturb maintenance of 
podocyte structure and function. A higher binding activity of mutant -actinin-4 to actin fibers, 
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thus stiffening the actin network, has been proposed as a possible mechanism in the 
development of familial FSGS caused by mutations in the ACTN4 gene (Kaplan et al. 2000, Weins 
et al. 2005, Ward et al. 2008). A stiffer actin cytoskeleton has also been proposed to be a reason 
for podocyte injury in the nail-patella syndrome, a disease caused by mutations in the 
transcription factor LMX1B (Burghardt et al. 2013). The activity of cofilin A, an actin binding 
protein able to sever and depolymerize actin fibers to enable actin rearrangement, is necessary 
for maintenance of podocyte architecture (Garg et al. 2010), also proving that an inflexible actin 
cytoskeleton eases podocyte injury. Thus, a stiffer actin cytoskeleton due to a non-physiological 
stimulation of FYN activity might be one mechanism leading to podocyte injury. 
FYN also phosphorylates the slit diaphragm component NEPH1, which results in the recruitment 
of the adaptor protein GRB2, an event important for NEPH1-induced actin polymerization (Garg 
et al. 2007). A dysregulation of the miRNAs regulating FYN presumably leads to an upregulating 
of FYN levels in vivo, which might lead to an increased phosphorylation of its targets. FYN 
phosphorylates NEPH1 at two tyrosine residues at the positions 637 and 638, a prerequisite for 
NEPH1-GRB2 binding, and an increased phosphorylation at the tyrosine residue 637 was 
observed in in vivo models of podocyte injury (Harita et al. 2008). As the phosphorylation 
dependent NEPH1-GRB2 binding also modulates ERK (Extracellular-signal regulated kinase) 
signaling, a process important for cell survival, differentiation, proliferation, metabolism and 
motility (reviewed by Mendoza et al. 2011, De Luca et al. 2012), it might be an explanation for 
miRNA-loss dependent podocyte injury, leading to foot process effacement and loss of podocyte 
cytoarchitecture. 
Boundaries of luciferase assay 
The luciferase reporter assay is a suitable system for the identification of miRNA-mRNA target 
pairs, including determination of the distinct binding site of a mature miRNA. However, the 
method also harbors some disadvantages. The assay is performed in immortalized cell lines, 
which might not fully reflect the in vivo situation, as binding partners or cofactors might be 
missing. Because of the overexpression of the targeted luciferase as well as the candidate 
miRNA, the relative expression level of 3’-UTR and putative regulator might be totally different 
from the in vivo situation. The assay was performed with an altered reporter plasmid already 
coding for the targeted luciferase as well as the untargeted control, enabling relative 
quantification of the signals. Still, double transfection of the reporter plasmid and the miRNA 
overexpression plasmid is needed for a functional assay. As the transfection efficiency is 
important, the assay was performed in HEK293T cells which are easy to transfect, instead of 
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hPCLs which might be closer to the in vivo situation, but show poor transfection efficiencies. The 
transfection efficiency of the assay was monitored by transfection of a plasmid coding for GFP in 
every experiment. To avoid the insecurities of a double transfection, cell lines with a stable 
miRNA overexpression using pSuperior constructs harboring a puromycin resistance might be 
used for a stable background for the reporter assay. 
Alternative methods for miRNA-mRNA pair identification 
As an alternative for luciferase assays, a dual fluorescence strategy has been proposed for 
miRNA-mRNA pair validation (Goldoni et al. 2012). Instead of using luminescence generating 
enzymes as reporters, fluorescent proteins can be used. The 3’-UTR to be investigated for miRNA 
binding sites is cloned downstream of a mCherry red fluorescent protein, while miRNAs were 
overexpressed with a vector also coding for eGFP. By calculating the red/green fluorescence 
intensity ratio by automated image analysis, the putative miRNA-mRNA pairs can be checked for 
binding. As the cells do not have to be lysed for analysis, time course experiments are possible 
and every cell can be treated as one data point, enabling more statistical analyses. With this 
method, miR-125a-5p was identified to target WT1 (Tatsumi et al. 2015). 
In a protein-RNA complex immunoprecipitation, the complexes can be crosslinked with UV light 
to increase the yield. By CLIP (Cross-linking and immunoprecipitation) experiments, e.g. RNAs 
bound to the protein NOVA1 (Neuro-oncological ventral antigen 1) in the human brain were 
identified (Ule et al. 2003). The isolated RNAs can be analyzed by subsequent high-throughput 
sequencing, the HITS-CLIP (High-throughput sequencing of RNA isolated by crosslinking 
immunoprecipitation) (Licatalosi et al. 2008). It was shown that Ago-IPs can be combined with 
the CLIP method (Jaskiewicz et al. 2012), which could increase the RNA yield in the Ago-IPs from 
freshly isolated murine podocytes, increasing the amount of isolated RNA. The UV exposure 
might be performed directly after the first isolation of murine glomeruli or later, at the single cell 
suspension state. Additionally, a deep-sequencing analysis is an alternative to transcript 
identification by microarray. The PAR-CLIP (Photoactivatable-ribonucleoside-enhanced 
crosslinking and immunoprecipitation) method was developed to identify the binding sites of 
RNPs (Ribonucleoprotein complexes), including the RISCs, to RNA transcripts (Hafner et al. 
2010). Cells are fed with a uridine analogon, which, after exposure to UV light and reverse 
transcription, leads to a T to C point mutation in the transcript sequence at the miRNA binding 
site. By mapping the sequenced products to the known transcripts, binding sites can be 
identified through their single base mutation and the regulating miRNA can be distinguished. 
The problem in applying this technique in laboratory animals is the delivery of the uridine 
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analogon. High amounts would have to be injected into the organism, which might be toxic or at 
least causing stress or other reactions, like inflammations, influencing the physiological state of 
the cells. 
5.4 miRNA level manipulation methods 
To influence the miRNA levels in living cells, different techniques have successfully applied in the 
present work. However, each technique possesses distinct advantages and disadvantages. 
5.4.1 miRNA knockdown in cell culture by sponge expression  
Sponges are transcripts possessing binding sites for miRNAs in their 3’-UTR, mimicking the 
natural situation between a target transcript and a fitting miRNA. Since perfect complementary 
of the miRNA sequence and the target sequence is not necessary for binding, members of 
miRNA families can bind to the same binding sites. Thus, expression of a sponge transcript leads 
to the knockdown of a whole family. The binding to the sponge only affects the mature miRNAs, 
meaning that the levels of the miRNA derived from the other strand of the same precursor are 
not affected.  
For the knockdown of a whole family of mature miRNAs in vivo, competitive inhibitor transcripts, 
“sponges”, harboring binding sites for miRNA families highly expressed in podocytes were 
designed. The expression of the target miRNAs was controlled by Northern Blotting of RNA 
isolated from proliferating hPCLs. The functionality of the sponges was monitored by luciferase 
assays. In hPCLs cotransfected with a targeted luciferase containing binding sites for a miRNA in 
its 3’-UTR and a matching sponge, the luciferase activity was rescued compared to the samples 
cotransfected with a sponge not harboring any binding sites. As first sponge candidates, miRNA 
families highly expressed in glomeruli and podocytes were selected. The sponge functionality 
could be confirmed for sponges targeting miR-23a/b-3p, miR-24-3p, miR-27a/b-3p, miR-29a-c-3p 
and miR-92a/b-3p. Since the precursors of the miR-23 and the mir-27 family as well as the two 
genomic loci of mir-24 are organized in two clusters, it was planned to design mixed sponges 
using the sequences tested successfully. Thus the generation of podocyte specific cluster 
knockdown mice as well as mice with a knockdown for the miR-29 and the miR-92 family, two 
families known to be important for glomerular functionality (Liu et al. 2010A, Long et al. 2011, 
Qin et al. 2011, Wang et al. 2012, Lin et al. 2014, Marrone et al. 2014), would have been 
possible. Since the genomic knockout system available at that time, the zinc finger nucleases, 
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showed varying knockout efficiencies as well as off-target effects, the knockdown of miRNA 
levels on the cytoplasmic level was a very promising way for miRNA level manipulation in 
cultured cells and laboratory animals. 
A big disadvantage of this method is the need to freshly transfect cultured cells with the sponge 
coding plasmid. When working with immortalized podocyte cell lines, the cells can be 
differentiated by culturing at 37°C or 38°C, respectively, for two weeks. Since the differentiated 
cells are very hard to transfect, the transfection would have to be done with proliferating cells. 
Using plasmids coding for resistance genes, the generation of a stably transfected cell line would 
be possible. However, the presence of antibiotics would be necessary to maintain the selective 
pressure on the cells, which might influence the differentiation efficiency of the cells. Thus, a 
permanent depletion of miRNAs by an irreversable genomic knockout enables the 
differentiation of manipulated immortalized podocytes. 
5.4.2 TALEN mediated genomic miRNA knockout  
In 2013, TALE nucleases were introduced as a novel genome editing tool. A TALEN pair, each 
composed of a sequence specific TALE array and a part of an unspecific nuclease, binds to the 
DNA and generates double-strand breaks in the genome. This technique is more reliable than its 
predecessor, the zinc-finger nucleases. 
For the genomic knockout of a miRNA highly expressed in podocytes, miR-30a-5p, HEK293T cells 
were cotransfected with plasmids coding for two TALENs directed against the human genomic 
locus of miR-30a-5p obtained from www.talenlibrary.net and a plasmid coding for antibiotics 
resistance into cells. After selection with antibiotics, clones were picked and investigated for 
miR-30a-5p expression. After a first screening by Northern Blotting, clones with a reduced 
expression of mature miR-30a-5p were selected and checked for Notch1 expression, a validated 
miR-30a-5p target in podocytes (Wu et al. 2014), by qPCR. Additionally, the genomic locus of 
mir-30a was amplified by PCR and sequenced. The three knockout clones show different 
reorganization patterns: While the seed region of the miR-30a-5p is nearly completely deleted in 
clone 1, the whole mir-30a precursor sequence is missing in clone 2. Knockout clone 3 is 
heterozygous for the knockout: While one allele is not affected by the knockout at all, the other 
allele shows an insertion of one base. The presence of one wildtype allele in knockout clone 3 
might explain why the Notch1 expression is not dysregulated in this clone. 
The sequencing of the PCR products of the genomic locus of mir-30a show different 
reorganization patterns. After the double strand break, the cell repairs the DNA double strand by 
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non homologous end-joining or homology directed repair. During both processes, parts of the 
genome can be deleted, like the seed region of miR-30a-5p in knockout clone 1 or the whole 
precursor in knockout clone 2. Additionally, insertions and homozygous mutations like both 
observed in knockout clone 3 are possible. 
The different repairs of double strand breaks in cells might lead to different phenotypes. When 
the whole miRNA precursor is deleted, the expression of both mature miRNAs derived from the 
same precursor is disturbed. If the deleted region is very small or a small amount of bases is 
inserted, a changed hairpin precursor might be able to form, now coding for an altered miRNA, 
which might have completely different function in a cell. Thus, a detailed analysis of the genomic 
rearrangement after the double-strand break is important. One possibility to circumvent this 
problem is the addition of a donor in the cotransfection that can be integrated at the site of the 
double strand break by the cell by homology directed repair. With the insertion of a longer DNA 
fragment, not only a putatively altered precursor is disturbed, but also the insertion of a marker, 
like GFP expression, can be achieved. 
Following the promising results obtained using HEK293T cells, immortalized human podocyte 
cell lines harboring a knockout of miR-30a-5p have been generated (L. Hübner, 2015). Knockout 
cell lines for miR-146b-5p and miR-92a-3p have also been generated and will be characterized 
accordingly. As miR-92a-3p is encoded in the genome at two different loci, the knockouts will be 
performed stepwise and a final clone harboring two genomic knockouts will be selected.  
A relatively new system for genomic engineering is the CRISPR-Cas9 system, derived from a 
bacterial adaptive immune system that is also able to generate double strand breaks (Gupta & 
Musunuru 2014). By heterologous expression of the Cas9 protein from Streptococcus pyogenes 
together with a chimeric guide RNA, double strand breaks at the target sites of the guide RNAs 
can be generated (Gupta & Musunuru 2014). Since the so called protospacer sequence of the 
guide RNA of ca. 20 nt is responsible for the recognition of the target, the system can easily be 
adapted for different targets including the so-called “multiplexing”, i.e. using different guide 
RNAs together with one Cas9 protein for simultaneous knockout of different targets in one cell 
(Gupta & Musunuru, 2014). However, compared to the TALEN technology, the CRISPR-Cas9 
system still harbors some disadvantages. Firstly, downstream of the desired location of the 
double strand break, a NGG nucleotide sequence, the so called PAM (Protospacer adjacent 
motif) is needed (Gupta & Musunuru 2014). While finding such a sequence might not be a 
problem in a long, protein coding gene, this sequence might not occur in the relatively short 
miRNA sequence of 20 nt. Secondly, the protospacer region of the guide RNA consists of 20 nt, 
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but allows single, sometimes even multiple mismatches, increasing the risk of off-target effects 
(Gupta & Musunuru, 2014). With the TALEN system, a perfect match of two times around 9 to 
18 nt is needed, minimizing the risk of off-target effects. If the targeting of the CRISPR-Cas9 
system can be improved to lower the risk of off-target effects, it might be a good and faster 
alternative to the TALEN system. 
5.4.3 Podocyte specific knockdown/knockout techniques in mice 
To investigate the role of a certain miRNA in vivo, a cell type specific, and preferably a inducible 
manipulation of a miRNA level is desirable. The application of the different knockdown and 
knockout methods harbors diverse advantages and disadvantages. 
One possibility to influence miRNA levels in vivo is the application of antisense oligonucleotides, 
e.g. Vivo-Morpholinos. The molecules harboring an antisense sequence against the miRNA to be 
downregulated can be injected into the laboratory animals. Unfortunately, the targeting is 
rather unspecific. By direct injection into the renal aorta with parallel clamping of the renal vein, 
the retention time in the kidney and the uptake of the antisense oligonucleotides can be 
improved. Nonetheless, a specific targeting of a single cell population like the podocytes cannot 
be reached with this technique. A siRNA delivery system with a sheep anti-mouse podocyte 
antibody coupled to a siRNA was developed to exploit the endocytotic activity of podocytes for 
targeted siRNA delivery (Hauser et al. 2010). However, the injection of antisense 
oligonucleotides can only be used as a short term treatment. 
The classical Cre/loxP system can be used for a genomic knockout, e.g. of the locus of the 
precursor of a single miRNA of a cluster, like the putative podocyte cluster. A broad variety of 
inducible, cell type specific Cre expressions and also fluorescent reporter strains can be used for 
the knockout and its visual control. As a disadvantage, a knock-in mouse harboring the mutation 
of a genomic locus containing the loxP sites has to be generated by embryonic stem cell injection 
followed by homologous recombination to yield a mouse with the desired genotype.  
Another possibility for a genomic knockout is the TALEN mediated genomic knockout. Knockout 
of a miRNA locus in mice was performed by injection of the RNA coding for a TALEN pair directed 
against the mir-10a locus into the one cell stage of embryos (Takada et al. 2013). While the 
generation of TALEN knockout animals might be faster and straighter forward than the 
generation of a classical knock-in mouse, this model generated a constitutive knockout model, 
with no possibility to induce a cell-type specific alteration of a miRNA level at a later time point 
of development. 
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An interesting alternative for the genomic knockout of miRNAs by the Cre/loxP system or 
TALENs is the generation of a transgenic sponge mouse. The knockout of a genomic miRNA locus 
results in the disruption of the two miRNAs encoded in the same precursor. Sponge expression is 
only directed against one of the sequences encoded by a precursor, but is able to bind all mature 
miRNAs of the same family. It might be a helpful tool for a miRNA knockdown if the miRNA is 
encoded at different loci in the genome. Another application might be the knockdown of a 
whole miRNA family that is suspected to be interchangeable in their regulatory role. Transgenic 
mice expressing sponge transcripts have been constructed by microinjection (Ma et al. 2011) 
into fertilized eggs (Zhu et al. 2011). Combined with a cell type specific promoter like the P2.5 
podocyte specific promoter, sponges are an interesting tool for family specific miRNA 
knockdown. 
5.5 miRNA expression in podocytes of NPS mouse model 
The NPS (Nail-patella syndrome) is a disease caused by mutations in the transcription factor 
LMX1B. A possible role for miRNAs in the progression of this disease was investigated using a 
mouse model. 
miRNA expression regulation by transcription factors 
It was shown for many miRNAs that their expression can be regulated by transcription factors. 
p73 and p63 have been identified as activators for miR-200 family upregulation (Knouf et al. 
2011), while a regulatory circuit for Lmx1b and miR-135a-2 in brain development was described 
(Anderegg et al. 2013). Since Lmx1b is important for maintenance of murine podocyte structure 
and function, the effects of Lmx1b knockout on miRNA levels in glomeruli and podocytes were 
investigated. The knockout of Lmx1b in mice leads to the upregulation of its target genes Abra 
and Arl4c (Burghardt et al. 2013). Thus, Lmx1b seems to act as a transcriptional suppressor in 
podocytes for these genes. It might also act as an upregulating transcription factor as dendrin 
and semaphorin-3g are downregulated in glomeruli after the Lmx1b knockout (Burghardt et al. 
2013). A possible way for indirect upregulation of a target gene might be inhibiting the 
transcription of miRNAs, indirectly influencing the target transcripts of these miRNAs (Fig. 5.4). 
If LMX1B regulates the expression of miRNAs, it would increase the number of LMX1B regulated 
targets in podocytes and enable it to work in two directions for different target genes, as a direct 
suppressor and indirect enhancer. 
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Fig. 5.4: Putative regulatory pathways of transcription factor LMX1B 
miRNA expression in podocytes of Lmx1b knockout animals 
In the inducible, podocyte specific Lmx1b knockout mice, the glomerular expression levels of 
seven miRNAs were reduced after the knockout, including four members of the miR-200 family, 
a family consisting of five members in human and mice that is genomically organized in two 
clusters. 
The miR-200 has been described to be involved in kidney fibrosis and diabetic nephropathy, 
regulating the EMT (Epithelial mesenchymal transition) and the EndMT (Endothelial 
mesenchymal transition), two processes playing a role in the development of kidney fibrosis 
(Srivastava et al. 2013). The miR-200 family regulates renal tubular epithelial to mesenchymal 
transition induced by TGF- through the Smad pathway by targeting ZEB1 and ZEB2 (Xiong et al. 
2011). In the progression of breast cancer, it was shown that the miR-200 family and the miR-
221 family play opposing effects for EMT progression (Howe et al. 2012). A feedback loop 
between the ZEB transcription factors and the miR-200 family, each controlling the expression of 
each other, was identified to be an important player in the progression of cancer, inducing stem-
cell properties and preventing apoptosis and senescence (Brabletz & Brabletz 2010). This 
feedback loop was also termed a “cross road of signaling” in cancer, as it is linked to other 
signaling pathways like TGF-, Notch, p53 and others (Hill et al. 2012). 
Another mature miRNA downregulated in the Lmx1b knockout glomeruli is miR-192-5p. It has 
been described as a signature miRNA of renal ischemia reperfusion injury (Godwin et al. 2010), 
to mediate TGF-/Smad3-driven renal fibrosis (Chung et al. 2010) and to regulate E-cadherin 
expression (Wang et al. 2010). Loss of miR-192-5p was reported to promote fibrosis in diabetic 
nephropathy (Krupa et al. 2010), while inhibiting miR-192-5p ameliorated diabetic nephropathy 
in a different study (Putta et al. 2012). These studies propose that a tightly regulated miR-192-5p 
level is important for prevention of renal fibrosis. Additionally, crosstalk between miR-192-5p 
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and the transcription factor p53 induced by TGF-was observed in the pathogenesis of diabetic 
nephropathy (Deshpande et al. 2013). miR-192-5p represses the transcription factors ZEB1 and 
ZEB2, leading to pro- as well as anti-fibrotic effects (reviewed by Jenkins et al. 2012) and linking 
miR-192-5p dependent regulation to regulation by the miR-200 family. 
To identify miRNAs directly affected by the Lmx1b knockout, inducible podocyte specific Lmx1b 
knockout mice were crossed with the Cre reporter mice to generate sortable, green fluorescent 
Lmx1b knockout podocytes. In the podocyte profiles generated from knockout and control mice, 
the miR-200 family was strongly enriched in the red fluorescent cell population with nearly no 
expression in podocytes, while miR-192-5p was expressed in podocytes as well as in the red 
fluorescent cell population. 
The low transcription levels of the miR-200 family in podocytes together with their involvement 
in EMT hints that the altered expression level might be a secondary effect in the non-podocyte 
cells of the glomerulus. miR-192-5p is expressed in podocytes as well as in non-podocyte cells 
and plays a major role in the progression of kidney fibrosis. The altered level of miR-192-5p 
might be a direct or a secondary effect of the Lmx1b knockout. 
The deep sequencing profiles of green fluorescent Lmx1b knockout podocytes revealed 48 
mature miRNAs to be upregulated and 40 mature miRNAs to be downregulated in podocytes 
after the Lmx1b knockout. For this analysis, only miRNAs with expression levels unchanged in 
the red fluorescent cell population were counted in order to identify direct Lmx1b knockout 
effects. miR-192-5p was also downregulated in podocytes after Lmx1b knockout, making it, 
together with the other altered miRNAs, a very interesting target for further studies. 
Using the profile generated from podocytes and red fluorescent glomerular cells from animals 
not harboring a mutated Lmx1b gene and thus, not suffering from the Lmx1b knockout, a third 
wildtype profile of miRNAs expressed in podocytes and mesangial and endothelial cells can be 
generated. However, several differences between the samples have to be considered. The 
original podocyte profiles were generated using male animals aged 12 to 14 weeks, while the 
third profile was generated from female mice aged 12 to 14 weeks. Secondly, both mouse 
strains possess a different background. The double fluorescent Cre reporter mice as well as the 
quadruple transgenic Lmx1b knockout strain possess a 50 : 50 mixed background of C57bl/6 and 
the Cre reporter mouse harboring the mT/mG cassette (Muzumdar et al. 2007), but both strands 
are bred independently from one another. The third big difference is the treatment of the 
animals before the isolation of glomerular cells. The control mice of the Lmx1b knockout 
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experiment received drinking water containing doxycycline for 9 days to induce the switch from 
expression of a red fluorescent protein to a green fluorescent protein, enabling also correction 
for doxycycline induced effect when being compared to the Lmx1b knockout animals. These 
doxycycline dependent effects are also an explanation for differences between the profiles. 
Nonetheless, 15 podocyte miRNAs, miR-125b-5p, miR-146b-5p, miR-148a-3p, miR-196b-5p, miR-
27b-5p, miR-30a-3p, miR-30b-3p, miR-30d-5p, miR-322-3p, miR-330-5p, miR-340-5p, miR-351-
5p, miR-503-3p, miR-503-5p and miR-615-3p were also identified to be enriched in the third 
podocyte library. 
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6 SUMMARY 
In the last decade, thousands of small, highly conserved regulative RNAs, e.g. the miRNAs, could 
be identified to be expressed in various tissues and organs of many different species using the 
improved sequencing techniques. Meanwhile it is known that they play important roles in the 
post-transcriptional regulation of various cellular processes, e.g. different signaling pathways, in 
mammalian organisms. 
Podocytes are unique, specialized cells with a very elaborate three-dimensional 
cytoarchitecture. Being located in the glomeruli of the kidney, they cover the glomerular 
capillaries with their interdigitating foot processes. In-between these processes, they build up 
slit diaphragms, complex protein structures responsible for the filtration of the blood, forming 
the primary urine. From different studies working with mice harboring a podocyte specific 
knockout for miRNA processing enzymes Dicer and Drosha (Harvey et al. 2008, Ho et al. 2008, 
Shi et al. 2008, Zhdanova et al. 2011), it is known that miRNAs are not only important for the 
development, but also responsible for maintenance of podocyte structure and function. Since 
this complex cytoarchitecture of the podocyte foot processes is lost in the described knockout 
mice, the proteins building up and stabilizing the slit diaphragms in-between the foot processes 
represent putative targets of miRNA dependent regulation.  
In the present work, deep sequencing miRNA profiles were generated using glomeruli and 
tubules isolated from C57bl/6 wildtype mice and validated by Northern Blotting as well as qPCR 
analysis. However, to identify miRNAs enriched in podocytes, cells where freshly isolated from a 
double fluorescent Cre reporter mouse (Möller et al. 2003, Muzumdar et al. 2007). Analyzing 
deep sequencing profiles of miRNAs expressed in murine podocytes and the other glomerular 
cells, endothelial and mesangial cells, a subset of 38 mature miRNAs was identified to be 
enriched in podocytes compared to the other glomerular cell types. The enrichment of a subset 
of miRNAs in the glomerular cell populations, including podocyte candidate miRNAs, was 
validated by qPCR. By analyses of the human and murine 3’-UTR of transcripts coding for 
proteins important for podocyte structure and function and subsequent in silico predictions, 
putative regulatory miRNA-mRNA pairs in podocytes were predicted. A subset of four putative 
structural target genes: CD2AP, FYN, NCK2 and NEPH1 were analyzed in more detail. All of them 
are known to interact directly with the main protein building up the slit diaphragm, nephrin. To 
investigate these putative targets, luciferase assays were performed. HEK293T cells were 
transfected using a plasmid coding for a targeted luciferase together with a plasmid 
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overexpressing a mature miRNA or a control sequence. A possible regulation of CD2AP by miR-
30a-5p could be identified via luciferase assay. A regulation by miR-92a-3p is likely, but could not 
be proven yet. Additionally, regulation of FYN by miR-146b-5p was detected. The effect of these 
miRNAs on the transcript and protein level of their targets will be analyzed in immortalized 
human podocytes, e.g. in miRNA knockout cell lines, in future studies. 
To identify miRNA-target genes in podocytes in vivo, Ago-IP (Argonaute immunoprecipitation) 
combined with subsequent microarray analysis of the miRNA regulated targets was performed 
using freshly isolated murine podocytes. A new subset of candidate genes could be generated 
searching the Ago-bound transcripts for mRNAs coding for proteins important for podocyte 
structure and function. Additionally, Cd2ap and Fyn could both be identified to be enriched in 
the Ago-bound sample derived from podocytes, confirming the results from the luciferase 
assays. By repeating the analysis with an independent second sample, the enrichment of these 
candidates in the Ago-bound sample will be validated.  
Two methods for miRNA level manipulation, “miRNA-sponges” for a knockdown of miRNA 
families and the genomic knockout of miRNAs using TALE nucleases were applied successfully in 
different cultured cell types. Sponges directed against several miRNA families highly expressed in 
podocytes were proven to be functional by luciferase assays in immortalized human podocytes. 
The genomic locus of mir-30a could be knocked out using TALE nucleases in HEK293T cells, 
yielding knockout cell lines. The downregulation of the mature miR-30a-5p as well as the 
upregulation of a known miR-30a-5p target in podocytes, Notch1 (Wu et al. 2014), could be 
shown in these knockout cell clones. With a TALE nuclease mediated knockout of miR-30a-5p, 
miR-92a-3p and miR-146b-5p in immortalized human podocytes, the role of these miRNAs will 
be investigated further, including the role they play in the regulation of CD2AP and FYN levels in 
the cells. As the genomic miRNA knockout is stable, the effect on the cellular structure can be 
analyzed in differentiated cells. 
The transcription factor LMX1B plays an important role for the maintenance of podocyte 
structure and function. To investigate its possible effect on miRNA levels in vivo, glomeruli and 
podocytes were isolated from inducible Lmx1b knockout mice and compared to control mice. In 
the Lmx1b knockout podocytes, 48 mature miRNAs were found to be upregulated and 40 
miRNAs were found to be downregulated compared to the control animals. This indicates a role 
of this transcription factor in controlling miRNA expression in podocytes. A miRNA family that 
was earlier found to be downregulated in glomeruli after Lmx1b knockout, the miR-200 family, 
was identified to be expressed in the non-podocyte glomerular cells, indicating a secondary 
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effect of the transcription factor inactivation. The miRNAs showing altered expression levels 
after Lmx1b knockout are putative starting points for further analyses of the genesis of the nail-
patella syndrome, a human genomic disease caused by mutations in the LMX1B gene. 
The overall goal of the present work was the investigation of the processes leading to podocyte 
injury and foot process effacement after dysregulation of miRNA levels. Firstly, it was required to 
identify podocyte miRNAs from the generated glomerular profiles, which was achieved using 
freshly isolated murine podocytes from the double fluorescent Cre reporter mice. By a 
combination of in silico predictions, Ago-IPs and luciferase assays, two transcripts coding for 
proteins important for podocyte structure and function, CD2AP and FYN, could be identified to 
be regulated by miRNAs. Specific interaction could be shown between FYN and miR-146b-5p. 
Furthermore, CD2AP might be regulated by miR-30a-5p as well as miR-92a-3p. In an Ago-IP from 
freshly isolated murine podocytes followed by microarray analysis, these targets could also be 
validated. Additionally, a new subset of target genes to be further analyzed has been generated. 
Techniques for miRNA level manipulation were successfully applied and will be used to 
characterize the identified specific regulatory miRNA-mRNA pairs. 
The present work sheds light on the miRNA-mediated regulatory network in podocytes, which 
aids in the maintenance of their complex cytoarchitecture and function in renal filtration. 
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7 ZUSAMMENFASSUNG 
Mit Hilfe verbesserter Sequenzierungstechniken konnte in den letzten zehn Jahren die 
Expression tausender kleiner, hoch konservierter RNAs, der miRNAs, in einer Vielzahl von 
Geweben und Organen in ganz unterschiedlichen Organismen identifiziert werden. Inzwischen 
ist bekannt, dass sie in Säugetieren eine wichtige Rolle in der post-transkriptionellen Regulation 
vieler zellulärer Prozesse, beispielsweise in verschiedenen Signalwegen, spielen. 
Podozyten sind hochspezialisierte Zellen, die eine komplexe, dreidimensionale Zytoarchitektur 
besitzen. Sie befinden sich in den Nierenkörperchen, wo sie die Kapillaren mit ihren 
ineinandergreifenden Fußfortsätzen bedecken. Zwischen diesen bilden sie eine komplexe 
Proteinstruktur, das Schlitzdiaphragma, aus, das für die Filtration des Blutes zum Primärharn 
verantwortlich ist. Durch mehrere Studien an Mäusen, die unter einem podozyten-spezifischen 
Knockout der miRNA prozessierenden Enzyme Drosha und Dicer leiden (Harvey et al. 2008, Ho et 
al. 2008, Shi et al. 2008, Zhdanova et al. 2011), wurde gezeigt, dass miRNAs nicht nur für die 
Entwicklung, sondern auch für die Erhaltung der Podozytenstruktur und -funktion essentiell sind. 
Da die komplexe Zytoarchitektur der Podozytenfußfortsätze in diesen Knockout-Mäusen 
verloren geht, stellen die Proteine, die für den Aufbau und die Stabilisierung der 
Schlitzdiaphragmen zwischen den Fußfortsätzen verantwortlich sind, potentielle Ziele für die 
miRNA vermittelte Regulation dar.  
Im Rahmen der vorliegenden Arbeit konnten aus Glomeruli und Tubuli, die aus C57/bl6-wildtyp 
Mäusen isoliert wurden, miRNA-Expressionsprofile mittels deep sequencing generiert und durch 
Northern Blotting und qPCR-Analyse validiert werden. Zur Identifizierung von miRNAs, die in 
Podozyten angereichert sind, wurden diese frisch aus einer doppelt-fluoreszierenden Cre-
Reporter-Maus isoliert (Möller et al. 2003, Muzumdar et al. 2007). Die generierten miRNA-deep 
sequencing-Profile der murinen Podozyten und der glomerulären Endothel- und den 
Mesangialzellen wurden analysiert. Auf diese Weise wurden 38 miRNAs identifiziert, die in 
Podozyten gegenüber den Endothel- und Mesangialzellen angereichert sind. Die Anreicherung 
spezifischer miRNAs in den glomerulären Zellpopulationen, einschließlich der podozytären 
miRNA-Kandidaten, wurde stichprobenartig per qPCR-Analyse validiert. Durch die Analyse der 3‘-
UTRs humaner und muriner Transkripte, die für Proteine kodieren, welche für die 
Podozytenstruktur und –funktion wichtig sind, und anschließende in silico-Vorhersagen wurden 
mögliche regulatorische miRNA-mRNA Paare vorhergesagt. Eine Gruppe von vier möglichen 
Zielgenen: CD2AP, FYN, NCK2 und NEPH1, wurde genauer untersucht. Von diesen Proteinen ist 
eine direkte Interaktion mit dem wichtigsten Protein des Schlitzdiaphragmas, Nephrin, bekannt. 
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Zur Untersuchung dieser möglichen Zielgene wurden Luciferase Assays durchgeführt. Dazu 
wurden HEK293T Zellen mit einem Plasmid, das eine Luciferase mit der jeweiligen 3‘-UTR kodiert 
und einem Plasmid, das entsprechend eine spezifische reife miRNA oder eine Kontrollsequenz 
überexprimiert, transfiziert. Im Luciferase Assay konnte eine mögliche Regulation von CD2AP 
durch miR-30a-5p identifiziert werden. Eine Regulation durch miR-92a-3p erscheint 
wahrscheinlich, konnte jedoch noch nicht bewiesen werden. Zusätzlich wurde eine Regulation 
von FYN durch miR-146b-5p detektiert. Die Effekte dieser miRNAs auf die Transkript- und 
Proteinspiegel der Zielgene werden in immortalisierten humanen Podozyten, beispielsweise in 
miRNA Knockout-Zelllinien, weiter analysiert werden. 
Darüber hinaus wurde zur Identifikation von miRNA Zielgenen in vivo eine Ago-IP (Argonaute 
Immunprezipitation) aus frisch isolierten murinen Podozyten durchgeführt und mit einer 
anschließenden Microarray-Analyse der miRNA regulierten Transkripte kombiniert. Durch die 
Suche nach Transkripten möglicher Zielgene, die in der podozytären Ago-gebundenen Probe 
angereichert und für die Podozytenstruktur und –funktion wichtig sind, konnte eine neue 
Gruppe von möglichen Zielgenen generiert werden. Zusätzlich konnten Cd2ap und Fyn in der 
podozytären Ago-angereicherten Probe identifiziert werden, was die Ergebnisse der Luciferase 
Assays bestätigt. Die Anreicherung dieser Kandidaten in der Ago-gebundenen Probe soll durch 
die Wiederholung des Experiments mit einer zweiten, unabhängigen Probe validiert werden. 
Zwei Methoden zur Manipulation der miRNA-Spiegel, „miRNA-sponges“ für den Knockdown von 
miRNA-Familien und der genomische Knockout von miRNAs mit Hilfe von TALE Nukleasen, 
wurden erfolgreich in verschiedenen immortalisierten Zelllinien angewendet. Die Funktionalität 
von „miR-sponges“ gegen mehrere miRNA-Familien, die in Podozyten stark exprimiert sind, 
konnte mit Hilfe von Luciferase Assays in humanen immortalisierten Podozyten nachgewiesen 
werden. Mit Hilfe von TALE-Nukleasen konnten mir-30a Knockout-Zelllinien aus HEK293T Zellen 
hergestellt werden. Sowohl die verminderte Expression der reifen miR-30a-5p als auch die 
vermehrte Expression eines bekannten miR-30a-5p Zielgens in Podozyten, Notch1 (Wu et al. 
2014), konnte in diesen Klonen gezeigt werden. Durch einen TALE-Nuklease vermittelten 
Knockout von miR-30a-5p, miR-92a-3p und miR-146b-5p in immortalisierten, humanen 
Podozyten, wird die Rolle dieser miRNAs, einschließlich ihrer Rolle bei der Regulation der CD2AP- 
und FYN-Spiegel in den Zellen untersucht werden. Die Folgen des stabilen miRNA knock-outs für 
die Zellstruktur können so in differenzierten Zellen analysiert werden. 
Der Transkriptionsfaktor LMX1B spielt für die Erhaltung der Podozytenstruktur und –funktion 
eine wichtige Rolle. Um seinen möglichen Einfluss auf die miRNA-Spiegel in vivo zu analysieren, 
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wurden Glomeruli und Podozyten von Lmx1b Knockout-Mäusen isoliert und mit Kontrollmäusen 
verglichen. In Lmx1b Knockout-Podozyten wurden 48 reife hochregulierte und 40 
herunterregulierte miRNAs gefunden. Dies weist auf eine Rolle dieses Transkriptionsfaktors in 
der Expressionskontrolle von miRNAs in Podozyten hin. In Lmx1b Knockout-Glomeruli wurde 
eine Reduktion der miR-200 Familie festgestellt. Diese miRNA-Familie wurde später als in den 
nicht-podozytären, glomerulären Zellen exprimiert identifiziert, was auf einen sekundären Effekt 
des Lmx1b Knockouts hinweist. Die miRNAs mit veränderten Expressionsspiegeln nach dem 
Lmx1b Knockout sind mögliche Ausgangspunkte für die Aufklärung der Entstehung des Nagel-
Patella-Syndroms, einer humanen genetischen Erkrankung, die durch Mutationen im LMX1B Gen 
verursacht wird, sein. 
In der vorliegenden Arbeit wurden die Vorgänge, die zur Störung der Podozytenarchitektur nach 
einer Dysregulation der podozytären miRNA-Spiegel führen, untersucht. Zunächst konnten die in 
Podozyten endogen exprimierten miRNAs konnten mit Hilfe der frisch isolierten Zellen aus den 
gekreuzten doppelt-fluoreszenten Cre-Reportermäusen identifiziert werden. Durch eine 
Kombination von in silico-Vorhersagen, Ago-IPs und Luciferase Assays konnte die Regulation 
zweier Transkripte, CD2AP und FYN, identifiziert werden. Eine spezifische Interaktion zwischen 
FYN und miR-146b-5p konnte gezeigt werden. Zusätzlich könnte CD2AP sowohl durch miR-30a-
5p als auch durch miR-92a-3p reguliert werden. Durch eine Ago-IP mit frisch isolierten murinen 
Podozyten, die mit einem Microarray kombiniert wurde, konnten diese Zielgene bestätigt und 
darüber hinaus neue potentielle Zielgene identifiziert werden. Methoden zur Manipulation der 
miRNA-Spiegel wurden in Zellkulturen erfolgreich angewendet und stehen zur weiteren 
Charakterisierung der spezifischen regulativen miRNA-mRNA Paare zur Verfügung. 
Die vorliegende Arbeit trägt zur Aufklärung über das miRNA-gesteuerte regulative Netzwerk in 
Podozyten, das die Erhaltung der komplexen Zytoarchitektur und die Funktion in der renalen 
Filtration unterstützt, bei. 
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8 LIST OF ABBREVIATIONS 
Human proteins are written in all capital letters, 
murine proteins written starting with a capital 
letter; the corresponding genes are written in 
italics. 
 
27G Needle size; outer diameter: 
0.4128 mm; inner diameter: 
0.210 mm 
3’-end  Strand terminating at the hydroxyl 
group of the third carbon in the 
sugar-ring 
5’-end Strand terminating at the hydroxyl 
group of the fifth carbon in the 
sugar-ring  
3p Mature miRNA derived from the 
3‘-end of the precursor 
5p Mature miRNA derived from the 
5‘-end of the precursor 
  Mass concentration 
  Wave length 
µg  Microgram(s) 
µl  Microliter(s) 
µm  Micrometer(s) 
A  Adenine 
Abra Actin-Binding Rho Activating 
Protein 
Actbl2  Actin, beta-like 2 
Actg1  Actin, gamma, cytoplasmic 1 
ACTN4  -Actinin-4 gene 
ACTR2  Actin related protein 2 
Ago1-4 Argonaute protein 1-4 
Ago-IP Argonaute immunoprecipitation 
AGTII  Angiotensin 2 
AKT   Protein kinase B 
Apa Acetobacter pasteurianus sub. 
pasteurianus 
aPKC  Atypical protein kinase C 
APS   Ammoniumpersulfate 
Arl4c ADP-Ribosylation Factor-Like 4C 
Arp2/3 Arp2/3 complex 
Asn  Asparagine 
Asp  Aspartic acid 
AT1 receptor  Angiotensin II receptor type 1 
ATP  Adenosine triphosphate 
BCL2   B-cell lymphoma 2 
Bgl  Bacillus globigii 
BLAST Basic Local Alignment Search Tool 
bp  Base pairs 
BSA  Bovine serum albumin 
c  Molar concentration 
C  Cytosine 
C. elegans Caenorhabditis elegans 
c-terminus Carboxyl-terminus 
C57bl/6 C57black6 mouse strain 
Ca2+  Bivalent calcium ion 
CaCl2  Calcium chloride 
CaMKII Ca2+/calmodulin-dependent 
protein kinase 
CAMTA1 Calmodulin binding transcription 
activator 1 
CapZ Capping protein (actin filament) 
muscle Z-line 
Cas9 CRISPR associated protein 9 
CCR4 Chemokine (C-C Motif) Receptor 4 
CD2AP CD2 associated protein 
CD31 Cluster of differentiation 31 
CDC42 Cell division control protein 42 
homolog 
cDNA Complementary DNA 
chr  Chromosome 
ciRS-7 Circular RNA sponge for miR-7 
CLIP  Cross-linking and 
immunoprecipitation 
CLIC5 Chloride intracellular channel 
protein 5 
CMV  Cytomegalovirus 
CO2  Carbon dioxide 
ColE1 origin Origin of replication of ColE1 
plasmid (carrying gene for colicin 
E1) 
cp  Crossing point 
Cre  Cre Recombinase 
CRISPR Clustered regularly interspaced 
short palindromic repeats 
CTGF  Connective tissues growth factor 
cxcr4 C-X-C chemokine receptor type 4 
D  Differentiated 
d2eGFP Destabilized GFP 
DAG  Diacylglycerol 
DABCO   1, 4-Diazabicyclo[2.2.2]octane  
DAPI   4′, 6-Diamidin-2-phenylindol 
db/db mice Mice with deficient leptin receptor 
activity 
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DEPC   Diethylpyrocarbonate 
DG  Dystroglycan 
DGCR8  DiGeorge syndrome critical region 
gene 8 
DMEM Dulbecco's modified Eagle's 
medium 
DMSO  Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid 
DNase  Deoxyribonuclease 
dNTPs  Deoxynucleotide triphosphates 
Dox  Doxycycline 
DTT  1, 4-Dithio-DL-threitol 
e.g.  examples given 
E11/E12/E13 Embryonic days: day 11, day 12, 
day 13 
E2F1  Transcription factor E2F1 
E2F3  Transcription factor E2F3 
EcoR  Escherichia coli RY13 
EDC  1-Ethyl-3-(3-dimethylamino-
propyl)carbodiimid 
EDTA Ethylenediaminetetraacetic acid 
EF  Fenestrated endothelium 
eGFP Enhanced green fluorescent 
protein 
Eml2  Echinoderm microtubule 
associated protein like 2 
EMT Epithelial mesenchymal transition 
ENCODE Encyclopedia of DNA Elements 
EndMT  Endothelial mesenchymal 
transition 
EPAP   E.coli poly-A polymerase 
ER  Endoplasmic reticulum 
ERK Extracellular-signal-regulated 
kinase 
EZR  Ezrin 
F  Forward 
FACS  Fluorescent activated cell sorting 
FAK  Focal adhesion kinase 
Fam114a1  Family with sequence similarity 
114, member A1 
FAT1  Protocadherin Fat 1 
FCS   Fetal calf serum 
Fig  Figure 
FLAT Far linked AT rich elements 
FP  Foot process 
FSGS  Focal segmental 
glomerulosclerosis 
FYN Proto-oncogene tyrosin kinase Fyn 
G  Guanine 
g  Gram(s) 
g  Multiple of acceleration of gravity 
G1 phase Growth 1/Gap 1 phase 
G418  Geneticin 
GBM Glomerular basement membrane 
genloc  Genomic locus 
GFP Green fluorescent protein 
Glom  Glomeruli 
Gly  Glycine 
Gpc1   Glypican 1  
GRB2 Growth factor receptor-bound 
protein 2 
GRCh Genome Reference Consortium 
Human genome 
GTPase Guanine triphosphate hydrolyzing 
enzyme 
GW  Glycin-tryptophan repeat 
containing 
h  Hour(s) 
H-2Kb  Mouse major histocompatibility 
complex promoter 
H2O  Water 
HBSS   Hank’s buffered saline solution 
HCl  Hydrochloric acid 
HDAC4  Histone deacetylase 4 
HDR   Homology directed repair 
HEK293T Human Embryonic Kidney 293 cells 
containing SV40 Large T-antigen 
HeLa HeLa cell line, human cervical 
cancer cell line 
HEPES 4-(2-Hydroxyethyl)-1-
piperazineethanesulfonic acid 
HF  High Fidelity 
Hind  Haemophilus influenzae 
His  Histidine 
Hnrpk  Heterogeneous nuclear 
ribonuclear protein K 
Hoxa9  Homeobox A9 
Hoxc5   Homeobox C5 
hPCL   Human podocyte cell line 
HRP  Horse radish peroxidase 
hsa  Homo sapiens 
Hsp90  Heat shock protein 90 
i.e.  it est 
IgA  Immunoglobulin A 
IgG  Immunoglobulin G 
Ile  Isoleucine 
ILK  Integrin-linked kinase 
IP  Immunoprecipitation 
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IP3  Inositol triphosphate 
IQGAP-1 IQ motif containing GTPase 
activating protein 
Itga3  Integrin alpha 3 
Itgb1  Integrin beta 1 
JAM4 Junctional cell adhesion molecule 
4 
kb  Kilobase(s) 
KCl  Potassium chloride 
kDa  Kilodalton 
KFB  Kompetenzzentrum fluoreszente 
Bioanalytik 
KH2PO4 Potassiumdihydrogen phosphate 
Kirrel1  Kin of IRRE like protein 1 
KO  knockout 
l  Liter(s) 
LB  Lysogeny broth 
LC1 Tet-On inducible Cre recombinase 
Lim domain Domain discovered in Lin11, Isl-1, 
Mec-3 
lincRNA Long intergenic non-coding RNA 
Lingo2 Leucine rich repeat and Ig domain 
containing 2 
Lmx1b LIM Homeobox Transcription 
Factor 1, Beta 
LNA  Locked nucleic acid 
loxP sites Locus of X-over P1, Cre 
recombinase recognition site 
LPS   Lipopolysaccharide 
M  Molar 
MAGI-1/2 Membrane-associated guanylate 
kinase, WW and PDZ domain-
containing protein 1/2 
MET  Mesenchymal–epithelial transition 
mG  Monomeric green fluorescent 
protein 
MgCl2  Magnesiumchloride  
MgSO4 Magnesiumsulfate 
min  Minute(s) 
miR  Mature miRNA 
mir  Precursor miRNA 
ml  Milliliter(s) 
mM  Millimolar 
mmHg  Millimeters of mercury 
mmu  Mus musculus 
MO   Missouri 
mPCL  Murine podocyte cell line 
mT Targeted tandem dimer Tomato 
mT/mG Tomato mouse reporter cassette 
mut  Mutant 
n-terminus Aminoterminus of a protein 
N-Wasp Neural Wiskott-Aldrich syndrome 
protein 
n.s.  Not significant 
NaCl  Sodiumchloride 
NaF  Sodiumfluoride 
Na2HPO4 Sodiumhydrogenphosphate 
NaN3  Sodiumazide 
Nck1/2 Non-catalytic region of tyrosine 
kinase adaptor protein 1/2 
neg  Negative 
Neph1  Kin of IRRE-like protein 1 
Neph2  Kin of IRRE-like protein 3 
Neph3  Kin of IRRE-like protein 2 
NFYC  Nuclear transcription factor Y 
gamma 
ng  Nanogram(s) 
NHEJ  Non homologous end-joining 
NHERF1/2 Sodium-hydrogen antiporter 3 
regulator 1/2 
nm  Nanometer(s) 
nonRT  Not reversely transcribed sample 
NOSTRIN Nitric oxide synthase trafficking 
NOT9  RCD1 required for cell 
differentiation1 homolog 
Notch1 Notch homolog 1, translocation-
associated 
NPC  Nuclear pore complex 
NPHS1 Nephrin 
NPHS2 Podocin 
NPS   Nail patella syndrome 
nt  Nucleotide 
O  Oxygen 
P  Proliferating 
p27 Cyclin-Dependent Kinase Inhibitor 
1B  
p53  Tumor protein P53 
p63  Tumor protein p63 
p73  Tumor protein p73 
PAGE  Polyacrylamide gel electrophoresis 
PAKs  p21 activated kinases 
PAM   Protospacer adjacent motif 
PAN   Puromycin amino-glycoside 
PAN2 Poly(A) Specific Ribonuclease 
Subunit 2 
PAN3 Poly(A) Specific Ribonuclease 
Subunit 3 
Pank1   Pantothenate kinase 1  
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Par3  Partitioning defective 3 homolog 
Par6 Partitioning defective 6 homolog 
PARN   Poly(A) specific ribonuclease 
PBS  Phosphate buffered saline 
PCNA  Proliferating cell nuclear antigen 
PCR  Polymerase chain reaction 
PDZ domain Protein domain found in PSD95, 
Dlg1 and ZO-1 
PECs   Pariethal endothelial cells  
PEI   Polyethylenimine 
PFA   Paraformaldehyde 
Pfu  Pyrococcus furiosus 
PI3K Phosphatidylinositol-4,5-
bisphosphate 3-kinase 
PINCH-1 Particularly interesting new 
cysteine-histidine-rich protein 
PIP2 Phosphatidylinositol 4,5-
bisphosphate 
PLC1  Phospholipase C, epsilon 1 
PLCG1  Phospholipase C, gamma 1  
PNK   Polynucleotide Kinase 
PODXL  Podocalyxin 
pos  Positive  
ppm  Parts per million 
pre-miRNA miRNA precursor 
pri-miRNA Primary transcript of a miRNA 
Protein G Immunoglobulin-binding protein 
PVDF   Polyvinylidene fluoride 
PVP   Polyvinylpyrrolidone 
qPCR Quantitative polymerase chain 
reaction 
R  Reverse 
RAC1 Ras-related C3 botulinum toxin 
substrate 1 
RHOA Ras homolog gene family, member 
A 
RISC  RNA induced silencing complex 
RMC  Complement system protein 
RNA  Ribonucleic acic 
RNAse Ribonuclease, RNA degrading 
enzyme 
RNF130  Ring finger protein 130 
rno  Rattus norvegicus 
RNP   Ribonucleoprotein complex 
RPMI  Roswell Park Memorial Institute 
RQCD1 RCD1 required for cell 
differentiation1 homolog 
RT  Room temperature 
RT-PCR Reverse transcription polymerase 
chain reaction 
rtTA  Reverse tetracyclin transactivator 
s  Second(s) 
S phase  Synthesis phase 
Sac  Streptomyces achromogenes 
SDS   Sodium dodecylsulfate 
SH2/3 domainSrc homology 2/3 domain 
shRNA  short hairpin RNA 
siRNAs small interference RNA 
Smad2/3 Smad family member 2/3 
Smurf1 E3 ubiquitin-protein ligase 
Smurf2  SMAD specific E3 ubiquitin protein 
ligase 2 
SNP Single nucleotide polymorphism 
snRNA  small nuclear RNA 
SOCS1  Suppressor of cytokine signaling 1 
Spe  Sphaerotilus natans 
Spry1  Sprouty homolog 1 
SS-13BN rats Control strain for Dahl sensitive 
rats 
SSC Sodium citrate/sodium chloride 
buffer 
Src SRC proto-oncogene, non-receptor 
tyrosine kinase 
Sry  Sex-determining region Y 
SV40  Simian vacuolating virus 40 
Synpo  Synaptopodin 
T  Thymine 
Tab  Table 
TAE buffer Tris-acetate-EDTA buffer 
TALE  Transcription activator-like 
effector 
TALEN Transcription activator-like 
effector nuclease 
Taq  Thermus aquaticus 
TBE buffer Tris-borate-EDTA buffer 
TEMED  Tetramethylethylenediamine 
Tet-On Tetracycline-Controlled 
Transcriptional Activation 
TGF-1 Transforming growth factor beta 1 
TK  Thymidin kinase promoter 
TLN1  Talin-1 
Tmem164  Transmembrane protein 164 
Tmem180  Transmembrane protein 180 
TNRC6A-C Trinucleotide repeat containing 6 
A-C 
TRIS  Tris(hydroxymethyl)-aminomethan 
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TRPC1  Transient receptor potential cation 
channel, subfamily C, member 1 
TRPC6 Transient receptor potential cation 
channel, subfamily C, member 6 
Tub  Tubules 
U  Enzyme unit (1 µm/min) 
U6  U6 snRNA, spliceosomal RNA 
URT primer Universal reverse transcription 
primer 
UTR  Untranslated region 
UV  Ultraviolet 
V  Volt(s) 
VEGF(A) Vascular endothelial growth factor 
(A) 
VEGFR-2 Vascular endothelial growth factor 
receptor 2 
WASL Neural Wiskott-Aldrich syndrome 
protein 
WASP Wiskott-Aldrich syndrome protein 
Wipf3 WAS/WASL interacting protein 
family, member 3 
Wnt1 Proto-oncogene protein Wnt-
1/Wnt 
wt  Wildtype 
WT1  Wilms Tumor protein 1 
Xho  Xanthomonas holcicola 
Xlim1/Lhx1 Lim homeobox 1 
XPO-5   Exportin-5 
YDxV domain Domain consisting of Tyrosine – 
Aspartic Acid – any amino acid - 
Valine 
ZEB1 Zinc Finger E-Box Binding 
Homeobox 1 
ZEB2 Zinc Finger E-Box Binding 
Homeobox 2 
ZO-1  Zonula occludens 1
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10 APPENDIX 
Tab. 10.1: miRNAs expressed in murine glomeruli and tubules 
miRNA 
Glomeruli Tubules 
Ratio 
Glom/ 
Tub 
Glomeruli Tubules 
Ratio 
Glom/ 
Tub 
total RNA Total RNA small RNA small RNA 
good 
reads 
‰ of 
good 
reads 
good 
reads 
‰ of 
good 
reads 
good 
reads 
‰ of 
good 
reads 
good 
reads 
‰ of 
good 
reads 
 5,381,269 3,775,151 4,436,757  5,710,310
mmu-let-7a-1-3p, 
mmu-let-7c-2-3p 63 0.01 22 0.01 2.01 93 0.02 52 0.01 2.30
mmu-let-7a-5p 41,255 7.67 18,219 4.83 1.59 27,034 6.09 19,687 3.45 1.77
mmu-let-7a-5p,  
mmu-let-7c-5p 122 0.02 113 0.03 0.76 311 0.07 116 0.02 3.45
mmu-let-7b-3p 25 0.00 2 0.00 8.77 21 0.00 12 0.00 2.25
mmu-let-7b-5p 16,312 3.03 5,872 1.56 1.95 27,601 6.22 16,891 2.96 2.10
mmu-let-7c-5p 33,524 6.23 13,516 3.58 1.74 39,557 8.92 26,053 4.56 1.95
mmu-let-7d-3p 454 0.08 168 0.04 1.90 1,923 0.43 1,218 0.21 2.03
mmu-let-7d-5p 2,790 0.52 1,619 0.43 1.21 1,454 0.33 1,815 0.32 1.03
mmu-let-7e-3p 26 0.00 7 0.00 2.61 39 0.01 15 0.00 3.35
mmu-let-7e-5p 5,950 1.11 2,387 0.63 1.75 4,530 1.02 1,865 0.33 3.13
mmu-let-7f-2-3p 41 0.01 23 0.01 1.25 58 0.01 43 0.01 1.74
mmu-let-7f-5p 42,422 7.88 42,569 11.28 0.70 36,019 8.12 27,564 4.83 1.68
mmu-let-7g-5p 12,689 2.36 11,051 2.93 0.81 2,990 0.67 7,736 1.35 0.50
mmu-let-7i-5p 13,809 2.57 7,849 2.08 1.23 10,489 2.36 6,920 1.21 1.95
mmu-miR-100-5p 426 0.08 131 0.03 2.28 521 0.12 272 0.05 2.47
mmu-miR-101a-3p 296 0.06 122 0.03 1.70 254 0.06 210 0.04 1.56
mmu-miR-101a-3p, 
mmu-miR-101c 14,770 2.74 7,352 1.95 1.41 11,694 2.64 12,966 2.27 1.16
mmu-miR-101b-3p 1,038 0.19 643 0.17 1.13 655 0.15 806 0.14 1.05
mmu-miR-101c 9,487 1.76 7,214 1.91 0.92 8,019 1.81 11,534 2.02 0.89
mmu-miR-103-3p 3,275 0.61 2,440 0.65 0.94 1,233 0.28 2,543 0.45 0.62
mmu-miR-103-3p, 
mmu-miR-107-3p 339 0.06 426 0.11 0.56 319 0.07 809 0.14 0.51
mmu-miR-106b-3p 125 0.02 83 0.02 1.06 98 0.02 107 0.02 1.18
mmu-miR-106b-5p 43 0.01 28 0.01 1.08 28 0.01 28 0.00 1.29
mmu-miR-107-3p 175 0.03 348 0.09 0.35 67 0.02 398 0.07 0.22
mmu-miR-10a-3p 50 0.01 40 0.01 0.88 47 0.01 92 0.02 0.66
mmu-miR-10a-5p 1,299,061 241.40 860,036 227.81 1.06 1,158,586 261.13 1,292,589 226.36 1.15
mmu-miR-10b-5p 1,342,787 249.53 756,932 200.50 1.24 991,872 223.56 997,889 174.75 1.28
mmu-miR-1198-5p 70 0.01 60 0.02 0.82 153 0.03 256 0.04 0.77
mmu-miR-1247-5p    2 0.00 29 0.01 0.09
mmu-miR-125a-3p 8 0.00 3 0.00 1.87 25 0.01 19 0.00 1.69
mmu-miR-125a-5p 8,639 1.61 2,912 0.77 2.08 11,467 2.58 6,081 1.06 2.43
mmu-miR-125b-2-3p 59 0.01 44 0.01 0.94 11 0.00 69 0.01 0.21
mmu-miR-125b-5p 396 0.07 313 0.08 0.89 582 0.13 784 0.14 0.96
mmu-miR-126-3p 7,271 1.35 512 0.14 9.96 14,215 3.20 1,104 0.19 16.57
mmu-miR-126-5p 18,476 3.43 900 0.24 14.40 20,770 4.68 2,000 0.35 13.37
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miRNA 
Glomeruli Tubules 
Ratio 
Glom/ 
Tub 
Glomeruli Tubules 
Ratio 
Glom/ 
Tub 
total RNA Total RNA small RNA small RNA 
good 
reads 
‰ of 
good 
reads 
good 
reads 
‰ of 
good 
reads 
good 
reads 
‰ of 
good 
reads 
good 
reads 
‰ of 
good 
reads 
 5,381,269 3,775,151 4,436,757  5,710,310
mmu-miR-127-3p 26,515 4.93 1,122 0.30 16.58 24,763 5.58 1,775 0.31 17.96
mmu-miR-128-3p 32 0.01 47 0.01 0.48 29 0.01 143 0.03 0.26
mmu-miR-130a-3p 867 0.16 242 0.06 2.51 492 0.11 447 0.08 1.42
mmu-miR-132-3p 314 0.06 30 0.01 7.34 108 0.02 32 0.01 4.34
mmu-miR-133a-3p 70 0.01 4 0.00 12.28 33 0.01 16 0.00 2.65
mmu-miR-134-5p 21 0.00 2 0.00 7.37 30 0.01 1 0.00 38.61
mmu-miR-139-3p 44 0.01 5 0.00 6.17 340 0.08 22 0.00 19.89
mmu-miR-139-5p 297 0.06 22 0.01 9.47 141 0.03 26 0.00 6.98
mmu-miR-140-3p 2,300 0.43 1,767 0.47 0.91 1,387 0.31 2,512 0.44 0.71
mmu-miR-143-3p 1,075,605 199.88 84,425 22.36 8.94 969,109 218.43 157,049 27.50 7.94
mmu-miR-143-5p 17 0.00 5 0.00 2.39 72 0.02 8 0.00 11.58
mmu-miR-145-5p 2,860 0.53 178 0.05 11.27 195 0.04 81 0.01 3.10
mmu-miR-146a-5p 437 0.08 85 0.02 3.61 3,999 0.90 574 0.10 8.97
mmu-miR-146b-5p 5,365 1.00 992 0.26 3.79 5,264 1.19 1,935 0.34 3.50
mmu-miR-148a-3p 4,470 0.83 2,162 0.57 1.45 1,368 0.31 2,069 0.36 0.85
mmu-miR-148b-3p 1,132 0.21 1,318 0.35 0.60 109 0.02 542 0.09 0.26
mmu-miR-149-5p 70 0.01 49 0.01 1.00 25 0.01 41 0.01 0.78
mmu-miR-150-5p 523 0.10 47 0.01 7.81 387 0.09 76 0.01 6.55
mmu-miR-151-3p 4,631 0.86 1,561 0.41 2.08 10,885 2.45 4,955 0.87 2.83
mmu-miR-151-5p 3,216 0.60 1,006 0.27 2.24 2,924 0.66 1,977 0.35 1.90
mmu-miR-152-3p 1,340 0.25 675 0.18 1.39 512 0.12 812 0.14 0.81
mmu-miR-152-5p 399 0.07 216 0.06 1.30 276 0.06 337 0.06 1.05
mmu-miR-15a-5p 314 0.06 109 0.03 2.02 156 0.04 202 0.04 0.99
mmu-miR-15b-5p 74 0.01 67 0.02 0.77 9 0.00 46 0.01 0.25
mmu-miR-16-5p 5,047 0.94 2,034 0.54 1.74 1,598 0.36 2,222 0.39 0.93
mmu-miR-17-5p 30 0.01 24 0.01 0.88 5 0.00 19 0.00 0.34
mmu-miR-181a-1-3p 183 0.03 145 0.04 0.89 103 0.02 191 0.03 0.69
mmu-miR-181a-5p 39,180 7.28 18,799 4.98 1.46 35,869 8.08 39,948 7.00 1.16
mmu-miR-181b-5p 2,348 0.44 2,202 0.58 0.75 1,359 0.31 3,946 0.69 0.44
mmu-miR-181c-3p 74 0.01 43 0.01 1.21 69 0.02 68 0.01 1.31
mmu-miR-181c-5p 2,737 0.51 769 0.20 2.50 1,562 0.35 1,237 0.22 1.63
mmu-miR-181d-5p 356 0.07 140 0.04 1.78 295 0.07 222 0.04 1.71
mmu-miR-182-5p 428 0.08 4,456 1.18 0.07 197 0.04 5,356 0.94 0.05
mmu-miR-183-5p 219 0.04 1,152 0.31 0.13 151 0.03 1,773 0.31 0.11
mmu-miR-1839-5p 386 0.07 776 0.21 0.35 117 0.03 529 0.09 0.28
mmu-miR-1843-3p 35 0.01 34 0.01 0.72 13 0.00 72 0.01 0.23
mmu-miR-1843-5p 197 0.04 156 0.04 0.89 204 0.05 275 0.05 0.95
mmu-miR-1843-5p, 
mmu-miR-1843b-5p 125 0.02 124 0.03 0.71 144 0.03 228 0.04 0.81
mmu-miR-1843b-5p 97 0.02 72 0.02 0.95 117 0.03 170 0.03 0.89
mmu-miR-184-3p 113 0.02 53 0.01 1.50 98 0.02 135 0.02 0.93
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mmu-miR-185-3p 5 0.00 23 0.01 0.15 8 0.00 53 0.01 0.19
mmu-miR-185-5p 59 0.01 257 0.07 0.16 49 0.01 236 0.04 0.27
mmu-miR-186-5p 311 0.06 104 0.03 2.10 275 0.06 492 0.09 0.72
mmu-miR-190-5p 5 0.00 199 0.05 0.02 3 0.00 172 0.03 0.02
mmu-miR-191-5p 8,505 1.58 6,414 1.70 0.93 7,043 1.59 10,601 1.86 0.86
mmu-miR-192-5p 942 0.18 16,630 4.41 0.04 722 0.16 25,275 4.43 0.04
mmu-miR-194-5p 66 0.01 523 0.14 0.09 19 0.00 744 0.13 0.03
mmu-miR-195-3p 84 0.02 5 0.00 11.79 103 0.02 11 0.00 12.05
mmu-miR-195-5p 1,371 0.25 149 0.04 6.46 356 0.08 133 0.02 3.45
mmu-miR-196a-5p 1,773 0.33 2,208 0.58 0.56 555 0.13 1,268 0.22 0.56
mmu-miR-196b-5p 1,193 0.22 1,557 0.41 0.54 770 0.17 887 0.16 1.12
mmu-miR-1981-5p 19 0.00 54 0.01 0.25 22 0.00 210 0.04 0.13
mmu-miR-199a-3p, 
mmu-miR-199b-3p 2,736 0.51 243 0.06 7.90 973 0.22 259 0.05 4.84
mmu-miR-19a-3p 39 0.01 12 0.00 2.28 38 0.01 71 0.01 0.69
mmu-miR-19b-3p 495 0.09 123 0.03 2.82 270 0.06 534 0.09 0.65
mmu-miR-1a-3p 1,193 0.22 162 0.04 5.17 382 0.09 67 0.01 7.34
mmu-miR-200a-3p 304 0.06 5,126 1.36 0.04 142 0.03 6,676 1.17 0.03
mmu-miR-200a-5p 19 0.00 281 0.07 0.05 5 0.00 318 0.06 0.02
mmu-miR-200b-3p 170 0.03 3,374 0.89 0.04 261 0.06 8,239 1.44 0.04
mmu-miR-200c-3p 22 0.00 382 0.10 0.04 50 0.01 1,218 0.21 0.05
mmu-miR-203-3p 138 0.03 340 0.09 0.28 48 0.01 400 0.07 0.15
mmu-miR-204-5p 632 0.12 389 0.10 1.14 190 0.04 403 0.07 0.61
mmu-miR-205-5p 9 0.00 71 0.02 0.09 1 0.00 108 0.02 0.01
mmu-miR-20a-5p 98 0.02 93 0.02 0.74 35 0.01 71 0.01 0.63
mmu-miR-210-3p 32 0.01 18 0.00 1.25 29 0.01 39 0.01 0.96
mmu-miR-21-5p 4,046 0.75 10,579 2.80 0.27 890 0.20 8,037 1.41 0.14
mmu-miR-218-5p 5 0.00 95 0.03 0.04 4 0.00 113 0.02 0.05
mmu-miR-221-3p 161 0.03 241 0.06 0.47 94 0.02 592 0.10 0.20
mmu-miR-222-3p 664 0.12 1,431 0.38 0.33 735 0.17 4,582 0.80 0.21
mmu-miR-22-3p 14,742 2.74 17,655 4.68 0.59 33,150 7.47 66,147 11.58 0.65
mmu-miR-224-5p 30 0.01 9 0.00 2.34 24 0.01 30 0.01 1.03
mmu-miR-23a-3p 3,286 0.61 321 0.09 7.18 513 0.12 383 0.07 1.72
mmu-miR-23b-3p 12,617 2.34 1,155 0.31 7.66 1,442 0.33 1,069 0.19 1.74
mmu-miR-23b-3p, 
mmu-miR-23a-3p 29 0.01 7 0.00 2.91 15 0.00 6 0.00 3.22
mmu-miR-24-2-5p 81 0.02 7 0.00 8.12 62 0.01 19 0.00 4.20
mmu-miR-24-3p 10,906 2.03 1,228 0.33 6.23 4,810 1.08 2,236 0.39 2.77
mmu-miR-25-3p 2,709 0.50 1,237 0.33 1.54 725 0.16 1,395 0.24 0.67
mmu-miR-26a-5p 58,229 10.82 14,473 3.83 2.82 21,052 4.74 18,816 3.30 1.44
mmu-miR-26b-5p 6,252 1.16 2,936 0.78 1.49 896 0.20 1,991 0.35 0.58
mmu-miR-27a-3p 2,728 0.51 343 0.09 5.58 949 0.21 325 0.06 3.76
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mmu-miR-27a-5p 42 0.01 2 0.00 14.73 44 0.01 7 0.00 8.09
mmu-miR-27b-3p 61,434 11.42 9,252 2.45 4.66 53,473 12.05 14,268 2.50 4.82
mmu-miR-27b-3p, 
mmu-miR-27a-3p 79 0.01 12 0.00 4.62 67 0.02 21 0.00 4.11
mmu-miR-27b-5p 85 0.02 11 0.00 5.42 284 0.06 39 0.01 9.37
mmu-miR-28-3p 183 0.03 182 0.05 0.71 91 0.02 194 0.03 0.60
mmu-miR-28-5p 37 0.01 35 0.01 0.74 23 0.01 36 0.01 0.82
mmu-miR-28-5p, 
mmu-miR-28c 208 0.04 168 0.04 0.87 144 0.03 244 0.04 0.76
mmu-miR-299-3p, 
mmu-miR-299b-3p 46 0.01 4 0.00 8.07 45 0.01 1 0.00 57.92
mmu-miR-29a-3p 1,623 0.30 669 0.18 1.70 2,202 0.50 1,674 0.29 1.69
mmu-miR-29b-3p 73 0.01 40 0.01 1.28 41 0.01 109 0.02 0.48
mmu-miR-29c-3p 429 0.08 148 0.04 2.03 503 0.11 406 0.07 1.59
mmu-miR-300-3p 76 0.01 1 0.00 53.32 33 0.01 
mmu-miR-301a-3p 78 0.01 45 0.01 1.22 13 0.00 67 0.01 0.25
mmu-miR-3068-5p 71 0.01 84 0.02 0.59 19 0.00 93 0.02 0.26
mmu-miR-30a-3p 4,234 0.79 1,790 0.47 1.66 3,396 0.77 3,000 0.53 1.46
mmu-miR-30a-5p 149,029 27.69 51,143 13.55 2.04 53,363 12.03 63,316 11.09 1.08
mmu-miR-30b-3p 35 0.01 11 0.00 2.23 44 0.01 38 0.01 1.49
mmu-miR-30b-5p 1,236 0.23 444 0.12 1.95 677 0.15 558 0.10 1.56
mmu-miR-30c-1-3p 14 0.00 25 0.01 0.39 33 0.01 85 0.01 0.50
mmu-miR-30c-2-3p 1,632 0.30 606 0.16 1.89 2,557 0.58 1,662 0.29 1.98
mmu-miR-30c-5p 4,313 0.80 3,064 0.81 0.99 2,748 0.62 4,950 0.87 0.71
mmu-miR-30d-3p 61 0.01 33 0.01 1.30 20 0.00 40 0.01 0.64
mmu-miR-30d-5p 29,149 5.42 12,954 3.43 1.58 15,116 3.41 22,349 3.91 0.87
mmu-miR-30e-3p 420 0.08 1,233 0.33 0.24 279 0.06 1,279 0.22 0.28
mmu-miR-30e-5p 4,057 0.75 11,397 3.02 0.25 1,722 0.39 15,183 2.66 0.15
mmu-miR-31-5p 23 0.00 55 0.01 0.29 23 0.01 92 0.02 0.32
mmu-miR-320-3p 1,254 0.23 779 0.21 1.13 1,676 0.38 1,341 0.23 1.61
mmu-miR-322-3p 1,623 0.30 97 0.03 11.74 865 0.19 146 0.03 7.63
mmu-miR-322-5p 440 0.08 25 0.01 12.35 101 0.02 33 0.01 3.94
mmu-miR-326-3p 30 0.01 5 0.00 4.21 27 0.01 7 0.00 4.96
mmu-miR-328-3p 253 0.05 191 0.05 0.93 422 0.10 600 0.11 0.91
mmu-miR-335-3p 241 0.04 18 0.00 9.39 41 0.01 11 0.00 4.80
mmu-miR-335-5p 156 0.03 12 0.00 9.12 103 0.02 18 0.00 7.36
mmu-miR-338-3p 94 0.02 6 0.00 10.99 75 0.02 6 0.00 16.09
mmu-miR-339-5p 33 0.01 24 0.01 0.96 41 0.01 52 0.01 1.01
mmu-miR-340-5p 495 0.09 756 0.20 0.46 128 0.03 811 0.14 0.20
mmu-miR-342-3p 147 0.03 51 0.01 2.02 13 0.00 33 0.01 0.51
mmu-miR-34a-5p 30 0.01 97 0.03 0.22 17 0.00 54 0.01 0.41
mmu-miR-350-5p 24 0.00 4 0.00 4.21 26 0.01 5 0.00 6.69
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mmu-miR-351-5p 2,633 0.49 137 0.04 13.48 3,239 0.73 329 0.06 12.67
mmu-miR-361-3p 27 0.01 11 0.00 1.72 26 0.01 24 0.00 1.39
mmu-miR-361-5p 108 0.02 57 0.02 1.33 120 0.03 159 0.03 0.97
mmu-miR-365-3p 258 0.05 386 0.10 0.47 224 0.05 550 0.10 0.52
mmu-miR-374-5p 28 0.01 30 0.01 0.65 32 0.01 25 0.00 1.65
mmu-miR-375-3p 38 0.01 619 0.16 0.04 65 0.01 2,061 0.36 0.04
mmu-miR-378-3p 9,418 1.75 32,214 8.53 0.21 9,549 2.15 56,099 9.82 0.22
mmu-miR-378b 28 0.01 59 0.02 0.33 12 0.00 69 0.01 0.22
mmu-miR-379-5p 715 0.13 46 0.01 10.90 446 0.10 13 0.00 44.16
mmu-miR-381-3p 128 0.02 4 0.00 22.45 38 0.01 5 0.00 9.78
mmu-miR-382-5p 64 0.01 6 0.00 7.48 27 0.01 6 0.00 5.79
mmu-miR-383-5p 29 0.01 83 0.02 0.25 28 0.01 228 0.04 0.16
mmu-miR-409-3p 69 0.01 1 0.00 48.41 116 0.03 8 0.00 18.66
mmu-miR-410-3p 53 0.01 3 0.00 12.39 12 0.00 3 0.00 5.15
mmu-miR-411-5p 211 0.04 9 0.00 16.45 196 0.04 7 0.00 36.04
mmu-miR-421-3p 14 0.00 32 0.01 0.31 7 0.00 74 0.01 0.12
mmu-miR-423-3p 378 0.07 379 0.10 0.70 453 0.10 1,128 0.20 0.52
mmu-miR-423-5p 425 0.08 386 0.10 0.77 878 0.20 630 0.11 1.79
mmu-miR-425-3p 41 0.01 43 0.01 0.67 43 0.01 60 0.01 0.92
mmu-miR-425-5p 50 0.01 83 0.02 0.42 38 0.01 162 0.03 0.30
mmu-miR-429-3p 72 0.01 1,325 0.35 0.04 75 0.02 2,584 0.45 0.04
mmu-miR-434-3p 199 0.04 7 0.00 19.94 73 0.02 18 0.00 5.22
mmu-miR-450a-5p 135 0.03 8 0.00 11.84 118 0.03 19 0.00 7.99
mmu-miR-450b-3p 34 0.01 4 0.00 5.96 6 0.00 1 0.00 7.72
mmu-miR-450b-5p 53 0.01 2 0.00 18.59 9 0.00 6 0.00 1.93
mmu-miR-455-5p 30 0.01 169 0.04 0.12 19 0.00 258 0.05 0.09
mmu-miR-484 914 0.17 738 0.20 0.87 432 0.10 642 0.11 0.87
mmu-miR-486-5p, 
mmu-miR-3107-5p 6,380 1.19 945 0.25 4.74 7,653 1.72 1,761 0.31 5.59
mmu-miR-497-5p 20 0.00 2 0.00 7.02 193 0.04 27 0.00 9.20
mmu-miR-503-5p 90 0.02 12 0.00 5.26 159 0.04 23 0.00 8.90
mmu-miR-5099 170 0.03 267 0.07 0.45 176 0.04 580 0.10 0.39
mmu-miR-532-5p 299 0.06 436 0.12 0.48 200 0.05 520 0.09 0.50
mmu-miR-541-5p 597 0.11 22 0.01 19.04 978 0.22 62 0.01 20.30
mmu-miR-542-3p 171 0.03 13 0.00 9.23 49 0.01 8 0.00 7.88
mmu-miR-574-3p 246 0.05 28 0.01 6.16 33 0.01 10 0.00 4.25
mmu-miR-574-5p 82 0.02 6 0.00 9.59 84 0.02 13 0.00 8.32
mmu-miR-598-3p 93 0.02 42 0.01 1.55 10 0.00 15 0.00 0.86
mmu-miR-615-3p 69 0.01 64 0.02 0.76 131 0.03 162 0.03 1.04
mmu-miR-652-3p 670 0.12 121 0.03 3.88 706 0.16 259 0.05 3.51
mmu-miR-664-5p 16 0.00 23 0.01 0.49 63 0.01 98 0.02 0.83
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mmu-miR-669c-5p 64 0.01 58 0.02 0.77 33 0.01 36 0.01 1.18
mmu-miR-671-3p 149 0.03 82 0.02 1.27 124 0.03 176 0.03 0.91
mmu-miR-672-5p 46 0.01 80 0.02 0.40 53 0.01 123 0.02 0.55
mmu-miR-676-3p 89 0.02 61 0.02 1.02 146 0.03 199 0.03 0.94
mmu-miR-676-5p 23 0.00 26 0.01 0.62 11 0.00 33 0.01 0.43
mmu-miR-744-5p 404 0.08 93 0.02 3.05 457 0.10 300 0.05 1.96
mmu-miR-7a-5p 69 0.01 180 0.05 0.27 31 0.01 68 0.01 0.59
mmu-miR-872-3p 46 0.01 44 0.01 0.73 32 0.01 61 0.01 0.68
mmu-miR-872-5p 108 0.02 105 0.03 0.72 59 0.01 141 0.02 0.54
mmu-miR-92a-3p 31,280 5.81 10,066 2.67 2.18 14,169 3.19 16,593 2.91 1.10
mmu-miR-9-5p 14 0.00 271 0.07 0.04 5 0.00 331 0.06 0.02
mmu-miR-98-5p 265 0.05 777 0.21 0.24 180 0.04 471 0.08 0.49
mmu-miR-99a-5p 375 0.07 393 0.10 0.67 589 0.13 852 0.15 0.89
mmu-miR-99b-3p 106 0.02 51 0.01 1.46 82 0.02 75 0.01 1.41
mmu-miR-99b-5p 24,751 4.60 10,139 2.69 1.71 26,197 5.90 16,620 2.91 2.03
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mmu-let-7a-1-3p, 
mmu-let-7c-2-3p 636 0.12 602 0.11 1.06 826 0.16 527 0.10 1.62
mmu-let-7a-5p 343,792 64.83 251,694 47.30 1.37 554,218 106.46 281,820 52.45 2.03
mmu-let-7a-5p,  
mmu-let-7c-5p 3,979 0.75 3,577 0.67 1.12 4,787 0.92 2,413 0.45 2.05
mmu-let-7b-3p 26 0.00 74 0.01 0.35 34 0.01 79 0.01 0.44
mmu-let-7b-5p 147,755 27.86 209,201 39.31 0.71 212,135 40.75 189,786 35.32 1.15
mmu-let-7c-5p 250,916 47.32 324,273 60.94 0.78 431,323 82.85 364,208 67.78 1.22
mmu-let-7d-3p 6,967 1.31 3,784 0.71 1.85 4,144 0.80 1,619 0.30 2.64
mmu-let-7d-5p 30,753 5.80 23,440 4.40 1.32 37,053 7.12 27,523 5.12 1.39
mmu-let-7e-3p 214 0.04 81 0.02 2.65 211 0.04 79 0.01 2.76
mmu-let-7e-5p 51,770 9.76 37,054 6.96 1.40 47,319 9.09 36,237 6.74 1.35
mmu-let-7f-2-3p 634 0.12 422 0.08 1.51 495 0.10 209 0.04 2.44
mmu-let-7f-5p 538,119101.48 408,158 76.70 1.32 551,521 105.94 363,598 67.67 1.57
mmu-let-7g-5p 30,231 5.70 54,258 10.20 0.56 83,554 16.05 71,891 13.38 1.20
mmu-let-7i-3p 33 0.01 49 0.01 0.68        
mmu-let-7i-5p 31,929 6.02 81,456 15.31 0.39 30,657 5.89 46,055 8.57 0.69
mmu-let-7k 111 0.02 164 0.03 0.68 158 0.03 145 0.03 1.12
mmu-miR-100-5p 10 0.00 206 0.04 0.05 2 0.00 365 0.07 0.01
mmu-miR-101a-3p 812 0.15 1,746 0.33 0.47 371 0.07 806 0.15 0.48
mmu-miR-101a-3p, 
mmu-miR-101c 51,740 9.76 76,830 14.44 0.68 50,791 9.76 44,912 8.36 1.17
mmu-miR-101b-3p 7,099 1.34 6,011 1.13 1.19 9,394 1.80 3,927 0.73 2.47
mmu-miR-101c 6,880 1.30 13,294 2.50 0.52 6,197 1.19 7,477 1.39 0.86
mmu-miR-103-3p 9,529 1.80 21,329 4.01 0.45 13,119 2.52 16,960 3.16 0.80
mmu-miR-103-3p, 
mmu-miR-107-3p 2,828 0.53 5,054 0.95 0.56 2,102 0.40 3,515 0.65 0.62
mmu-miR-106b-3p 311 0.06 601 0.11 0.52 370 0.07 517 0.10 0.74
mmu-miR-106b-5p 169 0.03 230 0.04 0.74 297 0.06 182 0.03 1.68
mmu-miR-107-3p 2.513 0.47 530 0.10 4.76 3.170 0.61 788 0.15 4.15
mmu-miR-10a-3p 40 0.01 704 0.13 0.06 40 0.01 491 0.09 0.08
mmu-miR-10a-5p 38,001 7.17 583,123 109.58 0.07 55,607 10.68 652,874 121.50 0.09
mmu-miR-10b-5p 428,640 80.83 173,877 32.67 2.47 529,253 101.66 348,000 64.76 1.57
mmu-miR-1198-5p 250 0.05 460 0.09 0.55 279 0.05 535 0.10 0.54
mmu-miR-122-5p       10 0.00 45 0.01 0.23
mmu-miR-125a-3p 170 0.03 141 0.03 1.21 102 0.02 98 0.02 1.07
mmu-miR-125a-5p 6,102 1.15 3,523 0.66 1.74 12,728 2.44 4,506 0.84 2.92
mmu-miR-125b-2-3p 436 0.08 70 0.01 6.25 248 0.05 59 0.01 4.34
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mmu-miR-125b-5p 952 0.18 333 0.06 2.87 1,273 0.24 642 0.12 2.05
mmu-miR-1249-3p        20 0.00 77 0.01 0.27
mmu-miR-126-3p 37 0.01 62,042 11.66 0.00 17 0.00 56,544 10.52 0.00
mmu-miR-126-5p 96 0.02 137,998 25.93 0.00 38 0.01 93,880 17.47 0.00
mmu-miR-127-3p 9 0.00 21,542 4.05 0.00 4 0.00 3,792 0.71 0.00
mmu-miR-127-5p   519 0.10    104 0.02  
mmu-miR-128-3p 53 0.01 91 0.02 0.58 72 0.01 84 0.02 0.88
mmu-miR-129-5p 21 0.00 481 0.09 0.04 26 0.00 328 0.06 0.08
mmu-miR-130a-3p 4.660 0.88 994 0.19 4.70 3,059 0.59 998 0.19 3.16
mmu-miR-132-3p 408 0.08 1,478 0.28 0.28 285 0.05 1,627 0.30 0.18
mmu-miR-133a-3p 2 0.00 1,268 0.24 0.00 2 0.00 613 0.11 0.00
mmu-miR-134-5p   337 0.06    130 0.02  
mmu-miR-136-3p   92 0.02         
mmu-miR-139-3p 3 0.00 1,600 0.30 0.00   972 0.18  
mmu-miR-139-5p 5 0.00 1,635 0.31 0.00   1,457 0.27  
mmu-miR-140-3p 3,348 0.63 7,536 1.42 0.45 2,741 0.53 6,700 1.25 0.42
mmu-miR-140-5p 256 0.05 397 0.07 0.65 178 0.03 433 0.08 0.42
mmu-miR-1249-3p          126 0.02  
mmu-miR-143-3p 26,606 5.02 457,545 85.98 0.06 16,557 3.18 415,094 77.25 0.04
mmu-miR-143-5p 13 0.00 103 0.02 0.13 5 0.00 162 0.03 0.03
mmu-miR-145a-3p       9 0.00 93 0.02 0.10
mmu-miR-145a-5p 16 0.00 317 0.06 0.05 61 0.01 745 0.14 0.08
mmu-miR-146a-5p 25 0.00 3,807 0.72 0.01 20 0.00 2,278 0.42 0.01
mmu-miR-146b-5p 13,295 2.51 542 0.10 24.62 7,755 1.49 455 0.08 17.59
mmu-miR-148a-3p 6,333 1.19 1,376 0.26 4.62 5,082 0.98 2,292 0.43 2.29
mmu-miR-148b-3p 1,066 0.20 1,462 0.27 0.73 955 0.18 1,058 0.20 0.93
mmu-miR-149-5p 310 0.06 24 0.00 12.96 448 0.09 61 0.01 7.58
mmu-miR-150-5p 1 0.00 397 0.07 0.00 1 0.00 550 0.10 0.00
mmu-miR-151-3p 2,171 0.41 14,094 2.65 0.15 2,072 0.40 10,653 1.98 0.20
mmu-miR-151-5p 1,705 0.32 13,157 2.47 0.13 1,681 0.32 10,544 1.96 0.16
mmu-miR-152-3p 6,545 1.23 7,340 1.38 0.89 6,460 1.24 6,011 1.12 1.11
mmu-miR-152-5p 73 0.01 58 0.01 1.26 77 0.01 60 0.01 1.32
mmu-miR-154-5p   69 0.01         
mmu-miR-15a-5p 158 0.03 691 0.13 0.23 108 0.02 457 0.09 0.24
mmu-miR-15b-5p 63 0.01 132 0.02 0.48 86 0.02 82 0.02 1.08
mmu-miR-16-1-3p 15 0.00 50 0.01 0.30 20 0.00 42 0.01 0.49
mmu-miR-16-2-3p       33 0.01 54 0.01 0.63
mmu-miR-16-5p 2,012 0.38 5,927 1.11 0.34 2,307 0.44 6,465 1.20 0.37
mmu-miR-17-3p 40 0.01 62 0.01 0.65 18 0.00 40 0.01 0.46
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mmu-miR-17-5p 148 0.03 135 0.03 1.10 526 0.10 202 0.04 2.69
mmu-miR-181a-1-3p 320 0.06 775 0.15 0.41 423 0.08 697 0.13 0.63
mmu-miR-181a-5p 44,145 8.33 48,910 9.19 0.91 34,773 6.68 28,659 5.33 1.25
mmu-miR-181b-5p 4,911 0.93 9,007 1.69 0.55 4,415 0.85 5,996 1.12 0.76
mmu-miR-181c-3p 2 0.00 198 0.04 0.01   123 0.02  
mmu-miR-181c-5p 94 0.02 4,027 0.76 0.02 53 0.01 2,470 0.46 0.02
mmu-miR-181d-5p 6 0.00 936 0.18 0.01 16 0.00 712 0.13 0.02
mmu-miR-182-5p 18 0.00 1,286 0.24 0.01 11 0.00 2,250 0.42 0.01
mmu-miR-183-5p 3 0.00 132 0.02 0.02   192 0.04  
mmu-miR-1839-5p 1,122 0.21 1,014 0.19 1.11 2,419 0.46 1,131 0.21 2.21
mmu-miR-1843a-3p 515 0.10 311 0.06 1.66 534 0.10 377 0.07 1.46
mmu-miR-1843a-5p 427 0.08 354 0.07 1.21 453 0.09 287 0.05 1.63
mmu-miR-1843a-5p,                                  
mmu-miR-1843b-5p 459 0.09 308 0.06 1.50 538 0.10 190 0.04 2.92
mmu-miR-1843b-3p 150 0.03 123 0.02 1.22 102 0.02 96 0.02 1.10
mmu-miR-1843b-5p 418 0.08 330 0.06 1.27 341 0.07 230 0.04 1.53
mmu-miR-184-3p 46 0.01 117 0.02 0.39 54 0.01 117 0.02 0.48
mmu-miR-185-3p 38 0.01 66 0.01 0.58 39 0.01 37 0.01 1.09
mmu-miR-185-5p 151 0.03 220 0.04 0.69 165 0.03 226 0.04 0.75
mmu-miR-186-5p 588 0.11 610 0.11 0.97 445 0.09 379 0.07 1.21
mmu-miR-187-3p       20 0.00 42 0.01 0.49
mmu-miR-190a-5p       44 0.01 46 0.01 0.99
mmu-miR-190b-5p 16 0.00 69 0.01 0.23 37 0.01 54 0.01 0.71
mmu-miR-191-5p 4,267 0.80 3,615 0.68 1.18 3,590 0.69 3,622 0.67 1.02
mmu-miR-192-5p 315 0.06 208 0.04 1.52 271 0.05 146 0.03 1.92
mmu-miR-193a-5p 9 0.00 104 0.02 0.09 15 0.00 128 0.02 0.12
mmu-miR-1943-5p 8 0.00 63 0.01 0.13        
mmu-miR-194-5p 92 0.02 54 0.01 1.71 175 0.03 87 0.02 2.08
mmu-miR-194-2-3p       75 0.01 48 0.01 1.61
mmu-miR-195a-3p   464 0.09    215 0.04  
mmu-miR-195a-5p 4 0.00 1,358 0.26 0.00 2 0.00 1,476 0.27 0.00
mmu-miR-196a-5p 2,062 0.39 1,333 0.25 1.55 3,282 0.63 4,048 0.75 0.84
mmu-miR-196b-5p 4,904 0.92 908 0.17 5.42 9,553 1.83 1,396 0.26 7.06
mmu-miR-1966-3p       38 0.01 16 0.00 2.45
mmu-miR-1981-5p 206 0.04 196 0.04 1.05 170 0.03 231 0.04 0.76
mmu-miR-199a-3p,                                             
mmu-miR-199b-3p 366 0.07 3,475 0.65 0.11 639 0.12 4,950 0.92 0.13
mmu-miR-199a-5p   56 0.01         
mmu-miR-19a-3p 196 0.04 892 0.17 0.22 346 0.07 416 0.08 0.86
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mmu-miR-19b-3p 1,750 0.33 4,894 0.92 0.36 3,428 0.66 3,096 0.58 1.14
mmu-miR-1a-3p 45 0.01 11,056 2.08 0.00 52 0.01 6,815 1.27 0.01
mmu-miR-200a-3p 54 0.01 2,315 0.44 0.02 46 0.01 5,660 1.05 0.01
mmu-miR-200a-5p 2 0.00 59 0.01 0.03   139 0.03  
mmu-miR-200b-3p 34 0.01 1,093 0.21 0.03 21 0.00 6,198 1.15 0.00
mmu-miR-200b-5p       2 0.00 62 0.01 0.03
mmu-miR-200c-3p 2 0.00 636 0.12 0.00 11 0.00 2,479 0.46 0.00
mmu-miR-203-3p 236 0.04 1,296 0.24 0.18 534 0.10 1,581 0.29 0.35
mmu-miR-204-3p 5 0.00 96 0.02 0.05 2 0.00 94 0.02 0.02
mmu-miR-204-5p 200 0.04 4,648 0.87 0.04 272 0.05 7,460 1.39 0.04
mmu-miR-205-5p 13 0.00 223 0.04 0.06 1 0.00 192 0.04 0.01
mmu-miR-20a-5p 376 0.07 354 0.07 1.07 1,469 0.28 548 0.10 2.77
mmu-miR-210-3p 1,595 0.30 199 0.04 8.04 856 0.16 166 0.03 5.32
mmu-miR-218-5p   66 0.01    224 0.04  
mmu-miR-219-1-3p 42 0.01 40 0.01 1.05        
mmu-miR-21a-5p 7,418 1.40 16,657 3.13 0.45 7,822 1.50 15,671 2.92 0.52
mmu-miR-221-3p 44 0.01 1,908 0.36 0.02 99 0.02 2,829 0.53 0.04
mmu-miR-222-3p 25 0.00 1,943 0.37 0.01 24 0.00 1,857 0.35 0.01
mmu-miR-22-3p 86,470 16.31 31,672 5.95 2.74 52,295 10.05 28,347 5.28 1.90
mmu-miR-224-5p   86 0.02    54 0.01  
mmu-miR-22-5p 65 0.01 35 0.01 1.86 36 0.01 34 0.01 1.09
mmu-miR-23a-3p 1,746 0.33 9,443 1.77 0.19 2,180 0.42 7,369 1.37 0.31
mmu-miR-23a-5p 35 0.01 32 0.01 1.10 40 0.01 31 0.01 1.33
mmu-miR-23b-3p 20,360 3.84 8,916 1.68 2.29 22,111 4.25 7,866 1.46 2.90
mmu-miR-23b-3p,                                                 
mmu-miR-23a-3p 335 0.06 678 0.13 0.50 246 0.05 361 0.07 0.70
mmu-miR-24-1-5p 60 0.01 27 0.01 2.23 113 0.02 27 0.01 4.32
mmu-miR-24-2-5p 159 0.03 471 0.09 0.34 136 0.03 191 0.04 0.73
mmu-miR-24-3p 43,356 8.18 33,083 6.22 1.32 42,487 8.16 29,820 5.55 1.47
mmu-miR-25-3p 5,532 1.04 14,795 2.78 0.38 6,267 1.20 13,808 2.57 0.47
mmu-miR-26a-2-3p       58 0.01 17 0.00 3.52
mmu-miR-26a-5p 211,150 39.82 141,726 26.63 1.50 214,852 41.27 103,799 19.32 2.14
mmu-miR-26b-3p        54 0.01 16 0.00 3.48
mmu-miR-26b-5p 32,816 6.19 43,370 8.15 0.76 46,077 8.85 35,647 6.63 1.33
mmu-miR-27a-3p 1,278 0.24 6,425 1.21 0.20 821 0.16 3,022 0.56 0.28
mmu-miR-27a-5p 486 0.09 364 0.07 1.34 2.065 0.40 922 0.17 2.31
mmu-miR-27b-3p 125,181 23.61 84,018 15.79 1.50 78,425 15.06 46,432 8.64 1.74
mmu-miR-27b-3p, 
mmu-miR-27a-3p 4,008 0.76 4,003 0.75 1.00 2,943 0.57 2,780 0.52 1.09
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mmu-miR-27b-5p 847 0.16 339 0.06 2.51 760 0.15 279 0.05 2.81
mmu-miR-28a-3p 228 0.04 1,189 0.22 0.19 392 0.08 1,595 0.30 0.25
mmu-miR-28a-5p 36 0.01 112 0.02 0.32 32 0.01 187 0.03 0.18
mmu-miR-28a-5p,                                                      
mmu-miR-28c 193 0.04 820 0.15 0.24 130 0.02 744 0.14 0.18
mmu-miR-28c 31 0.01 125 0.02 0.25 28 0.01 107 0.02 0.27
mmu-miR-296-3p 23 0.00 32 0.01 0.72        
mmu-miR-298-5p 5 0.00 58 0.01 0.09        
mmu-miR-299a-3p,                                            
mmu-miR-299b-3p 1 0.00 558 0.10 0.00 2 0.00 166 0.03 0.01
mmu-miR-299b-3p   166 0.03    79 0.01  
mmu-miR-29a-3p 10,846 2.05 7,963 1.50 1.37 8,226 1.58 4,288 0.80 1.98
mmu-miR-29b-3p 234 0.04 187 0.04 1.26 75 0.01 71 0.01 1.09
mmu-miR-29c-3p 1,411 0.27 1,698 0.32 0.83 686 0.13 887 0.17 0.80
mmu-miR-300-3p   427 0.08    103 0.02  
mmu-miR-301a-3p 112 0.02 87 0.02 1.29 57 0.01 42 0.01 1.40
mmu-miR-3068-5p 31 0.01 26 0.00 1.20 52 0.01 17 0.00 3.16
mmu-miR-3096a-5p, 
mmu-miR-3096b-5p 69 0.01 96 0.02 0.72        
mmu-miR-3096b-5p 83 0.02 83 0.02 1.00        
mmu-miR-30a-3p 60,898 11.48 17,250 3.24 3.54 92,817 17.83 23,919 4.45 4.01
mmu-miR-30a-5p 1,080,588203.78 221,539 41.63 4.90 738,560 141.87 110,666 20.60 6.89
mmu-miR-30b-3p 623 0.12 195 0.04 3.21 946 0.18 237 0.04 4.12
mmu-miR-30b-5p 8,906 1.68 2,663 0.50 3.36 10,086 1.94 3,197 0.59 3.26
mmu-miR-30b-5p,  
mmu-miR-30c-5p 94 0.02 58 0.01 1.63 60 0.01 21 0.00 2.95
mmu-miR-30c-1-3p 63 0.01 69 0.01 0.92 90 0.02 139 0.03 0.67
mmu-miR-30c-2-3p 19,948 3.76 4,969 0.93 4.03 24,398 4.69 5,423 1.01 4.64
mmu-miR-30c-5p 36,253 6.84 11,104 2.09 3.28 58,989 11.33 14,980 2.79 4.06
mmu-miR-30d-3p 355 0.07 114 0.02 3.13 282 0.05 70 0.01 4.16
mmu-miR-30d-5p 146,004 27.53 27,942 5.25 5.24 127,730 24.54 24,399 4.54 5.40
mmu-miR-30e-3p 1,558 0.29 1,370 0.26 1.14 2,779 0.53 3,130 0.58 0.92
mmu-miR-30e-5p 12,171 2.30 8,685 1.63 1.41 7,907 1.52 6,984 1.30 1.17
mmu-miR-31-5p   59 0.01  2 0.00 169 0.03 0.01
mmu-miR-320-3p 1,439 0.27 3,967 0.75 0.36 2,810 0.54 3,795 0.71 0.76
mmu-miR-322-3p 14,940 2.82 1,810 0.34 8.28 13,469 2.59 3,093 0.58 4.49
mmu-miR-322-5p 1,374 0.26 1,194 0.22 1.15 528 0.10 910 0.17 0.60
mmu-miR-324-5p 28 0.01 26 0.00 1.08        
mmu-miR-326-3p 184 0.03 129 0.02 1.43 103 0.02 60 0.01 1.77
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mmu-miR-328-3p 4,426 0.83 2,862 0.54 1.55 3,806 0.73 2,782 0.52 1.41
mmu-miR-329-5p 2 0.00 283 0.05 0.01   117 0.02  
mmu-miR-330-3p 222 0.04 25 0.00 8.91 120 0.02 23 0.00 5.39
mmu-miR-330-5p 306 0.06 37 0.01 8.30 112 0.02 21 0.00 5.50
mmu-miR-335-3p 1 0.00 1,579 0.30 0.00   1,508 0.28  
mmu-miR-335-5p 4 0.00 1,800 0.34 0.00   1,680 0.31  
mmu-miR-338-3p 1 0.00 263 0.05 0.00   116 0.02  
mmu-miR-339-5p 397 0.07 1,077 0.20 0.37 212 0.04 592 0.11 0.37
mmu-miR-340-5p 3,535 0.67 1,281 0.24 2.77 3,263 0.63 925 0.17 3.64
mmu-miR-341-3p   93 0.02         
mmu-miR-342-3p 1 0.00 54 0.01 0.02 3 0.00 85 0.02 0.04
mmu-miR-3473b 5 0.00 62 0.01 0.08        
mmu-miR-34a-5p 276 0.05 357 0.07 0.78 396 0.08 242 0.05 1.69
mmu-miR-34c-5p 11 0.00 80 0.02 0.14        
mmu-miR-350-5p 59 0.01 178 0.03 0.33 55 0.01 126 0.02 0.45
mmu-miR-351-3p 54 0.01 3 0.00 18.06 46 0.01 15 0.00 3.17
mmu-miR-351-5p 8,439 1.59 1,332 0.25 6.36 5,192 1.00 1,400 0.26 3.83
mmu-miR-3535       240 0.05 233 0.04 1.06
mmu-miR-361-3p 254 0.05 391 0.07 0.65 228 0.04 335 0.06 0.70
mmu-miR-361-5p 173 0.03 318 0.06 0.55 125 0.02 282 0.05 0.46
mmu-miR-362-3p 123 0.02 142 0.03 0.87 50 0.01 66 0.01 0.78
mmu-miR-365-3p 13 0.00 121 0.02 0.11 5 0.00 155 0.03 0.03
mmu-miR-369-3p   78 0,01         
mmu-miR-374b-5p 84 0.02 35 0,01 2.41 73 0.01 45 0.01 1.67
mmu-miR-374b-5p,                                            
mmu-miR-374c-5p 100 0.02 69 0,01 1.45 85 0.02 45 0.01 1.95
mmu-miR-375-3p 2 0.00 207 0,04 0.01 5 0.00 1,164 0.22 0.00
mmu-miR-376b-3p   78 0,01         
mmu-miR-376c-3p   75 0,01         
mmu-miR-378a-3p 26,410 4.98 14,695 2,76 1.80 22,955 4.41 21,464 3.99 1.10
mmu-miR-378a-3p, 
mmu-miR-378c 3,205 0.60 1,686 0,32 1.91 1,916 0.37 2,055 0.38 0.96
mmu-miR-378a-3p, 
mmu-miR-378b,  
mmu-miR-378c       33 0.01 29 0.01 1.17
mmu-miR-378a-5p 115 0.02 75 0,01 1.54 78 0.01 50 0.01 1.61
mmu-miR-378b 212 0.04 161 0,03 1.32 274 0.05 152 0.03 1.86
mmu-miR-379-5p 7 0.00 5,558 1,04 0.00   2,489 0.46  
mmu-miR-381-3p   568 0,11  1 0.00 177 0.03 0.01
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mmu-miR-382-5p   758 0,14  2 0.00 539 0.10 0.00
mmu-miR-383-5p   78 0,01    68 0.01  
mmu-miR-409-3p   551 0,10    265 0.05  
mmu-miR-410-3p   226 0,04    104 0.02  
mmu-miR-411-3p   84 0,02         
mmu-miR-411-5p   1,486 0,28    627 0.12  
mmu-miR-421-3p 59 0.01 70 0,01 0.85 43 0.01 28 0.01 1.59
mmu-miR-423-3p 726 0.14 1,956 0,37 0.37 464 0.09 1,040 0.19 0.46
mmu-miR-423-5p 653 0.12 1,853 0,35 0.35 389 0.07 1,459 0.27 0.28
mmu-miR-425-3p 127 0.02 102 0,02 1.25 69 0.01 57 0.01 1.25
mmu-miR-425-5p 143 0.03 205 0,04 0.70 113 0.02 194 0.04 0.60
mmu-miR-429-3p 6 0.00 753 0,14 0.01 10 0.00 3,355 0.62 0.00
mmu-miR-433-3p   197 0,04    69 0.01  
mmu-miR-434-3p   1,396 0,26    897 0.17  
mmu-miR-434-5p   274 0,05    128 0.02  
mmu-miR-450a-5p 962 0.18 272 0,05 3.55 1,000 0.19 378 0.07 2.73
mmu-miR-450a-1-3p       35 0.01 30 0.01 1.20
mmu-miR-450b-3p 283 0.05 120 0,02 2.37 364 0.07 266 0.05 1.41
mmu-miR-450b-5p 334 0.06 64 0,01 5.24 296 0.06 64 0.01 4.77
mmu-miR-455-5p 3 0.00 143 0,03 0.02   113 0.02  
mmu-miR-455-5p         163 0.03  
mmu-miR-484 70 0.01 202 0,04 0.35 95 0.02 183 0.03 0.54
mmu-miR-485-5p   61 0,01         
mmu-miR-486-5p, 
mmu-miR-3107-5p 211 0.04 218 0,04 0.97 140 0.03 317 0.06 0.46
mmu-miR-488-3p   67 0,01         
mmu-miR-497-5p 4 0.00 688 0,13 0.01   391 0.07  
mmu-miR-503-3p 152 0.03 38 0,01 4.01 197 0.04 50 0.01 4.07
mmu-miR-503-5p 2,677 0.50 591 0,11 4.55 1,832 0.35 713 0.13 2.65
mmu-miR-5099 754 0.14 5,438 1,02 0.14 507 0.10 1,285 0.24 0.41
mmu-miR-5109 81 0.02 98 0,02 0.83        
mmu-miR-5117-3p 109 0.02 76 0,01 1.44        
mmu-miR-532-5p 1,704 0.32 2,527 0,47 0.68 1,532 0.29 2,099 0.39 0.75
mmu-miR-540-3p   116 0,02         
mmu-miR-541-5p 2 0.00 3,050 0,57 0.00   1,550 0.29  
mmu-miR-542-3p 1,829 0.34 550 0,10 3.34 3,334 0.64 626 0.12 5.50
mmu-miR-542-5p 100 0.02 41 0,01 2.45 42 0.01 43 0.01 1.01
mmu-miR-543-3p   333 0,06    70 0.01  
mmu-miR-574-3p 1,473 0.28 369 0,07 4.01 2,017 0.39 725 0.13 2.87
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mmu-miR-574-5p 498 0.09 330 0,06 1.51 307 0.06 366 0.07 0.87
mmu-miR-598-3p 173 0.03 584 0,11 0.30 161 0.03 515 0.10 0.32
mmu-miR-615-3p 167 0.03 21 0,00 7.98 134 0.03 45 0.01 3.07
mmu-miR-615-5p 49 0.01 12 0,00 4.10        
mmu-miR-6240 25 0.00 39 0,01 0.64 2 0.00 62 0.01 0.03
mmu-miR-6243 174 0.03 251 0,05 0.70        
mmu-miR-652-3p 878 0.17 315 0,06 2.80 847 0.16 278 0.05 3.14
mmu-miR-664-3p       67 0.01 42 0.01 1.65
mmu-miR-664-5p 166 0.03 110 0,02 1.51 98 0.02 85 0.02 1.19
mmu-miR-669c-5p 153 0.03 110 0,02 1.40 405 0.08 359 0.07 1.16
mmu-miR-671-3p 492 0.09 257 0,05 1.92 448 0.09 255 0.05 1.81
mmu-miR-672-5p 99 0.02 511 0,10 0.19 74 0.01 638 0.12 0.12
mmu-miR-673-5p   126 0,02         
mmu-miR-674-3p 29 0.01 66 0,01 0.44 39 0.01 90 0.02 0.45
mmu-miR-676-3p 895 0.17 380 0,07 2.36 858 0.16 692 0.13 1.28
mmu-miR-676-5p 57 0.01 20 0,00 2.86 43 0.01 39 0.01 1.14
mmu-miR-709       8 0.00 64 0.01 0.13
mmu-miR-744-5p 3,493 0.66 3,769 0,71 0.93 1,411 0.27 1,449 0.27 1.01
mmu-miR-7a-5p 181 0.03 522 0,10 0.35 481 0.09 475 0.09 1.05
mmu-miR-8103       19 0.00 59 0.01 0.33
mmu-miR-872-3p 33 0.01 63 0,01 0.53 44 0.01 42 0.01 1.08
mmu-miR-872-5p 424 0.08 578 0,11 0.74 343 0.07 430 0.08 0.82
mmu-miR-873a-5p 170 0.03     80 0.02 1 0.00 82.57
mmu-miR-874-3p       15 0.00 59 0.01 0.26
mmu-miR-92a-1-5p 25 0.00 74 0,01 0.34 25 0.00 74 0.01 0.35
mmu-miR-92a-3p 32,326 6.10 80,733 15,17 0.40 38,591 7.41 93,747 17.45 0.42
mmu-miR-92b-3p 493 0.09 190 0,04 2.60 111 0.02 259 0.05 0.44
mmu-miR-92b-5p 463 0.09 76 0,01 6.11 81 0.02 63 0.01 1.33
mmu-miR-93-5p 1,924 0.36 1,857 0,35 1.04 4,921 0.95 1,798 0.33 2.82
mmu-miR-9-5p 13 0.00 993 0,19 0.01 7 0.00 1,446 0.27 0.00
mmu-miR-98-3p       29 0.01 27 0.01 1.11
mmu-miR-98-5p 2,581 0.49 3,625 0.68 0.71 2,699 0.52 2,793 0.52 1.00
mmu-miR-99a-3p 495 0.09 64 0.01 7.76 169 0.03 33 0.01 5.29
mmu-miR-99a-5p 795 0.15 134 0.03 5.95 485 0.09 182 0.03 2.75
mmu-miR-99b-3p 1,273 0.24 797 0.15 1.60 970 0.19 460 0.09 2.18
mmu-miR-99b-5p 7,750 1.46 8,455 1.59 0.92 9,927 1.91 10,472 1.95 0.98
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Tab. 10.3: Alignment of RT-PCR products with mRNA sequences of potential human target genes;  
cDNA from RNA derived from proliferating hPCLs; top rows: sequenced products; bottom rows: 
sequence of mRNA transcripts; 
Potential 
Target 
Sequence 
used for 
BLAST 
Alignment 
E2F1 NM_005225 GCCTGGGTGATTTATTTATTGGGAAAGTGAGGGAGG   
|||||||||||||||||||||||||||||||||||| 
GCCTGGGTGATTTATTTATTGGGAAAGTGAGGGAGG   
CD2AP NM_012120 AGGCTGGTGGAGTGGAACCCTGAATAACAAGTTGGGACTGTTTCCCTCAAA   
||||||||||||||||||||||||||||||||||||||||||||||||||| 
AGGCTGGTGGAGTGGAACCCTGAATAACAAGTTGGGACTGTTTCCCTCAAA   
FYN NM_002037 CCGCGACAGAGCCCCAGTACCAACCTGGTGAAAACCTGTAAGGCC   
||||||||||||||||||||||||||||||||||||||||||||| 
CCGCGACAGAGCCCCAGTACCAACCTGGTGAAAACCTGTAAGGCC   
NCK2 NM_003581 GGCCGAGCGGGAGGATGAGTTGTCCCTGGTGA   
|||||||||||||||||||||||||||||||| 
GGCCGAGCGGGAGGATGAGTTGTCCCTGGTGA   
NEPH1 NM_018240 GGGATAGCCTGGCCAGTCCCTCTGTT   
|||||||||||||||||||||||||| 
GGGATAGCCTGGCCAGTCCCTCTGTT 
 
Tab. 10.4: Alignment of RT-PCR products with mRNA sequences of potential murine target genes;  
cDNA from RNA derived from proliferating hPCLs; top rows: sequenced products; bottom rows: 
sequence of mRNAs; 
Potential 
target gene 
Sequence  used 
for alignment 
Alignment 
E2f1 NM_007891 GGGGTTTGGTTGCTGCCACATTGAGCAGACCAAAATGGGAAGGATGTTG          
||||||||||||||||||||||||||||||||||||||||||||||||| 
GGGGTTTGGTTGCTGCCACATTGAGCAGACCAAAATGGGAAGGATGTTG   
Cd2ap NM_009847 ACCGTTGCCATCTCCGGGGAATGGGAGTGAACCTGCTCCCGGATCAGTTGCACA             
|||||||||||||||||||||||||||||||||||||||||||||||||||||| 
ACCGTTGCCATCTCCGGGGAATGGGAGTGAACCTGCTCCCGGATCAGTTGCACA   
Fyn NM_008054 AGATTGCTGACTTTGGATTGGCTCGGTTGATTGAAGA 
||||||||||||||||||||||||||||||||||||| 
AGATTGCTGACTTTGGATTGGCTCGGTTGATTGAAGA 
Nck2 NM_010879 AATTTTTCCAGTCACCTCTTGTAACTGCGTGCCAAA 
|||||||||||||||||||||||||||||||||||| 
AATTTTTCCAGTCACCTCTTGTAACTGCGTGCCAAA 
Neph1 NM_130867 AGTAGGTCCCTCCTATGGAAATAAGAGCAGCACTAAGGAGAACTCTGAGAGTCAAGCGCA              
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
AGTAGGTCCCTCCTATGGAAATAAGAGCAGCACTAAGGAGAACTCTGAGAGTCAAGCGCA   
 
CAGCCATGCGAGGGACAGGAAACAG 
||||||||||||||||||||||||| 
CAGCCATGCGAGGGACAGGAAACAG 
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Tab. 10.5: miRNA expression in Cre- control mice and Cre+ Lmx1b knockout mice  
miRNA 
Cre- Control mice Cre+ Lmx1b-KO mice 
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16,483,415 26,499,566 14,350,712 28,671,121
mmu-let-7a 329,353 19.98 433,901 16.37 441,238 30.75 389,478 13.58 1.54 0.83
mmu-let-7a, 
mmu-let-7b,  
mmu-let-7c 
258 0.02 1,184 0.04 132 0.01 1,017 0.04 0.59 0.79
mmu-let-7a,  
mmu-let-7c 
5,017 0.30 17,355 0.65 7,060 0.49 15,450 0.54 1.62 0.82
mmu-let-7a-1*, 
mmu-let-7c-2* 
188 0.01 2,919 0.11 151 0.01 3,450 0.12 0.92 1.09
mmu-let-7b 119,980 7.28 244,374 9.22 186,472 12.99 282,348 9.85 1.79 1.07
mmu-let-7b* 186 0.01 756 0.03 183 0.01 1,687 0.06 1.13 2.06
mmu-let-7c 208,655 12.66 455,783 17.20 269,706 18.79 459,478 16.03 1.48 0.93
mmu-let-7c-1*   68 0.00  58 0.00 0.79
mmu-let-7d 14,510 0.88 38,195 1.44 18,300 1.28 34,004 1.19 1.45 0.82
mmu-let-7d* 6,464 0.39 46,553 1.76 8,808 0.61 76,591 2.67 1.57 1.52
mmu-let-7e 26,693 1.62 47,002 1.77 31,713 2.21 61,650 2.15 1.36 1.21
mmu-let-7e* 56 0.00 668 0.03 140 0.01 909 0.03 2.87 1.26
mmu-let-7f 215,092 13.05 648,555 24.47 184,519 12.86 506,785 17.68 0.99 0.72
mmu-let-7f-1* 19 0.00 251 0.01 47 0.00 338 0.01 2.84 1.24
mmu-let-7f-2* 3 0.00 366 0.01  441 0.02 1.11
mmu-let-7g 71,068 4.31 55,398 2.09 58,877 4.10 43,651 1.52 0.95 0.73
mmu-let-7g*   7 0.00  28 0.00 3.70
mmu-let-7g,  
mmu-let-7i 
25 0.00 73 0.00 1 0.00 94 0.00 0.05 1.19
mmu-let-7g,  
mmu-miR-3962 
  4 0.00  5 0.00 1.16
mmu-let-7i 19,561 1.19 37,221 1.40 11,737 0.82 31,591 1.10 0.69 0.78
mmu-let-7i* 1 0.00 168 0.01 55 0.00 196 0.01 63.17 1.08
mmu-miR-100 3,533 0.21 5,317 0.20 2,400 0.17 6,783 0.24 0.78 1.18
mmu-miR-101a 243 0.01 1,600 0.06 120 0.01 1,162 0.04 0.57 0.67
mmu-miR-101a* 16 0.00 52 0.00 1 0.00 25 0.00 0.07 0.44
mmu-miR-101a,  
mmu-miR-101b 
  16 0.00  21 0.00 1.21
mmu-miR-101a,  
mmu-miR-101c 
8,017 0.49 25,259 0.95 5,140 0.36 22,057 0.77 0.74 0.81
mmu-miR-101b 732 0.04 2,170 0.08 443 0.03 1,660 0.06 0.70 0.71
mmu-miR-101c 8,937 0.54 30,826 1.16 6,986 0.49 28,324 0.99 0.90 0.85
mmu-miR-103 2,572 0.16 5,316 0.20 1,471 0.10 4,637 0.16 0.66 0.81
mmu-miR-103,  
mmu-miR-107 
188 0.01 733 0.03 388 0.03 424 0.01 2.37 0.53
mmu-miR-106b 200 0.01 299 0.01 219 0.02 574 0.02 1.26 1.77
mmu-miR-106b* 125 0.01 777 0.03 63 0.00 536 0.02 0.58 0.64
mmu-miR-107 167 0.01 264 0.01  62 0.00 0.22
mmu-miR-107*       16 0.00  
mmu-miR-10a 1,298,399 78.77 4,658,335 175.79 1,130,198 78.76 4,824,35
6
168.27 1.00 0.96
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16,483,415 26,499,566 14,350,712 28,671,121
mmu-miR-10a* 121 0.01 1,001 0.04 210 0.01 705 0.02 1.99 0.65
mmu-miR-10b 798,042 48.41 4,025,869 151.92 835,609 58.23 5,176,02
8
180.53 1.20 1.19
mmu-miR-10b*   202 0.01 71 0.00 251 0.01 1.15
mmu-miR-1186b   15 0.00      
mmu-miR-1187 24 0.00 18 0.00      
mmu-miR-1191 10 0.00        
mmu-miR-1193-3p   80 0.00  86 0.00 0.99
mmu-miR-1194 21 0.00    1 0.00  
mmu-miR-1195 51 0.00 340 0.01 17 0.00 246 0.01 0.38 0.67
mmu-miR-1196 12 0.00 70 0.00 1 0.00 55 0.00 0.10 0.73
mmu-miR-1198-5p 369 0.02 1,487 0.06 290 0.02 1,176 0.04 0.90 0.73
mmu-miR-1199   9 0.00      
mmu-miR-122     22 0.00    
mmu-miR-1247   16 0.00  29 0.00 1.68
mmu-miR-1249 183 0.01 50 0.00 99 0.01 121 0.00 0.62 2.24
mmu-miR-125a-3p 66 0.00 203 0.01 19 0.00 158 0.01 0.33 0.72
mmu-miR-125a-5p 35,991 2.18 132,335 4.99 52,410 3.65 230,763 8.05 1.67 1.61
mmu-miR-125b-1-3p   61 0.00      
mmu-miR-125b-2-3p 49 0.00 134 0.01  202 0.01 1.39
mmu-miR-125b-5p 4,339 0.26 16,172 0.61 4,784 0.33 20,684 0.72 1.27 1.18
mmu-miR-126-3p 20,417 1.24 249,701 9.42 28,995 2.02 214,712 7.49 1.63 0.79
mmu-miR-126-5p 33,115 2.01 509,117 19.21 47,552 3.31 467,650 16.31 1.65 0.85
mmu-miR-127 682,210 41.39 734,753 27.73 505,247 35.21 687,951 23.99 0.85 0.87
mmu-miR-127*   6 0.00 34 0.00 37 0.00 5.70
mmu-miR-128 93 0.01 391 0.01 149 0.01 320 0.01 1.84 0.76
mmu-miR-128-1* 19 0.00    24 0.00  
mmu-miR-129-1-3p   58 0.00  59 0.00 0.94
mmu-miR-129-2-3p   6 0.00      
mmu-miR-129-5p 40 0.00 162 0.01 63 0.00 108 0.00 1.81 0.62
mmu-miR-1306-3p   13 0.00  36 0.00 2.56
mmu-miR-1306-5p 7 0.00 29 0.00  17 0.00 0.54
mmu-miR-130a 1,090 0.07 16,617 0.63 1,136 0.08 14,878 0.52 1.20 0.83
mmu-miR-130a*   36 0.00  61 0.00 1.57
mmu-miR-130b 19 0.00 106 0.00  122 0.00 1.06
mmu-miR-130b* 18 0.00 253 0.01 48 0.00 144 0.01 3.06 0.53
mmu-miR-132 239 0.01 1,767 0.07 601 0.04 1,157 0.04 2.89 0.61
mmu-miR-132* 25 0.00 44 0.00  251 0.01 5.27
mmu-miR-133a 71 0.00 173 0.01 62 0.00 289 0.01 1.00 1.54
mmu-miR-133a,  
mmu-miR-133b 
  74 0.00  80 0.00 1.00
mmu-miR-134 158 0.01 212 0.01 132 0.01 311 0.01 0.96 1.36
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16,483,415 26,499,566 14,350,712 28,671,121
mmu-miR-134*   37 0.00  8 0.00 0.20
mmu-miR-135a   4 0.00  30 0.00 6.93
mmu-miR-136 19 0.00 128 0.00  129 0.00 0.93
mmu-miR-136* 44 0.00 999 0.04  854 0.03 0.79
mmu-miR-138   11 0.00      
mmu-miR-139-3p 284 0.02 2,115 0.08 201 0.01 3,445 0.12 0.81 1.51
mmu-miR-139-5p 1,133 0.07 4,861 0.18 1,119 0.08 5,476 0.19 1.13 1.04
mmu-miR-140 41 0.00 294 0.01  120 0.00 0.38
mmu-miR-140* 1,590 0.10 4,727 0.18 1,586 0.11 5,200 0.18 1.15 1.02
mmu-miR-141 48 0.00 427 0.02 60 0.00 244 0.01 1.44 0.53
mmu-miR-142-3p 25 0.00 210 0.01 40 0.00 58 0.00 1.84 0.26
mmu-miR-142-5p 218 0.01 2,560 0.10 120 0.01 2,201 0.08 0.63 0.79
mmu-miR-143 1,118,613 67.86 3,587,001 135.36 790,543 55.09 3,526,83
9
123.01 0.81 0.91
mmu-miR-143* 33 0.00 209 0.01  402 0.01 1.78
mmu-miR-144 38 0.00 113 0.00 64 0.00 94 0.00 1.93 0.77
mmu-miR-144*   14 0.00      
mmu-miR-145 33,375 2.02 54,323 2.05 40,392 2.81 72,925 2.54 1.39 1.24
mmu-miR-145* 2,395 0.15 19,001 0.72 3,985 0.28 19,144 0.67 1.91 0.93
mmu-miR-146a 943 0.06 64,991 2.45 2,730 0.19 60,210 2.10 3.33 0.86
mmu-miR-146a,  
mmu-miR-146b 
10 0.00 969 0.04 61 0.00 992 0.03 7.01 0.95
mmu-miR-146b 2,470 0.15 14,684 0.55 3,706 0.26 24,201 0.84 1.72 1.52
mmu-miR-148a 2,195 0.13 7,367 0.28 2,169 0.15 8,889 0.31 1.14 1.12
mmu-miR-148a* 40 0.00 45 0.00  116 0.00 2.38
mmu-miR-148b 1,885 0.11 2,436 0.09 1,276 0.09 1,903 0.07 0.78 0.72
mmu-miR-148b*   30 0.00      
mmu-miR-149 544 0.03 803 0.03 533 0.04 843 0.03 1.13 0.97
mmu-miR-150 4,816 0.29 12,200 0.46 5,961 0.42 15,033 0.52 1.42 1.14
mmu-miR-150*   9 0.00      
mmu-miR-151-3p 6,062 0.37 74,465 2.81 9,818 0.68 84,051 2.93 1.86 1.04
mmu-miR-151-5p 7,367 0.45 50,645 1.91 12,516 0.87 47,985 1.67 1.95 0.88
mmu-miR-152 3,475 0.21 14,563 0.55 4,361 0.30 10,714 0.37 1.44 0.68
mmu-miR-152* 259 0.02 920 0.03 279 0.02 1,809 0.06 1.24 1.82
mmu-miR-154 13 0.00 3 0.00      
mmu-miR-154*   15 0.00      
mmu-miR-155 9 0.00 27 0.00  39 0.00 1.34
mmu-miR-15a 559 0.03 2,827 0.11 927 0.06 2,666 0.09 1.90 0.87
mmu-miR-15b 705 0.04 1,663 0.06 542 0.04 900 0.03 0.88 0.50
mmu-miR-15b* 15 0.00 142 0.01 116 0.01  8.88 
mmu-miR-16 10,542 0.64 44,092 1.66 9,699 0.68 34,326 1.20 1.06 0.72
mmu-miR-16-1*   21 0.00  12 0.00 0.53
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16,483,415 26,499,566 14,350,712 28,671,121
mmu-miR-16-2*   58 0.00      
mmu-miR-17 101 0.01 95 0.00 69 0.00 138 0.00 0.78 1.34
mmu-miR-17* 19 0.00 95 0.00  66 0.00 0.64
mmu-miR-181a 19,149 1.16 87,386 3.30 21,917 1.53 74,755 2.61 1.31 0.79
mmu-miR-181a-1* 165 0.01 453 0.02 188 0.01 371 0.01 1.31 0.76
mmu-miR-181a-2*   51 0.00  88 0.00 1.59
mmu-miR-181b 1,394 0.08 4,468 0.17 1,206 0.08 4,341 0.15 0.99 0.90
mmu-miR-181b-1*   9 0.00 67 0.00 31 0.00 3.18
mmu-miR-181c 695 0.04 4,213 0.16 664 0.05 4,316 0.15 1.10 0.95
mmu-miR-181c* 32 0.00 83 0.00 97 0.01 162 0.01 3.48 1.80
mmu-miR-181d 264 0.02 614 0.02 122 0.01 687 0.02 0.53 1.03
mmu-miR-182 380 0.02 1,913 0.07 504 0.04 1,724 0.06 1.52 0.83
mmu-miR-183 865 0.05 901 0.03 352 0.02 703 0.02 0.47 0.72
mmu-miR-1839-3p 31 0.00 7 0.00  31 0.00 4.09
mmu-miR-1839-5p 733 0.04 1,423 0.05 246 0.02 708 0.02 0.39 0.46
mmu-miR-184   123 0.00 98 0.01 400 0.01 3.01
mmu-miR-1843-3p 91 0.01 497 0.02 62 0.00 516 0.02 0.78 0.96
mmu-miR-1843-5p 80 0.00 392 0.01 56 0.00 269 0.01 0.80 0.63
mmu-miR-1843-5p, 
mmu-miR-1843b-5p 
116 0.01 347 0.01  254 0.01 0.68
mmu-miR-1843b-3p 31 0.00 228 0.01 144 0.01 216 0.01 5.34 0.88
mmu-miR-1843b-5p 43 0.00 153 0.01  14 0.00 0.08
mmu-miR-185 356 0.02 659 0.02 362 0.03 806 0.03 1.17 1.13
mmu-miR-185* 13 0.00 36 0.00  71 0.00 1.82
mmu-miR-186 177 0.01 3,054 0.12 384 0.03 3,037 0.11 2.49 0.92
mmu-miR-187 63 0.00 411 0.02  368 0.01 0.83
mmu-miR-187* 36 0.00 90 0.00 50 0.00 57 0.00 1.60 0.59
mmu-miR-188-3p   10 0.00      
mmu-miR-188-5p   24 0.00  13 0.00 0.50
mmu-miR-1892       17 0.00  
mmu-miR-18a   9 0.00 52 0.00    
mmu-miR-190   65 0.00      
mmu-miR-190*   27 0.00      
mmu-miR-190b   11 0.00      
mmu-miR-191 22,076 1.34 107,527 4.06 23,465 1.64 99,680 3.48 1.22 0.86
mmu-miR-191* 39 0.00 180 0.01  233 0.01 1.20
mmu-miR-192 6,431 0.39 22,915 0.86 3,820 0.27 12,763 0.45 0.68 0.51
mmu-miR-193 7 0.00 47 0.00  101 0.00 1.99
mmu-miR-193* 30 0.00 85 0.00 46 0.00 57 0.00 1.76 0.62
mmu-miR-1930   9 0.00      
mmu-miR-1931   15 0.00      
mmu-miR-1933-3p   9 0.00      
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mmu-miR-1934*       18 0.00  
mmu-miR-1936 1 0.00        
mmu-miR-193b 62 0.00 123 0.00 151 0.01 77 0.00 2.80 0.58
mmu-miR-193b*   6 0.00  30 0.00 4.62
mmu-miR-194 574 0.03 734 0.03 523 0.04 285 0.01 1.05 0.36
mmu-miR-1940 970 0.06 66 0.00 2,850 0.20 78 0.00 3.37 1.09
mmu-miR-1941-3p       107 0.00  
mmu-miR-1941-5p   31 0.00  73 0.00 2.18
mmu-miR-194-2*   2 0.00  25 0.00 11.55
mmu-miR-1943 398 0.02 1,412 0.05 452 0.03 2,135 0.07 1.30 1.40
mmu-miR-1943*     45 0.00    
mmu-miR-1946a   9 0.00      
mmu-miR-1946a, 
mmu-miR-1946b 
17 0.00        
mmu-miR-1947 18 0.00 16 0.00      
mmu-miR-195* 29 0.00 521 0.02 87 0.01 739 0.03 3.45 1.31
mmu-miR-1951   10 0.00      
mmu-miR-1954   5 0.00      
mmu-miR-1955-5p   33 0.00  34 0.00 0.95
mmu-miR-1964-3p   155 0.01  122 0.00 0.73
mmu-miR-1965   4 0.00      
mmu-miR-1966       32 0.00  
mmu-miR-1968   12 0.00  61 0.00 4.70
mmu-miR-196a 3,394 0.21 7,285 0.27 2,485 0.17 6,778 0.24 0.84 0.86
mmu-miR-196a-1*   9 0.00      
mmu-miR-196a-2*   26 0.00  72 0.00 2.56
mmu-miR-196b 1,014 0.06 2,023 0.08 705 0.05 1,924 0.07 0.80 0.88
mmu-miR-1981 84 0.01 160 0.01  386 0.01 2.23
mmu-miR-1981* 7 0.00 43 0.00 1 0.00 100 0.00 0.16 2.15
mmu-miR-1982.1, 
mmu-miR-1982.2 
     29 0.00 
mmu-miR-1983   9 0.00      
mmu-miR-199a-3p, 
mmu-miR-199b 
3,013 0.18 33,618 1.27 4,272 0.30 32,710 1.14 1.63 0.90
mmu-miR-199a-5p 1,540 0.09 3,587 0.14 1,588 0.11 4,693 0.16 1.18 1.21
mmu-miR-199b*   2 0.00 2 0.00 35 0.00 16.17
mmu-miR-19a 56 0.00 128 0.00  359 0.01 2.59
mmu-miR-19b 1,030 0.06 1,261 0.05 232 0.02 3,265 0.11 0.26 2.39
mmu-miR-19b-1* 10 0.00        
mmu-miR-1a 5,606 0.34 5,641 0.21 2,423 0.17 4,173 0.15 0.50 0.68
mmu-miR-1b-3p 13 0.00        
mmu-miR-200a 598 0.04 4,188 0.16 93 0.01 1,449 0.05 0.18 0.32
mmu-miR-200a* 140 0.01 167 0.01 46 0.00 111 0.00 0.38 0.61
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mmu-miR-200b 770 0.05 6,601 0.25 176 0.01 2,683 0.09 0.26 0.38
mmu-miR-200b* 22 0.00 200 0.01  1 0.00 0.00
mmu-miR-200c 246 0.01 707 0.03  256 0.01 0.33
mmu-miR-203 774 0.05 658 0.02 161 0.01 350 0.01 0.24 0.49
mmu-miR-203*     54 0.00    
mmu-miR-204 3,485 0.21 10,290 0.39 2,999 0.21 10,315 0.36 0.99 0.93
mmu-miR-204*   26 0.00      
mmu-miR-205 15 0.00 31 0.00      
mmu-miR-20a 85 0.01 205 0.01 88 0.01 185 0.01 1.19 0.83
mmu-miR-20a*   18 0.00 41 0.00 17 0.00 0.87
mmu-miR-20b   1 0.00      
mmu-miR-21 4,576 0.28 12,458 0.47 2,806 0.20 10,455 0.36 0.70 0.78
mmu-miR-21*   26 0.00      
mmu-miR-210 50 0.00 116 0.00 73 0.01 169 0.01 1.68 1.35
mmu-miR-210* 20 0.00 23 0.00      
mmu-miR-211   8 0.00  2 0.00 0.23
mmu-miR-212-3p 81 0.00 87 0.00  45 0.00 0.48
mmu-miR-212-5p 128 0.01 980 0.04 231 0.02 791 0.03 2.07 0.75
mmu-miR-2137 14 0.00    1 0.00  
mmu-miR-214 522 0.03 1,502 0.06 641 0.04 1,140 0.04 1.41 0.70
mmu-miR-214* 47 0.00 78 0.00  74 0.00 0.88
mmu-miR-215   18 0.00  31 0.00 1.59
mmu-miR-216b   14 0.00      
mmu-miR-218   143 0.01      
mmu-miR-218-1*   12 0.00      
mmu-miR-219-3p* 20 0.00 142 0.01 34 0.00 188 0.01 1.95 1.22
mmu-miR-22 10,888 0.66 100,511 3.79 14,540 1.01 118,201 4.12 1.53 1.09
mmu-miR-22* 36 0.00 4 0.00 76 0.01 30 0.00 2.42 6.93
mmu-miR-221 144 0.01 884 0.03 260 0.02 843 0.03 2.07 0.88
mmu-miR-221* 28 0.00 131 0.00  284 0.01 2.00
mmu-miR-222 216 0.01 1,811 0.07 190 0.01 2,579 0.09 1.01 1.32
mmu-miR-222* 14 0.00 44 0.00 63 0.00 34 0.00 5.17 0.71
mmu-miR-223 104 0.01 744 0.03 150 0.01 730 0.03 1.66 0.91
mmu-miR-223* 7 0.00    41 0.00  
mmu-miR-224 50 0.00 604 0.02 141 0.01 621 0.02 3.24 0.95
mmu-miR-224*   14 0.00      
mmu-miR-23a 8,656 0.53 45,003 1.70 15,906 1.11 41,650 1.45 2.11 0.86
mmu-miR-23a*   10 0.00  57 0.00 5.27
mmu-miR-23b 23,909 1.45 98,629 3.72 53,022 3.69 97,985 3.42 2.55 0.92
mmu-miR-23b* 33 0.00 172 0.01  188 0.01 1.01
mmu-miR-23b,  
mmu-miR-23a 
127 0.01 1,336 0.05 295 0.02 1,185 0.04 2.67 0.82
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mmu-miR-24 20,211 1.23 107,157 4.04 25,634 1.79 128,607 4.49 1.46 1.11
mmu-miR-24-1* 69 0.00 134 0.01 50 0.00 253 0.01 0.83 1.75
mmu-miR-24-2* 477 0.03 2,360 0.09 734 0.05 2,739 0.10 1.77 1.07
mmu-miR-25 2,583 0.16 6,169 0.23 2,396 0.17 4,723 0.16 1.07 0.71
mmu-miR-25* 16 0.00 104 0.00  190 0.01 1.69
mmu-miR-26a 82,760 5.02 455,141 17.18 87,123 6.07 411,157 14.34 1.21 0.83
mmu-miR-26a-1*   81 0.00 49 0.00 29 0.00 0.33
mmu-miR-26a-2* 30 0.00 42 0.00 64 0.00 54 0.00 2.45 1.19
mmu-miR-26b 12,616 0.77 21,918 0.83 7,496 0.52 14,103 0.49 0.68 0.59
mmu-miR-26b* 386 0.02 1,648 0.06 537 0.04 1,132 0.04 1.60 0.63
mmu-miR-27a 9,463 0.57 43,317 1.63 19,336 1.35 50,733 1.77 2.35 1.08
mmu-miR-27a* 42 0.00 168 0.01 44 0.00 227 0.01 1.20 1.25
mmu-miR-27b 102,065 6.19 358,974 13.55 136,149 9.49 340,264 11.87 1.53 0.88
mmu-miR-27b* 144 0.01 696 0.03 318 0.02 874 0.03 2.54 1.16
mmu-miR-27b,  
mmu-miR-27a 
605 0.04 7,214 0.27 748 0.05 8,897 0.31 1.42 1.14
mmu-miR-28 99 0.01 367 0.01 1 0.00 199 0.01 0.01 0.50
mmu-miR-28* 729 0.04 979 0.04 784 0.05 1,301 0.05 1.24 1.23
mmu-miR-28, 
mmu-miR-28c 
363 0.02 2,036 0.08 583 0.04 1,823 0.06 1.84 0.83
mmu-miR-28c 35 0.00 120 0.00 2 0.00 132 0.00 0.07 1.02
mmu-miR-296-3p 24 0.00 49 0.00  35 0.00 0.66
mmu-miR-296-5p   18 0.00      
mmu-miR-297b-5p   14 0.00      
mmu-miR-298   30 0.00  152 0.01 4.68
mmu-miR-299 60 0.00 47 0.00 135 0.01 132 0.00 2.58 2.60
mmu-miR-299* 22 0.00 44 0.00  163 0.01 3.42
mmu-miR-29a 4,261 0.26 76,287 2.88 7,795 0.54 78,483 2.74 2.10 0.95
mmu-miR-29a*   32 0.00  35 0.00 1.01
mmu-miR-29b 678 0.04 5,900 0.22 1,341 0.09 5,437 0.19 2.27 0.85
mmu-miR-29b,  
mmu-miR-29c 
35 0.00 20 0.00  49 0.00 2.26
mmu-miR-29b-1* 16 0.00 7 0.00      
mmu-miR-29b-2*   11 0.00  29 0.00 2.44
mmu-miR-29c 653 0.04 15,839 0.60 875 0.06 18,730 0.65 1.54 1.09
mmu-miR-29c* 14 0.00  17 0.00 22 0.00 1.39 
mmu-miR-300 38 0.00 140 0.01 59 0.00 275 0.01 1.78 1.82
mmu-miR-301a 59 0.00 374 0.01 49 0.00 398 0.01 0.95 0.98
mmu-miR-301a*   27 0.00  31 0.00 1.06
mmu-miR-3057-5p 61 0.00 120 0.00 72 0.01 35 0.00 1.36 0.27
mmu-miR-3058 22 0.00 4 0.00      
mmu-miR-3062 5 0.00        
mmu-miR-3064-3p 4 0.00 2 0.00      
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mmu-miR-3064-5p 10 0.00 12 0.00  68 0.00 5.24
mmu-miR-3068 62 0.00 325 0.01 213 0.01 451 0.02 3.95 1.28
mmu-miR-3068*   9 0.00  1 0.00 0.10
mmu-miR-3076-3p       46 0.00  
mmu-miR-3081   27 0.00  62 0.00 2.12
mmu-miR-3082-3p 13 0.00 25 0.00      
mmu-miR-3083*   4 0.00      
mmu-miR-3086-5p   73 0.00  122 0.00 1.54
mmu-miR-3087   12 0.00      
mmu-miR-3087*   21 0.00      
mmu-miR-3096-5p 75 0.00 16 0.00 82 0.01 38 0.00 1.26 2.20
mmu-miR-3096-5p, 
mmu-miR-3096b-5p 
17,864 1.08 31 0.00 11,032 0.77 147 0.01 0.71 4.38
mmu-miR-3096b-5p 24,957 1.51 12 0.00 17,012 1.19 162 0.01 0.78 12.48
mmu-miR-30a 363,847 22.07 531,009 20.04 394,925 27.52 562,411 19.62 1.25 0.98
mmu-miR-30a* 4,854 0.29 25,426 0.96 5,633 0.39 18,234 0.64 1.33 0.66
mmu-miR-30a*,  
mmu-miR-30e* 
1 0.00 44 0.00 1 0.00 2 0.00 1.15 0.04
mmu-miR-30b 2,976 0.18 25,477 0.96 3,689 0.26 15,255 0.53 1.42 0.55
mmu-miR-30b* 86 0.01 346 0.01 61 0.00 538 0.02 0.81 1.44
mmu-miR-30b,  
mmu-miR-30c 
65 0.00 101 0.00  60 0.00 0.55
mmu-miR-30c 10,702 0.65 98,037 3.70 14,256 0.99 94,186 3.29 1.53 0.89
mmu-miR-30c-1* 26 0.00 117 0.00 58 0.00 161 0.01 2.56 1.27
mmu-miR-30c-2* 1,148 0.07 10,142 0.38 1,039 0.07 12,185 0.42 1.04 1.11
mmu-miR-30d 170,860 10.37 345,010 13.02 206,643 14.40 318,133 11.10 1.39 0.85
mmu-miR-30d*   443 0.02  260 0.01 0.54
mmu-miR-30e 17,728 1.08 37,934 1.43 14,258 0.99 34,504 1.20 0.92 0.84
mmu-miR-30e* 622 0.04 3,779 0.14 554 0.04 1,596 0.06 1.02 0.39
mmu-miR-31 22 0.00 58 0.00      
mmu-miR-3102 1,074 0.07 735 0.03 1,450 0.10 817 0.03 1.55 1.03
mmu-miR-3102-3p.2 14 0.00 78 0.00 95 0.01 204 0.01 7.79 2.42
mmu-miR-3102-5p.2   30 0.00  112 0.00 3.45
mmu-miR-3103   7 0.00      
mmu-miR-3105-3p 72 0.00 38 0.00      
mmu-miR-3109   15 0.00      
mmu-miR-3110       30 0.00  
mmu-miR-3112   17 0.00      
mmu-miR-3112*   18 0.00      
mmu-miR-32 48 0.00 237 0.01  95 0.00 0.37
mmu-miR-320 1,830 0.11 2,338 0.09 1,864 0.13 2,436 0.08 1.17 0.96
mmu-miR-322 770 0.05 3,753 0.14 1,011 0.07 3,444 0.12 1.51 0.85
mmu-miR-322* 10,212 0.62 41,696 1.57 13,678 0.95 38,682 1.35 1.54 0.86
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mmu-miR-323-3p 11 0.00 26 0.00  28 0.00 1.00
mmu-miR-324-3p   84 0.00      
mmu-miR-324-5p 21 0.00 37 0.00  299 0.01 7.47
mmu-miR-326 79 0.00 485 0.02 280 0.02 592 0.02 4.07 1.13
mmu-miR-328 1,364 0.08 8,577 0.32 1,870 0.13 10,431 0.36 1.57 1.12
mmu-miR-328*   3 0.00      
mmu-miR-329   62 0.00 47 0.00 149 0.01 2.22
mmu-miR-329*   13 0.00 50 0.00 37 0.00 2.63
mmu-miR-33   26 0.00  93 0.00 3.31
mmu-miR-330   139 0.01  116 0.00 0.77
mmu-miR-330* 15 0.00 96 0.00  42 0.00 0.40
mmu-miR-331-3p 101 0.01 156 0.01 357 0.02 139 0.00 4.06 0.82
mmu-miR-331-5p   13 0.00      
mmu-miR-335-3p 774 0.05 1,953 0.07 798 0.06 1,583 0.06 1.18 0.75
mmu-miR-335-5p 488 0.03 2,581 0.10 689 0.05 1,365 0.05 1.62 0.49
mmu-miR-337-3p   11 0.00      
mmu-miR-338-3p 51 0.00 722 0.03 57 0.00 957 0.03 1.28 1.23
mmu-miR-338-5p 40 0.00 285 0.01 132 0.01 206 0.01 3.79 0.67
mmu-miR-339-3p   109 0.00  78 0.00 0.66
mmu-miR-339-5p 42 0.00 246 0.01 73 0.01 139 0.00 2.00 0.52
mmu-miR-340-3p   115 0.00 55 0.00 80 0.00 0.64
mmu-miR-340-5p 468 0.03 679 0.03 58 0.00 534 0.02 0.14 0.73
mmu-miR-341   12 0.00  33 0.00 2.54
mmu-miR-342-3p 3,570 0.22 2,786 0.11 1,785 0.12 2,153 0.08 0.57 0.71
mmu-miR-342-5p 21 0.00 43 0.00  63 0.00 1.35
mmu-miR-345-3p       28 0.00  
mmu-miR-345-5p 13 0.00 61 0.00 78 0.01 57 0.00 6.89 0.86
mmu-miR-3470a 156 0.01 95 0.00 5 0.00 125 0.00 0.04 1.22
mmu-miR-3470a, 
mmu-miR-3470b 
6 0.00    29 0.00  
mmu-miR-3470b 514 0.03 402 0.02 124 0.01 410 0.01 0.28 0.94
mmu-miR-3471   40 0.00      
mmu-miR-3473 1 0.00 13 0.00 57 0.00 15 0.00 65.47 1.07
mmu-miR-3473,  
mmu-miR-3473b 
30 0.00        
mmu-miR-3473b 389 0.02 3,364 0.13 773 0.05 5,481 0.19 2.28 1.51
mmu-miR-3474   32 0.00 42 0.00    
mmu-miR-3475   11 0.00      
mmu-miR-34a 103 0.01 169 0.01 91 0.01 179 0.01 1.01 0.98
mmu-miR-34a* 10 0.00 2 0.00  8 0.00 3.70
mmu-miR-34b-3p 104 0.01 125 0.00  189 0.01 1.40
mmu-miR-34b-5p   54 0.00  36 0.00 0.62
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mmu-miR-34c 136 0.01 951 0.04 350 0.02 976 0.03 2.96 0.95
mmu-miR-34c* 23 0.00 14 0.00  74 0.00 4.89
mmu-miR-350 89 0.01 48 0.00 28 0.00 33 0.00 0.36 0.64
mmu-miR-350* 14 0.00    100 0.00  
mmu-miR-351 21,676 1.32 38,131 1.44 16,224 1.13 39,112 1.36 0.86 0.95
mmu-miR-351* 103 0.01 865 0.03 102 0.01 1,423 0.05 1.14 1.52
mmu-miR-3572       10 0.00  
mmu-miR-361 101 0.01 1,566 0.06 172 0.01 1,181 0.04 1.96 0.70
mmu-miR-361* 39 0.00 209 0.01 21 0.00 234 0.01 0.62 1.03
mmu-miR-362-3p   24 0.00      
mmu-miR-362-5p 6 0.00 25 0.00  115 0.00 4.25
mmu-miR-363-3p 19 0.00 15 0.00  30 0.00 1.85
mmu-miR-363-5p   6 0.00      
mmu-miR-365 1,294 0.08 4,168 0.16 1,500 0.10 4,795 0.17 1.33 1.06
mmu-miR-365-2* 22 0.00 43 0.00  64 0.00 1.38
mmu-miR-369-3p   15 0.00 60 0.00    
mmu-miR-369-5p   33 0.00  21 0.00 0.59
mmu-miR-370 1 0.00 46 0.00 55 0.00 33 0.00 63.17 0.66
mmu-miR-374 129 0.01 780 0.03 172 0.01 876 0.03 1.53 1.04
mmu-miR-374,  
mmu-miR-374c 
96 0.01 403 0.02 115 0.01 563 0.02 1.38 1.29
mmu-miR-374c   14 0.00 1 0.00 2 0.00 0.13
mmu-miR-375 105 0.01 1,603 0.06 166 0.01 1,017 0.04 1.82 0.59
mmu-miR-376a   20 0.00 51 0.00 92 0.00 4.25
mmu-miR-376b 15 0.00 62 0.00 67 0.00 85 0.00 5.13 1.27
mmu-miR-376b*   45 0.00  92 0.00 1.89
mmu-miR-376c   15 0.00  68 0.00 4.19
mmu-miR-377 16 0.00 33 0.00 41 0.00 54 0.00 2.94 1.51
mmu-miR-377* 17 0.00        
mmu-miR-378 24,783 1.50 54,879 2.07 10,549 0.74 54,551 1.90 0.49 0.92
mmu-miR-378* 29 0.00 63 0.00 52 0.00 67 0.00 2.06 0.98
mmu-miR-378,  
mmu-miR-378b 
159 0.01 342 0.01 136 0.01 257 0.01 0.98 0.69
mmu-miR-378b 66 0.00 210 0.01 46 0.00 75 0.00 0.80 0.33
mmu-miR-379 2,088 0.13 3,568 0.13 1,471 0.10 3,001 0.10 0.81 0.78
mmu-miR-379*   15 0.00      
mmu-miR-380-3p 42 0.00 199 0.01 67 0.00 204 0.01 1.83 0.95
mmu-miR-380-5p 23 0.00        
mmu-miR-381 45 0.00 74 0.00 245 0.02 71 0.00 6.25 0.89
mmu-miR-382 206 0.01 158 0.01 238 0.02 181 0.01 1.33 1.06
mmu-miR-382*   12 0.00      
mmu-miR-383 14 0.00 50 0.00  111 0.00 2.05
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16,483,415 26,499,566 14,350,712 28,671,121
mmu-miR-3960   8 0.00  1 0.00 0.12
mmu-miR-3962 7 0.00 2 0.00 4 0.00 1 0.00 0.66 0.46
mmu-miR-3963 2 0.00 3 0.00  1 0.00 0.31
mmu-miR-409-3p 623 0.04 2,513 0.09 550 0.04 2,330 0.08 1.01 0.86
mmu-miR-409-5p 17 0.00 65 0.00 30 0.00  2.03 
mmu-miR-410   25 0.00  126 0.00 4.66
mmu-miR-411 196 0.01 1,402 0.05 320 0.02 1,121 0.04 1.88 0.74
mmu-miR-411* 35 0.00 241 0.01  57 0.00 0.22
mmu-miR-421 41 0.00 838 0.03  792 0.03 0.87
mmu-miR-423-3p 381 0.02 12,483 0.47 1,140 0.08 17,243 0.60 3.44 1.28
mmu-miR-423-5p 546 0.03 5,282 0.20 1,051 0.07 10,093 0.35 2.21 1.77
mmu-miR-425 51 0.00 740 0.03 73 0.01 735 0.03 1.64 0.92
mmu-miR-425* 77 0.00 794 0.03 59 0.00 755 0.03 0.88 0.88
mmu-miR-429 484 0.03 1,983 0.07 43 0.00 788 0.03 0.10 0.37
mmu-miR-431   8 0.00  33 0.00 3.81
mmu-miR-431*       8 0.00  
mmu-miR-433   144 0.01  171 0.01 1.10
mmu-miR-434-3p 1,369 0.08 2,727 0.10 1,750 0.12 2,653 0.09 1.47 0.90
mmu-miR-434-5p 21 0.00 342 0.01  363 0.01 0.98
mmu-miR-449a   45 0.00 69 0.00 17 0.00 0.35
mmu-miR-450a 262 0.02 2,746 0.10 453 0.03 2,892 0.10 1.99 0.97
mmu-miR-450a-1*   81 0.00 41 0.00 74 0.00 0.84
mmu-miR-450b-3p 35 0.00 102 0.00  82 0.00 0.74
mmu-miR-450b-5p 69 0.00 251 0.01 36 0.00 333 0.01 0.60 1.23
mmu-miR-451 96 0.01 403 0.02  226 0.01 0.52
mmu-miR-455 103 0.01 1,382 0.05 219 0.02 965 0.03 2.44 0.65
mmu-miR-455* 20 0.00 265 0.01 55 0.00 154 0.01 3.16 0.54
mmu-miR-466a-3p, 
mmu-miR-466b-3p, 
mmu-miR-466c-3p, 
mmu-miR-466e-3p, 
mmu-miR-466p-3p 
  8 0.00      
mmu-miR-466c-5p   8 0.00      
mmu-miR-466d-3p   18 0.00  14 0.00 0.72
mmu-miR-466h-3p   12 0.00      
mmu-miR-466i-5p 516 0.03 371 0.01 516 0.04 246 0.01 1.15 0.61
mmu-miR-467a   13 0.00  34 0.00 2.42
mmu-miR-467a*, 
mmu-miR-467d* 
  13 0.00    
mmu-miR-467c       67 0.00  
mmu-miR-467d       29 0.00  
mmu-miR-470   82 0.00 64 0.00 24 0.00 0.27
mmu-miR-484 2,928 0.18 6,263 0.24 3,709 0.26 8,976 0.31 1.45 1.32
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16,483,415 26,499,566 14,350,712 28,671,121
mmu-miR-485   38 0.00 43 0.00 60 0.00 1.46
mmu-miR-485* 14 0.00        
mmu-miR-486*, 
mmu-miR-3107* 
  24 0.00  31 0.00 1.19
mmu-miR-486, 
mmu-miR-3107 
135,099 8.20 149,285 5.63 119,531 8.33 143,459 5.00 1.02 0.89
mmu-miR-487b   10 0.00      
mmu-miR-488 44 0.00 310 0.01  101 0.00 0.30
mmu-miR-490-3p   11 0.00      
mmu-miR-493*   4 0.00      
mmu-miR-494 17 0.00 45 0.00  57 0.00 1.17
mmu-miR-495 15 0.00 80 0.00 56 0.00  4.29 
mmu-miR-496   34 0.00  25 0.00 0.68
mmu-miR-497 34 0.00 1,333 0.05  1,662 0.06 1.15
mmu-miR-500   97 0.00  87 0.00 0.83
mmu-miR-501-3p 163 0.01 189 0.01 328 0.02 235 0.01 2.31 1.15
mmu-miR-503 292 0.02 1,305 0.05 84 0.01 1,073 0.04 0.33 0.76
mmu-miR-503* 73 0.00 248 0.01 51 0.00 499 0.02 0.80 1.86
mmu-miR-505-3p 7 0.00    13 0.00  
mmu-miR-505-5p       36 0.00  
mmu-miR-5097   1 0.00      
mmu-miR-5099 12,430 0.75 644 0.02 17,723 1.23 1,267 0.04 1.64 1.82
mmu-miR-5100 17 0.00        
mmu-miR-5101   5 0.00      
mmu-miR-5105 3 0.00 26 0.00 199 0.01 173 0.01 76.19 6.15
mmu-miR-5109 135 0.01 466 0.02 897 0.06 1,927 0.07 7.63 3.82
mmu-miR-5113   18 0.00      
mmu-miR-511-3p 15 0.00        
mmu-miR-5115 7 0.00 23 0.00 5 0.00 7 0.00 0.82 0.28
mmu-miR-511-5p   14 0.00  51 0.00 3.37
mmu-miR-5117 284 0.02  79 0.01  0.32 
mmu-miR-5121 20 0.00 105 0.00  118 0.00 1.04
mmu-miR-5122   10 0.00  7 0.00 0.65
mmu-miR-5126 14 0.00 43 0.00  64 0.00 1.38
mmu-miR-5128   8 0.00  2 0.00 0.23
mmu-miR-5130   4 0.00      
mmu-miR-532-3p 20 0.00 166 0.01 60 0.00 118 0.00 3.45 0.66
mmu-miR-532-5p 351 0.02 649 0.02 162 0.01 810 0.03 0.53 1.15
mmu-miR-539-5p   23 0.00      
mmu-miR-540-3p 13 0.00 153 0.01  26 0.00 0.16
mmu-miR-540-5p   28 0.00      
mmu-miR-541 759 0.05 2,660 0.10 448 0.03 2,564 0.09 0.68 0.89
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16,483,415 26,499,566 14,350,712 28,671,121
mmu-miR-541*   8 0.00      
mmu-miR-542-3p 232 0.01 416 0.02 57 0.00 339 0.01 0.28 0.75
mmu-miR-542-5p 44 0.00 834 0.03 129 0.01 830 0.03 3.37 0.92
mmu-miR-543   131 0.00  132 0.00 0.93
mmu-miR-547       36 0.00  
mmu-miR-574-3p 1,359 0.08 4,047 0.15 1,803 0.13 5,523 0.19 1.52 1.26
mmu-miR-574-5p 1,382 0.08 914 0.03 1,344 0.09 685 0.02 1.12 0.69
mmu-miR-582-3p       13 0.00  
mmu-miR-582-5p 18 0.00 39 0.00      
mmu-miR-598 95 0.01 174 0.01 275 0.02 71 0.00 3.32 0.38
mmu-miR-598*   12 0.00      
mmu-miR-615-3p 235 0.01 952 0.04 483 0.03 2,164 0.08 2.36 2.10
mmu-miR-615-5p   63 0.00  66 0.00 0.97
mmu-miR-652 834 0.05 6,639 0.25 1,991 0.14 7,418 0.26 2.74 1.03
mmu-miR-664 76 0.00 190 0.01  118 0.00 0.57
mmu-miR-664* 79 0.00 273 0.01 32 0.00 420 0.01 0.47 1.42
mmu-miR-665       34 0.00  
mmu-miR-667 7 0.00 50 0.00  98 0.00 1.81
mmu-miR-668   49 0.00 57 0.00 68 0.00 1.28
mmu-miR-669a-3p, 
mmu-miR-669o-3p 
 23 0.00      
mmu-miR-669a-5p, 
mmu-miR-669p 
     30 0.00  
mmu-miR-669c 83 0.01 69 0.00 107 0.01 73 0.00 1.48 0.98
mmu-miR-671-3p 642 0.04 2,613 0.10 1,124 0.08 3,080 0.11 2.01 1.09
mmu-miR-671-5p 40 0.00 23 0.00      
mmu-miR-672 165 0.01 324 0.01 222 0.02 447 0.02 1.55 1.28
mmu-miR-673-3p   26 0.00  33 0.00 1.17
mmu-miR-673-5p 235 0.01 859 0.03 356 0.02 782 0.03 1.74 0.84
mmu-miR-674 51 0.00 278 0.01  159 0.01 0.53
mmu-miR-674* 62 0.00 616 0.02 298 0.02 1,314 0.05 5.52 1.97
mmu-miR-676 146 0.01 498 0.02 159 0.01 338 0.01 1.25 0.63
mmu-miR-676*   94 0.00 67 0.00    
mmu-miR-677   19 0.00      
mmu-miR-690 59 0.00 249 0.01 58 0.00 135 0.00 1.13 0.50
mmu-miR-696 25 0.00 24 0.00      
mmu-miR-700 31 0.00 448 0.02 124 0.01 425 0.01 4.59 0.88
mmu-miR-700* 78 0.00 39 0.00  77 0.00 1.82
mmu-miR-701 16 0.00        
mmu-miR-702   15 0.00  72 0.00 4.44
mmu-miR-703     7 0.00    
mmu-miR-706   12 0.00      
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16,483,415 26,499,566 14,350,712 28,671,121
mmu-miR-708 15 0.00 69 0.00      
mmu-miR-708* 13 0.00        
mmu-miR-709 7,420 0.45 383 0.01 3,992 0.28 454 0.02 0.62 1.10
mmu-miR-712 56 0.00 83 0.00 165 0.01 60 0.00 3.38 0.67
mmu-miR-714 15 0.00        
mmu-miR-720 272 0.02 2,645 0.10 484 0.03 4,431 0.15 2.04 1.55
mmu-miR-744 1,310 0.08 5,265 0.20 1,935 0.13 7,242 0.25 1.70 1.27
mmu-miR-744* 77 0.00 249 0.01 264 0.02 149 0.01 3.94 0.55
mmu-miR-758   10 0.00      
mmu-miR-760-3p   6 0.00      
mmu-miR-770-3p 21 0.00        
mmu-miR-7a 367 0.02 296 0.01 280 0.02 505 0.02 0.88 1.58
mmu-miR-7a-1*   33 0.00  15 0.00 0.42
mmu-miR-802 10 0.00 38 0.00      
mmu-miR-802*   19 0.00      
mmu-miR-871-3p   34 0.00      
mmu-miR-872 134 0.01 622 0.02 201 0.01 485 0.02 1.72 0.72
mmu-miR-872* 308 0.02 889 0.03 592 0.04 758 0.03 2.21 0.79
mmu-miR-873 22 0.00 24 0.00  35 0.00 1.35
mmu-miR-873* 45 0.00 236 0.01  236 0.01 0.92
mmu-miR-874 1,148 0.07 2,045 0.08 1,094 0.08 1,348 0.05 1.09 0.61
mmu-miR-874* 81 0.00 95 0.00 97 0.01 42 0.00 1.38 0.41
mmu-miR-876-5p   28 0.00      
mmu-miR-877 34 0.00 106 0.00  146 0.01 1.27
mmu-miR-877* 14 0.00 77 0.00      
mmu-miR-9   167 0.01 42 0.00 11 0.00 0.06
mmu-miR-92a 13,364 0.81 34,805 1.31 13,138 0.92 40,839 1.42 1.13 1.08
mmu-miR-92a-1*   30 0.00  174 0.01 5.36
mmu-miR-92a-2*   14 0.00      
mmu-miR-92b 383 0.02 2,485 0.09 752 0.05 3,700 0.13 2.26 1.38
mmu-miR-93 866 0.05 1,030 0.04 652 0.05 673 0.02 0.86 0.60
mmu-miR-93* 5 0.00 288 0.01 52 0.00 289 0.01 11.95 0.93
mmu-miR-96 32 0.00 126 0.00      
mmu-miR-98 519 0.03 1,034 0.04 579 0.04 963 0.03 1.28 0.86
mmu-miR-98* 114 0.01 618 0.02  565 0.02 0.84
mmu-miR-99a 5,289 0.32 23,486 0.89 4,413 0.31 22,388 0.78 0.96 0.88
mmu-miR-99a*       41 0.00  
mmu-miR-99b 453,297 27.50 699,412 26.39 485,756 33.85 694,570 24.23 1.23 0.92
mmu-miR-99b* 25 0.00 224 0.01 12 0.00 500 0.02 0.55 2.06
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mmu-let-7a-1-3p. 
mmu-let-7c-2-3p 3 32 17 20 0.5 7.4 3.0 5.7 0.1 0.5 0.2 
mmu-let-7a-5p 10927 7841 8143 2996 1874.2 1802.3 1435.1 848.2 1.0 1.7 1.3 
mmu-let-7a-5p. 
mmu-let-7c-5p 678 844 429 646 116.3 194.0 75.6 182.9 0.6 0.4 1.5 
mmu-let-7b-3p 33 6   11 5.7 1.4 0.0 3.1 4.1 0.0 ----- 
mmu-let-7b-5p 20531 31851 23246 19681 3521.4 7321.2 4096.8 5571.6 0.5 0.7 0.9 
mmu-let-7c-5p 37946 37056 28447 20748 6508.4 8517.6 5013.4 5873.7 0.8 0.9 1.3 
mmu-let-7d-3p 1297 330 404 119 222.5 75.9 71.2 33.7 2.9 2.1 3.1 
mmu-let-7d-5p 465 883 1362 368 79.8 203.0 240.0 104.2 0.4 2.3 0.3 
mmu-let-7e-3p 27 58 17 17 4.6 13.3 3.0 4.8 0.3 0.6 1.5 
mmu-let-7e-5p 3063 1924 1629 885 525.4 442.2 287.1 250.5 1.2 1.1 1.8 
mmu-let-7f-2-3p 19 30 12 5 3.3 6.9 2.1 1.4 0.5 1.5 1.5 
mmu-let-7f-5p 4721 3212 4321 1387 809.7 738.3 761.5 392.7 1.1 1.9 1.1 
mmu-let-7g-5p 502 1152 1623 882 86.1 264.8 286.0 249.7 0.3 1.1 0.3 
mmu-let-7i-5p 29271 44335 62203 43345 5020.5 10190.8 10962.3 12270.8 0.5 0.9 0.5 
mmu-miR-100-5p 32 6 113 83 5.5 1.4 19.9 23.5 4.0 0.8 0.3 
mmu-miR-101a-3p 25 117 181 213 4.3 26.9 31.9 60.3 0.2 0.5 0.1 
mmu-miR-101a-3p. 
mmu-miR-101c 14913 35279 28830 25002 2557.8 8109.2 5080.9 7077.9 0.3 0.7 0.5 
mmu-miR-101b-3p 1443 3495 2509 1979 247.5 803.4 442.2 560.2 0.3 0.8 0.6 
mmu-miR-101c 1630 4696 3712 3879 279.6 1079.4 654.2 1098.1 0.3 0.6 0.4 
mmu-miR-103-3p 5943 6431 6456 6370 1019.3 1478.2 1137.8 1803.3 0.7 0.6 0.9 
mmu-miR-103-3p. 
mmu-miR-107-3p 2779 2729 3319 2591 476.6 627.3 584.9 733.5 0.8 0.8 0.8 
mmu-miR-106b-3p 1552 947 2212 862 266.2 217.7 389.8 244.0 1.2 1.6 0.7 
mmu-miR-106b-5p 57 3 25 35 9.8 0.7 4.4 9.9 14.2 0.4 2.2 
mmu-miR-107-3p 177 89 95 36 30.4 20.5 16.7 10.2 1.5 1.6 1.8 
mmu-miR-10a-3p 20 8 38 25 3.4 1.8 6.7 7.1 1.9 0.9 0.5 
mmu-miR-10a-5p 58809 64911 381110 495521 10086.7 14920.4 67164.9 140279.5 0.7 0.5 0.2 
mmu-miR-10b-5p 658494 214717 91598 74553 112942.4 49354.6 16142.8 21105.6 2.3 0.8 7.0 
mmu-miR-1191b-5p 15 29 1 20 2.6 6.7 0.2 5.7 0.4 0.0 14.6 
mmu-miR-1198-5p 233 73 106 68 40.0 16.8 18.7 19.3 2.4 1.0 2.1 
mmu-miR-122-5p 79 4 41 16 13.5 0.9 7.2 4.5 14.7 1.6 1.9 
mmu-miR-1249-3p   6 29 10 0.0 1.4 5.1 2.8 0.0 1.8 0.0 
mmu-miR-125a-3p 78 107 166 53 13.4 24.6 29.3 15.0 0.5 1.9 0.5 
mmu-miR-125a-5p 2915 2449 1829 1130 500.0 562.9 322.3 319.9 0.9 1.0 1.6 
mmu-miR-125b-2-3p 314 529 209 90 53.9 121.6 36.8 25.5 0.4 1.4 1.5 
mmu-miR-125b-5p 513 437 245 131 88.0 100.4 43.2 37.1 0.9 1.2 2.0 
mmu-miR-126a-3p 17 107 11062 12712 2.9 24.6 1949.5 3598.7 0.1 0.5 0.0 
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mmu-miR-126a-5p   8 2951 1099 0.0 1.8 520.1 311.1 0.0 1.7 0.0 
mmu-miR-127-3p 398 13 11811 89 68.3 3.0 2081.5 25.2 22.8 82.6 0.0 
mmu-miR-127-5p     245 1 0.0 0.0 43.2 0.3 ----- 152.5 0.0 
mmu-miR-128-1-5p 37 19 6 8 6.3 4.4 1.1 2.3 1.5 0.5 6.0 
mmu-miR-129-5p 125 2292 497 481 21.4 526.8 87.6 136.2 0.0 0.6 0.2 
mmu-miR-130a-3p 366 272 371 104 62.8 62.5 65.4 29.4 1.0 2.2 1.0 
mmu-miR-130b-3p   11 25 9 0.0 2.5 4.4 2.5 0.0 1.7 0.0 
mmu-miR-132-3p   83 57 52 0.0 19.1 10.0 14.7 0.0 0.7 0.0 
mmu-miR-133a-3p   10 189 184 0.0 2.3 33.3 52.1 0.0 0.6 0.0 
mmu-miR-134-5p     289 1 0.0 0.0 50.9 0.3 ----- 179.9 0.0 
mmu-miR-139-3p   16 1657 1136 0.0 3.7 292.0 321.6 0.0 0.9 0.0 
mmu-miR-139-5p   10 348 416 0.0 2.3 61.3 117.8 0.0 0.5 0.0 
mmu-miR-140-3p 6312 5277 6484 4687 1082.6 1213.0 1142.7 1326.9 0.9 0.9 0.9 
mmu-miR-140-5p 46 16 24 15 7.9 3.7 4.2 4.2 2.1 1.0 1.9 
mmu-miR-143-3p 219276 784667 1E+06 2E+06 37609.4 180362.7 180205.2 428194.2 0.2 0.4 0.2 
mmu-miR-143-5p 37 54 55 74 6.3 12.4 9.7 20.9 0.5 0.5 0.7 
mmu-miR-145a-5p 112 697 872 2040 19.2 160.2 153.7 577.5 0.1 0.3 0.1 
mmu-miR-146a-5p 37 542 2752 3013 6.3 124.6 485.0 853.0 0.1 0.6 0.0 
mmu-miR-146b-5p 32276 24281 14618 2945 5535.9 5581.2 2576.2 833.7 1.0 3.1 2.1 
mmu-miR-148a-3p 10541 5390 4314 1277 1808.0 1238.9 760.3 361.5 1.5 2.1 2.4 
mmu-miR-148a-5p 35 86 29 8 6.0 19.8 5.1 2.3 0.3 2.3 1.2 
mmu-miR-148b-3p 166 94 62 103 28.5 21.6 10.9 29.2 1.3 0.4 2.6 
mmu-miR-149-5p 80 196 112 33 13.7 45.1 19.7 9.3 0.3 2.1 0.7 
mmu-miR-150-5p   15 128 106 0.0 3.4 22.6 30.0 0.0 0.8 0.0 
mmu-miR-151-3p 6896 2855 15848 8053 1182.8 656.2 2793.0 2279.8 1.8 1.2 0.4 
mmu-miR-151-5p 148 35 379 290 25.4 8.0 66.8 82.1 3.2 0.8 0.4 
mmu-miR-152-3p 3359 2461 1711 1315 576.1 565.7 301.5 372.3 1.0 0.8 1.9 
mmu-miR-152-5p 109 80 40 44 18.7 18.4 7.0 12.5 1.0 0.6 2.7 
mmu-miR-15a-5p 7 14 11 19 1.2 3.2 1.9 5.4 0.4 0.4 0.6 
mmu-miR-15b-5p     56 3 0.0 0.0 9.9 0.8 ----- 11.6 0.0 
mmu-miR-16-1-3p 77 26 44 27 13.2 6.0 7.8 7.6 2.2 1.0 1.7 
mmu-miR-16-5p 102 84 321 178 17.5 19.3 56.6 50.4 0.9 1.1 0.3 
mmu-miR-17-3p 8 21 30 44 1.4 4.8 5.3 12.5 0.3 0.4 0.3 
mmu-miR-17-5p   7 34 16 0.0 1.6 6.0 4.5 0.0 1.3 0.0 
mmu-miR-181a-1-3p 970 655 677 492 166.4 150.6 119.3 139.3 1.1 0.9 1.4 
mmu-miR-181a-5p 14452 9642 7860 6410 2478.8 2216.3 1385.2 1814.6 1.1 0.8 1.8 
mmu-miR-181b-5p 2041 1048 1144 929 350.1 240.9 201.6 263.0 1.5 0.8 1.7 
mmu-miR-181c-3p 25 9 174 152 4.3 2.1 30.7 43.0 2.1 0.7 0.1 
mmu-miR-181c-5p 1 13 228 226 0.2 3.0 40.2 64.0 0.1 0.6 0.0 
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mmu-miR-181d-5p 46 10 431 484 7.9 2.3 76.0 137.0 3.4 0.6 0.1 
mmu-miR-182-5p 85 61 1119 406 14.6 14.0 197.2 114.9 1.0 1.7 0.1 
mmu-miR-183-5p 1   52 23 0.2 0.0 9.2 6.5 ----- 1.4 0.0 
mmu-miR-1839-5p 340 411 231 263 58.3 94.5 40.7 74.5 0.6 0.5 1.4 
mmu-miR-184-3p 41   6 5 7.0 0.0 1.1 1.4 ----- 0.7 6.7 
mmu-miR-1843a-5p 1205 579 539 336 206.7 133.1 95.0 95.1 1.6 1.0 2.2 
mmu-miR-1843a-5p. 
 mmu-miR-1843b-5p 652 700 443 184 111.8 160.9 78.1 52.1 0.7 1.5 1.4 
mmu-miR-1843b-3p 34 1   4 5.8 0.2 0.0 1.1 25.4 0.0 ---- 
mmu-miR-1843b-5p 533 564 575 265 91.4 129.6 101.3 75.0 0.7 1.4 0.9 
mmu-miR-185-5p 191 570 401 230 32.8 131.0 70.7 65.1 0.3 1.1 0.5 
mmu-miR-186-5p 219 282 203 154 37.6 64.8 35.8 43.6 0.6 0.8 1.0 
mmu-miR-191-5p 2982 1924 2008 1249 511.5 442.2 353.9 353.6 1.2 1.0 1.4 
mmu-miR-192-5p 106 33 55 26 18.2 7.6 9.7 7.4 2.4 1.3 1.9 
mmu-miR-1934-3p 86 35 9 15 14.8 8.0 1.6 4.2 1.8 0.4 9.3 
mmu-miR-193a-5p 67 57 31 40 11.5 13.1 5.5 11.3 0.9 0.5 2.1 
mmu-miR-194-2-3p 78 7 26 27 13.4 1.6 4.6 7.6 8.3 0.6 2.9 
mmu-miR-194-5p 138 32 36 17 23.7 7.4 6.3 4.8 3.2 1.3 3.7 
mmu-miR-1940   15 3 24 0.0 3.4 0.5 6.8 0.0 0.1 0.0 
mmu-miR-1943-5p 11 18 53 46 1.9 4.1 9.3 13.0 0.5 0.7 0.2 
mmu-miR-1955-3p   25   2 0.0 5.7 0.0 0.6 0.0 0.0 ---- 
mmu-miR-195a-3p 17 6 98 67 2.9 1.4 17.3 19.0 2.1 0.9 0.2 
mmu-miR-195a-5p     109 144 0.0 0.0 19.2 40.8 ---- 0.5 0.0 
mmu-miR-196a-2-3p 22 31 29 9 3.8 7.1 5.1 2.5 0.5 2.0 0.7 
mmu-miR-196a-5p 193 125 57 56 33.1 28.7 10.0 15.9 1.2 0.6 3.3 
mmu-miR-196b-5p 2831 4121 1327 974 485.6 947.2 233.9 275.7 0.5 0.8 2.1 
mmu-miR-1981-5p 358 107 140 89 61.4 24.6 24.7 25.2 2.5 1.0 2.5 
mmu-miR-199a-3p. 
mmu-miR-199b-3p 93 199 163 326 16.0 45.7 28.7 92.3 0.3 0.3 0.6 
mmu-miR-199a-5p     30 29 0.0 0.0 5.3 8.2 ---- 0.6 0.0 
mmu-miR-199b-5p   22     0.0 5.1 0.0 0.0 0.0 ---- ----- 
mmu-miR-19a-3p 40 158 172 444 6.9 36.3 30.3 125.7 0.2 0.2 0.2 
mmu-miR-19b-3p 687 2669 3123 5555 117.8 613.5 550.4 1572.6 0.2 0.3 0.2 
mmu-miR-1a-3p     47 31 0.0 0.0 8.3 8.8 ---- 0.9 0.0 
mmu-miR-200a-3p   23 254 139 0.0 5.3 44.8 39.4 0.0 1.1 0.0 
mmu-miR-200a-5p     31 4 0.0 0.0 5.5 1.1 ---- 4.8 0.0 
mmu-miR-200b-3p   2 40 39 0.0 0.5 7.0 11.0 0.0 0.6 0.0 
mmu-miR-200c-3p   3 47 13 0.0 0.7 8.3 3.7 0.0 2.3 0.0 
mmu-miR-203-3p 176 306 397 303 30.2 70.3 70.0 85.8 0.4 0.8 0.4 
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mmu-miR-204-3p   15 68 29 0.0 3.4 12.0 8.2 0.0 1.5 0.0 
mmu-miR-204-5p 45 8 158 156 7.7 1.8 27.8 44.2 4.2 0.6 0.3 
mmu-miR-20a-5p 13 42 25 54 2.2 9.7 4.4 15.3 0.2 0.3 0.5 
mmu-miR-210-3p 1732 4662 2670 616 297.1 1071.6 470.5 174.4 0.3 2.7 0.6 
mmu-miR-214-3p 1 2 16 31 0.2 0.5 2.8 8.8 0.4 0.3 0.1 
mmu-miR-21a-3p 1 117 14 15 0.2 26.9 2.5 4.2 0.0 0.6 0.1 
mmu-miR-21a-5p 1173 7308 2026 3483 201.2 1679.8 357.1 986.0 0.1 0.4 0.6 
mmu-miR-22-3p 118760 110370 45048 29023 20369.3 25369.5 7939.0 8216.3 0.8 1.0 2.6 
mmu-miR-22-5p   29 25 9 0.0 6.7 4.4 2.5 0.0 1.7 0.0 
mmu-miR-221-3p 30 36 185 122 5.1 8.3 32.6 34.5 0.6 0.9 0.2 
mmu-miR-222-3p 103 119 487 393 17.7 27.4 85.8 111.3 0.6 0.8 0.2 
mmu-miR-23a-3p 54 325 682 507 9.3 74.7 120.2 143.5 0.1 0.8 0.1 
mmu-miR-23a-5p 99 220 46 73 17.0 50.6 8.1 20.7 0.3 0.4 2.1 
mmu-miR-23b-3p 1335 2140 2685 704 229.0 491.9 473.2 199.3 0.5 2.4 0.5 
mmu-miR-23b-3p. 
mmu-miR-23a-3p 55 70 62 48 9.4 16.1 10.9 13.6 0.6 0.8 0.9 
mmu-miR-23b-5p 37 6 34 1 6.3 1.4 6.0 0.3 4.6 21.2 1.1 
mmu-miR-24-2-5p 23 188 107 98 3.9 43.2 18.9 27.7 0.1 0.7 0.2 
mmu-miR-24-3p 79633 63764 35380 22890 13658.4 14656.7 6235.2 6480.0 0.9 1.0 2.2 
mmu-miR-25-3p 7574 2340 6973 3387 1299.1 537.9 1228.9 958.8 2.4 1.3 1.1 
mmu-miR-26a-5p 37732 56419 46042 32426 6471.7 12968.4 8114.2 9179.6 0.5 0.9 0.8 
mmu-miR-26b-5p 2609 3259 2876 2422 447.5 749.1 506.9 685.7 0.6 0.7 0.9 
mmu-miR-27a-3p 395 484 1573 706 67.7 111.3 277.2 199.9 0.6 1.4 0.2 
mmu-miR-27a-5p 1434 3977 1250 1185 246.0 914.1 220.3 335.5 0.3 0.7 1.1 
mmu-miR-27b-3p 49262 64316 44226 29530 8449.2 14783.6 7794.2 8359.8 0.6 0.9 1.1 
mmu-miR-27b-3p. 
mmu-miR-27a-3p 1179 923 865 613 202.2 212.2 152.4 173.5 1.0 0.9 1.3 
mmu-miR-27b-5p 1077 523 487 204 184.7 120.2 85.8 57.8 1.5 1.5 2.2 
mmu-miR-28a-3p 1042 560 1020 599 178.7 128.7 179.8 169.6 1.4 1.1 1.0 
mmu-miR-296-3p 64 38 170 65 11.0 8.7 30.0 18.4 1.3 1.6 0.4 
mmu-miR-299a-3p. 
mmu-miR-299b-3p     45 3 0.0 0.0 7.9 0.8 ---- 9.3 0.0 
mmu-miR-29a-3p 824 938 896 353 141.3 215.6 157.9 99.9 0.7 1.6 0.9 
mmu-miR-29b-3p   98 90 5 0.0 22.5 15.9 1.4 0.0 11.2 0.0 
mmu-miR-29c-3p 160 159 232 157 27.4 36.5 40.9 44.4 0.8 0.9 0.7 
mmu-miR-3057-5p 36 31 57 41 6.2 7.1 10.0 11.6 0.9 0.9 0.6 
mmu-miR-3081-3p     32 12 0.0 0.0 5.6 3.4 ---- 1.7 0.0 
mmu-miR-30a-3p 24968 17428 12271 6662 4282.4 4006.0 2162.6 1886.0 1.1 1.1 2.0 
mmu-miR-30a-5p 1E+06 985651 704816 275942 181617.0 226560.6 124213.2 78117.8 0.8 1.6 1.5 
mmu-miR-30b-3p 153 19 26 8 26.2 4.4 4.6 2.3 6.0 2.0 5.7 
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mmu-miR-30b-5p 294 1194 925 475 50.4 274.5 163.0 134.5 0.2 1.2 0.3 
mmu-miR-30c-1-3p 140 54 55 43 24.0 12.4 9.7 12.2 1.9 0.8 2.5 
mmu-miR-30c-2-3p 75956 72243 67658 22258 13027.7 16605.7 11923.7 6301.1 0.8 1.9 1.1 
mmu-miR-30c-5p 1473 3334 3033 1627 252.6 766.3 534.5 460.6 0.3 1.2 0.5 
mmu-miR-30d-3p 79 119 55 62 13.5 27.4 9.7 17.6 0.5 0.6 1.4 
mmu-miR-30d-5p 184118 113915 80361 34082 31579.2 26184.4 14162.4 9648.4 1.2 1.5 2.2 
mmu-miR-30e-3p 207 126 100 58 35.5 29.0 17.6 16.4 1.2 1.1 2.0 
mmu-miR-30e-5p 13281 11000 10167 4326 2277.9 2528.4 1791.8 1224.7 0.9 1.5 1.3 
mmu-miR-31-5p 23   62 24 3.9 0.0 10.9 6.8 ---- 1.6 0.4 
mmu-miR-3102-3p 5 93 19 34 0.9 21.4 3.3 9.6 0.0 0.3 0.3 
mmu-miR-3102-5p   54 6 2 0.0 12.4 1.1 0.6 0.0 1.9 0.0 
mmu-miR-320-3p 5329 5182 5645 5825 914.0 1191.1 994.8 1649.0 0.8 0.6 0.9 
mmu-miR-322-3p 6689 9903 2402 1668 1147.3 2276.3 423.3 472.2 0.5 0.9 2.7 
mmu-miR-322-5p 31 74 46 41 5.3 17.0 8.1 11.6 0.3 0.7 0.7 
mmu-miR-324-5p   2 37 6 0.0 0.5 6.5 1.7 0.0 3.8 0.0 
mmu-miR-326-3p 119 157 163 54 20.4 36.1 28.7 15.3 0.6 1.9 0.7 
mmu-miR-328-3p 1100 602 983 332 188.7 138.4 173.2 94.0 1.4 1.8 1.1 
mmu-miR-329-5p     209   0.0 0.0 36.8 0.0 ---- ---- 0.0 
mmu-miR-330-3p 69 19 49 19 11.8 4.4 8.6 5.4 2.7 1.6 1.4 
mmu-miR-330-5p 63 24 8   10.8 5.5 1.4 0.0 2.0 ---- 7.7 
mmu-miR-331-3p   34 50 31 0.0 7.8 8.8 8.8 0.0 1.0 0.0 
mmu-miR-338-3p     103 164 0.0 0.0 18.2 46.4 ---- 0.4 0.0 
mmu-miR-339-5p 131 100 231 120 22.5 23.0 40.7 34.0 1.0 1.2 0.6 
mmu-miR-340-5p 316 493 145 121 54.2 113.3 25.6 34.3 0.5 0.7 2.1 
mmu-miR-341-3p   4 63   0.0 0.9 11.1 0.0 0.0 ---- 0.0 
mmu-miR-345-3p 51 5 42 12 8.7 1.1 7.4 3.4 7.6 2.2 1.2 
mmu-miR-3470b 29 11 23 23 5.0 2.5 4.1 6.5 2.0 0.6 1.2 
mmu-miR-3473b 1 23 42 27 0.2 5.3 7.4 7.6 0.0 1.0 0.0 
mmu-miR-3473b. 
mmu-miR-3473e 5 44 72 42 0.9 10.1 12.7 11.9 0.1 1.1 0.1 
mmu-miR-3474 192 66 22 9 32.9 15.2 3.9 2.5 2.2 1.5 8.5 
mmu-miR-34a-5p 58 206 98 99 9.9 47.4 17.3 28.0 0.2 0.6 0.6 
mmu-miR-350-5p 194 56 177 83 33.3 12.9 31.2 23.5 2.6 1.3 1.1 
mmu-miR-351-3p 143 165 94 17 24.5 37.9 16.6 4.8 0.6 3.4 1.5 
mmu-miR-351-5p 18841 12745 8202 3121 3231.5 2929.6 1445.5 883.5 1.1 1.6 2.2 
mmu-miR-3535 390 110 186 103 66.9 25.3 32.8 29.2 2.6 1.1 2.0 
mmu-miR-361-3p 192 315 302 246 32.9 72.4 53.2 69.6 0.5 0.8 0.6 
mmu-miR-361-5p 112 32 50 55 19.2 7.4 8.8 15.6 2.6 0.6 2.2 
mmu-miR-362-3p   18 18 41 0.0 4.1 3.2 11.6 0.0 0.3 0.0 
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mmu-miR-374b-5p     37   0.0 0.0 6.5 0.0 ---- ---- 0.0 
mmu-miR-375-3p 32 1 136 93 5.5 0.2 24.0 26.3 23.9 0.9 0.2 
mmu-miR-378a-3p 26708 29234 18541 8896 4580.9 6719.7 3267.6 2518.4 0.7 1.3 1.4 
mmu-miR-378a-3p. 
mmu-miR-378b. 
mmu-miR-378c 37 36 81 18 6.3 8.3 14.3 5.1 0.8 2.8 0.4 
mmu-miR-378a-3p. 
mmu-miR-378c 1353 2601 1607 993 232.1 597.9 283.2 281.1 0.4 1.0 0.8 
mmu-miR-378a-5p 107 91 101 33 18.4 20.9 17.8 9.3 0.9 1.9 1.0 
mmu-miR-378b 120 91 96 74 20.6 20.9 16.9 20.9 1.0 0.8 1.2 
mmu-miR-379-5p     453 11 0.0 0.0 79.8 3.1 ---- 25.6 0.0 
mmu-miR-381-3p     31 4 0.0 0.0 5.5 1.1 ---- 4.8 0.0 
mmu-miR-382-5p 128   2929 39 22.0 0.0 516.2 11.0 ---- 46.8 0.0 
mmu-miR-383-5p     125 52 0.0 0.0 22.0 14.7 ---- 1.5 0.0 
mmu-miR-409-3p 25   236   4.3 0.0 41.6 0.0 ---- ---- 0.1 
mmu-miR-411-5p     60   0.0 0.0 10.6 0.0 ---- ---- 0.0 
mmu-miR-423-3p 160 84 193 92 27.4 19.3 34.0 26.0 1.4 1.3 0.8 
mmu-miR-423-5p 1541 1540 2464 1590 264.3 354.0 434.2 450.1 0.7 1.0 0.6 
mmu-miR-425-3p 24 48 30 33 4.1 11.0 5.3 9.3 0.4 0.6 0.8 
mmu-miR-425-5p 134 39 48 40 23.0 9.0 8.5 11.3 2.6 0.7 2.7 
mmu-miR-434-3p     36 3 0.0 0.0 6.3 0.8 ---- 7.5 0.0 
mmu-miR-434-5p     100   0.0 0.0 17.6 0.0 ---- ---- 0.0 
mmu-miR-450a-5p 74 27 71 11 12.7 6.2 12.5 3.1 2.0 4.0 1.0 
mmu-miR-450b-3p 29 10 14 10 5.0 2.3 2.5 2.8 2.2 0.9 2.0 
mmu-miR-484 185 168 212 145 31.7 38.6 37.4 41.0 0.8 0.9 0.8 
mmu-miR-486-3p. 
mmu-miR-3107-3p   53   7 0.0 12.2 0.0 2.0 0.0 0.0 ----- 
mmu-miR-486-5p. 
mmu-miR-3107-5p 3091 7577 1616 681 530.2 1741.6 284.8 192.8 0.3 1.5 1.9 
mmu-miR-488-3p     64 23 0.0 0.0 11.3 6.5 ---- 1.7 0.0 
mmu-miR-497-5p     28 24 0.0 0.0 4.9 6.8 ---- 0.7 0.0 
mmu-miR-503-3p 199 173 69 23 34.1 39.8 12.2 6.5 0.9 1.9 2.8 
mmu-miR-503-5p 1395 792 638 227 239.3 182.0 112.4 64.3 1.3 1.7 2.1 
mmu-miR-5099 780 164 448 343 133.8 37.7 79.0 97.1 3.5 0.8 1.7 
mmu-miR-5114 35   26 10 6.0 0.0 4.6 2.8 ---- 1.6 1.3 
mmu-miR-532-5p 687 854 972 584 117.8 196.3 171.3 165.3 0.6 1.0 0.7 
mmu-miR-540-3p     82   0.0 0.0 14.5 0.0 ---- ---- 0.0 
mmu-miR-541-5p 1   529 9 0.2 0.0 93.2 2.5 ---- 36.6 0.0 
mmu-miR-542-3p 659 2535 662 643 113.0 582.7 116.7 182.0 0.2 0.6 1.0 
mmu-miR-542-5p 43 42 52 5 7.4 9.7 9.2 1.4 0.8 6.5 0.8 
mmu-miR-574-3p 1058 772 1296 840 181.5 177.5 228.4 237.8 1.0 1.0 0.8 
mmu-miR-574-5p 861 376 593 200 147.7 86.4 104.5 56.6 1.7 1.8 1.4 
mmu-miR-582-3p 55 17 37 74 9.4 3.9 6.5 20.9 2.4 0.3 1.4 
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 Total reads of miRNA sequences fraction of miRNA reads in rpm Ratio 
miRNA 
po
do
cy
te
s (
W
T)
 
po
do
cy
te
s (
Lm
x1
b 
KO
) 
re
d 
ce
lls
 (W
T)
 
re
d 
ce
lls
 (L
m
x1
b 
KO
) 
po
do
cy
te
s (
W
T)
 
rp
m
 
po
do
cy
te
s (
Lm
x1
b 
KO
) r
pm
 
re
d 
ce
lls
 (W
T)
 rp
m
 
re
d 
ce
lls
 (L
m
x1
b 
KO
) r
pm
 
Po
do
cy
te
s W
T/
KO
 
re
d 
ce
lls
 W
T/
KO
 
Po
do
cy
te
sW
T/
 
re
d 
ce
lls
 W
T 
mmu-miR-598-3p 16 13 22 12 2.7 3.0 3.9 3.4 0.9 1.1 0.7 
mmu-miR-615-3p 348 120 89 24 59.7 27.6 15.7 6.8 2.2 2.3 3.8 
mmu-miR-615-5p 364 202 82 22 62.4 46.4 14.5 6.2 1.3 2.3 4.3 
mmu-miR-652-3p 353 192 292 117 60.5 44.1 51.5 33.1 1.4 1.6 1.2 
mmu-miR-6538   18 33 12 0.0 4.1 5.8 3.4 0.0 1.7 0.0 
mmu-miR-6539 34 10 10 4 5.8 2.3 1.8 1.1 2.5 1.6 3.3 
mmu-miR-664-5p 1163 894 655 226 199.5 205.5 115.4 64.0 1.0 1.8 1.7 
mmu-miR-669c-5p 60 27 33 11 10.3 6.2 5.8 3.1 1.7 1.9 1.8 
mmu-miR-671-3p 855 489 476 180 146.6 112.4 83.9 51.0 1.3 1.6 1.7 
mmu-miR-671-5p 36 38 74 42 6.2 8.7 13.0 11.9 0.7 1.1 0.5 
mmu-miR-672-5p 367 756 279 195 62.9 173.8 49.2 55.2 0.4 0.9 1.3 
mmu-miR-674-3p   20   23 0.0 4.6 0.0 6.5 0.0 0.0 ---- 
mmu-miR-676-3p 4418 4956 3342 1135 757.8 1139.2 589.0 321.3 0.7 1.8 1.3 
mmu-miR-7068-3p 38       6.5 0.0 0.0 0.0 ---- ---- ----- 
mmu-miR-708-3p   24 34 20 0.0 5.5 6.0 5.7 0.0 1.1 0.0 
mmu-miR-709 65 214 134 124 11.1 49.2 23.6 35.1 0.2 0.7 0.5 
mmu-miR-744-3p   30 7 4 0.0 6.9 1.2 1.1 0.0 1.1 0.0 
mmu-miR-744-5p 905 348 559 234 155.2 80.0 98.5 66.2 1.9 1.5 1.6 
mmu-miR-760-3p 34   7 11 5.8 0.0 1.2 3.1 ---- 0.4 4.7 
mmu-miR-7a-5p 20 72 8 46 3.4 16.5 1.4 13.0 0.2 0.1 2.4 
mmu-miR-8103 21 7 33 4 3.6 1.6 5.8 1.1 2.2 5.1 0.6 
mmu-miR-872-3p   11 30 3 0.0 2.5 5.3 0.8 0.0 6.2 0.0 
mmu-miR-872-5p 117 158 100 105 20.1 36.3 17.6 29.7 0.6 0.6 1.1 
mmu-miR-873a-5p 77 266 428 117 13.2 61.1 75.4 33.1 0.2 2.3 0.2 
mmu-miR-874-3p 53 10 42 14 9.1 2.3 7.4 4.0 4.0 1.9 1.2 
mmu-miR-877-5p 2 10 21 22 0.3 2.3 3.7 6.2 0.1 0.6 0.1 
mmu-miR-9-5p 90 68 651 330 15.4 15.6 114.7 93.4 1.0 1.2 0.1 
mmu-miR-92a-1-5p   23 30 54 0.0 5.3 5.3 15.3 0.0 0.3 0.0 
mmu-miR-92a-3p 20677 5785 19990 12820 3546.4 1329.7 3522.9 3629.3 2.7 1.0 1.0 
mmu-miR-92b-5p 72 22   4 12.3 5.1 0.0 1.1 2.4 0.0 ---- 
mmu-miR-93-5p 4224 5757 4643 4156 724.5 1323.3 818.3 1176.5 0.5 0.7 0.9 
mmu-miR-98-5p 2516 6938 5505 3851 431.5 1594.8 970.2 1090.2 0.3 0.9 0.4 
mmu-miR-99a-3p 87 52 56 8 14.9 12.0 9.9 2.3 1.2 4.4 1.5 
mmu-miR-99a-5p 279 283 293 75 47.9 65.1 51.6 21.2 0.7 2.4 0.9 
mmu-miR-99b-3p 1258 1040 1038 464 215.8 239.1 182.9 131.4 0.9 1.4 1.2 
mmu-miR-99b-5p 11609 14926 15608 9133 1991.1 3430.9 2750.7 2585.5 0.6 1.1 0.7 
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Tab. 10.7: Human genomic organization of podocyte miRNAs 
miRNAs Genomic coordinates of the precursor mirna in human 
Genomic organization in human  
(UCSC. ensembl) 
clustered miRNAs 
(<10kb) human 
hsa-let-7e-3p chr19: 51,692,786-51,692,864 [+] antisense to lncRNA SPACA6P-AS. 
upstream of SPACA6P  
hsa-mir-99b.  
hsa-let-7e. 
 hsa-mir-125a 
hsa-miR-107-3p chr10: 89,592,747-89,592,827 [-] intron of Pank1 (pantothenate kinase 1)   
hsa-miR-125b-2-3p chr21: 16,590,237-16,590,325 [+] locus 2: intron of lincRNA MIR99AHG (mir-
99a host gene) 
  
hsa-miR-125b-5p locus 1:  
chr11: 122,099,757-122,099,844 [-] 
locus 2: 
 chr21: 16,590,237-16,590,325 [+] 
locus 1: intron sense overlapping gene 
RP11-166D19.1. intron of lncRNA 
MIR100HG (mir-100 host gene)  
locus 2: intron of lincRNA MIR99AHG (mir-
99a host gene) 
  
hsa-miR-130a-3p chr11: 57,641,198-57,641,286 [+] intron of AP000662  
(sense overlapping to CLP1) 
  
hsa-miR-146b-5p chr10: 102,436,512-102,436,584 [+] intergenic   
hsa-miR-148a-3p chr7: 25,949,919-25,949,986 [-] intergenic   
hsa-miR-149-5p chr2: 240,456,001-240,456,089 [+] intron of GPC1 (glypican1)   
hsa-miR-196b-5p chr7: 27,169,480-27,169,563 [-] intron of Hoxa9. Hoxa10;  
exon of Hoxa10-as 
  
hsa-miR-210-3p chr11: 568,089-568,198 [-] intron of lncRNA MIR210HG  
(mir-210 host gene) 
  
hsa-miR-23b-3p chr9: 95,085,208-95,085,304 [+] intron of C9orf3 (chromosome9 open 
reading frame 3. protein coding). 
clustered with mir-27b. mir-24??? mir-
3074(antisense!!!) 
hsa-mir-23b 
hsa-mir-27b  
hsa-mir-3074 
(antisense) 
hsa-mir-24-1 
hsa-miR-24-1-5p chr9: 95,086,021-95,086,088 [+]   hsa-mir-23b 
hsa-mir-27b  
hsa-mir-3074 
(antisense) 
hsa-mir-24-1 
hsa-miR-27b-5p chr9: 95,085,445-95,085,541 [+]   hsa-mir-23b 
hsa-mir-27b  
hsa-mir-3074 
(antisense) 
hsa-mir-24-1 
hsa-miR-30a-3p chr6: 71,403,551-71,403,621 [-] intron of lncRNA RP3-331H24.5 together 
with mir-30c-2 
hsa-mir-30a.  
hsa-mir-30c-2 
hsa-miR-30a-5p chr6: 71,403,551-71,403,621 [-] intron of lncRNA RP3-331H24.5 together 
with mir-30c-2 
  
hsa-miR-30b-3p chr8: 134,800,520-134,800,607 [-] intergenic hsa-mir-30d  
hsa-mir-30b 
hsa-miR-30b-5p chr8: 134,800,520-134,800,607 [-] intergenic   
hsa-miR-30c-2-3p chr6: 71,376,960-71,377,031 [-]     
hsa-miR-30c-5p Locus 1:  
chr1: 40,757,284-40,757,372 [+]  
Locus 2: 
chr6: 71,376,960-71,377,031 [-] 
locus 1: intron of NFYC (nuclear 
transcription factor Y. gamma) locus 2: 
intron of lncRNA RP3-331H24.5 together 
with mir-30a 
locus 1: 
hsa-mir-30e  
hsa-mir-30c-1 
hsa-miR-30d-3p chr8: 134,804,876-134,804,945 [-] integenic hsa-mir-30d. 
hsa-mir-30b 
hsa-miR-30d-5p chr8: 134,804,876-134,804,945 [-] intergenic hsa-mir-30d. 
 hsa-mir-30b 
hsa-miR-322-3p chrX: 134,546,614-134,546,711 [-]   hsa-mir-424  
hsa-mir-503  
hsa-mir-542  
hsa-mir-450a-2 
hsa-mir-450a-1  
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hsa-mir-450b 
hsa-miR-330-3p chr19: 45,638,994-45,639,087 [-] intron of EML2 (echinoderm microtubule 
associated protein like 2) 
  
hsa-miR-330-5p chr19: 45,638,994-45,639,087 [-] intron of EML2 (echinoderm microtubule 
associated protein like 2) 
  
hsa-miR-340-5p chr5: 180,015,303-180,015,397 [-]  intron of RNF130 (ring finger protein 130)   
hsa-miR-351-3p ------ ------   
hsa-miR-351-5p ------ ------   
hsa-miR-450a-5p Locus 1:  
chrX: 134,540,341-134,540,431 [-] 
Locus 2:  
chrX: 134,540,508-134,540,607 [-] 
intergenic   
hsa-miR-450b-5p chrX: 134,540,185-134,540,262 [-] intergenic   
hsa-miR-503-3p chrX: 134,546,328-134,546,398 [-] Intron of lncRNA MIR503HG  
(mir-503 host gene) 
  
hsa-miR-503-5p  chrX: 134,546,328-134,546,398 [-] Intron of lncRNA MIR503HG  
(mir-503 host gene) 
  
hsa-miR-542-3p chrX: 134,541,341-134,541,437 [-] intergenic   
hsa-miR-574-3p chr4: 38,868,032-38,868,127 [+] intron of Fam114a1 (family with sequence 
similarity 114. member A1); 
  
hsa-miR-615-3p chr12: 54,033,950-54,034,045 [+] intron of Hoxc4 (homeobox C4) and Hoxc5 
(homeobox C5) 
 
hsa-miR-652-3p chrX: 110,055,329-110,055,426 [+] intron of Tmem164 (transmembrane 
protein 164) 
  
hsa-miR-873a-5p chr9: 28,888,879-28,888,955 [-] intron of Lingo2 (leucine rich repeat and Ig 
domain containing 2) 
 
hsa-miR-99a-3p chr21: 16,539,089-16,539,169 [+] intron of lincRNA MIR99AHG  
together with mir-let-7c and mir-125b-2 
hsa-mir-99a.  
hsa-let-7c 
hsa-miR-99a-5p chr21: 16,539,089-16,539,169 [+] intron of lincRNA MIR99AHG  
together with mir-let-7c and mir-125b-2 
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